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ABNORMALITIES AFFECTING TYROSINE KINASE SIGNALLING IN 
ATYPICAL MYELOPROLIFERATIVE DISORDERS 
 
By Claire Hidalgo-Curtis 
 
 
The myeloproliferative disorders (MPDs) are a group of haematopoietic stem cell diseases, 
characterised by proliferation of one or more cells of the myeloid lineage. Several lines of 
evidence have highlighted the importance of aberrant tyrosine kinase signalling in the 
pathogenesis of these disorders. Cloning of rare chromosomal translocations and point 
mutation analysis in the MPDs has identified diverse deregulated tyrosine kinase genes, 
notably PDGFRA, PDGFRB, FGFR1 and JAK2. However the majority of atypical MPDs 
still remain to be characterised and identification of patients harbouring fusions, 
particularly those involving the PDGF receptors is of increasing importance, as they are 
likely to be responsive to targeted therapy with imatinib.  
 
I am investigating MPD patients for abnormalities affecting tyrosine kinase signalling, and 
have used three approaches, translocation cloning, expression analysis and SNP array 
analysis to detect regions of loss of heterozygosity (LOH). Thus far, by translocation 
cloning I have identified a previously undescribed partner gene fused to PDGFRB and two 
new PDGFRA fusion genes. I have also designed two reverse transcriptase PCR (RT-PCR) 
assays and a cDNA MLPA assay to detect over-expression of specific tyrosine kinases 
screening approximately 200 patients. Each assay identified all patients previously 
diagnosed with known fusions. Additionally, two patients identified with overexpression of 
PDGFRB have been found to have cryptic ETV6-PDGFRB fusions and overexpression of 
PDGFRA in one patient lead to the discovery of a previously undescribed fusion involving 
a novel partner gene (KIF5B).  
 Recent evidence has indicated that acquired isodisomy is a novel mechanism by which 
mutations in cancer may be reduced to homozygosity. Typically, acquired isodisomy is 
associated with oncogenic changes rather than tumour suppressor genes, eg. the activating 
JAK2 V617F mutation and 9p aUPD. I have undertaken a screen using Affymetrix 50K 
SNP arrays for regions of acquired isodisomy as a means to identify genomic regions that 
may harbour novel oncogenes in different subgroups of MPD patients. Large tracts of 
homozygosity (defined as >20Mb running to a telomere), strongly suggesting acquired 
isodisomy, were seen in 40% aMPD patients. The homozygous tracts encompassed diverse 
genomic regions in aMPD, but two common regions (3 cases for each region) were 
identified at 7q and 11q. Mutations in the CBL ubiquitin ligase gene were discovered in all 
three aCML patients with 11q aUPD as well as in an additional 23 MPD patients following 
further screening. 
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1   INTRODUCTION 
 
The focus of the Leukaemia Research group based at the Wessex Regional Genetics 
Laboratory in Salisbury is the study of a rare subset of neoplastic conditions known 
as the myeloproliferative disorders (MPDs) and in particular, the association between 
MPDs and deregulated tyrosine kinases. This introduction discusses normal 
haematopoiesis and its subversion leading to leukaemia, and specifically the 
involvement of mutations targeting tyrosine kinase genes. 
 
1.1   Normal Haematopoiesis 
 
Haematopoiesis is the dynamic process of blood cell formation from a common 
haematopoietic progenitor or stem cell, resulting in the production of a diverse range 
of cell types with very different functions, ranging from oxygen transport and clotting 
to the production of antibodies.  
 
Haematopoietic cells first appear in the yolk sac in the second week of 
embryogenesis. By 8 weeks, haematopoiesis has become established in the liver and 
spleen of the embryo and by 12-16 weeks these are the major sites of haematopoietic 
cell formation and they remain active until birth. At 20 weeks gestation the bone 
marrow takes over as the active site for haematopoiesis, gradually increasing its 
activity until it then becomes the major site of production. In infants, haematopoiesis 
occurs in the bone marrow of all bones, whilst in adults haematopoiesis is confined to 
the flat bones of the sternum, ribs, cranium, pelvis, and the proximal ends of the 
femur and humerus. 
 
The haematopoietic system itself consists of the haematopoietic stem cell and its 
progeny, and the supporting bone marrow stroma composed of endothelial cells, fat 
cells, fibroblasts, macrophages and an extracellular matrix. The stem cells are a self-
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renewing population that have the potential to differentiate and become committed to 
a particular blood cell lineage. Initial differentiation of haematopoietic stem cells is 
along one of two major pathways, the myeloid (erythrocytes, neutrophils, 
monocytes/macrophages, eosinophils, basophils and megakaryocytes/platelets) or 
lymphoid (T-cells, B-cells and natural killer-cells) lineages (Figure 1.1). At this stage 
the stem cells have become progenitor cells for each type of blood cell, and have lost 
the capacity for self-renewal and are thus committed to a given cell lineage. These 
progenitor cells then divide and generate mature blood cells. Commitment of a 
progenitor cell to a given cell lineage depends upon the acquisition of responsiveness 
to certain growth factors. The particular microenvironment within which the 
progenitor cell resides controls differentiation. The bone marrow stroma is where 
haematopoiesis is controlled providing an inductive microenvironment consisting of 
an extracellular matrix and either membrane bound or diffusible growth factors 
(Dexter and Spooncer 1987). Evidence suggests that the dynamics of transcription 
factor networks within a cell, in addition to the combination of growth factors and 
cytokines in the environment are associated with commitment of a progenitor cell and 
hence cell diversity (Hoang 2004). 
Haematopoiesis is a continuous process throughout adulthood, and indeed the 
numbers and distribution of the different cell types in the peripheral blood exhibit 
little variation under steady-state conditions. This process is regulated by the 
appropriate balance of cell division, differentiation and apoptosis to maintain a steady 
state. Apoptosis (also known as programmed cell death) is the process in which 
unwanted cells are removed. A great number of cells produced by haematopoiesis are 
destined to die by apoptosis before becoming fully differentiated (Williams, et al 
1990). An imbalance between cell proliferation and cell death as a result of genetic 
mutations are observed in a number of haematological malignancies (Adjei 2001, 
Cucuianu 2001, Warmuth, et al 1999).  
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Figure 1. 1:  A hierarchical model of haematopoiesis 
 
1.2 Leukaemia 
 
The term leukaemia comes from the Greek word meaning literally ‘white blood’ and 
was first described by Velpeau in 1827 (Velpeau 1827) but then took over a decade 
before the disease became recognised by other physicians (Bennett 1845, Cragie 
1845, Virchow 1845). Leukaemia is defined as the clonal proliferation and 
accumulation of blood cells as a result of disruption to normal control mechanisms. 
The outcome of this is the bone marrow produces large numbers of abnormal cells, 
assumed to be derived from a single haematopoietic stem cell, thus disrupting the 
normal production of blood cells. The resultant release of immature cells into the 
peripheral blood and infiltration of organs such as the liver and spleen causing 
enlargement are common consequences of the disruption of normal haematopoiesis. 
Frequently other co-morbidities such as anaemia, thrombocytopenia and 
immunological dysfunction are also observed.  
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 1.2.1   Clonality 
 
There is a large amount of evidence to suggest that haematological malignancies arise 
from a single ancestral cell that has acquired a selective growth advantage due to 
acquired somatic mutations, and are thus clonal. In normal individuals 
haematopoiesis is thought to be polyclonal and this has been shown by clonality 
assays based on Lyon’s hypothesis of X-inactivation (Lyon 1988). This states that 
there is random inactivation in females of one X-chromosome and the genes it carries 
during early embryogenesis. Therefore normal female tissue will be mosaic of cells 
expressing genes from one or other X-chromosomes whereas clonal tissue will 
express genes from one X-chromosome only. The assessment of clonality is now an 
essential element of the characterisation and definition of haematological malignancy. 
There are a number of different assays used to detect clonal derivation, most 
dependent on differential methylation patterns between active and inactive X-
chromosomes at various polymorphic loci. 
 
Clonality in leukaemia is now well established and is a basic concept for the 
definition of myeloid leukaemia (Fialkow, et al 1967, Raskind and Fialkow 1987, 
Wainscoat and Fey 1990). Most forms of leukaemia have demonstrated one variant of 
a polymorphic allele in all their leukaemic cells (Raskind, et al 1998). Another 
important step in defining clonality and leukaemia was demonstrated by the 
Philadelphia chromosome in CML patients, which is found in multiple cell types 
(neutrophils, basophils, monocytes and B-cells) suggesting that the disease derives 
from a stem cell rather than a myeloid progenitor (Fialkow, et al 1977). 
 
1.2.2   Classification 
 
Leukaemia is broadly classified as either acute or chronic, referring to the speed at 
which the leukaemia progresses. In chronic leukaemia the disease is both slow to 
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develop and progress and is characterised by the over-accumulation of mature cells. 
In acute leukaemia an amassing of immature haematopoietic blast or progenitor cells 
is seen due to the rapid progression of the disease. If left untreated, acute leukaemia is 
almost always fatal. Both classifications can be further subdivided into myeloid and 
lymphoid which refers to the phenotype of the affected cells. 
 
Classification of the myeloid neoplasms has been defined by the World Health 
Organisation (WHO) (Vardiman, et al 2002, Vardiman, et al 2009). The focus of my 
work encompasses two of these categories: the chronic myeloproliferative disorders 
(CMPD) and the myelodysplastic/myeloproliferative disorders (MDS/MPD). 
Although these disorders are classified separately, the entities comprising each 
category are similar in that they are clonal stem cell proliferations with excess 
myeloproliferation. They exhibit increased marrow cellularity and organomegaly, and 
are susceptible to undergo genetic evolution associated with bone marrow failure or 
transformation to blast crisis (acute leukaemia). Despite these similarities, there are 
differences in the pathogenesis of each specific disease subtype that lead to clinical 
and morphological disparity.  
 
1.3  The chronic myeloproliferative disorders (CMPD) and the 
myelodysplastic/myeloproliferative disorders (MDS/MPD)
  
 
The CMPD are haematological diseases that arise in a primitive bone marrow 
progenitor cell (Adamson, et al 1976, Fialkow, et al 1981, Fialkow, et al 1980, 
Jacobson, et al 1978). They are characterised by proliferation of one or more cells of 
the myeloid lineages (i.e., granulocytic, erythroid and megakaryocytic), believed to 
derive from a single neoplastic clone. The neoplastic haematopoiesis shows 
maturation followed by a corresponding increase in the number of one or more of the 
mature myeloid lineages in the peripheral blood (Figure 1.1). Splenomegaly and 
hepatomegaly are common features. These disorders are also prone to undergo 
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genetic evolution associated with bone marrow failure or transformation to blast 
phase. A finding of 10-19% blasts in the blood or bone marrow signifies disease 
acceleration and 20% or above indicates blast phase. There are seven entities 
identified within the CMPD classification: Chronic myelogenous leukaemia (CML), 
polycythaemia vera (PV), chronic idiopathic myelofibrosis (IMF), essential 
thrombocythaemia (ET), chronic neutrophilic leukaemia (CNL), chronic eosinophilic 
leukaemia (CEL) and unclassifiable CMPD.  
 
The MDS/MPD group was created to accommodate disorders that have both MDS-
like and MPD-like features, and as a consequence are difficult to assign to separate 
categories. They are also clonal haematopoietic neoplasms, however these disorders 
exhibit dysplastic and proliferative clinical, laboratory and morphological features at 
the time of initial presentation. They are characterised by hypercellular bone marrow 
with fibrosis, organomegaly and leukocytosis, commonly neutrophilic proliferation 
with or without monocytosis, similar to the CMPD. However, the cells are often 
morphologically dysplastic. Occasionally, simultaneous cytopenia of one or more of 
the other cell lineages is also observed due to ineffective proliferation or a decrease in 
the number of precursors. There are three main entities acknowledged in this 
classification: chronic myelomonocytic leukaemia (CMML), atypical chronic 
myeloid leukaemia (aCML) juvenile myelomonocytic leukaemia (JMML), in 
addition to unclassified MDS/MPD. 
 
With the overlap of clinical, laboratory and morphological findings among the 
individual CMPD and MDS/MPD entities, distinction between the diseases in each 
category is made more difficult. For this reason, and the lack of knowledge 
surrounding the underlying molecular pathogenesis, the diagnosis of these disorders 
is based mainly upon the lineage of the predominant proliferating cells and the 
prominence of marrow fibrosis, combined with clinical, morphological and 
laboratory features. Due to the considerable overlap in the disease spectrum of these 
disorders I shall refer broadly to both groups together as myeloproliferative disorders 
(MPDs).  
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 To date, there is no single molecular abnormality associated with this subset of 
disorders, although a pathognomonic molecular marker is associated with CML, and 
the V617F JAK2 mutation is seen in the great majority of cases of PV as well as other 
MPDs.  
 
1.4  The paradigm for deregulated tyrosine kinases - Chronic 
Myelogenous Leukaemia (CML) 
 
CML is perhaps the best characterised MPD it has an incidence of 1-1.5/100,000 
population annually (Faderl, et al 1999, Gunz 1977, Young, et al 1981). It is a bi- or 
tri-phasic disorder with an indolent chronic phase (CML-CP), followed by one or 
both of the aggressive transformed stages; accelerated phase and/or blast phase. CML 
usually presents in chronic phase, which is broadly defined by the absence of features 
of accelerated or blast phase. The haematological indications of CML-CP, as 
observed on blood smears, show leukocytosis due to the large number and variable 
maturation stages of neutrophils. Marrow blasts usually account for less than 2% of 
the white blood cells in the blood and absolute basophilia, a defining feature, is 
commonly present.  The natural course of the disease progression from CML-CP to a 
more aggressive phase is generally within 3-5 years, and is thought to be due to 
genetic instability (Mitelman 1993). 
 
1.4.1   Molecular pathogenesis of CML 
 
A molecular marker was first described in 1960, when Nowell and Hungerford 
discovered a ‘minute chromosome’ associated with the condition, a shortened 
chromosome 22 (Nowell and Hungerford 1960). It was not until much later in 1985 
that the underlying molecular lesion was defined (Shtivelman, et al 1985). The 
hallmark of CML is the Philadelphia (Ph) chromosome, a reciprocal translocation, 
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t(9;22)(q34;q11), that fuses BCR on chromosome 22 with the ABL tyrosine kinase on 
chromosome 9 (de Klein, et al 1982, Faderl, et al 1999, Gunz 1977, Rowley 1973, 
Shtivelman, et al 1985, Young, et al 1981). The ABL gene on chromosome 9 has 
homology with a known viral oncogene v-abl, which was identified as the cause of 
some murine leukaemias. The normal ABL gene encodes a non-receptor tyrosine 
kinase that is active in signal transduction. The chimaeric BCR-ABL gene however 
encodes an aberrant tyrosine kinase of higher molecular weight and depending on the 
location of the breakpoint within BCR (Quackenbush, et al 2000), three oncogenic 
BCR-ABL fusion proteins: p190, p210 and p230 can be formed. They are all found to 
be sufficient to generate leukaemia in murine models (Daley, et al 1990, Huettner, et 
al 2000). Fusion to BCR constitutively activates the ABL tyrosine kinase moiety, and 
this activation depends on the BCR N-terminal coiled-coil domain (McWhirter and 
Wang 1997). The effect of this is autophosphorylation of the protein and activation of 
a number of cellular pathways important for transducing proliferative and anti-
apoptotic signals (McGahon, et al 1994, Puil, et al 1994). It has been suggested that 
the strong resistance to apoptosis along with DNA repair deficiency induced by BCR-
ABL allows the accumulation of secondary genetic abnormalities leading to clonal 
evolution toward blast crisis. Cytogenetically, such abnormalities typically include 
+8, +Ph or i(17q).(Barnes and Melo 2002, Faderl, et al 1999, Mitelman 1993, 
Mitelman, et al 1976, Sokal, et al 1988). Abrogation of apoptosis suggests that the 
expansion of the neoplastic clone may be due not only to a proliferative advantage 
but also to prolonged survival. 
 
The Ph chromosome is now detected by routine cytogenetic techniques in 85-90% of 
CML patients at diagnosis. The remaining patients have variant translocations or a 
submicroscopic translocation of BCR-ABL that can only be detected by molecular 
techniques or fluorescence in situ hybridisation (FISH) (Hooberman, et al 1989, 
Sinclair, et al 1997, Werner, et al 1997, Westbrook and Keinanen 1992).  
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1.4.2   Therapy in CML and the development of Imatinib 
 
Allogeneic stem cell transplantation is currently believed to be the only curative 
therapy for CML, however only a minority of patients is eligible for this procedure 
due to a relatively limited number of HLA-matched donors. In the past, the therapy 
most commonly used to achieve haematological remission in CML-CP was 
interferon-alpha (IFNα). However, an important advance in the therapy of CML 
came with the development of imatinib mesylate, a small molecule inhibitor that 
competes with ATP for occupancy of its specific binding site within the kinase 
domain of BCR-ABL. Inhibition of tyrosine kinase activity occurs, as imatinib lacks 
the essential phosphate groups usually provided by ATP. Thus, phosphorylation of 
substrate proteins cannot occur and they therefore fail to adopt the conformational 
changes necessary for binding of effector proteins. Ultimately, downstream signalling 
is prevented (Druker, et al 1996). The initial clinical trials of imatinib included 83 
Ph(+) CML patients who had failed IFNα-based treatment and were in CML-CP. A 
complete haematological response was seen in 98% of patients, with complete 
cytogenetic responses in 13%. These initial studies were further expanded to include 
260 CML patients in myeloid blast crisis. The overall response rate was 64%, with 
11% achieving complete remission (<5% marrow blasts). However, 38% of patients 
either returned to CML-CP or had partial responses.  
 
The results from blast crisis CML suggest partial dependence of the BCR-ABL clone 
and the likely acquisition of further molecular abnormalities that are not targeted by 
imatinib (Druker, et al 2001). O’Brien and colleagues later went on to report a 
comparative study of imatinib mesylate versus combination therapy with IFNα and 
cytarabine in newly diagnosed CP-CML patients, and found that 97% of these 
patients achieved a complete haematological remission by 18 months after imatinib 
mesylate was employed. In addition, a complete cytogenetic response was achieved 
in greater than 76% of CML patients, and more than 90% had no evidence of disease 
progression after 18 months (O'Brien, et al 2003). However, to properly assess the 
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overall survival increases after treatment with imatinib, long-term studies are 
required.  
 
As previously mentioned, although patients with accelerated or blast phase CML 
show similar morphological and clinical changes with imatinib therapy, it is not 
effective in advanced disease (Druker, et al 2001, Druker, et al 1996). Furthermore, a 
drawback of imatinib is the emergence of acquired resistance, such as point mutations 
in the kinase domain or amplification of the BCR-ABL gene (Barthe, et al 2001, 
Branford, et al 2002, Gorre, et al 2001, Hochhaus, et al 2001, Mahon, et al 2000, 
von, et al 2002). The development of second generation ATP-competitive ABL 
kinase inhibitors are attempting to overcome some of the problems associated with 
imatinib resistance and advanced phase disease. These compounds include dasatinib 
(Sprycel®), nilotinib (Tasigna®), bosutinib (SKI-606) and INNO-406 (NS-187), all of 
which display increased potency against BCR-ABL. Nilotinib is a novel 
aminopyrimidine inhibitor (Weisberg, et al 2005) and has been developed as a 
selective potent BCR-ABL inhibitor. It has shown a good outcome in patients with 
CP-CML following imatinib resistance and intolerance (Kantarjian, et al 2007), in 
fact it has been shown in pre-clinical studies to be 30-fold more potent than imatinib. 
Dasatinib is a potent dual BCR-ABL and Src kinase inhibitor that is structurally 
unrelated to imatinib (Shah, et al 2004). Its greatest benefits have been observed in 
patients with CP-CML with 90% achieving a complete haematological response 
(Steinberg 2007). Much like imatinib, advanced phase-, blast crisis-CML or Ph 
positive ALL, all showed lower responses. A clinical trial comparing high dose 
imatinib (800mg/day) and dasatinib showed both produced complete haematological 
responses however, more achieved a major haematological response with dasatinib 
(32% versus 7%). Dasatinib has also been found to be effective against KIT and 
PDGFR, in addition to overcoming resistance exhibited by 18/19 imatinib resistant 
mutations reported (Shah, et al 2006). Neither of the second generation targeted 
compounds mentioned here are able to overcome the resistance displayed by the 
T135I mutant but nevertheless they offer the potential for combined therapy and 
additional hope in cases where imatinib resistance or intolerance has been observed. 
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 Other therapies are also continuing to be developed, such as those that target 
downstream signalling molecules using farnesyl transferase inhibitors (Peters, et al 
2001). It is unclear exactly how these compounds work however they are thought to 
inhibit the farnesylation of a wide range of target proteins, including RAS, ultimately 
resulting in cell growth arrest. In preclinical models these inhibitors showed great 
potency against tumour cells, however in clinical trials their activity was far less than 
expected. It is possible that inhibition of farnesylation is sufficient for deactivation of 
H-Ras, yet insufficient for K-Ras which may be activated by geranylgeranylation 
thereby suppressing the effect of the farnesyl transferase inhibitors (Appels, et al 
2005). Another area attracting the development of many haematological based 
inhibitors is apoptosis-centered therapies. Many agents have been developed that 
generally act by stimulating pro-apoptotic proteins and which are at various stages of 
preclinical and clinical development,. In particular, compounds have been devised 
that act against Akt, over activity of which can enable leukaemic cells to proliferate 
and survive. Akt is activated downstream of several oncogenes including BCR-ABL. 
An Akt inhibitor has been described that is relatively selective but unfortunately in 
preclinical trials proved weak (Mitsiades, et al 2002). Heat shock 90 (HSP90) 
inhibitors such as 17-AAG have also been shown to have an effect on Akt by acting 
to destabilise and cause overall reductions in Akt levels (Solit, et al 2003). 
 
BCR-ABL was the first human fusion gene to be identified in human malignancy. The 
leukaemogenic mechanism in CML now serves as a paradigm for other myeloid 
leukaemias, as subsequent to the discovery of BCR-ABL, many other oncogenic 
fusion genes have been reported, including several that involve tyrosine kinases. 
 
1.5   The tyrosine kinases  
 
Tyrosine kinases are enzymes that catalyse the transfer of the γ-phosphate of ATP to 
protein tyrosine substrates. The phosphorylation of tyrosine and to a lesser extent 
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threonine and serine is the major mechanism for reversible regulation of protein 
activity and function. Phosphorylation by protein kinases is central to cellular signal 
transduction and is responsible for a number of cell functions, including cell-cycle 
progression, differentiation, apoptosis, cell metabolism and DNA-replication. There 
are thought to be 518 putative protein kinase genes within the human genome 
(Manning, et al 2002) of which 90 are tyrosine kinases. These tyrosine kinases are 
classified as either non-receptor or receptor types (Blume-Jensen and Hunter 2001). 
The receptor tyrosine kinases (RTKs) contain a transmembrane domain and are 
involved in extracellular ligand binding. The non-receptor tyrosine kinases (NRTKs) 
are intracellular and do not span the plasma membrane. There are 58 RTKs and 32 
NRTKs in the human genome. 
 
1.5.1    Non-receptor tyrosine kinases (NRTKs) 
 
The NRTKs include SRC, JAK and ABL which are intrinsic to the cytosol and are 
maintained in an inactive state. Despite performing a similar role in signal 
transduction, apoptosis and differentiation as the receptor tyrosine kinases, activation 
is usually dependent on interaction with surface receptors that lack intrinsic catalytic 
activity. For example, the JAK family of NRTKs is involved in signal transduction by 
the cytokines IL-3 and G-CSF (Figure 1.2). The NRTKs can also be activated by 
intracellular signalling by enabling inhibitor dissociation which is how they are 
usually maintained in an inactive form. Interestingly, while most NRTKs are 
cytoplasmic, ABL is localised to both the cytosol and nucleus (Taagepera, et al 
1998). 
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Figure 1. 2:  IL-3 signalling pathway detailing JAK2 non-receptor tyrosine kinase signalling. 
JAK2 binds to the active cytokine receptor IL-3. JAK2 in turn phosphorylates 
tyrosine residues on the receptor allowing the recruitment of other signalling 
proteins, such as SHC and STAT5, which are then phosphorylated by JAK2. 
Activated (phosphorylated) STAT dimers can then accumulate in the cell nucleus 
and activate transcription. 
 
1.5.2   Receptor tyrosine kinases (RTKs) 
 
The RTKs are transmembrane enzymes that are involved in signal transduction at the 
cell surface and which have been sub-classified into 20 classes based on their kinase 
domain sequence (Robinson, et al 2000). The class III RTKs includes KIT, FLT3, 
PDGFRα, PDGFRβ and FMS. They are characterised by five immunoglobulin-like 
domains in the extracellular ligand-binding region, a single transmembrane domain 
and two intracellular tyrosine kinase domains (TK1 and TK2) separated by a kinase 
insert domain (KI) (Schlessinger 2000). They are all thought to play a crucial role in 
normal haematopoiesis and are thus normally tightly regulated due to the impact they 
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have on cellular signal transduction. In their inactive states the receptors are thought 
to exist as monomers embedded in the plasma membrane. Ligand binding to the 
receptor induces dimerisation, juxtaposing the two catalytic domains causing a 
conformational change resulting in partial activation of its enzymatic activity (Jiang 
and Hunter 1999). Full activity follows only after autophosphorylation of key 
tyrosine residues in the activation loop. These phosphorylated tyrosines then act as 
docking sites for adaptor proteins that further recruit other downstream cytoplasmic 
signalling molecules. Subsequently a cascade of signalling events through the 
JAK/STAT, PLCγ, PI3K and Ras-Raf-MEK/ERK occurs leading to changes in 
expression of genes involved in the control of cell proliferation, differentiation and 
cell survival (Kharas and Fruman 2005) (Figure 1.3). Activated receptors are rapidly 
endocytosed and either degraded or recycled to the plasma membrane. 
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Figure 1. 3:  A schematic representation of RTK activation and signalling. 
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 1.6   Molecular pathogenesis and deregulated tyrosine kinases 
 
Following the identification of BCR-ABL in CML, a number of other tyrosine 
kinases have been implicated in the pathogenesis of leukaemia. In fact, in the past 
two decades several mechanisms that deregulate tyrosine kinases, such as receptor 
amplification, chromosomal translocations and point mutations have been identified, 
with reports of more that 30 deregulated tyrosine kinases associated with cancer 
(Blume-Jensen and Hunter 2001). In MPD patients in particular, translocation cloning 
has lead to the identification of numerous fusion genes involving tyrosine kinase 
genes, for example the fibroblast growth factor receptor 1 (FGFR1) on chromosome 
8p11. The resulting myeloproliferative disorder is loosely referred to as the 8p11 
myeloproliferative syndrome (EMS), also known as stem cell leukaemia-lymphoma 
(SCLL) (Macdonald, et al 2002a). 
 
To date, nine fusion genes associated with translocations involving FGFR1 have been 
identified in MPD patients. The translocations reported include chromosomes 13q, 
9q, 6q, 22q, 17q, 7q, 12p, 19q and 12q resulting in the respective fusion of ZMYM2 
(ZNF198/RAMP/FIM), CEP110, FGFR1OP (FOP), BCR, MYO18A, Trim24 (TIF1), 
FGFR1OP2, HERV-K and CPSF6 to FGFR1 (Belloni, et al 2005, Demiroglu, et al 
2001, Grand, et al 2004a, Guasch, et al 2003a, Guasch, et al 2000, Hidalgo-Curtis, et 
al 2008, Popovici, et al 1999, Walz, et al 2005, Xiao, et al 1998). As a consequence, 
constitutively active fusion proteins are produced that are functionally and 
structurally similar to BCR-ABL. Other translocations involving tyrosine kinases are 
reported in MPD patients, including the platelet-derived growth factor receptors alpha 
(PDGFRA) and beta (PDGRFB), class III receptor tyrosine kinases that map to 4q12 
and 5q33, respectively  (discussed later, section 1.7). Other fusions have also been 
described in MPDs that involve JAK2, ABL, FLT3, SYK, ARG and TRKC (NTRK3) 
(Grand, et al 2007, Griesinger, et al 2005, Peeters, et al 1997, Reiter, et al 2005, Vu, 
et al 2006) (Cazzaniga, et al 1999, Eguchi, et al 1999, Golub, et al 1997, Hidalgo-
Curtis, et al 2008, Kuno, et al 2001). The resulting oncoproteins also have 
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constitutive enzymatic activity and deregulate cell growth in a similar fashion to that 
generated by BCR-ABL (Cross and Reiter 2002). 
 
In addition to translocation cloning, loss of heterozygosity (LOH) has recently re-
emerged as an extremely useful tool for identifying regions harbouring potential 
candidate oncogenes or tumour suppressor genes in leukaemia. This is exemplified by 
the recent discovery of the V617F JAK2 mutation in patients with PV, MF and ET. A 
study of PV patients in 2002 using microsatellite screening of the whole genome, 
showed significant loss of heterozygosity (LOH) of chromosome 9p in all PV patients 
tested (Kralovics, et al 2002). LOH was observed without change of copy number, 
indicating that it occurred by acquired uniparental disomy (UPD) as a consequence of 
mitotic recombination rather than heterozygous deletion. Within the minimal region 
of UPD they identified a number of possible candidate genes, including JAK2. UPD 
for other regions has also been associated with gain of function mutations, for 
example UPD 13q and FLT3 internal tandem duplications (Fitzgibbon, et al 2005, 
Griffiths, et al 2005). Although these results did not actually lead to the discovery of 
the JAK2 or FLT3 mutations, they suggest that screening for LOH/UPD may be a 
useful approach to identify candidate oncogenes. 
 
At the current time it is important to identify patients with molecular lesions 
involving imatinib responsive genes. Although designed for use against the ABL 
tyrosine kinase, imatinib has also been shown to inhibit the tyrosine phosphorylation 
of ARG, KIT, FMS, PDGFRA and PDGFRB. On identification of a lesion involving 
one of these genes in a MPD patient, imatinib therapy can be successfully initiated. 
Translocations involving imatinib responsive genes are commonly described in a 
minority of MPD patients, notably involving rearrangements of the PDGFR genes.  
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1.7   PDGFRA and PDGFRB rearrangements in MPDs  
 
PDGFRα and PDGFRβ are 2 highly related RTKs with 85% and 75% homology 
between the two intracellular kinase domains (Matsui, et al 1989). PDGF ligand 
consists of a family of four dimeric isoforms linked by disulphide bonds, PDGF-AA, 
PDGF-BB, PDGF-CC and PDGF-DD. The N-terminal region of each ligand must be 
proteolytically removed to enable binding to the receptor (Bergsten, et al 2001). 
PDGFRβ binds the ligands PDGF-BB and PDGF-DD agonistically, whereas 
PDGFRα binds all the isoforms with the exception of PDGF-DD. While PDGFRs 
can form homo-and heterodimers between the α and β receptors, it has also been 
shown to have the ability to dimerise with the epidermal growth factor receptor 
(EGFR) and the hybrid can also be stimulated by PDGF (Saito, et al 2001). Both 
PDGFR receptors have been linked to haematological malignancies and in particular 
the MPDs. 
 
1.7.1   Fusions involving PDGFRA 
 
Over-expression and amplification of PDGFRA has been described in only a minority 
of human malignancies (Bozzi, et al 2007, Ebert, et al 1995, Hermanson, et al 1996, 
Holtkamp, et al 2007, MacDonald, et al 2001, Puputti, et al 2006, Zhang, et al 2005), 
but specific abnormalities have been associated with patients with a CML-like MPD. 
A rare variant translocation, t(4;22)(q12;q11), resulting in a constitutively active 
BCR-PDGFRα fusion protein was first detected in a patient with atypical CML 
(Baxter, et al 2002). Following this discovery, Cools et. al., (2003) discovered an 
interstitial cytogenetically invisible deletion of 4q12 resulting in the fusion of FIP1L1 
to PDGFRA. The resulting oncoprotein was found to transform Ba/F3 cells to growth 
factor independence, similar to BCR-ABL. Although originally found in a patient 
described clinically with HES, patients with FIP1L1-PDGFRA are now classified as 
CEL since the presence of the fusion indicates clonality (Cools, et al 2003a). More 
recently, the link between PDGFRA fusion genes and CML-like MPDs has been 
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heightened by further reports of new rare PDGFRA fusions (Curtis, et al 2007, Score, 
et al 2006, Walz, et al 2006).  
 
1.7.2   Chronic eosinophilic leukaemia (CEL)  
 
CEL is the clonal proliferation of eosinophilic precursors that results in persistently 
increased numbers of eosinophils in the blood, bone marrow and peripheral tissues. 
Organ damage occurs because of leukaemic infiltration or the release of cytokines, 
enzymes or other proteins by the eosinophils. Unusually, eosinophilic leukaemia 
shows a marked male predominance, and in particular, HES has been found to have a 
9:1 male to female ratio. Due to the difficulty in differentiating CEL and HES, the 
prevalence of these disorders is unknown, although it is clear that both are rare. 
However if there is no evidence of clonality of the eosinophils, a diagnosis of HES is 
preferred, whereas the finding of a clonal myeloid abnormality supports the diagnosis 
of CEL (Bain 1996, Weller and Bubley 1994). The FIP1L1-PDGFRA cytogenetically 
cryptic fusion gene was first identified in patients with HES/CEL. Patients with the 
fusion protein show an excellent clinical response to imatinib mesylate (Cools, et al 
2003a). 
A staurosporine derivative, PKC412, has also been developed to inhibit the PDGFRs 
and other kinases such as KIT and FGFR3 (Chen, et al 2005, Gotlib 2005, Growney, 
et al 2005, Seo, et al 1999), and although it has not been used in patients with 
PDGFR-rearrangements yet, it has been shown to overcome imatinib-resistance in a 
murine model of FIP1L1-PDGFRα induced MPD (Cools, et al 2003b). It has also 
now entered Phase II trials for FLT3 inhibitor therapy in AML with encouraging 
results however the emergence of primary and secondary resistance does occur in the 
majority of patients (Stone, et al 2005). Other inhibitors such as Sorafenib are also 
active against FIP1L1-PDGFRA and its most common imatinib-resistant mutant 
(Lierman, et al 2006). 
 
 A number of other clonal cytogenetic abnormalities have also been reported in rare 
cases of CEL, CMML with eosinophilia and aCML primarily involving PDGFRB, 
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FGFR1 and JAK2. Acquired reciprocal chromosomal translocations involving the 
chromosome band 5q31-33 (PDGFRB), in particular, are associated with a significant 
minority of MPD patients.  
 
1.7.3   Fusions involving PDGFRB 
 
Aberrant activation of PDGFRB resulting in cell transformation was first 
substantiated by Waterfield et. al., (1983) (Waterfield, et al 1983) who provided 
evidence that SIS, an oncogenic form of the PDGFR ligand, transformed cells 
through activation of its receptor. Nevertheless, demonstration of the direct 
association with PDGFRB in leukaemogenesis took another decade, when a rare but 
recurring cytogenetic abnormality was reported in patients with atypical CML. The 
abnormality was shown to be a t(5;12)(q33;p13) resulting in an ETV6-PDGFRB 
fusion gene (Golub, et al 1994). In an analogous manner to the BCR-ABL 
oncoprotein, pathogenicity is dependent on both the ETV6 dimerisation motif and the 
tyrosine kinase activity of PDGFRβ. Reports of additional chromosomal 
translocations involving PDGFRB in patients with MPDs, strengthens the association 
between myeloid leukaemias and deregulated tyrosine kinases. To date, 21 partner 
genes have been reported (Table 1.1).  
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 TRANSLOCATION  PARTNER GENE  REFERENCE 
ETV6 (Golub, et al 1994, Wlodarska, et al 
1995) 
t(5;12)(q33;p13) 
H4/CCDC6 (Kulkarni, et al 2000, Schwaller, et 
al 2001) 
t(5;10)(q33;q21) 
HIP1 (Ross, et al 1998) t(5;7)(q33;q11) 
CEV14(TRIP11/GMAP21
0) 
(Abe, et al 1997) t(5;14)(q33;q32) 
Rabaptin-5/RABEP1 (Magnusson, et al 2001) t(5;17)(q33;p13) 
PDE4DIP (Wilkinson, et al 2003) t(1;5)(q23;q33) 
(myomegalin) 
NIN (Vizmanos, et al 2004) t(5;14)(q33;q24) 
HCMOGT-1/SPECC1 (Morerio, et al 2004) t(5;17)(q33;p11.2) 
TP53BP1 (Grand, et al 2004b) t(5;15)(q33;q15) 
KIAA1509 (Levine, et al 2005b) t(5;14)(q33;q32) 
ERC1 (Gorello, et al 2008) t(5;12)(q33;p13.3) 
TPM3 (Rosati, et al 2006) t(1;5)(q21;q33) 
WDR48 t(3;5)(q22;q33) SUBMITTED 
Bin2 t(5;12)(q33;q13.13) SUBMITTED 
GOLGA4 t(3;5)(q22;q33) SUBMITTED 
GIT2 (Walz, et al 2007) t(5;12)(q31-33;q24) 
PRKG2 (Gallagher, et al 2008, Walz, et al 
2007) 
t(4;5;5)(q23;q31;q33) 
t(4;5)(q21;q33) 
GPIAP1 (Walz, et al 2007) Der(1)t(1;5)(p34;q33),der(5)(1;5)(p34;q15),
der(11)ins(11;5)(p12;q15q33)[23];46XY[1]
NDEI (La Starza, et al 2007) t(5;16)(q33;p13) 
MYO18A (Walz, et al 2009) t(5;17)(q33-34;q11.2) 
SPTBN1 (Gallagher, et al 2008) t(2;5)(p21;q33) 
 
Table 1. 1:  5q33 translocations in leukaemia involving PDGFRB 
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 1.7.4   Chronic myelomonocytic leukaemia (CMML) 
 
CMML is a clonal disorder of a bone marrow stem cell, in which monocytosis is the 
hallmark. It is, however, a heterogeneous disorder; in some cases, the white blood 
cell (WBC) count is elevated due to neutrophilia and monocytosis with minimal 
dysplasia, but significant splenomegaly, and the disease is more reminiscent of a 
CMPD than MDS. In other patients, although monocytosis is present, neutrophil 
counts are reduced or normal and there is prominent dysplasia and no splenomegaly, 
so that the disease resembles MDS rather than CMPD. The median age at diagnosis 
of CMML is 65-75 years, with a male to female ratio reported to be between 1.5-3:1 
(Germing, et al 2000, Onida, et al 2002). The most frequent recurring chromosomal 
abnormalities include trisomy 8, monosomy 7/deletion (7q) and structural 
abnormalities of 12p and i(17q); approximately 20-40% of CMML patients have 
detectable clonal abnormalities (Fenaux, et al 1996, Toyama, et al 1993). 
 
A subset of CMML cases, generally those associated with marked eosinophilia, have 
also been associated with PDGFRB fusion genes (Golub, et al 1994, Kulkarni, et al 
2000, Magnusson, et al 2001, Sawyers and Denny 1994, Schwaller, et al 2001). 
Mutations of RAS are also detected, in approximately a third of CMML cases 
(Willman 1998). Mutations of FLT3 may also be present in this group, a recent study 
by Shih et. al, (2002) found 3 out of 7 CMML patients carried the internal tandem 
duplication (Shih, et al 2002).  
 
Apperley et. al., (2002) has also provided evidence that patients with rearrangements 
of the PDGFRB gene respond well to treatment with imatinib mesylate (Apperley, et 
al 2002). These findings make it increasingly important to gain an accurate molecular 
diagnosis of PDGFRA and PDGFRB gene rearrangements, as it is likely they will 
play a role in the disease management of such patients. 
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1.7.5   JAK2 and the myeloproliferative disorders 
 
Aberrant tyrosine kinase signalling has been implicated as the pathogenic mechanism 
of so many of the MPDs, it has not come as a surprise to find the presence of an 
acquired point mutation in the Janus Kinase 2 (JAK2) gene predominantly in patients 
with PV, IMF and ET. The JAK2 mutation itself has been the single most important 
discovery in the pathogenesis of MPDs in the last decade. The guanine to thymine 
substitution in exon 12 of JAK2 changes a highly conserved valine at position 617 to 
phenylalanine (V617F). This alteration is within the pseudokinase (JH2) domain and 
acts by disrupting the inhibitory regulation of JAK2, leaving it constitutively activated 
(Baxter, et al 2005, James, et al 2005, Jones, et al 2005, Kralovics, et al 2005a, 
Levine, et al 2005a). The activated kinase can then bind to a receptor and recruit 
STATs independent of haematopoietic growth factors. Five groups have 
independently confirmed the identification of the V617F mutation. The numbers of 
PV, IMF and ET patients found to have the mutation is remarkable, and will now act 
as an invaluable diagnostic tool to distinguish between the MPD and other reactive 
conditions such as secondary thrombocytosis and erythrocytosis (Table 1.2). 
Interestingly, this mutation does not occur in non-haematological malignancies and is 
uncommon in myeloid disorders other than the classic BCR-ABL negative MPDs 
(Scott, et al 2005). 
15(43%)
24(41%)
58(81%)
No. of 
V617F 
positive
35 
59 
72 
No. 
of 
cases 
Jones et. al., 
Blood (2005)
9(43%)
3 (43%)
40(89%)
No. of 
V617F 
positive
21
7
45
No. 
of 
cases
James C et. 
al., Nature 
(2005)
13(57%) 2316(35%)468(50%)16
Chronic idiopathic 
myelofibrosis 
21(23%) 9337(32%)11529(57%)51
Essential 
thrombocythaemia 
83(65%) 128121(74%)16471(97%)73
No. of 
V617F 
positive 
No. 
of 
cases
No. of 
V617F 
positive
No. 
of 
cases
No. of 
V617F 
positive
No. of 
casesDisease 
Kralovics R 
et. al., NEJM 
(2005)
Levine et. al., 
Can. Cell (2005)
Baxter et.al., 
Lancet (2005)
Polycythaemia vera 
 
:Table 1. 2   Percentages of patients found to have the V617F mutation categorised by disease 
entity. 
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 However, a number of questions regarding JAK2 V617F remain including: how an 
identical mutation can cause three separate clinical diseases, and why some patients 
are heterozygous for the mutation and others are homozygous. If those with 
homozygous mutations are the result of two separate steps, why is it that the first is 
enough to cause disease features alone?  
 
Since the discovery of the JAK2 V617F mutation a considerable amount of 
investigation has been performed trying to answer these, among other questions, with 
no definitive conclusions. It is odd that only a single point mutation occurs in this 
gene at this position. If this codon is prone to mutation why is only one amino acid 
substitution observed? What makes this single mutation activate JAK2 in the majority 
of patients with these disorders given the fact that other activating mutations such as 
T875N have been found in acute megakaryoblastic leukemia (Mercher, et al 2006). 
Work has recently been published looking at this anomaly: Dusa et. al., 2008 have 
used random site-directed mutagenesis to mutate codon 617 to each of the 20 amino 
acid possibilities and tested their ability to induce constitutive signalling in vitro in 
Ba/F3 cells expressing the erythropoietin receptor. Only 4 mutations, V617W, 
V617M, V617I and V617L were able to induce cytokine independence and 
constitutive downstream signalling. Additionally, V617W was the only mutant that 
produced constitutive activity comparable to that of V617F, and could generate an 
MPD in mice that displayed predominant erythrocytosis and megakaryocytic 
proliferation (Dusa, et al 2008). Nevertheless, to achieve this amino acid substitution 
would require a three base pair change (GTC>TTG) and this is unlikely to occur 
naturally in patients.  
 
Since this initial finding of V617F, other mutations have been identified in JAK2 
exon 12 in PV patients negative for the JAK2 V617F mutation. In contrast, these 
mutations are varied in terms of their molecular basis, with substitutions, complex 
deletions and insertions identified (Butcher, et al 2008, Scott, et al 2007b). These 
mutations account for one third of all bona fide V617F negative PV patients although 
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this figure will probably turn out to be greatly reduced with screening of increased  
numbers (Scott, et al 2007a).  
 
In vitro and in vivo data suggests JAK2 V617F is sufficient for the development of 
PV, ET and IMF, however this does not account for how three phenotypically related, 
but clinically distinct MPDs can arise from an identical JAK2 mutation. Additional 
genetic and epigenetic events have been hypothesised to contribute to this phenotypic 
pleiotropy. It is possible there are still unidentified mutations that contribute to the 
pathogenesis of these disorders or there may be unknown initiating events which 
precede the acquisition of the JAK2 V617F mutation. Pardanani et. al., 2007 screened 
for genetic differences in allele frequencies of SNPs in JAK2, EPOR, GSCF and MPL 
and found a number of SNP and haplotype associations linked with PV and not ET or 
IMF in the JAK2 gene. This group concluded that genetic variation in MPDs may 
contribute to phenotypic diversity in the presence of specific mutations (Pardanani, et 
al 2007). In addition, a study by Bellanne-Chantelot et. al., 2006 looked at familial 
MPDs. Somatic JAK2 V617F mutations were identified in some, but not all MPD 
patients. In fact some families showed both JAK2 V617F-positive and -negative 
affected members, and a small number of relatives without a diagnosis of PV, ET or 
MF had endogenous erythroid colony formation in the absence of the JAK2 V617F 
allele, suggesting perhaps that unidentified mutations may be contributing to the 
pathogenesis of PV, ET and MF, regardless of JAK2 mutational status (Bellanne-
Chantelot, et al 2006). In addition to phenotypic pleiotropy and inherited SNPs, 
epidemiological data and family studies have also suggested that inherited factors 
may also predispose to these specific MPDs (Landgren, et al 2008, Rumi, et al 2008). 
This work has been expanded and a strong association between JAK2 V617F disease 
and specific constitutional JAK2 haplotypes has recently been identified, providing 
the first evidence in MPDs of inherited genetic factors influencing the risk of 
acquiring a specific somatic mutation (Jones, et al 2009, Kilpivaara, et al 2009, 
Olcaydu, et al 2009). 
 
It has also been suggested that the JAK2 V617F mutation may arise in different 
progenitor cell populations thus accounting for the difference in clinical phenotype 
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between the three separate disorders found to harbour this mutation. Jaimeson et. al., 
2006 recently used flow cytometry to isolate different progenitor cell populations 
from PV patients and showed the mutation was observed in all cell fractions 
providing evidence that PV arises in haematopoietic stem cells (HSCs) and involves 
myeloid, erythroid and megakaryocytic lineages (Jamieson, et al 2006) and thus, like 
CML, V617F positive MPDs are believed to arise from an early haemopoietic 
progenitor or stem cell. 
 
 
A further interesting outcome has been the discovery that homozygous clones occur 
in most patients with PV but are never found in patients with ET. In addition to this 
observation is that ET JAK2 V617F positive patients have phenotypic similarities of 
PV for instance, increased haemoglobin, increased numbers of neutrophils, bone 
marrow erythropoiesis and granulopoiesis and a propensity to venous thromboses. ET 
patients lacking the JAK2 V617F mutation also differ in that they have more 
pronounced and isolated thrombocytosis, less active erythropoiesis and 
granulopoiesis. From these in-depth studies it has been suggested that V617F positive 
thrombocythaemia and polycythaemia could be viewed as a continuum of disease and 
not as two separate entities, with depleted iron stores, genetic modifiers and 
erythropoietin homeostasis tipping the disease in favour of ET and sex (mainly biased 
toward men), genetic modifiers and homozygosity for V617F pushing the disease 
balance toward PV (Campbell, et al 2005).  
 
Whilst these questions still remain unresolved, work has at least progressed toward 
possible therapeutic strategies that will hopefully become clinically effective.  
Targeted potent inhibitors of JAK2 are currently in development for the treatment of 
MPD (Geron, et al 2008, Hexner, et al 2008, Pardanani 2008).  Most of the 
compounds that are undergoing preclinical and clinical testing inhibit both wild-type 
JAK2 and JAK2 V617F. JAK2 signalling is important in many cellular functions 
hence inhibition of wild-type may result in unwanted haematopoietic side effects. 
Additionally JAK2 is one of a closely related family and wild-type JAK3 inhibition 
has to be considered due to its association between loss of function mutations and 
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severe combined immunodeficiency (Macchi, et al 1995, Russell, et al 1995). 
Nevertheless many compounds are now in clinical trials and early results indicate 
objective improvements in many patients but, disappointingly, only minimal 
reductions in the size of the neoplastic clone. 
 
1.8   Summary 
 
The BCR-ABL paradigm in CML has proved a useful model for the study of other 
MPDs and aberrant tyrosine kinase signalling has been identified as a common factor 
driving myeloproliferation. Chromosomal translocations have been instrumental in 
the identification of numerous deregulated kinases, however it is apparent from the 
discovery of the V617F JAK2 mutation that LOH/UPD analysis is also a valuable 
tool for identifying chromosomal regions containing novel oncogenes.  
 
The efficacy of targeted therapy of deregulated tyrosine kinases makes it critically 
important to identify patients harbouring these molecular lesions. This is especially 
true for mutations involving PDGFRA or PDGFRB as these are imatinib sensitive.  
 
1.9   Statement of aims 
 
The general aim of this study is to further our knowledge about the molecular 
pathogenesis of the MPDs and to pursue the hypothesis that these diseases are caused 
primarily by deregulation of tyrosine kinases. My specific aims are: 
  
i) To characterise acquired chromosomal translocations seen in 
association with MPDs 
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ii) To develop screening procedures capable of detecting overexpression 
of specific tyrosine kinase genes and to investigate the molecular basis 
for any observed overexpression 
 
iii) To investigate MPDs for regions of acquired uniparental disomy as an 
indicator towards possible oncogenes or tumour suppressor genes. 
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2   METHODS 
2.1   Sample processing 
2.1.1  Preparation of blood and bone marrow samples 
 
Patient samples were either (i) referred from Consultant Haematologists throughout 
the UK for routine diagnostic analysis (usually the detection of specific acquired 
genetic abnormalities or determination of in vitro sensitivity to imatinib), or (ii) 
provided by collaborators from abroad. For research purposes, UK samples were 
anonymised following diagnostic analysis and reporting of results. Samples from 
abroad were provided in coded form. Use of these samples for research was approved 
by the Salisbury and South Wiltshire LREC (LREC reference 05Q2008/6; 
mechanisms and consequences of tyrosine kinase activation in chronic 
myeloproliferative disorders and related conditions; chief investigator Professor NCP 
Cross). 
 
Patient material usually ranged from 5-50ml of peripheral blood, or 1-10ml bone 
marrow aspirate. In some cases fixed cell suspensions for cytogenetics were also 
provided. Mononuclear cells (MNCs) and granulocytes were separated by 
centrifugation over LymphoprepTM (Axis Shield, Oslo, Norway). The cell counts of 
the peripheral blood and bone marrow samples were determined using a Neubauer 
type haemocytometer (BDH, Poole, UK). 2x107 cells were diluted in Hanks’ 
balanced salt solution (HBSS) to a maximum volume of 25ml and this suspension 
was then layered over an equal volume of lymphoprep in a 50ml propylene tube 
(Sarstedt, UK). Centrifugation at 1,800rpm for 30 minutes without a brake created an 
interface comprised of MNCs. The MNCs were transferred to a new tube using a 
sterile pasteur pipette (BDH, Poole, UK). The recovered cells were then washed 
twice in RPMI 1640 supplemented with 10% foetal calf serum (FCS), L-glutamine 
and penicillin-streptomycin before counting. To obtain the granulocytes, the 
remainder of the lymphoprep mixture from the original 50ml tube was discarded, 
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leaving the red cell pellet. To the pellet, ice-cold red cell lysis buffer (RCLB) was 
added to lyse the red cells. The tubes were then placed on ice for 10 minutes 
(intermittent mixing), and then spun for 5 minutes at 1600rpm. Before counting, the 
white cell pellet obtained was washed twice in supplemented RPMI (as before). For 
RNA extraction 1x107 cells were lysed in either 1ml guanidinium thiocyanate (GTC; 
the composition of all solutions are given in section 2.5) freshly mixed with β-
mercaptoethanol at a ratio of 7μl of β-mercaptoethanol (Sigma) per 1ml GTC lysate  
or 1.5x107 cells were lysed in 1.5ml TRIZOL® reagent (Invitrogen, UK)  and stored 
at -70°C. For DNA extraction, cell pellets of 1-2.5x107 cells were frozen at -70°C. 
Excess MNCs were cryopreserved in aliquots of between 2.5 and 6x107 cells. Each 
cell aliquot was spun down and resuspended in 500μl of supplemented RPMI (10% 
FCS, L-glutamine and penicillin-streptomycin). An equal volume of freezing mix 
(composition detailed in section 2.5) is added dropwise to the resuspended cells. 
Finally, 1ml of this mixture was again added dropwise to a cryopreservation tube and 
frozen overnight at -70°C before being transferred to the liquid nitrogen stores. 
 
2.1.2   Enriching cultures for T-cells 
 
To investigate if a mutation has been acquired, DNA prepared from a granulocytic 
fraction can be compared to DNA from a T-cell fraction. T-cells are lymphoid in 
origin and are not thought to be involved in myeloproliferative disease. 
Phytohaemagglutinin (PHA) is a lectin extracted from white kidney beans and is used 
to stimulate mitotic division of lymphocytes maintained in cell culture. 
 
Peripheral blood was first separated by centrifugation over LymphoprepTM (Axis 
Shield, Oslo, Norway) into mononuclear cells (MNCs) and granulocytes as detailed 
in section 2.1.1. The cell count of the mononuclear cells was determined using a 
Neubauer type haemocytometer (BDH, Poole, UK). Two cultures of 5x106 cells were 
then resuspended in 5ml of RPMI 1640 supplemented with 10% foetal calf serum 
(FCS), L-glutamine and penicillin-streptomycin in a Nunclon® polystyrene flat-sided 
cell culture tube (Scientific Laboratory Supplies Ltd, Nottingham). To one culture 
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500µl of myeloid cytokine mix was added (GM-mix, for components see 2.5) and to 
the other 50µl of PHA. After 3 days incubation at 37 ºC the cell suspension was spun 
at 1500rpm for 5 minutes. The cell pellet was then resuspended in 2ml of 
supplemented RPMI 1640 (as above) and the cells counted (as previously). Two 
aliquots of 4 x104 cells were used to produce two post-PHA statspins. The remaining 
cells were spun at 1500rpm for 5 minutes and DNA made from the cell pellet 
according to the protocol in section 2.1.5.2. The statspins were taken to our Pathology 
department where both the pre- and post-PHA slides were stained using May-
Grunwald Giemsa stain in an automated machine. (This used to involve fixing the 
cells in methanol for 15 minutes, staining in May-Grunwald for 5 minutes, then 
staining in Giemsa for 10 minutes. The slide was then rinsed first in buffer pH 6.8, 
followed by a 50/50 buffer/acetone rinse, dehydration in acetone twice and cleared 
using three xylene washes). This stain enables different types of cell (erythrocytes, 
lymphocytes, etc.) and components within the cell, to be distinguishable from one 
another by their colour and shape when viewed under a microscope. Lymphocytes 
look like circular cells with large round blue nuclei that take up ~60% of the 
cytoplasm with no vessicles. Pre-and post-PHA statspins were used to assess the level 
of T cell enrichment. DNA made from post-PHA incubation was used as a control for 
the investigation of acquired mutations in the myeloid cell fraction. 
 
2.1.3   RNA extraction 
 
RNA was extracted from GTC samples using the Qiagen RNeasy kit (Qiagen, West 
Sussex). 350µl of GTC was mixed with an equal volume of 70% ethanol, mixed well, 
and applied to the Qiagen column then left to stand for 30 minutes. The column was 
spun for 10 seconds at 10000rpm in a Genofuge 16M centrifuge. The column was 
then washed with the buffers provided in the kit: 650μl of RW1 for 10 seconds at 
10000rpm, and then twice with 500μl RPE, the first time for 10 seconds at 10000rpm 
and the second wash at 14000rpm for 2 minutes. Columns were then left in a class II 
tissue culture cabinet with the lids open for 10 minutes to allow evaporation of any 
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remaining ethanol. The bound RNA was then eluted from the column with 25μl 
distilled water. RNA was usually directly reverse transcribed into cDNA. 
 
RNA was extracted from samples in TRIZOL® using chloroform followed by the 
Qiagen RNeasy kit. Briefly, to 350µl TRIZOL® sample 350µl of chloroform (Sigma 
Aldrich) was added and vortexed for 15 seconds. The sample was then spun at 14,000 
rpm for 5 minutes at room temperature. Centrifugation separates the solution into an 
aqueous phase and an organic phase, the RNA remains in the aqueous phase. The 
aqueous phase was transferred to a clean eppendorf and washed again with 350µl 
chloroform as before. The final aqueous phase was carefully transferred to a clean 
eppendorf containing 350 µl of 70% ethanol, mixed well and then applied to an 
RNeasy column. The protocol continues as specified above once on the column. 
 
2.1.4   cDNA synthesis 
 
After elution from the column the RNA was placed on ice and then heated to 65°C 
for 5 minutes. The cDNA synthesis was performed at 37°C for 2 hours utilising 1-
5μg RNA in 25μl (GTC samples) or 50µl (TRIZOL® samples) water. The RNA was 
combined with 21μl (GTC samples) or 42µl (TRIZOL® samples) of cDNA mix, 
which resulted in final concentrations of 50mM Tris pH8.3, 75mM KCl, 3mM 
MgCl2, 1mM DTT, 1mM dATP, dCTP, dTTP, dGTP, as well as 100μg/μl of random 
pd(N)6 hexamers (Amersham Pharmacia, Amersham, UK), 150 units of Moloney 
Murine Leukaemia Virus (MMLV) reverse transcriptase (Invitrogen, UK) and 15 
units/ml of RNasin (Promega, UK). Synthesis was terminated by heating to 65°C for 
10 minutes. cDNA was stored at -20°C. 
 
2.1.5   DNA Extraction 
2.1.5.1  DNA Extraction from fixed cell suspension 
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Fixed cell suspensions were centrifuged at 4000 rpm for 10 minutes in a Thermo IEC, 
Micromax centrifuge. The cell pellet was then resuspended in 1ml of sterile PBS 
before spinning the pellet as before and then the washing was repeated three times. 
After the third centrifugation step the pellet was resuspended in 200µl of sterile PBS 
(independent of the number of cells) and the Qiagen DNeasy Blood & Tissue kit 
protocol: ‘Purification of total DNA from animal blood or cells’ was followed 
starting from step 1c. To the resuspended pellet in 200µl of PBS, 20µl proteinase K 
and 200µl of Buffer AL (without ethanol added) was added. This was mixed 
thoroughly by vortexing before incubation at 56ºC for 10 minutes. 200µl ethanol (96-
100%) was then added and the sample mixed thoroughly by vortexing, this mixture 
was then added to the DNeasy Mini spin column and centrifuged at 8000rpm for 1 
minute. The collection tube containing the flow through was then discarded and the 
spin column containing the bound DNA placed in a new collection tube. 500µl of 
Buffer AW1 was added to the spin column and centrifuged at 8000 rpm for 1 minute. 
Again the collection tube was discarded and the spin column placed in a new 
collection tube, before the addition of 500µl Buffer AW2 and centrifugation at 14,000 
rpm for 20 minutes to dry the DNeasy membrane. The collection tube was discarded 
again and the spin column placed in a sterile 1.5ml microcentrifuge tube. 50µl Buffer 
AE was added directly to the DNeasy membrane and incubated at room temperature 
for 1 minute before centrifugation for 1 minute at 8000rpm. To increase the DNA 
yield the elution step above was repeated. 
 
2.1.5.2  Extraction from cell pellets 
 
Cell pellets from peripheral blood and bone marrow samples were stored at -70ºC. 
Depending on the cell count the volume below was either doubled (>2x107 cells) or 
halved (<5x106 cells). A 1x107 pellet was thawed quickly by hand before the addition 
of 500µl resuspension buffer (RSB – see section 2.5 for components), 10µl 10% SDS 
and 3µl proteinase K (Qiagen, West Sussex). The cell pellet was then incubated at 
37ºC overnight. On the second day, the pellet was first checked for proper digestion, 
if not digested properly a further 2µl of proteinase K was added and left for as long as 
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necessary. When properly digested, 150µl of 6M NaCl  was added and the sample 
shaken vigorously by hand for 20 seconds. The digested cell pellet was then spun at 
room temperature in a Thermo IEC, Micromax centrifuge at 14,000rpm for 20 
minutes. The supernatant was then removed to a clean sterile bijoux tube and 1.5 
times the volume of the supernatant was added of 100% ethanol. The bijoux was 
inverted to obtain a ‘hairball’ of DNA, and hooked out using a sterile needle into a 
sterile eppendorf containing 70% ethanol. The size of the DNA ‘hairball’ was 
assessed and an appropriate volume (50-1000µl) of sterile Tris-EDTA buffer 
(Promega, UK) was aliquoted into a sterile 2ml screw cap tube, to this the washed 
‘hairball’ of DNA was added and left to resuspend properly in the TE buffer before 
use. 
 
2.1.5.3  DNA Extraction from Guanidinium Thiocyanate  
 
This protocol uses the Qiagen DNA Mini Kit ‘Blood and Body Fluid spin protocol’ 
(Qiagen, West Sussex). To an equal volume of GTC, 200µl of Buffer AL was added 
and mixed by pulse-vortexing for 15 seconds. The sample was then incubated at 56ºC 
for 10 minutes and briefly centrifuged in a Thermo IEC, Micromax centrifuge to 
remove the drops from the inside lid. The mixture was then carefully applied to the 
QIAamp spin column (in a 2ml collection tube) without wetting the rim and the lid 
closed before centrifugation at 8000rpm for 1 minute. The collection tube containing 
the filtrate was discarded and the spin column placed in a new collection tube. 500µl 
of Buffer AW1 was added to the spin column and spun at 8000rpm for 1 minute, the 
filtrate discarded and 500µl of Buffer AW2 added to the column and spun at 
14,000rpm for 3 minutes. To remove excess ethanol the filtrate was discarded and the 
column spun for a further minute at 14,000rpm. The spin column was then placed in a 
sterile microcentrifuge tube and 200µl Buffer AE added, incubated for 1 minute at 
room temperature and then spun at 8000rpm for 1 minute. 
 
33 
 2.1.5.4  DNA Extraction from Mouthbrush samples 
 
DNA obtained from mouthbrush samples was used as a control for the investigation 
of acquired mutations. In general, two mouthbrush specimens were received for each 
patient. To one mouthbrush tube 200µl of resuspension buffer (see section 2.5) was 
added. The lid of the other mouthbrush is snapped off and the mouthbrush added to 
the tube containing the first mouthbrush and 200µl of RSB. The tube was then 
vortexed for 30 seconds before using a sterile Pasteur pipette to remove the 200µl to a 
sterile 2ml tube. To this, 10µl of 10% SDS and 3µl of Proteinase K (Qiagen, West 
Sussex) were added, before incubation at 37°C overnight. The following day 150µl of 
6M NaCl was added to the sample, vortexed to mix and then spun at 4°C at 
14,000rpm for 20 minutes. The supernatant was then collected into a new sterile 
bijoux and 1.5 times the volume of 100% ethanol (Sigma Aldrich, UK) added. A 
hairball of DNA is rarely visible and so the sample was split between two sterile 
eppendorfs and frozen at -20°C for >2 hours. The sample was then spun again at 4°C 
at 14,000rpm for 20 minutes and each pellet resuspended in 25µl of 1 x Tris-EDTA 
buffer. These were left to resuspend for 1 hour at 37°C before combining in a labelled 
sterile 2ml screw cap tube.   
 
2.1.5.5  DNA extraction from haematological stained slides 
 
DNA extracted from haematological stained slides was used as a control for the 
investigation of acquired mutations and to investigate when the patient acquired the 
mutation. The dried material on the slide was first moistened with a drop of sterile 
PBS (Sigma Aldrich, UK). To a sterile eppendorf 200µl of sterile PBS was added. 
The cytological material was then scraped into this tube from the slide using a sterile 
scalpel blade. The resulting ‘sludge’ was mixed by pipetting up and down before 
adding 20µl of proteinase K (Qiagen, West Sussex) and 200µl of buffer AL and 
further mixing by pulse-vortexing for 15 seconds. The sample was then left overnight 
at 56°C to digest before continuing the following day with the Qiagen Blood and 
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Body Fluid Spin Protocol from step 5. As there is only a small amount of DNA to be 
obtained, a carrier DNA was always used. Qiagen recommend poly dA:dT carrier as 
this works best with the Qiagen columns, 10µg of polydA:dT (Sigma, Poole) was 
added after the overnight digestion and then continued as stated above. 
 
2.1.5.6  GenomiPhi V2 DNA Amplification Kit 
 
The Illustra™ GenomiPhi™ V2 DNA Amplification Kit is part of the Phi29 DNA 
polymerase family of products (GE Healthcare, UK) for mini-scale whole genome 
DNA amplification. Our samples are often precious and whole genome amplification 
offers the possibility to greatly expand the amount of usable material. A typical DNA 
yield of 47 µg DNA can be achieved in less than two hours from an input of 1-10 ng 
genomic DNA with an average product length of >10 kb.  The template must be at 
least 1ng/µl and requires an initial denaturation. On ice in thin-walled PCR tubes, 1µl 
(typically 10 ng) of template genomic DNA was combined with 9µl of sample buffer. 
The sample was then denatured at 95ºC for 3 minutes before cooling to 4ºC. Whilst 
the sample was denaturing a master mix combining 9µl of reaction buffer with 1µl of 
enzyme per sample was made up on ice. This was then added to the cooled denatured 
sample on ice prior to incubation at 30ºC for 90 minutes. The enzyme was then heat 
inactivated at 65ºC for 10 minutes before cooling to 4ºC. To test the quality of the 
genomic DNA, a control gene PCR was set up (See section 2.2.3). 
 
2.2   Amplification and analysis 
2.2.1   Reverse Transcriptase PCR (RT-PCR)  
 
RT-PCRs were undertaken in a volume of 10-25μl. All amplifications were 
performed for between 30-32 cycles in a MJ Research Inc. thermocycler (single 
platform or Tetrad) in thin-walled PCR tubes. PCR mixes contained 0.5μM primers, 
0.2μM each of dCTP, dATP, dGTP and dTTP, 1x Buffer (10mM Tris-Cl pH8.3, 
50mM KCl, 0.1% gelatin), 1.75mM MgCl2 and 0.05U Taq DNA polymerase 
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(Invitrogen). Typically multiplex PCRs were performed with 0.2μM each primer and 
MgCl2 at a concentration of 2.5mM. 
 
2.2.2   Microsatellite PCR 
 
DNA samples were amplified with a series of fluorescently labelled primer pairs 
flanking highly polymorphic microsatellite markers on specific chromosomes of 
interest. All amplifications were performed in a MJ Research Inc. thermocycler 
(Tetrad) in thin walled 0.2ml 96-well plate format. The PCRs were undertaken in 
10µl volumes with 25-50ng of genomic DNA. All primers were designed to anneal at 
55°C and standard cycling parameters were used with 32 amplification cycles. The 
products were analysed on an ABI 3100 genetic analyser using the program 
Genotyper 2.0. The peak heights were compared to controls and scored as 
heterozygous for each marker if two peaks of similar intensity were clearly visible, or 
if the ratio of the two peaks was similar to normal controls. If only one peak was 
visible a patient was scored as homozygous. To allow for the presence of background 
normal cells, acquired homozygosity was also scored if one peak was one third or 
smaller than the expected size compared to normal controls.  
 
2.2.3   Control gene PCR 
 
The control gene PCR is a multiplex PCR capable of amplifying 5 different sized 
products (100bp, 200bp, 300bp, 400bp, 500bp & 600bp). This PCR is used to check 
the quality of genomic DNA, especially after GenomiPhi amplification. PCRs were 
undertaken in a volume of 50μl. All amplifications were performed for 35 cycles in a 
MJ Research Inc. thermocycler (Single platform or Tetrad) in thin-walled PCR tubes. 
The primers were combined to make two mixes: Mix A (25μl of 100bp.F, 100bp.R, 
200bp.F, 200bp.R, 300bp.F, 300bp.R, 400bp.F & 400bp.R) and Mix B (50μl 600bp.F 
& 600bp.R) (van Dongen, et al 2003). PCR mixes contained 0.5μM Mix A primers, 
1μM Mix B primers, 0.5μM of dNTPs, 1x Buffer, 2mM MgCl2 and 1U AmpliTaq 
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Gold DNA polymerase (Applied Biosystems, UK). The PCR was cycled as follows: 
94°C for 7 minutes hotstart; 94°C for 1 minute; 60°C for 1 minute; 72°C for 1 minute 
for 35 cycles and an extension of 72°C for 7 minutes. The products were run on a 2% 
agarose gel to allow separation of the bands. 
 
2.2.4   Powerplex® 16 System 
 
The Powerplex® 16 kit (Promega, UK) allows the co-amplification and three colour 
detection of sixteen loci; fifteen short tandem repeat loci plus Amelogenin for sex 
determination. The system encompasses the following loci: Penta E & D, D18S51, 
D21S11, THO1, D3S1358, FGA, TPOX, D8S1179, vWA, CSF1PO, D16S539, 
D7S820, D13S317, D5S818 and Amelogenin as described in detail at 
http://docs.appliedbiosystems.com/search.taf. All sixteen loci are co-amplified in a 
single tube and analysed in a single injection on an Applied Biosystems 3100. This 
kit was designed to allow a high discriminatory power for cases of identity and 
paternity. I used this kit as a method of confirming that DNA samples at different 
time points were indeed from the same individual.  
 
The Powerplex® 16 PCR was performed using the following mix per sample; 1.25µl 
Gold ST*R 10x Buffer, 1.25µl 10x Primer pair mix, 0.4µl Amplitaq Gold® DNA 
polymerase (Applied Biosystems, UK), 8.3µl sterile water. To 11.2µl of master mix 
1.2µl of DNA at 0.9ng/µl was added. PCR was performed according to the following 
amplification protocol: 95°C for 11 minutes, 96°C for 1 minute, 94°C for 30 seconds, 
ramp 68 seconds to 60°C (hold for 30 seconds, ramp 50 seconds to 70°C (hold for 45 
seconds), cycle the last two steps 10 times, 90°C for 30 seconds, ramp 60 seconds to 
60°C (hold for 30 seconds), ramp 50 seconds to 70 °C (hold for 45 seconds), and 
cycle the last two steps 20 times, final extension at 60°C for 30 minutes and a 4°C 
soak. 
 
After PCR the products were prepared for the ABI 3100. An additional lane was 
incorporated into the plate to include the Powerplex® allelic ladder which contains 
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the most common alleles for each locus. A master mix was made up of 9µl highly 
deionised formamide and 0.5µl Promega ILS600 size standard. The master mix was 
aliquoted into a 96 well plate (specific to the ABI 3100 machine) and 0.5 µl of each 
sample was then added. The samples were run under specific ABI 3100 settings for 
45 minutes. Genotypes were then assigned by comparing the sizes obtained for the 
unknown samples with the sizes obtained for the alleles in the allelic ladder. Different 
samples can then be compared against each other based on allele specificity at each 
locus. 
 
2.2.5   Long-Range PCR 
 
Amplification of products larger than 2.5kb was performed using long-range PCR. 
The High Fidelity PCR Master kit (Roche Diagnostics, Lewes, UK) was used to 
amplify genomic DNA up to 10kb in length. All primers were designed with a 
melting temperature of 66°C with approximately 50% GC content. Typically 100ng 
of DNA was amplified in the PCR master kit with primers at a final concentration of 
0.5μM. PCR was performed according to the following amplification protocol, 
allowing increased elongation times for the length of product: 94°C for 20 seconds, 
66°C for 4 minutes, 68°C for 12 minutes, cycled 10 times, then 94°C for 20 seconds, 
66°C for 40 seconds and 68°C for 14 minutes, cycled 22 times, final extension at 
72°C for 10 minutes. 
 
2.2.6   Bubble-PCR 
 
Bubble PCR (Zhang, et al 1995) is a one sided PCR technique capable of amplifying 
an unknown sequence that lies adjacent to a known sequence. The bubble 
oligonucleotide is composed of two strands that are complementary at both ends but 
non-complementary in the middle. For all primer sequences see appendix I, section I. 
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Sample DNA was first digested using two separate restriction enzymes (HaeIII and 
RsaI) designed to blunt end cut around the known sequence and regularly throughout 
the rest of the genome.  The bubble oligonucleotide was then blunt end ligated to the 
digested genomic DNA. The ligated DNA was then denatured at 72°C for 5 minutes 
before removal of unligated bubble oligonucleotides using the QiaQuick PCR 
purification kit (Qiagen, West Sussex). A sample specific primer, in this case 
PDAI12-R3, was annealed to 1µl of the ligated DNA and extended using Amplitaq 
Gold (Applied Biosystems, UK) to the end of the bubble oligonucleotide (if there was 
no bubble sequence the rest of the genome to which bubbles had been ligated would 
also be amplified with the bubble primer). A single step Hotstart PCR using the same 
PDAI12-R3 primer and a forward NVAMP-1 primer, complementary to the bubble 
oligonucleotide, was then performed to amplify this strand. This results in a copy of 
the known, unknown (if present) and bubble sequence.  The copied, non-
complementary part of the bubble sequence is only present if the specific DNA was 
amplified. This strand was then subsequently amplified using Hotstart PCR with a 
bubble specific primer. A nested PCR was then performed to increase the specificity 
of the reaction using NVAMP-2 and PDAI12-R4. Rearranged bands were excised 
and gel purified with QiaQuick Gel Purification kit (Qiagen) and either sequenced 
directly or cloned and sequenced. 
 
2.2.7   Gel Electrophoresis 
 
The protocol was altered accordingly dependent on the size of the gel former and the 
percentage gel required. For a 1% agarose gel in a gel tank with a capacity of 100ml, 
1g agarose (Bioline, UK) was added to 100ml 1x Tris-Borate EDTA (TBE) buffer 
(Sigma Aldrich, UK). This was then heated using a microwave to melt the agarose, 
before cooling slightly and adding 0.2mg/ml ethidium bromide to visualise the DNA. 
The melted gel was then poured into a gel former with combs and allowed to set for 
at least 20 minutes. Ensuring the gel was set the combs and formers were then 
removed and the gel and electrodes covered by 1 x TBE buffer. To 5µl of sample or 
PCR product 1-2µl of Orange-G sucrose loading buffer was mixed before loading the 
39 
whole amount into a well of the gel. One lane was always loaded with the 1kb plus 
DNA ladder (Invitrogen, UK) to enable sizing of products. The samples were run for 
15 minutes or longer depending on the expected product size and percentage gel 
before visualising the bands under UV light. 
   
2.2.8   Denaturing high-performance liquid chromatography (dHPLC) 
 
Amplification of each exon of each gene to be analysed was performed from 
approximately 50-100ng of patient genomic DNA. A high fidelity DNA Taq 
polymerase was used to ensure that PCR did not introduce any sequence errors. PCRs 
were undertaken in a volume of 75μl. All amplifications were performed for 35 
cycles in a MJ Research Inc. thermocycler (Tetrad) in thin-walled 12-strip PCR tubes. 
PCR mixes contained 0.5μM primers, 0.2μM each of dCTP, dATP, dGTP and dTTP, 
1x GeneAmp  PCR Buffer II (100mM Tris-HCl, pH8.3, 500mM KCl), 1.5mM MgCl2 
and 0.05U AmpliTaq Gold DNA polymerase (Applied Biosystems, Warrington, UK). 
The primers were designed at least 50 base pairs away from each end of the exon, 
with a maximum size of 500 base pairs for each amplicon. In some cases exons very 
close together were co-amplified with the intervening intron present. The primer 
sequences and the PCR conditions are in the appendix I, sections II & III. 
 
Following amplification, the PCR product from each patient for each exon was mixed 
equally with amplified product from the same exon from human placental DNA 
(Sigma-Aldrich, Poole, UK). The mixed products were then denatured at 95°C for 5 
minutes and then slowly reannealed to each other by reducing the temperature by 
1.5°C every 22 seconds to room temperature allowing stable formation of 
heteroduplexes. Conditions for dHPLC analysis were calculated using the 
manufacturer’s software WAVEmaker v4.1. The computer predicts the 
temperature(s) over which the DNA fragment will be between 50 and 100% 
reannealed. It is estimated that more than 95% of heteroduplexes are detected. For 
longer products or those that have a high GC content, there may be several 
temperatures required to profile the whole fragment. The temperatures required for 
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heteroduplex analysis of each amplicon are given in the appendix, section III. Before 
each dHPLC run a plasmid DNA control supplied by the manufacturer (WAVE 
mutation standard; Transgenomics, Crewe, UK), with a known melting profile was 
tested to ensure consistency of results between runs. For each exon normal placental 
DNA PCR products were run as a normal control, again to ensure consistency of 
results for each exon between experiments. All results were analysed using the 
WAVEmaker v4.1 software. Any heteroduplexes observed, indicated by shifts in the 
traces or split peaks, were subsequently re-amplified and sequenced to look for the 
presence of mutations. 
 
2.2.9   Multiplex Ligation-dependent Probe Amplification (MLPA) 
 
MLPA is a method to establish the copy number of up to 45 nucleic acid sequences in 
one single reaction (Schouten, et al 2002). It uses genomic DNA to detect amongst 
other things copy number. Deletions and amplifications of a gene (or part of) will 
usually not be detected by sequence analysis of PCR amplified gene fragments as a 
normal copy is still present. Amplification products are separated by sequence type 
electrophoresis. As only one pair of PCR primers is used, MLPA reactions result in a 
very reproducible gel pattern with fragments ranging from 130 to 490 bp. 
Comparison of this gel pattern to that obtained with a control sample indicates which 
sequences show an aberrant copy number.  
 
1µl (50ng) of DNA was added to 4µl of Tris-EDTA buffer in a 0.2ml PCR tube and 
overlaid with oil (this prevents evaporation overnight) before running on a MJ 
thermocycler tetrad ‘Denature’ programme (98°C 5 minutes; 25°C Hold). Whilst the 
DNA is denaturing the following mix was made up. For each sample, to 1.5µl 
relevant probe mix, 1.5µl MLPA buffer was added and mixed gently. 3µl of this mix 
was added to the denatured sample and the probes bound overnight at 60°C (95°C 1 
minute; 60°C Hold). Following the overnight binding of the probes, on ice 3µl of 
ligase buffer A and B, 25µl water and 1 unit ligase were combined for each sample 
and mixed. The 60°C overnight run was stopped and the samples held at 54°C for at 
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least 2 minutes before adding 32µl of the above mix to each sample and running the 
‘Ligate’ programme (54°C 15 minutes; 98°C 5 minutes; 4°C Hold). Whilst the probes 
were ligating, the PCR mix was made up. For each sample 2µl SALSA buffer (MRC 
Holland, Amsterdam), 1µl SALSA primers, 1µl Enzyme buffer, 15.75µl water and 
0.25µl (2.5 units) SALSA polymerase were mixed carefully and then aliquoted into 
new 0.2ml PCR tubes on ice. To this PCR mix 5µl of the ligation mix was added and 
run on a ‘Cycles’ programme on a tetrad (95°C 30 seconds; 60°C 30 seconds; 72°C 1 
minute; cycle 33 times; 72°C 20 minutes; 4°C hold). After PCR the samples were 
analysed on an ABI 3100 by mixing 1µl PCR product to 9µl of formamide and 0.1µl 
of ROX500 size standard (Applied Biosystems, UK). 
 
Analysis of the samples was performed using Applied Biosystems Genescan™ 
software using a GS500 size standard. Following this Applied Biosystems 
Genotyper™ software was used. Based on the number of probes in the MLPA kit the 
software can be manipulated. The number of peaks was specified in addition to 
selecting ‘highest’ peaks, ensuring only the correct number of highest peaks, within 
the size range, are selected. All peaks were labelled with the peak height before 
exporting the data into a table. MLPA analysis sheets for each MLPA probe kit have 
been set up in Microsoft excel. The data from the genotyper table was imported into 
the excel sheet and samples were compared to controls. The peak height of each 
probe is compared against every other probe and against the control. This gives a data 
sheet of numbers where 1 is normal, a horizontal row of 0.5 indicates a deletion and 
horizontal row of 1.5 a duplication.  
 
2.2.10   Exo-SAP and sequencing 
 
Exonuclease I and shrimp alkaline phosphatase (SAP), two hydrolytic enzymes, are 
combined at a ratio of 1:4 and used for the preparation of PCR products for 
fluorescent-based sequencing. Exonuclease I (New England Biolabs, UK) degrades 
any residual single stranded primers and extraneous single-stranded DNA, whilst 
SAP (Roche Diagnostics Ltd, UK) hydrolyses the remaining dNTPs from the PCR 
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reaction. On ice, 1μl of exonuclease I/SAP mix was added to 2μl of PCR product and 
incubated at 37°C for 15 minutes, followed by 65°C for 15 minutes to denature the 
enzymes. The product from this reaction was diluted 10 fold and then used directly 
for sequencing. 
 
2.2.10.1  Sequencing of PCR products 
 
Exonuclease I/SAP purified PCR products were sequenced using a final 
concentration of 1μM of a single primer (either forward or reverse) and the BigDye 
terminator kit v3.1 or v1.1 (Applied Biosystems, Foster City CA, USA). Dependent 
on numbers of samples to be sequenced, reactions were either cleaned up using 
ABgene® Dye Terminator Removal Kit (Abgene Limited, UK) and dried using a MJ 
Research Inc. thermocycler (Tetrad), or by using the Montage SEQ96 Cleanup Kit 
(Millipore, Watford, UK). The first is a gel-based separation matrix and the latter a 
membrane-based size-exclusion filtration system and requires final resuspension in 
15μl of washing buffer. DNA from both methods was resuspended in 10µl deionised 
formamide and run on an ABI 3100 or ABI3130xl sequencer. 
 
2.2.10.2  Sequencing following cloning 
 
Plasmid DNA was sequenced using 1µl of mini-prepped DNA (approximately 100-
500ng) for each PCR (See section 2.2.11.3). Sequencing was performed using the 
forward and reverse M13 vector primers for each plasmid DNA (two reactions). The 
single stranded inserts were amplified with BigDye terminator kit v3.1 or v1.1 
(Applied Biosystems, Foster City CA, USA), cleaned up using the Montage SEQ96 
Cleanup Kit (Millipore, Watford, UK) and resuspended in 15μl wash buffer. To the 
resuspended DNA 10µl deionised formamide was added and the reactions run on an 
ABI 3100 or ABI3130xl sequencer. 
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2.2.11   Cloning PCR products 
 
PCR products were cloned by ligation into a plasmid vector using the TA or TOP10 
cloning kits according to the manufacturer’s instructions (Invitrogen, Paisley, UK). 
 
2.2.11.1  Ligations 
 
On ice, 1-2µl PCR product (depending on the intensity of the product observed on an 
agarose gel), 1µl salt solution (1.2M NaCl, 0.06M MgCl2), 1µl pCR®4 vector 
(10ng/µl), and sterile water to a final volume of 5µl were combined. The reaction was 
then mixed gently, and incubated at room temperature for 5 minutes. This reaction 
relies on Taq polymerase nontemplate-dependent terminal transferase activity which 
adds a single deoxyadenosine to the 3’end of PCR products. The vector supplied in 
the kit is linearised and has complementary single, overhanging 3’ deoxythymidine 
residues allowing PCR inserts to ligate efficiently.  The ligation itself relies on the 
energy conserved by formation of a covalent bond between the 3’phosphate of the 
cleaved strand and the tyrosyl residue of the enzyme topoisomerase I which binds to 
and cleaves the phosphodiester backbone in certain regions of DNA. 
 
2.2.11.2  Transformations 
 
Chemically competent TOP10 cells provided with the Invitrogen kit were slowly 
thawed on ice. 2µl of the ligation reaction was added and stirred gently with a pipette 
tip to mix. The cells were then incubated on ice for 30 minutes. The remaining 
ligations were stored at -70°C. After 20 - 30 minutes, the cells were heat-shocked at 
42°C for 30 seconds and immediately placed on ice for at least 2 minutes. 250µl of 
SOC medium (2% Tryptone, 0.5% yeast extract, 10mM NaCl, 2.5mM KCl, 10mM 
MgCl2, 10mM MgSO4, 20mM glucose) was then added to each vial, and the cells 
were then shaken horizontally at 37°C for 1 hour. LB/agar plates with the appropriate 
antibiotic added were spread with 25µl of 50mg/ml X-Gal (Promega, Madison, USA) 
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and allowed to dry. Varying amounts of each transformation mix were spread on 
individual plates. Once the liquid was absorbed the plates were inverted and placed in 
a 37°C incubator overnight. After incubation the plates were placed at 4°C to allow 
for colour development. White colonies were picked for rapid screening of inserts by 
PCR using the following miniprep protocol. 
 
2.2.11.3  Qiagen™ Miniprep kit 
 
Picked colonies were grown up overnight in single 10ml culture tubes with 2ml L-
Broth (LB) and the appropriate antibiotic. The following day cells from 1.5ml culture 
medium were extracted using the Qiagen™Miniprep kit (Qiagen Ltd, West Sussex) 
and the remaining 500µl is stored in LB/Glycerol (3:1) solution at -70°C. The 1.5ml 
of culture medium was spun down in an eppendorf at 10,000rpm for 10 minutes in a 
Thermo IEC, microcentrifuge. The supernatant was then carefully removed leaving 
only the pellet which was resuspended in buffer P1, ensuring no clumps remained 
before adding the P2 lysis buffer. The tubes were then inverted gently 4-6 times to 
ensure complete lysis before addition of the neutralisation buffer P3. On addition of 
buffer P3 each tube was immediately inverted 4-6 times; the solution became cloudy 
and white as the denatured proteins, cellular debris and chromosomal DNA 
precipitate out of solution. The tubes were then spun at 14,000rpm for 10 minutes, in 
a Thermo IEC microcentrifuge, and the supernatant carefully transferred to an 
appropriately labelled QIAprep spin column. The column was then spun at 
14,000rpm for 1 minute allowing the DNA to bind to the column, and then washed 
twice for 1 minute 14,000rpm using firstly 500μl wash PB, followed by 750μl wash 
PE. The column was then spun for an additional 5 minutes at 14,000rpm to remove 
all residual PE buffer. To collect the DNA, 25µl of distilled water was added to the 
centre of the column, now in a new sterile labelled eppendorf, and spun for a further 1 
minute at 14,000rpm.  
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2.2.11.4  Digests and PCR 
 
5μl of each mini-prepped plasmid DNA was digested with 10 units EcoRI, (EcoRI 
sites flank the cloning site in pCR2.1 or pCR 4.0 vector), 2μl 5x EcoRI buffer and the 
appropriate amount of sterile water up to 10μl. Digests were performed at 37°C for 2-
4 hours. The digested clones were run on a 1% agarose gel to determine the insert 
size and cloning efficiency. The plasmid DNA was then sequenced according to the 
protocol in section 2.2.10.2. 
 
2.2.12   5’ Rapid amplification of cDNA ends (5’RACE) 
 
Fusion genes were identified using the 5’RACE GeneRacer™Kit (Invitrogen, 
Paisley, UK). In brief, after RNA extraction using the Qiagen RNeasy kit (Qiagen 
Ltd, West Sussex, UK), approximately 5μg of total RNA was dephosphorylated, 
decapped and ligated to the GeneRacer™ RNA oligonucleotide (Figure 2.1). The 
ligated RNA was reverse transcribed using Superscript II™ reverse transcriptase 
(Invitrogen, Paisley, UK) and random primers. The initial 5’RACE PCR was 
performed using the 5’GeneRacer™ primer and a reverse primer from the relevant 
exon of the tyrosine kinase gene in question, using the High Fidelity PCR Master kit 
(Roche Diagnostics, Lewes, UK). The second step, nested PCR was performed using 
the 5’GeneRacer™ nested primer and a nested primer designed in the tyrosine kinase 
gene. After nested PCR, if a product was visible by gel electrophoresis, the product 
was cloned using the TOPO TA cloning kit for Sequencing (Invitrogen, Paisley, UK), 
and sequenced. 
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Figure 2. 1:  A schematic representation of the process of 5’ Rapid Amplification of cDNA Ends 
(5’RACE). (1) Calf intestinal phosphatase (CIP) is first used for dephosphorylation 
of truncated or non-mRNA.  Full-length mRNA is protected from dephosphorylation 
due to its 7-methylguanosine cap structure. The truncated and non-mRNAs are thus 
eliminated; (2) Tobacco alkaline phosphatase (TAP) is then used to remove the cap 
structure of the full-length mRNA; (3) RNA ligase is then employed to ligate an 
RNA oligonucleotide of known sequence to the 5’ end of the full-length mRNA. 
Random primers are then used to reverse transcribe the ligated full-length RNA; (4) 
5’RACE PCR is then performed using an oligonucleotide complementary to the 
ligated sequence combined with a gene-specific primer; (5) The product obtained 
can then be cloned and sequenced.  
 
47 
2.2.13   Pyrosequencing 
 
Pyrosequencing™ is a technique used for accurate and quantitative analysis of DNA 
sequences that is based on the detection of released pyrophosphate (PPi) during DNA 
synthesis. A cascade of enzymatic reactions occurs resulting in the production of 
visible light that is proportional to the number of nucleotides incorporated. The 
enzymatic cascade begins with a nucleic acid polymerisation reaction as a result of 
nucleotide incorporation by polymerase, inorganic PPi is released. The released PPi is 
subsequently converted to ATP by ATP sulphurylase. ATP is the energy required by 
luciferase to oxidize luciferin and generate light. The amount of light is then detected 
by a photodiode, photomultiplier tube, or a charge-coupled device camera (CCD) 
camera (Figure 2.2).  
 
Figure 2. 2: Schematic representation of the progress of the enzyme reaction in pyrosequencing 
(Ronaghi 2001).  A primed DNA template and four enzymes are placed in a well of a 
microtiter plate. The four different nucleotides are added stepwise to the reaction and 
incorporation is followed using the enzyme ATP sulphurylase and luciferase. The 
nucleotides are continuously degraded by nucleotide-degrading enzyme apyrase, 
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allowing addition of the subsequent nucleotide. dXMP indicates one of the four 
nucleotides. 
 
Pyrosequencing was performed as follows: the amplicon in question was first 
generated  in a 50 µL reaction volume containing 10 pmol each of the forward and 
reverse PCR primers, 0.2 mM deoxynucleoside triphosphates (Amersham), 2.5 mM 
MgCl2, 1x Buffer II (Applied Biosystems), 1 U of AmpliTaq Gold (Applied 
Biosystems), and 1 µL ( 20 ng) of DNA. PCR was performed in a Tetrad with the 
following conditions; 94 °C for 7 min, followed by 45 cycles of 94 °C for 30 s, 58 °C 
for 30 s, and 72 °C for 30 s; 1 cycle at 72 °C for 7 min; and a final hold at 15 °C. All 
samples were analysed in duplicate. Pyrosequencing reactions were performed 
according to the manufacturer’s instructions, using the Gold PSQ 96 SNP Reagent Kit 
(Biotage AB). The sequence was read and peaks heights quantified by the AQ 
Software.  
 
2.3   Fluorescence in situ hybridisation (FISH) 
2.3.1   Maxiprep DNA isolation from BAC clones 
 
BACs were initially ordered from the Sanger Institute, Hinxton. The clones arrived as 
LB/Agar stabs supplemented with the appropriate antibiotic. BACs were also 
obtained from the 37K clone set which was subsequently acquired in house. BACs 
were colony purified before use by streaking out using a sterile loop onto a LB/Agar 
plate containing the relevant antibiotic. After overnight incubation, a single colony 
was picked and used to inoculate 5mls L-Broth, again containing the appropriate 
antibiotic. The cultures were incubated overnight in a shaking incubator (225rpm) at 
37°C.  
 
The starter culture was then used to inoculate 30ml of L-Broth medium with 
antibiotic in a 50ml fluted flask (Triple Red, Buckinghamshire, UK) and incubated as 
before. To harvest the bacteria, the overnight culture was transferred to a 50ml falcon 
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tube and spun at 3,000rpm in a RC5C Sorvall centrifuge. After centrifugation the 
supernatant was completely removed and the cell pellet was resuspended in 1.8ml of 
Solution I (see section 2.5 for all solution details). The resuspended pellet was then 
transferred to a plastic centrifuge tube. The cell suspension was then lysed by adding 
1.8ml of freshly prepared Solution II and left to stand for 5 minutes at room 
temperature. Bacterial proteins and DNA were then precipitated out by adding 1.8ml 
of Solution III and leaving the tubes on ice for 5 minutes. This was then centrifuged 
at 10,000rpm for 10 minutes at 4°C in the RC5C Sorvall centrifuge (SS-34 rotor). 
Leaving the cell debris, the supernatant was then carefully removed by pipette, and 
aliquoted into a number of sterile eppendorf tubes containing 700µl chloroform 
(Sigma-Aldrich, Haverhill). After shaking to mix the chloroform-vector DNA 
mixture, they were spun at 13,000rpm for 5 minutes in a Thermo IEC, Micromax 
centrifuge. The supernatant was then removed and transferred to pre-prepared 
eppendorfs containing 800µl of ice-cold isopropanol (Sigma-Aldrich, Haverhill), 
inverted to mix and then placed at -20°C overnight to maximise DNA precipitation.  
 
The following day, the tubes were removed from the freezer and centrifuged at 
14,000rpm for 15 minutes in a Thermo IEC, Micromax centrifuge. The supernatant 
was then poured off and 500µl of 70% ethanol (BDH, Dorset) was added, the pellet 
was washed by inversion before centrifuging again at 14,000rpm for 5 minutes. The 
supernatant was then carefully removed by pipette, and the pellet allowed to air dry 
until it become translucent. Each pellet was then resuspended in 40µl of sterile water. 
 
2.3.2   Labelling  
 
1μg BAC DNA was labelled by nick-translation in the presence of 10U DNA 
polymerase I (Invitrogen, Paisley, UK) and 0.05U DNase 1 (Invitrogen, Paisley, UK). 
The labelling reaction was performed at 16°C for 1.75 hours using a standard 
labelling mix (see section 2.5). The reaction was stopped by denaturing the enzymes 
at 68°C for 10 minutes. 10μl of the product was then run on a 1% agarose gel to 
check the efficiency of the labelling reaction.  
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 2.3.3   Slide making 
 
Fixed cell material (approximately 5 x 106 cells) was spun down and washed with 3:1 
methanol:acetic acid fixative and finally resuspended in 1-2mls of fixative. In a 
humidity-controlled room, one drop of suspension was dropped onto a microscope 
slide from a short height and the slide was allowed to dry. The slides were checked 
for spreading of nuclei, under phase contrast light microscopy. The slides were left at 
room temperature overnight, or exposed to UV for 10 seconds to age them before use. 
 
2.3.4   Probe preparation  
 
Labelled DNA was co-precipitated using an equal volume of 1.05mg/ml COT-1 DNA 
(EurX, Poland), one tenth the volume of 3M sodium acetate pH5.2 and twice the total 
volume of 100% ethanol and then frozen for 1 hour at -20°C. The labelled DNA was 
then spun down at 14,000rpm for 20 minutes, washed several times in 70% ethanol, 
and resuspended in 12µl hybridisation buffer (see section 2.5).  
 
2.3.5   Slide preparation 
 
Slides were incubated for 2 hours at 37°C in 2 x SSC pH 7.0 (for all solution details 
see section 2.5), then treated with 100ng/ml pepsin in 0.01M HCl for 10 minutes. 
Following the pepsin digestion the slides were washed three times with phosphate 
buffered saline (PBS), before being fixed in a 1% paraformaldehyde PBS for 10 
minutes. The PBS wash was repeated (as described above), and then the slides were 
dehydrated through an ethanol series of 2 minutes in 70% ethanol, 2 minutes 90% 
ethanol and 2 minutes 100% ethanol. The slides were then dried. The previously 
prepared probe was then aliquoted onto a cover slip, placed on the dried slide and 
sealed with vulcanising rubber solution (Weldtite, Barton-on-Humber). When the 
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rubber solution had dried the slides were denatured on a 75°C hotplate for 5 minutes, 
and hybridised in a moist chamber for 48 hours at 37°C.  
 
2.3.6   Post hybridisation and visualisation 
 
Following hybridisation the cover slips were removed and the slides washed briefly 
in 2 x SSC. Washes were then performed at 42°C: 3 x 5 minutes washes in 50% 
formamide/2 x SSC pH7.0, and 3 x 5 minutes washes in 2 x SSC. Post-hybridisation 
biotin and digoxygenin signals were detected using the following combined antibody 
layers: 1) 1/100 sheep anti-digoxigenin (1mg/ml, Roche Diagnostics, Germany), 2) 
1/400 texas red avidin (2mg/ml, Vector Laboratories Inc, California, USA) and 1/200 
rabbit anti-sheep FITC (1mg/ml, Vector Laboratories Inc, California, USA), 3) 1/100 
goat anti-avidin biotinylated (1mg/ml, Vector Laboratories Inc, California, USA), and 
swine anti-rabbit FITC (1.1mg/ml, Dako, Denmark) and 4) 1/400 texas red avidin 
(Lichter and Cremer 1992). All dilutions were made with SSCTB (see section 2.5 for 
solution composition). The slides were incubated for 30 minutes to 1 hour at room 
temperature in a dark moist chamber, and then washed 3 x 5 minutes in SSCT (4 x 
SSC, 0.1% Triton-X, pH7.0) between each incubation. After application of all 
antibody layers the slides were rinsed with PBS and allowed to dry. The slides were 
then mounted, under a coverslip, with Vectorshield (Vector Laboratories, California, 
USA) containing 1µg/ml 4,6-diamidino-2-phenylindole (DAPI). Slides were 
examined using an Axioskop microscope (Zeiss, Germany). The images were 
captured using a CCD camera and image analysis software (MacProbe v4.3, Applied 
Imaging International, UK).  
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2.4   Tissue culture  
2.4.1   Imatinib sensitivity assay 
2.4.1.1  Thawing of primary haematopoietic cells 
 
Peripheral blood mononuclear cells (MNCs) were separated using lymphoprep (Axis-
Shield, Oslo, Norway) and grown either directly or following cryopreservation in 
methylcellulose supplemented with the recombinant cytokines; SCF (20ng/ml), GM-
CSF (1ng/ml) and IL-3 (5ng/ml)+ (Stem Cell Technologies Ltd., Vancouver, British 
Columbia, Canada).  Frozen vials typically contained between 2x107 and 6x107 
cryopreserved cells. The cryopreserved MNCs were thawed quickly by incubating at 
37°C, before transferring the cells to a 50ml tube. Dropwise, 20ml of pre-warmed 
thawing solution (section 2.5) was then added. The tube was topped up to 50ml with 
RPMI, supplemented with 10% foetal calf serum (FCS), L-glutamine and penicillin-
streptomycin (as before), and then spun at 1,500rpm for 5 minutes. After 
centrifugation, the supernatant was discarded and 200,000U of DNase I was added 
directly to the cell pellet. The tube was gently shaken to disrupt the pellet and to 
prevent the formation of clumps. To the pellet, 10ml supplemented RPMI was then 
added and the cells centrifuged, as before. The DNaseI and RPMI wash was then 
repeated before finally discarding the supernatant and resuspending the cells in 10ml 
RPMI. To the resuspended cells, 200,000U DNaseI was added and the cells were left 
for one hour at room temperature. The cells were finally spun and resuspended in 
RPMI for counting and viability. The cells were counted using an equal volume of 
trypan blue (Sigma), to differentiate between live and dead cells.  
 
2.4.1.2  Colony assay 
 
A cell count of between 3 x 105 and 2 x 106 can be used to set up the in vitro assay 
that measures the effect of imatinib on colony growth (Crescenzi, et al 2007). After 
counting, the cells were spun down and resuspended in 1ml of RPMI supplemented 
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with 10% foetal calf serum (FCS), L-glutamine and penicillin-streptomycin (as 
before). The assay was set up using zero, 1μM or 5μM imatinib mesylate (Novartis, 
Basel, Switzerland), in triplicate. To each 3ml aliquot of methylcellulose (one for 
each concentration of imatinib) an equal volume of cell suspension was added to the 
top. The amount of imatinib required for each concentration was then calculated from 
a 1mM stock solution and also added to the top of the methylcellulose aliquot. After 
the addition of the cells and the imatinib, the methylcellulose was mixed thoroughly 
using a 1ml syringe.  
 
From each aliquot of methylcellulose containing equal cell numbers, 3 x 1ml aliquots 
were dispensed into 3 separate 40 x 12mm tissue culture dishes (Fisher Scientific, 
Leicestershire). All the 40 x 12mm tissue culture dishes were then separated into 2 
large tissue culture trays (144 x 21mm), ensuring at least one of each concentration 
were in separate trays in case of infection. A small 40 x 12mm dish was placed in the 
middle of the large tray with sterile water in it to prevent the methylcellulose drying 
out. The dishes were then left in a 37ºC incubator to grow for 7 days before the 
number of colonies was counted. The assay was counted again on day 14. An index 
of response was then calculated, as the mean response at 1 and 5µM at days 7 and 14 
compared to the untreated control. This allows quantitative comparison of the 
response of different patients. For comparison, normal controls had been previously 
tested by Dr Andy Chase and the average response index was found to be 0.4. A 
number of CML patients, acting as positive controls were also tested by Dr Chase, 
these showed a much greater inhibition with a response index of 0.1. On the basis of 
these controls an index of below 0.2 was used to define a positive response as 
previously described (Crescenzi, et al 2007).  
 
2.4.2   Midi prep & nucleotide removal kit 
2.4.2.1  Midi-prep 
 
The PureYield™ Plasmid Midiprep System (Promega, UK) is used for the isolation 
of large quantities of high-quality plasmid DNA that can be specifically used in 
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eukaryotic transfection and in vitro expression experiments. It contains an endotoxin 
removal wash that removes substantial amounts of protein, RNA and endotoxin 
contaminants from purified plasmid DNA.  
 
A subculture was grown up overnight in 5ml L-Broth plus the relevant antibiotic 
before spiking a larger 25 or 45ml volume of L-broth plus antibiotic and leaving this 
to grow again overnight. In brief, preparation and lysis of the bacterial cell cultures 
was performed by pelleting the cells at 10,000 x g for 10 minutes in a Sorvall 
centrifuge. The supernatant was then discarded and the cells resuspended in 3ml Cell 
Resuspension Solution. To this 3ml of Cell Lysis Solution is added and mixed by 
inversion 3-5 times before leaving at room temperature for 3 minutes to incubate. 
Following this 5ml Neutralisation Solution was added to the lysed cells, mixed by 
inversion 3-5 times before allowing the lysate to settle in an upright position for 2-3 
minutes. The DNA was then purified. The lysate was poured into a PureYield™ 
clearing column in a clean 50ml falcon (Sarstedt, UK) incubated for 2 minutes to 
allow the cellular debris to rise to the surface before centrifuging at 3,000 x g for 5 
minutes (repeating if the not all the lysate has passed through the column). The 
filtered lysate was then poured into a PureYield™ binding column in a clean 50ml 
falcon and centrifuged for 3 minutes at 3,000 x g. The column-bound DNA was first 
washed with 5ml endotoxin removal wash solution and centrifuged as above, the 
supernatant was discarded and the column washed with 20ml column wash solution 
for 5 minutes at 3,000 x g. To ensure complete removal of ethanol the supernatant 
was discarded and the column spun for an additional 10 minutes at 3,000 x g. Elution 
of the DNA was performed by placing the binding column in a new falcon and 
adding 300µl nuclease-free water, centrifuging at 1,500 x g for 5 minutes and then 
transferring the filtrate to a 1.5ml tube. 
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2.4.2.2  QIAquick nucleotide removal kit 
 
To ensure the midi-prepped DNA is of high enough quality for transfection protocols 
it is further cleaned up using a QIAquick nucleotide removal kit (Qiagen, West 
Sussex) according to the manufacturer’s instructions for use with a microcentrifuge. 
 
2.4.2.3  Transfection by electroporation 
 
Transfection is a method of introducing nucleic acids into eukaryotic cells by non-
viral means. There are various transfection protocols published, all of which are 
based on neutralising or obviating the issue of introducing negatively charged 
molecules such as DNA into cells with negatively charged membranes. Chemicals 
such as calcium phosphate or cationic lipid-based reagents are used to coat the DNA 
resulting in neutralising or creating an overall positive charge improving the ability of 
the DNA to cross the membrane. Physical methods, such as electroporation, are based 
on simply punching a hole in the membrane allowing the DNA to be introduced 
directly to the cytoplasm. Electroporation was first used for gene transfer studies into 
mouse cells (Wong and Neumann 1982). It works by creating a transient pore that 
allows the DNA to be introduced into the cell by disturbing the cell membrane using 
an electrical pulse (Shigekawa and Dower 1988). Electroporation often requires more 
cells than chemical methods due to substantial cell death, thus initial optimisation is 
critical to ensure good transfection efficiency against cell viability. 
 
The murine haemopoietic cell line Ba/F3 was used to transfect in the newly identified 
fusions involving the tyrosine kinase gene PDGFRβ. The Ba/F3 mouse pro B cells 
are dependent on IL-3 for growth and have an extremely low rate of spontaneous 
reversion to factor independence (Palacios and Steinmetz 1985). In addition, Ba/F3 
cells express no detectable endogenous PDGFRβ (Drummond-Barbosa, et al 1995, 
Petti, et al 1997).  
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2.4.2.4  Electroporation 
 
The day prior to electroporation, the Ba/F3 cells were split. The following day the 
cells were washed twice with sterile PBS and then counted using a Neubauer type 
haemocytometer (BDH, Poole, UK). The cells were then resuspended  in pre-warmed 
RPMI at a concentration of 1 x 107 cell per ml. 400µl of these cells (4 x 106) was then 
put into a 0.4cm Gene-pulser Cuvette (BioRad, Hertfordshire) and 16µg of the DNA 
to be integrated with the cells added. A mock transfection of the cells with no DNA 
and a vector only transfection (pcDNA 3.1) were carried out in the same way. The 
Gene Pulser was set to 140kV (Programme 10, mammalian, HL60) and the cuvette 
inserted into the electroporating pod (only one possible orientation). The cells are 
pulsed once by pressing the red button on the front of the Gene-Pulser machine 
before placing the cells in the cuvette on ice for 10 minutes. After this time the cells 
were transferred into a sterile 25cm2 flask (Fisher Scientific, Leicestershire) 
containing 10mls of RPMI 1640 medium with 10% FCS and 10% WEHI (supernatant 
for IL-3) and left for 2-3 days to allow the cells to recover. 
 
2.4.2.5  Antibiotic selection 
 
After the recovery period the cells were plated out at two different concentrations (2 x 
103 and 5 x 103 cells) in 96 well plates (VWR International, Leicestershire) with 
selective media, in this case Geneticin® (Invitrogen, Paisley) at a concentration of 
1mg/ml. The cells were counted as described previously and plated out using a 
multichannel pipette with 100µl per well (80 wells total). The two outer rows of each 
96 well plate were filled with 100µl sterile water to prevent evaporation. The plates 
were left at least two weeks to allow selection. Wells with Geneticin® resistant clones 
were observed under phase microscopy as healthy clumps of cells. The clone 
positions were noted and then picked into 24 well plates (Fisher Scientific, 
Leicestershire) with 2 ml of RPMI 1640 medium containing 10% FCS and 10% 
WEHI supplemented with 1mg/ml Geneticin®. 96 well plates with control cells were 
expected to be completely dead, whereas 96 well plates with pcDNA 3.1 vector 
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control (containing Geneticin® resistance) were expected to show a significant 
proportion of resistant clones. 
 
2.4.2.6  IL-3 independent growth 
 
To confirm if the gene of interest confers IL-3 independent growth, the clones were 
replated over time into media with 1mg/ml Geneticin® without IL-3. The cells were 
subjected to a withdrawal of IL-3 over a two week period, beginning with a 50% 
reduction in IL-3, followed by 25%, 10%, 5%, 2% and finally no IL-3. Clones can 
only survive without IL-3 if the gene of interest has conferred this ability upon the 
cells.  
 
 2.5   Solutions 
 
Freezing mix 4ml RPMI supplemented with 10% foetal calf 
serum, L-glutamine and penicillin-streptomycin, 
4ml DMSO and 12ml foetal calf serum. 
 
Guanidinium Thiocyanate (GTC) 4M Guanidinium thiocyanate, 5mM EDTA, 
25mM  citrate pH7.0, 0.5% sarcosyl. 7μl β-
mercaptoethanol per 1ml of GTC was added 
fresh prior to use. 
 
GM-mix Granulocyte Macrophage-Colony Stimulating 
factor (GM-CSF) 1ng/ml final concentration, 
Stem Cell Factor (SCF) 20ng/ml final 
concentration, Granulocyte- Colony Stimulating 
factor (G-CSF) 100ng/ml final concentration & 
IL-3 5ng/ml final concentration (All from First 
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Link Ltd, Birmingham, UK) in a volume of 
50ml dH2O. 
 
Hybridisation buffer (HB)  50% formamide, 2 x SSC, 20% dextran 
sulphate, at pH 7.0. 
 
L-Broth 25g L-Broth per litre dH2O. Autoclave before 
use. 
 
LB/Agar 3g Agar per 200ml L-Broth. Autoclave before 
use. 
 
6M NaCl    350.64g NaCl dissolved in 1L dH2O. 
 
1% Parafomaldehyde PBS PBS was prepared according to manufacturers 
instructions. One tablet was dissolved in 100ml 
of dH2O, plus 1g Paraformaldehyde. 
Concentrated sodium hydroxide is used to aid 
dissolving.  
 
Phosphate Buffered Saline (PBS)  PBS was prepared according to manufacturers 
instructions (Oxoid, Basingstoke, UK). One 
tablet was dissolved in 100ml of dH2O. 
 
1 x PBS/Tween PBS was prepared as above with the addition of 
4ml 25% Tween. 
 
Proteinase K    50mg/ml in dH2O. 
 
Red Cell Lysis Buffer (RCLB)  155mM KHCO3, 0.1mM EDTA, pH7.4 at 4°C. 
 
59 
Resuspension Buffer (RSB)  0.075M NaCl, 0.024M EDTA, pH8.0. 
 
10% SDS    10g SDS dissolved in 100ml dH2O. 
 
Solution I 5mM glucose, 25mM Tris-Cl pH8.0, 10mM 
EDTA pH8.0 
 
Solution II    0.2M NaOH, 1% SDS 
 
Solution III    5M potassium acetate, 3M glacial acetic acid 
 
20 x SSC 175.3g NaCl and 88.2g sodium citrate were 
dissolved in 800mls water. The pH was adjusted 
to 7.0 using concentrated HCl and the volume 
brought up to 1 litre. 
 
SSCT     4 x SSC, 0.1% Triton-X, pH 7.0. 
 
SSCTB     2 x SSC, 0.1% Triton-X, 0.03g/ml BSA. 
 
Standard labelling mix 0.5M Tris-Cl pH7.8, 0.05M MgCl2, 0.1M β-
mercaptoethanol, 20µM dATP, 20µM dCTP, 
20µM dGTP, 20µM dTTP, 0.5µg BSA and 
25µg of dUTP conjugated with biotin or 
digoxygenin.  
 
Thawing Solution 20mls HBSS (Invitrogen, Paisley, UK), 
100,000U DNase I (Invitrogen, Paisley, UK) 
and 200U sodium heparin (CP Pharmaceuticals, 
Wrexham, UK). 
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2.6   List of probes used for FISH 
 
RP11-100O5   centromeric of PDGFRB, 5q33 
RP11-2303L4   telomeric of PDGFRB, 5q33 
 
RP11-467K9   centromeric of GOLGA4, 3p22 
RP11-158E7   telomeric of GOLGA4, 3p22 
 
RP11-434C1   telomeric of ETV6, 12p13 
RP11-525I3   centromeric of ETV6, 12p13. 
 
 
61 
3  IDENTIFICATION OF NOVEL FUSION 
GENES ASSOCIATED WITH VISIBLE 
CHROMOSOME ABNORMALITIES 
3.1  Introduction 
 
As described in the introduction, activation of tyrosine kinases is a recurrent theme in 
the pathogenesis of myeloproliferative disorders (MPDs). However, the molecular 
basis of disease in many individuals remains obscure. In this chapter I describe the 
identification of new tyrosine kinase fusion genes that arise as a consequence of 
chromosomal translocations. 
 
3.2  A novel PDGFRB fusion gene 
3.2.1  Patient details 
 
A patient (from here on referred to as Patient 1) was referred to us with a diagnosis of 
atypical CML, and pronounced peripheral blood eosinophilia (27%). The bone 
marrow aspirate showed markedly increased cellularity with granulocytic hyperplasia 
(90%, with left shift, but no excess of blasts) with marked increase in eosinophils and 
their precursors. Erythropoiesis was reduced but normoblastic. He was also described 
as having persistent breathlessness. Cytogenetics was performed after the initial 
referral, and a t(3;5)(p21;q33) was identified. The clinical phenotype of the patient 
combined with the karyotype suggested that the PDGFRB gene at 5q33 might be 
rearranged. Fluorescence in situ hybridisation (FISH) was first employed to 
determine if this was indeed the case. 
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3.2.2   Two-colour fluorescence in situ hybridisation (FISH) 
 
FISH is commonly used to detect translocation breakpoints (Baxter, et al 2003). The 
PDGFRB probes were labelled with differently coloured fluorochromes, and signals 
appear as two red/green (yellow) adjacent signals in the nucleus when hybridised to 
normal interphase cells (Figure 3.1). In cells with a translocation and breakpoint in 
PDGFRB the signals hybridise to the normal PDGFRB allele creating a yellow fusion 
signal, with two separate signals indicating the ‘split’ in the translocated PDGFRB 
allele. FISH with the BAC clones RP11-100O5 and CTD-2303L4 confirmed the 
rearrangement of the PDGFRB gene. The BAC clone RP11-100O5 lies centromeric 
to PDGFRB, and was labelled with Biotin-16-2’-deoxy-uridine-5’-triphosphate 
(Biotin-16-dUTP) (Roche Mannheim, Germany). CTD-2303L4 is telomeric to 
PDGFRB and was labelled with alkali stable digoxigenin-dUTP. Interphase FISH 
showed a separation of the red and green signals in some cells (Figure 3. 1). Some 
separation of signals may occur when the chromosomes are uncondensed at 
interphase, therefore I counted 100 cells and found 56% of interphase cells to have a 
separation in signals, compared to <10% of cells with split signals seen with these 
probes in normal controls (Baxter, et al 2003). These FISH results confirmed 
rearrangement of the PDGFRB gene.  
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Figure 3. 1:  FISH analysis of patient sample P1157. PDGFRB BACs RP11-100O5 (green) and 
CTD-2303L4 (red) hybridised to two interphase cells: (A) Normal cell with two 
pairs of signals fused, (B) A cell carrying a PDGFRB rearrangement, one fused pair 
and one separated pair of signals is observed. The schematic to the right indicates the 
position of the probes relative to PDGFRB and the labelling for each clone. 
 
3.2.3   5’Rapid Amplification of cDNA Ends (5’RACE) 
 
Having established the disruption of PDGFRB by FISH I set out to determine if the 
t(3;5) resulted in a novel fusion gene. The majority of tyrosine kinase fusions involve 
the joining of a partner gene to the kinase in a 5’ to 3’ orientation. To detect the 
‘unknown,’ 5’ partner gene sequence I performed 5’Rapid Amplification of cDNA 
Ends (5’RACE) using the Invitrogen GeneRacer™Kit. The basic principle of this kit 
is to ligate a known sequence onto the 5’ end of the unknown mRNA, enabling 
subsequent PCR to be performed using an oligonucleotide that is complementary to 
the ligated sequence.  
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Three independent RNA samples for the t(3;5) patient were available, designated 
P1157, E38 and E112. All three samples were analysed in duplicate by 5’RACE 
PCR. I performed the 5’RACE PCRs with the High Fidelity PCR Master kit (Roche 
Diagnostics, Lewes, UK) according to manufacturer instructions, using the 
5’GeneRacer™ primer and a reverse primer in PDGRFB exon 15.1R (for all primer 
sequences see appendix I, section IV). The amplification was performed under long-
range PCR conditions (according to that specified in section 2.2.5) to enable 
fragments up to 10 kb to be amplified. No products were observed on a 1 % agarose 
gel after the first round PCR. I then performed a nested PCR using the same PCR 
conditions. For the nested PCR, I employed the 5’GeneRacer™ nested primer and a 
nested PDGFRB primer, exon 14.1R. As shown in Figure 3.2, several different size 
bands were obtained after nested PCR, two of which were very strong on the gel 
(indicated by the red arrows) and were sized at approximately 1 kb and 2.5 kb 
respectively. A third reaction yielded two medium intensity bands at approximately 
0.5 kb plus a slightly larger weaker band (indicated by the white arrow).  
 
Despite the fact that the amplified products were not consistent in size between 
samples, I cloned all three products using the TOPO TA cloning kit. Although visible 
colonies were observed on all recombinant plates, none of the picked colonies grew 
overnight, implying contamination, possibly via the SOC medium. Due to the strong 
sharp band achieved from nested 5’RACE PCR I went on to directly sequence the 
product from P1157 (Figure 3.2 - indicated by a star) in duplicate using the 
5’GeneRacer™ nested primer (forward) and the PDGFRB exon 14.1R primer 
(reverse). 
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    P1157   E38   E112  P1157  E38   E112   -ve 
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1 kb 
 
0.5kb 
  L1      L2      L3     L4      L5      L6    L7        
Figure 3. 2:  1% Agarose gel showing nested 5’RACE PCR for all three samples, in duplicate, 
of patient 1. Three different size bands were observed one in each of the samples; 
P1157 (L1), E112 (L3) and E38 (L5). The negative control shows no product (L7).  
 
The sequences were first analysed by BLAT analysis (http://genome.ucsc.edu) 
against the whole human genome. The sequence was 630 bp in length and found to 
have 140 bp homology to chromosome 3, and 305 bp homology to chromosome 5. 
The chromosome 5 sequence was as expected, PDGFRB and the chromosome 3 
sequence was 98.6% homologous to the gene GOLGA4. GOLGA4 is a member of the 
Golgin subfamily A and is located at chromosome 3p22.3 and is close to the 
cytogenetic breakpoint in the t(3;5). Using the accession numbers retrieved from the 
UCSC genome browser I then went on to BLAST the sequence 
(www.ncbi.nlm.nih.gov/) first against PDGFRB (NM_002609), to check the 
fragment was homologous to the region expected from the primers used and to 
identify the breakpoint. The sequence was found to diverge at nucleotide 1936 of 
PDGFRB (Figure 3. 3).  
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Figure 3. 3:  BLAST results – comparison of PDGFRB cDNA (NM_002609) against sequenced 
product from nested 5’RACE PCR (P1157). Note that position 267 and subsequent 
sequence matches PDGFRB. 
 
BLAST analysis was then performed on the same sequence against GOLGA4 
(NM_002078) and this also matched, ending at nucleotide 1513 (Figure 3.4). There 
were a number of bases not assigned by the sequencing programme due to dye spots 
in the original sequencing, I manually filled these in after BLAST analysis and 
determined the breakpoint to be at nucleotide 1520 in GOLGA4. 
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Figure 3. 4:  BLAST results – comparison of GOLGA4 (NM_002078) against sequenced product 
from nested 5’RACE PCR (P1157). Note sequence ends at nucleotide 1513. 
 
The individual full-length mRNA sequences for PDGFRB and GOLGA4 were then 
copied into DNA Strider™ (a software program used to analyse DNA sequences). 
The open reading frame for each sequence was determined and the sequence 
translated, using both the DNA Strider™ software compared with the reported protein 
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sequence on the NCBI website. The results from the NCBI alignment between the 
RACE product sequence and the mRNA sequence were then used to establish the 
location of the breakpoint in relation to the exons of each gene. A fusion of exon 10 
GOLGA4 to exon 11 PDGFRB was revealed. Subsequent DNA Strider™ analysis of 
the fused mRNA sequence showed the fusion is in-frame (Figure 3.5A). To confirm 
the mRNA fusion I used reverse transcriptase PCR (RT-PCR), before going on to 
clone the genomic breakpoint. This confirmation is important as 5’RACE-PCR can 
give rise to a variety of artifacts. 
 
3.2.4  Confirmation of the GOLGA4-PDGFRB fusion and cloning of the 
genomic breakpoints. 
 
To confirm the GOLGA4-PDGFRB fusion, I employed RT-PCR using the primers 
GOLGA4 exon 8.1F and PDGFRB exon 12.1R with the High Fidelity PCR master kit 
according to manufacturer’s conditions (see appendix I, section VI for all primer 
sequences). The PCR was performed on a generic 66°C annealing temperature PCR 
protocol. The in-frame fusion was detectable by single step RT-PCR, as seen in Lane 
5, Figure 3. 5B. Using the same High Fidelity PCR kit and amplification protocol I 
used RT-PCR with PDGFRB exon 9.1F and GOLGA4 exon 10.1R to try and amplify 
the reciprocal translocation. PDGFRB-GOLGA4 reciprocal products were not 
detectable by single step, Lane 6, Figure 3. 5B or nested PCR.  
 
Having confirmed the in-frame mRNA, I went on to amplify the genomic breakpoint 
to further substantiate the presence of this fusion. To do this I retrieved the sequences 
for the introns where I presumed the breakpoint to be in each gene (intron 10 of 
PDGFRB and intron 10 of GOLGA4, the intron directly before or after the exon in 
which the mRNA breakpoint was observed), focusing on these before considering 
any complexities, such as alternative splicing. The PDGFRB intron is about 3.2 kb 
and I designed eight reverse primers approximately every 250 bp. In some cases the 
primers were separated by up to 800 bp due to areas of repetitive sequence (for all 
primer sequences see appendix I, section VII). GOLGA4 intron 10 is approximately 
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13kb and for this intron I designed a primer approximately every 1kb, again avoiding 
areas of repeat sequence (for all primer sequences see appendix I, section VIII). After 
checking the primers on the NCBI nucleotide BLAST site to ensure they only 
annealed to the gene in question, I set up a number of amplification reactions for the 
patient.  
 
A 
B 
C 
 CAG AAA GAA AAG TCC GAA AGA GCT GCC TTG CCC TTT AAG GTG GTG GTG ATC TCA 
 Q   K   E   K   S   E   R   A   A   L   P   F   K   V   V   V   I   S 
mRNA breakpoint
GOLGA4 exon 10 PDGFRB exon 11 
500bp 
PDGFRB, NM_002609  Exon 11 
3’ 5’ 
    N    N    N    N  
L1   L2   L3  L4  L5   L6  L7  L8  
t(3;5) Recip B1 B2 
1kb 
K A 
GOLGA4, NM_002078  Exon 10 
 
Figure 3. 5:  Characterisation of the GOLGA4-PDGFRB mRNA fusion. (A) Schematic showing 
sequence and amino acid translation of the in-frame fusion, (B) Amplification of the 
GOLGA4-PDGFRB fusion by single step RT-PCR: Lanes 1-4 represent normal 
controls, L5 represent the patient (sample P1157), L6 represents the reciprocal 
breakpoint PCR (sample P1157) and L7-8 represent no DNA controls, (C) 
Electropherogram showing the sequencing of the single step confirmatory PCR (L5) 
and the mRNA junction sequence of the in-frame fusion. 
 
All amplifications were carried out on a long range PCR program (for details of PCR 
program see section 2.2.5). I began by setting up fifteen reactions according to Table 
L P F K V A S E R 
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3. 1, the first seven using a common GOLGA4 forward primer and the remaining 
eight using a common PDGFRB reverse primer. No product was amplified from any 
of these PCRs.  
 
Reaction No. Common Primer Variable primer 
1 cGOLGA4 exon 8.1F PDB.I11.7R  
2 cGOLGA4 exon 8.1F PDB.I11.6R 
3 cGOLGA4 exon 8.1F PDB.I11.5R 
4 cGOLGA4 exon 8.1F PDB.I11.4R 
5 cGOLGA4 exon 8.1F PDB.I11.3R 
6 cGOLGA4 exon 8.1F PDB.I11.2R 
7 cGOLGA4 exon 8.1F PDB.I11.1R 
8 PDB.I11.1R gGOLGA4.I9.1F 
9 PDB.I11.1R gGOLGA4.I9.2F 
10 PDB.I11.1R gGOLGA4.I9.3F 
11 PDB.I11.1R gGOLGA4.I9.4F 
12 PDB.I11.1R gGOLGA4.I9.5F 
13 PDB.I11.1R gGOLGA4.I9.6F 
14 PDB.I11.1R gGOLGA4.I9.7F 
15 PDB.I11.1R gGOLGA4.I9.8F 
 
Table 3. 1:   First set of primers used to amplify the genomic breakpoint in the t(3;5) patient. The 
successful primer pair is highlighted. 
 
As a result, I designed another GOLGA4 primer in exon 10 (cGOLGA4 exon 10.1F) 
closer to the mRNA breakpoint, also enabling any breakpoint between the end of the 
exon and the first intronic primer to be discovered (appendix I, section IX). I carried 
out the same amplifications, as shown in Table 3.1, but substituted the GOLGA4 exon 
8 primer for the new exon 10 primer. On this occasion a band sized at >2.5 kb was 
observed as result of amplification with the primer pair gGOLGA4.I9.7F, and 
PDB.I11.1R (Figure 3.6, Lane 15).  
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Figure 3. 6:  1% Agarose gel of the amplification products of the GOLGA4-PDGFRB genomic 
fusion. Lanes 1-7 represent the common cGOLGA4 exon 10.1F primer combined 
with each of the PDGFRB intronic primers (7-1R respectively), Lanes 8-15 represent 
the common PDGFRB primer I11.1R combined with cGOLGA4 exon 10.1F through 
to gGOLGA4.I9.7F in ascending order.  Note the product in lane 15.  
 
I cloned the amplified band using the TOPO TA cloning kit (Invitrogen) and then 
sequenced it. In the forward reaction, the traces showed sequence reading from 
gGOLGA4 I9.7F into GOLGA4 intronic sequence up to nucleotide 9797 (according 
to my DNA Strider map of intron 10 GOLGA4). The reverse reaction showed only 
PDGFRB sequence from the mRNA breakpoint at base 1936 reading into PDGFRB 
for 33 base pairs (bp). Following this result I used a primer internal to gGOLGA4 
I9.7F, gGOLGA4.I9.9F (at nucleotide 9684), combined with each of the PDGFRB 
intronic primers (1aR-7R), performing the PCR from the cloned product (lane 15, 
Figure 3.6). I used a generic 66°C annealing temperature PCR program with a high 
fidelity Hotstart Taq DNA polymerase (Qiagen). Figure 3.7 represents the resulting 
genomic fusion products from this amplification: all but one lane produced a band 
(L7) indicating that the breakpoint was before PDGFRB intronic primer PDB.I11.7R.  
 
Using the plasmid DNA from the previously cloned product, I then directly 
sequenced across the genomic breakpoint using PDBI11.6R as this had produced the 
smallest product size of all the primer pairs. A fusion of GOLGA4 intron 10 to 
PDGFRB intron 10 was discovered (Figure 3.8A). 
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Figure 3. 7: 1% Agarose gel of the amplification products of the GOLGA4-PDGFRB genomic 
fusion amplified from plasmid DNA diluted 1:1000. Lanes 1-7 represent the 
common cGOLGA4 exon 10.1F primer combined with each of the PDGFRB 
intronic primers (1aR-7R respectively). 
 
To confirm the genomic breakpoint I designed primers closer to the breakpoint in 
GOLGA4 and PDGFRB and re-amplified the fusion using patient DNA in a single 
step PCR reaction, using the High Fidelity PCR Master Mix. The forward genomic 
primer used was in GOLGA4 intron 10 (7F) in combination with a new PDGFRB 
reverse primer in intron 11 (Brkpt.R) (see appendix I, section X for primer 
sequences). This confirmed the presence of the fusion of intron 10 GOLGA4 to 
PDGFRB intron 10 (Figure 3.8A). Using the same High Fidelity PCR kit and 
amplification protocol I used PDB.I11.recip.F and PDB.I11.recip.2F combined with a 
common intronic GOLGA4 primer, gGOLGA4.I9.recip.R to amplify the reciprocal 
translocation (for primer sequences see appendix I, section XI). PDGFRB-GOLGA4 
reciprocal products were not detectable by single step or nested PCR (Lanes 3 and 4, 
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Figure 3.8B). This may have been because of a deletion, commonly seen at the site of 
the chromosomal breakpoints.  
 
 
 
Figure 3. 8:  GOLGA4-PDGFRB genomic fusion in patient 1 with t(3;5). (A) Schematic showing 
the individual sequences and the GOLGA4-PDGFRB fusion, (B) Amplification of 
GOLGA4-PDGFRB by single step PCR; Lanes 1-2 represent normal controls, lanes 
3-4 the reciprocal PDGFRB-GOLGA4 genomic fusion, lane 5 the GOLGA4-
PDGFRB genomic fusion and a no DNA control in lane 6 (C) Electropherogram 
showing the junction sequence in the intron of each gene. 
 
Intron 10, GOLGA4, chromosome 3 Intron 10, PDGFRB, chromosome 5 
A 
B 
C 
1kb 
ladder 
PDGFRB intron 10  AAT CGT CTA CTG AAG AAT GCC CAA TCT CCA GTC ACT CCT GTA
GOLGA4 intron 10  AAT GAA AAC AGA AAA TTC ACT AGT ATT GAC TAC ATA GTT TTG 
GOLGA4 - PDGFRB  AAT GAA AAC AGA AAA TTC ACT CAA TCT CCA GTC ACT CCT GTA  
1kb 
500bp 
L1     L2    L3     L4      L5     L6 
    N1    N2   Recip  Recip  t(3;5)    B 
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3.2.5   Consequence of the t(3;5) 
 
The experiments performed indicate that the t(3;5) fuses GOLGA4 exon 10 to 
PDGFRB exon 11. The predicted length of the fusion mRNA is 3662 bp with an open 
reading frame of 2976 bp that is predicted to generate a chimaeric protein of 992 
amino acids, of which 412 amino acids are derived from GOLGA4 and 580 amino 
acids are derived from PDGFRβ (Figure 3.9). The predicted molecular weight of the 
protein is 251 kDa.  
 
Normal GOLGA4 is a 2230 amino acid protein. At its c-terminus is a GRIP domain 
that targets GOLGA4 to the trans-golgi network (TGN) membranes in a G-protein 
dependent manner (see Figure 3.9 – indicated in yellow). GRIP domain proteins in 
general contain extensive coiled-coil regions (represented by the blue regions – 
Figure 3.9), that enable them to self associate and form rod-like homodimers (Luke, 
et al 2003). The chimaeric protein formed from the GOLGA4-PDGFRB fusion is 
expected to be structurally very similar to other tyrosine kinase fusions reported. It 
retains the entire catalytic domain of the tyrosine kinase fused to a portion of 
GOLGA4 containing substantial regions of coiled-coil domains. 
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Figure 3. 9:  Schematic representation of the normal PDGFRβ, GOLGA4 and GOLGA4-
PDGFRβ. The fusion protein retains the entire catalytic tyrosine kinase domain of 
PDGRFβ and has a substantial proportion of the amino terminal GOLGA4 partner 
protein containing coiled-coil domains. These oligomerisation motifs in GOLGA4 
are likely to be essential for the putative constitutive tyrosine kinase activity of the 
fusion and the subsequent downstream signalling through proliferation and survival 
pathways. 
 
3.2.6  Identification of a second MPD patient with a GOLGA4-PDGFRB 
fusion  
  
Following the identification of the GOLGA4-PDGFRB fusion, a second patient with 
an eosinophilic MPD and a t(3;5)(p21-25;q31-35) was referred to us for analysis 
(patient reference number 2).  
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Figure 3. 10:  Characterisation of the GOLGA4-PDGFRB mRNA fusion in Patient 2. (A) 
Schematic showing sequence and amino acid translation of the in-frame fusion, (B) 
The gel picture on the left represents the amplification of the KIAA1449-PDGFRB 
fusion; lanes 1 & 4 are patient 2, lane 5 a normal control and finally the no DNA 
controls are shown in lanes 2 and 3. Amplification of the GOLGA4-PDGFRB fusion 
by single step PCR is represented by the picture on the right, lanes 1 and 5 represent 
patient 2, lane 2 patient 1 used as a positive control, lane 3 and 4 are no DNA 
controls and lane 5 a normal control. A band of approximately 500bp is visible for 
the GOLGA4-PDGFRB fusion only and is the same size as that for the positive 
control; (C) Electropherogram comparing the mRNA junction sequence of the in-
frame fusion in both patients with a GOLGA4-PDGFRB fusion gene. The upper 
trace corresponds to patient 2 (E923) and patient 1 (P1157) is shown in the lower 
trace.  
KIAA1449-PDGFRB 
1  E923 
2  Negative 
3  Negative 
4  E923  
5  Normal 
 CAG AAA GAA AAG TCC GAA AGA GCT GCC TTG CCC TTT AAG GTG GTG GTG ATC TCA 
 Q   K   E   K   S   E   R   A   S   L   P   F   K   V   V   V   I   S 
GOLGA4 exon 10 PDGFRB exon 11 
mRNA breakpoint 
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RT-PCR 
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KIAA1449-PDGFRB  GOLGA4-PDGFRB 
GOLGA4-PDGFRB 
1  E923 
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3  Negative 
4  Negative 
5  Normal 
6  E923
1Kb 
500bp 
 
In this case, I performed RT-PCR to analyse the patient sample for specific 3p partner 
genes fused to PDGFRB. I tested for the GOLGA4-PDGRFB fusion, using the 
primers cGOLGA4 exon 7.1F and PDGFRB exon 12.1R (for primer sequences see 
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appendix I, section XII). A second variant PDGFRB fusion gene had also been 
cloned in our group, involving a gene called at 3p22 called WDR48 (also known as 
KIAA1449). This was also tested for using RT-PCR using the primers KIAA1449.2F 
combined with PDGFRB.exon15.2R (for primer sequences see appendix I, section 
XIII). Patient was found to be positive for GOLGA4-PDGFRB and negative for 
WDR48-PDGFRB. On sequencing of the product, I determined the cDNA breakpoint 
was the same as that for the first patient (Figure 3.10A, B and C). Again, PDGFRB-
GOLGA4 reciprocal products were not detectable by single step amplification.  
 
3.2.7  Two-colour fluorescence in situ hybridisation (FISH) 
  
The BAC clones RP11-100O5 and CTD-2303L4 were again used to confirm the 
rearrangement involved the PDGFRB gene. 100 interphase cells were counted and of 
these 52% showed a split in signals, in agreement with the PCR result (Figure 
3.11A). The 52% separation in signals observed by the PDGFRB FISH is well above 
the false positive rate of 3% as determined by Baxter et. al., (2003) confirming the 
rearrangement of PDGFRB (Baxter, et al 2003). To further confirm the PCR result, 
two-colour FISH was also performed using a BAC clone that lies centromeric to the 
PDGFRB breakpoint, RP11-100O5 and a chromosome 3p BAC RP11-158E7 that lies 
telomeric to the GOLGA4 breakpoint. Interphase FISH verified the presence of the 
GOLGA4-PDGFRB fusion, as the signals appeared to be fused in 36% of cells 
(Figure 3.11B), also indicating the fusion initially found by RT-PCR to be real.  
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Figure 3. 11:  Fluorescent in situ hybridisation for PDGFRB and GOLGA4. (A) PDGFRB BAC 
RP11 100O5 (green) and GOLGA4 RP11-158E7 (red) BAC hybridised to an 
interphase from patient E923, note the fused signal observed in one of the cells; (B) 
PDGFRB BACs RP11-100O5 (green) and CTD-2303L4 (red) hybridised to an 
interphase from patient E923, the cell shows one pair of signals separated. 
 
3.2.8   Imatinib sensitivity assay 
 
Patients with rearrangements of PDGFRB usually show a good clinical response to 
imatinib (Apperley, et al 2002). To specifically test if the novel GOLGA4-PDGFRB 
fusion was sensitive to imatinib, I analysed colony-forming unit, granulocyte-
macrophage growth (CFU-GM) production for cryopreserved cells from patient 2, in 
the presence of 0μmol/L, 1μmol/L or 5μmol/L imatinib. A normal control individual 
and a BCR-ABL positive CML patient were tested for comparison. Peripheral blood 
from the normal control showed a reduction in colony numbers of approximately 
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50% with 1μmol/L imatinib at 7 and 14 days (Figure 3.12A) and a further 10% 
reduction was observed at 5μmol/L imatinib. This degree of non-specific inhibition of 
CFU-GM numbers has been found previously with a large number of other normal 
controls, as previously tested by Dr Andy Chase.   
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Figure 3. 12:  CFU-GM growth of blood mononuclear cells from (A) normal control, (B) a CML 
patient and (C) patient 2. 
 
The positive control CML patient, showed a much greater reduction in the number of 
CFU-GM after exposure to imatinib. Approximately 90% growth inhibition was 
observed in the presence of 1μmol/L and 5μmol/L imatinib at both 7 and 14 days 
(Figure 3.12B). This replicated similar data obtained in multiple imatinib sensitive 
CML samples. Marked inhibition was also observed for CFU-GM grown from the 
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t(3;5) patient, with approximately 95% reduction in colony numbers at day 7 and 14 
in the presence of 1μmol/L and 5μmol/L imatinib (Figure 3.12C). The index of 
response (see methods, section 2.4.1.2) for the t(3;5) patient was 0.05, markedly 
lower than the 0.2 control which has been used to distinguish imatinib responders 
from imatinib non-responders. These data suggest that the t(3;5)-associated disease is 
indeed sensitive to imatinib.  
 
3.2.9   Discussion 
 
I have identified the gene found fused in a recurrent t(3;5) by using a combination of 
FISH and translocation cloning. I have discovered a novel partner gene, GOLGA4, 
fused to the tyrosine kinase gene PDGFRB. The breakpoint was analogous to all 
other reported fusions involving PDGFRB, with the exception of the t(5;14) 
(Vizmanos, et al 2004). The translocation breakpoint on chromosome 3 lies in intron 
10 of GOLGA4.  GOLGA4 contains extensive coiled-coils domains that are thought 
to act as oligomerisation motifs essential for GOLGA4-PDGFRβ constitutive 
activation.  
 
GOLGA4 (Golgin-245) was first identified by two groups that were probing cDNA 
libraries with sera from patients with Sjrogens syndrome (an autoimmune disease) 
(Fritzler, et al 1995, Kooy, et al 1992). Golgin-245 is a member of the Golgin family 
of coiled-coil proteins, associated with the Golgi apparatus. Golgins play a role in 
tethering events in membrane fusion and as structural supports for Golgi cisternae. 
Golgin-245 belongs to a subfamily known as the GRIP domain proteins. Van 
Valkenburgh et. al., (2001) showed that the GRIP domain binds the ARF-like 
GTPases Arl1 and Arl3 with significantly higher affinity than Rab 6. Recently Rao et. 
al., (2003), provided evidence for the function of the Arl proteins. Through yeast 
GFP-GRIP fusion proteins they were able to show a GTPase cycle involving Arl3p 
that regulates the golgi localisation of Arl1p which in turn binds the GRIP domain 
and recruits the golgin to the golgi (Rao, et al 2003). Although, it has been suggested 
that Golgin-245 might function as a vesicle coat, it is perhaps more likely that it is 
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involved in the organisation of membrane subcompartments of the trans-Golgi 
network (TGN) (Brown, et al 2001, Luke, et al 2003). Nevertheless, the function of 
Golgin-245 remains to be fully elucidated. 
 
To date eighteen fusion partners for PDGFRB have been reported: ETV6, TRIP11, 
HIP1, CCDC6, RABEP1, PDE4DIP, SPECC1, NIN, KIAA1509, TP53BP1, TPM3, 
NDE1, ERC1, PRKG2, GPIAP1, GIT2, SPTBN1 and MYO18A (Abe, et al 1997, 
Gallagher, et al 2008, Gorello, et al 2008, Grand, et al 2004b, Kulkarni, et al 2000, 
La Starza, et al 2007, Levine, et al 2005, Magnusson, et al 2001, Morerio, et al 2004, 
Rosati, et al 2006, Ross, et al 1998, Vizmanos, et al 2004, Walz, et al 2009, Walz, et 
al 2007, Wilkinson, et al 2003, Wlodarska, et al 1995), with a further three fusion 
partners known within our laboratory, including GOLGA4 (Hidalgo-Curtis et. al., 
submitted 2009).  With the exception of the t(5;14)(q33;q24), all breakpoints within 
PDGFRB occur in intron 10 and this is also the case with the novel GOLGA4-
PDGFRB fusion detailed here. The partner proteins in these tyrosine kinase fusions 
typically contribute dimerisation motifs leading to the constitutive activation of the 
receptor and inappropriate activation of growth signalling and anti-apoptotic 
pathways (Cross and Reiter 2002). In an analogous manner to the BCR-ABL 
oncoprotein, constitutively active tyrosine kinase fusion proteins deregulate 
haematopoiesis.   
 
Interestingly GOLGA4 shows a functional overlap with the previously identified 
PDGFRβ fusion partners BIN2, HIP1, RABEP1 and SPTBN1.  BAR domain proteins 
like BIN2 are involved in membrane curvature and receptor endocytosis (Ge and 
Prendergast 2000).  Other fusion partners also demonstrate links to intracellular 
sorting of receptors, a well known example is BCR. BCR is a component of the 
endosomal sorting complex required for transport (ESCRT) (Olabisi OO 2006). 
MPDs are well known to be characterised by hyper-responsiveness to growth factors. 
Suppression of BCR in HeLa cells by small interfering RNA impairs epidermal 
growth factor receptor turnover, and it is conceivable that as components of fusions, 
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partner proteins such as BIN2, WDR48 and GOLGA4 may contribute to defective 
receptor internalisation and sorting.  
 
Patients with rearrangements of the PDGFRB gene respond well to treatment with 
imatinib mesylate (Apperley, et al 2002). The identification of PDGFRB gene 
rearrangements is therefore critical for disease management. The identification of 
PDGFRB fusions in these two cases has enabled them to be treated has and permitted 
their response to be monitored by RT-PCR and FISH, techniques which can help to 
provide early clinical indications of resistance to imatinib therapy. 
 
3.3  IDENTIFICATION OF TWO NOVEL PDGFRA FUSION 
GENES 
 
The PDGFRA gene is located at 4q12 and to date has been described fused to six 
different partners: BCR, FIP1L1, KIF5B, CDK5RAP2, STRN and ETV6 (Baxter, et al 
2002, Cools, et al 2003, Curtis, et al 2007, Score, et al 2006, Walz, et al 2006).  As 
with PDGFRB fusions, identification of patients that harbour PDGFRA fusions is 
particularly important as they respond well to targeted therapy with imatinib (Cools, 
et al 2003, Reiter, et al 2007). PDGFRA fusions are most commonly associated with 
chronic eosinophilic leukaemia (CEL), with the most frequent abnormality being seen 
in approximately 12% of cases with a provisional diagnosis of idiopathic 
hypereosinophilic syndrome (Cools, et al 2003, Griffin, et al 2003), is the FIP1L1-
PDGFRA fusion gene. Here I describe two patients with imatinib responsive CEL 
who presented with acquired chromosomal rearrangements of 4q.  
 
3.3.1   Patient details 
 
Case 1 was diagnosed with CEL and has been described in further detail by Musto et 
al, 2004. In brief, the patient was a 64 year old male who presented with an 
eosinophil count of 12x109/L and a bone marrow indicative of an MPD. Cytogenetic 
analysis revealed 60% of bone marrow metaphases harboured a t(2;4)(p24;q12). 
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Daily treatment with 100mg imatinib was commenced and following treatment 
haematologic and cytogenetic remission was achieved. This dose was continued for 9 
months and then progressively reduced to 100mg on alternate days followed by 
100mg twice a week. Following 24 months of imatinib, the patient refused further 
therapy despite not having any significant side effects. After 14 months after 
discontinuation of treatment elevated eosinophil counts were again detected.  
 
Case 2 was another male, 51 years of age, who presented with late onset asthma and 
Type 2 diabetes. Again the patient exhibited an elevated eosinophil count of 12.9 x 
109/L and a hypercellular bone marrow suggestive of an MPD. Cytogenetics revealed 
100% of bone marrow metaphases carried a t(4;12)(q2?3;p1?2). For over 7 years the 
patient was managed with hydroxycarbamide but with recurrent problems due to 
anaemia, thrombocytopenia and very poor control of the same translocation: 
46,XY,t(4;12)(q2?3;p1?2)[14]/46,XY[6]. Following the molecular diagnosis as 
detailed by the work done below, hydroxycarbamide was stopped and imatinib started 
at 100mg daily. Within four weeks, the full blood counts completely normalised, 
resulting in significant resolution of symptoms (apart from the asthma) and greatly 
improved quality of life. Following 9 months of treatment, cytogenetic analysis was 
again performed and indicated complete cytogenetic remission (30 metaphases). 
 
Upon referral it was known that both cases were negative for BCR-ABL and FIP1L1-
PDGFRA by RT-PCR or FISH analysis using standard procedures. The presence of a 
4q translocation in conjunction with persistent eosinophilia suggested that PDGFRA 
might be involved. 
 
3.3.2   Bubble PCR  
 
 
To establish if the 4q12 translocations resulted in a novel fusion genes involving 
PDGFRA, I employed bubble PCR. Bubble PCR (Zhang, et al 1995) is a one sided 
PCR technique capable of amplifying an unknown sequence that lies adjacent to a 
known sequence (see section 2.2.6 for more details and appendix I, section I for 
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primer sequences). Like 5’RACE, this relies on the fact that fusion of tyrosine 
kinases involves the joining of a partner gene to the kinase in a 5’ to 3’ orientation. 
This technique also relies on the tight clustering of genomic breakpoints observed in 
PDGFRA fusions, with almost all involving a truncated exon 12 (Reiter, et al 2007). 
The technique is also dependent on specific restriction enzyme sites distal to the 
fusion point but equally within an amplifiable distance. The 4 bp cutters HaeIII and 
RsaI are used to target this region in the PDGFRA gene and in combination with the 
primer PDAI12-R4 target genomic regions of 978 bp and 615 bp, respectively 
(Figure 3.13). 
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Figure 3. 13:  Schematic of bubble PCR strategy showing PCR primers and restriction sites in the 
region where all breakpoints have been reported to fall. Arrows indicate primer 
locations. 
 
On average these enzymes cut approximately every 256 bp, thus products from any 
rearranged PDGFRA allele are generally expected to be smaller than the wild-type 
allele. An advantage of using this approach, over that of the 5’RACE kit, is that it 
relies on genomic DNA not RNA. This was fortunate as the only material available 
for case 1 was a stained haematological slide. I employed bubble PCR and detected 
rearranged bands were detected for both cases 1 and 2 (Figure 3.14). 
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The rearranged PDGFRA alleles were subsequently subcloned into pCR 4-TOPO 
vector and sequenced using BigDye terminator v1.1 (Applied Biosystems, UK). 
Sequencing of the rearranged allele for case 1 identified a novel fusion between 
STRN (NM_003162) and PDGFRA, whereas a novel fusion between ETS-variant 
gene 6 (ETV6, NM_001987) and PDGFRA was found for case 2. 
 
1011bp
648bp
no
rm
al
C
as
e 
1
bl
an
k
**
HaeIII RsaI
no
rm
al
no
rm
al
bl
an
k
C
as
e 
2
C
as
e 
1
C
as
e 
2
no
rm
al
C
as
e 
1
bl
an
k
no
rm
al
no
rm
al
bl
an
k
C
as
e 
2
C
as
e 
1
C
as
e 
2
no
rm
al
C
as
e 
1
bl
an
k
no
rm
al
no
rm
al
bl
an
k
C
as
e 
2
C
as
e 
1
C
as
e 
2
 
 
Figure 3. 14: Agarose gel picture of nested bubble PCR after digestion with HaeIII and RsaI. The 
normal controls show the expected germline bands of 1011 bp and 648 bp 
respectively (the distance between primer PDAI12-R4 and the relevant restriction 
site plus 33 bp contributed by the bubble oligo). Smaller bands derived from the 
rearranged allele are visible for cases 1 and 2 after HaeIII digestion and for case 2 
after RsaI digestion. The normal allele is often out competed due to size in the 
amplification reaction.  
 
3.3.3   Confirming the STRN-PDGFRA fusion  
 
The rearranged allele resulted in a fusion of STRN intron 6 and a truncated PDGFRA 
exon 12. Hence, primers were designed to confirm the presence of the fusion (see 
appendix I, section XVI). Hot-start amplifications were performed for between 30-35 
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cycles in a MJ Research Inc. Tetrad thermocycler with a 66°C annealing temperature. 
The genomic STRN-PDGFRA fusion was amplified using STRN-Fusion-Ex6-1F and 
PDGFRA-Fusion-Ex12-2R. A 285 bp product was amplified from the patient DNA 
but not from control DNA. A reciprocal PDGFRA-STRN fusion product was not 
detected with primers PDGFRA-recip-Ex11-1F and STRN-Recip-Int6-1R with either 
single step or nested PCR (appendix I, section XVI for primer sequences) (Figure 
3.15).   
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PDGFRA exon 12 ATCAGCCCAGATGGACATGAATATATTTATGTGGACCCGATG
STRN intron 6 GCATAAAAGAATCCATGTTCTTTAATCTTAACCCGTAGCTTT
STRN-PDGFRA GCATAAAAGAATCCATGTTCT.ATATTTATGTGGACCCGATG
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Figure 3. 15:  Characterisation of the STRN-PDGFRA fusion gene. (A) Electropherogram of the 
genomic DNA junction amplified by bubble PCR; (B) Sequence of PDGFRA exon 
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12 and STRN intron 6 (underlined) flanking the breakpoints, aligned with STRN-
PDGFRA genomic fusion sequence; (C) Amplification of the STRN-PDGFRA but 
not the reciprocal genomic DNA fusion from case 1 versus normal controls. (D) 
Predicted in frame STRN-PDGFRA mRNA fusions. 
 
Due to the lack of adequate pre-treatment patient material, identification of the 
mRNA fusion was not possible. Nonetheless, analogous PDGFRA breakpoints for 
FIP1L1-PDGFRA usually result in the use of cryptic splice sites within PDGFRA 
exon 12 downstream of the breakpoint. Two potential AG splice acceptor sites were 
identified and would result in in-frame mRNA fusions with STRN exon 6. It is likely 
that either or both of these might represent the real mRNA fusion in case 1 (Figure 
3.15D). 
 
3.3.4   Consequence of the STRN-PDGFRA fusion 
 
The t(2;4) is likely to fuse STRN exon 6 to part of PDGFRA exon 12. The predicted 
length of the fusion mRNA is dependent on the PDGFRA splice site used and I refer 
to the most likely mRNA fusions as (i) and (ii) (see Figure 3.15D). The predicted 
length of the mRNA fusion (i) is 5309 base pairs with an open reading frame of 2328 
bp. The predicted length of the mRNA fusion (ii) is 5289 bp with an open reading 
frame of 2304 bp. The t(2;4)(p24;q12) is thus predicted to generate a chimaeric 
protein of (i) 776 amino acids or (ii) 768 amino acids, of which 265 amino acids are 
derived from Striatin (Figure 3.16). The predicted molecular weight of the protein is 
(i) 187.5 kDA or (ii) 189.4 kDa. Normal Striatin is a 780 amino acid protein. At its C-
terminus is a region of WD40 repeats and its N-terminus a coiled-coil domain. This 
coiled-coil region is thought to be crucial for homo- and hetero-oligomerisation of the 
protein. Striatin is a scaffolding protein involved in calcium dependent signalling 
(Bartoli, et al 1999) and is also thought to have a putative role in trafficking (Baillat, 
et al 2001). It is highly expressed in the brain, in particular the neurons, and has been 
shown to directly bind caveolin (Gaillard, et al 2001). The chimaeric protein formed 
from the STRN-PDGFRA fusion is structurally very similar to other reported tyrosine 
kinase fusions. The entire catalytic domain of the tyrosine kinase is retained and 
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found fused to a portion of Striatin containing coiled-coil domains which probably 
mediate dimerisation of the fusion protein. 
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Figure 3. 16: Structure of Pdgfrα, Striatin and the predicted fusion protein. Relevant domains are 
shown: transmembrane (tm), WW-like (WW) and tyrosine kinase domains for 
Pdgfrα; coiled-coil region and WD40 repeats for Striatin.The partially deleted 
autoinhibitory WW domain of Pdgfrα is shown in Striatin-Pdgfrα . 
 
3.3.5   Confirming the ETV6-PDGFRA fusion 
 
As mentioned previously, the sequencing of the rearranged bubble PCR band from 
case 2 identified a second novel fusion between ETV6, intron 6 and PDGFRA intron 
11 (Figure 3.17A and B). To confirm the fusion a 210 bp product (Figure 3.17C) was 
specifically amplified from case 2 peripheral blood genomic DNA using breakpoint-
specific primers ETV6.Fusion.Int6.4F and PDGFRA.fusion.Ex12.1R on a standard 
66°C Hotstart PCR amplification, a band was not observed in control DNA (for all 
primer sequences see appendix I, section XVII). A reciprocal PDGFRA-ETV6 fusion 
product was not detected with PDGFRA-recip-Ex11-1F and ETV6-Recip-Ex7-1R at 
either single or nested PCR. Expression of ETV6-PDGFRA was confirmed by single-
step from case 2, using primers ETV6.Fusion.Ex6.1F and PDGFRA.Fusion.Ex12.2R, 
yielding a 276 bp product that was not observed in normal control cDNA (Figure 
3.27C). Sequencing of this product revealed an in-frame whole exon fusion between 
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ETV6 exon 6 and PDGFRA exon 12 (Figure 3.17D). To further confirm the presence 
of the ETV6-PDGFRA fusion, two-colour interphase FISH analysis was performed.  
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Figure 3. 17:  Characterisation of the ETV6-PDGFRA fusion. (A) Electropherogram of the 
genomic DNA junction amplified by bubble PCR; B) Sequence of PDGFRA intron 
12 (italics) and ETV6 intron 6 (underlined) flanking the breakpoints, aligned with the 
ETV6-PDGFRA genomic fusion sequence; (C) Amplification of the ETV6-PDGFRA 
fusion from genomic DNA but not the reciprocal genomic DNA fusion from case 2, 
versus normal controls. (D) Predicted in-frame ETV6-PDGFRA mRNA fusion as 
determined by sequence analysis of case 2 RT-PCR product. 
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 3.3.6   Two-colour fluorescent in situ hybridisation 
 
FISH was only performed on Case 2 due to availability of material. FISH was 
executed using the bacterial artificial chromosome (BAC) clones RP11-24O10 (3’ of 
PDGFRA) and RP11-434C1 (5’ of ETV6) selected from sequences flanking PDGFRA 
and ETV6 (www.ensembl.org) or commercially available probe sets. BAC DNA was 
grown, extracted and labelled by nick translation with digoxygenin or biotin-16-
dUTP (Roche, East Sussex) and hybridised using standard procedures. On normal 
cells the combined BACs gave four separate signals corresponding to the normal 
chromosomes 4 and 12. However, in 56% of cells for case 2, overlapping probe 
signals consistent with co-localisation of ETV6 and PDGFRA were observed (Figure 
3.18). 
434C1
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Figure 3. 18: (A) Relative positions of FISH probes with the orientation of each gene indicated by 
the arrows. (B) A normal cell shows four distinct signals whereas 56% of cells from 
case 2 showed a fused red/green signal indicative of the t(4;12).  
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 3.3.7   Consequence of the ETV6-PDGFRA fusion 
 
The t(4;12) fuses ETV6 exon 6 to PDGFRA exon 12 resulting in a novel fusion gene. 
The predicted length of the fusion mRNA is 6015 bp with an open reading frame of 
2769 bp. ETV6-PDGFRA fusion is predicted to encode a chimaeric protein of 923 
amino acids, of which 384 amino acids are derived from ETV6 and 539 amino acids 
derived from PDGFRα (Figure 3.19). The predicted molecular weight of the protein 
is 229.3 kDa.  Normal ETV6 is a 452 amino acid protein with two functional 
domains: a C-terminus pointed domain (PNT) that plays a role in protein-protein 
interactions including self association and interactions with other proteins. At its C-
terminus is the ETS domain that is crucial for DNA-binding. The entire catalytic 
domain of PDGFRα is retained and found fused to almost the entire ETV6 protein 
containing the whole pointed domain and a part of the ETS domain. 
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Figure 3. 19:  Structure of PDGFRα, ETV6 and the predicted fusion protein. The pointed and ETS 
domains are shown for ETV6. The dotted vertical line indicates the breakpoint 
region in each protein. 
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3.3.8  Detection of MRD and response to Imatinib in Cases 1 & 2  
 
Characterisation of the fusion in each case enabled a molecular assessment of 
minimal residual disease to be made. Minimal residual disease (MRD) was analysed 
for cases 1 and 2 by two step nested PCR to maximize sensitivity of detection. 
Primers used for the detection of the STRN-PDGFRA fusion were: STRN-Ex6-1F and 
PDGFRA-Ex12-2R and for nested PCR, STRN-Ex6-2F and PDGFRA-STRN-Ex12-
1R. Primers used for the ETV6-PDGFRA fusion were: ETV6-Ex6-1F and PDGFRA-
Ex12-2R and for nested PCR ETV6.Ex6.2F and the same PDGFRA.STRN.Ex12.1R 
(see appendix I, section XVIII for all MRD primers). Peripheral blood for cases 1 and 
2 was analysed approximately 28 and 9 months after starting imatinib, respectively. 
MRD was not detected using cDNA or genomic DNA for case 1, indicating the 
achievement of molecular remission. For case 2, analysis was only performed using 
genomic DNA. Of four replicate reactions, two were positive indicating low level 
disease, consistent with a major molecular response. 
 
3.3.9  Discussion: PDGFRA fusions 
 
Over the last decade, our understanding of the molecular pathophysiology of IHES 
and CEL has advanced dramatically. PDGFRA fusions are the most commonly 
associated with CEL, with the most frequent being FIP1LI-PDGFRA which is seen in 
up to 12% of cases provisionally diagnosed as IHES (Cools, et al 2003, Griffin, et al 
2003). Using bubble-PCR analysis I have characterised the genomic breakpoints in 
two CEL cases with chromosome 4q rearrangements and identified STRN at 2p22 and 
ETV6 at 12p13 as novel PDGFRA fusion partners. This increases the number of 
known PDGFRA partner genes to six, with PDGFRA being the tenth tyrosine kinase 
reported to fuse to ETV6. It has not been possible to estimate the frequency of these 
abnormalities since these fusions were referred specifically for investigation of 4q 
rearrangements and were not part of a series that underwent systematic cytogenetic 
investigation. However it is thought they probably only account for < 1% of CEL 
cases.  
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STRN encodes striatin, a 780 amino acid protein. It is a member of the calmodulin-
binding WD repeat family of proteins. It contains four protein-protein interaction 
domains, a caveolin binding domain (55-63 amino acids), a coiled-coil domain (70-
116 amino-acids), a calcium dependent calmodulin-binding domain (149-166 amino 
acids) and a series of WD repeat motifs (419-780 amino acids) (22). Striatin is 
thought to be a scaffolding protein that targets proteins such as the oestrogen receptor 
to the cell membrane allowing the assembly of other proteins required for rapid 
activation (Lu, et al 2004). Interestingly, in case 1 the fusion identified between 
intron 6 STRN to a truncated exon 12 of PDGFRA, results in the loss of a large region 
of WD repeat motifs within striatin. However, the N-terminal coiled-coil domain 
remains and it is this domain that could act as a necessary oligomerisation motif, 
constitutively activating the PDGFRα-derived tyrosine kinase moiety. Alternatively, 
truncation of the WW-like domain may be the critical activating event (Figure 3.26) 
(Stover, et al 2006).  
 
ETV6 is a member of the ets family of transcription factors and is frequently 
rearranged in both myeloid and lymphoid malignancies (Bohlander 2005). It was first 
cloned by Golub et al (1994) as a result of an ETV6-PDGFRB fusion gene in a patient 
with chronic myelomonocytic leukaemia (CMML) (Golub, et al 1994). More then 40 
distinct translocations involving ETV6 have been identified cytogenetically with 
greater then 20 partners described so far (Odero, et al 2001, Rowley 1999). ETV6 
fusion partners can be categorised loosely into fusions with 1) protein tyrosine 
kinases; 2) transcription factors and 3) unproductive fusions, where ectopic 
expression of nearby genes not normally expressed within the haematopoietic system 
are thought to be expressed (Bohlander 2005, Cools, et al 2002). There is also 
evidence that ETV6 functions as a tumour suppressor gene in RUNX-ETV6 positive 
childhood ALL, where in 70% of cases the wild-type or normal ETV6 allele is 
deleted. In cases where a deletion is not observed a point mutation can be found that 
abrogates ETV6 expression (Cave, et al 1997, Griesinger, et al 2002, Montpetit, et al 
2002, Patel, et al 2003).  
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BCR was the first described PDGFRα fusion partner. BCR-PDGFRA was amplified 
in two patients with an atypical chronic myeloid leukaemia (aCML) and a t(4;22) 
(Baxter, et al 2002). Two more cases with varied haematological malignancies have 
since been discovered and whilst the fusion breakpoints are diverse in BCR (exons 1, 
7, 12 and 17) all show fusion to PDGFRA exon 12, ensuring the entire catalytic 
domain of PDGFRα is retained (Safley, et al 2004, Trempat, et al 2003). Analysis of 
FIP1L1-PDGFRA breakpoints show FIP1L1 breakpoints are widely clustered in 
exons 7–10 and consistently result in truncation of PDGFRA between the two 
conserved tryptophan residues (the WW domain) of exon 12 (Cools, et al 2003, 
Griffin, et al 2003, Klion, et al 2003, La Starza, et al 2005, Pardanani, et al 2003, 
Roche-Lestienne, et al 2005, Vandenberghe, et al 2004). Consistent with all other 
reported PDGFRA fusions, I found that STRN disrupts the region encoding the 
negative regulatory WW-like domain of PDGFRα. In contrast, for ETV6-PDGFRA 
the WW-like domain is intact (Figure 3.29). This is the first case of a PDGFRA 
fusion where disruption of PDGFRA exon 12 within the WW domain has not 
occurred. The ETV6-PDGFRA fusion fuses ETV6 exon 6 to the entire length of 
PDGFRA exon 12. In a recent paper by Stover and colleagues the significance of the 
breakpoint restrictions in PDGFRA was demonstrated by the production of a 
truncated exon 12 PDGFRA construct. Despite the absence of any partner gene, 
truncation of the PDGFRα WW-like domain was sufficient to activate the kinase and 
transform BaF/3 cells to growth factor independence. This paper may in part explain 
why the ETV6-PDGFRA fusion is still leukaemogenic, despite the fact that the 
breakpoint in PDGFRA does not disrupt the WW domain. An artificial ETV6-
PDGFRA fusion that retained the region encoding the WW-like domain transformed 
Ba/F3 cells to growth factor independence, indicating that autoinhibition by the WW-
like domain can be overcome by enforced homodimerisation. However the growth of 
the transformed cells was slower than those transformed by similar fusions in which 
the WW-like domain was truncated (Stover, et al 2006).  It remains unclear why the 
WW-like domain is truncated with other fusion partners that provide an 
oligomerisation domain such as BCR, and also why truncation of this domain is not 
usually seen for fusions involving PDGFRβ. 
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 Both patients are now being treated with imatinib. Case 1 has achieved complete 
chromosomal and molecular remission whilst on treatment, and Case 2 has been 
treated with low dose imatinib (100mg/day) which has induced a rapid 
haematological improvement however, follow up is currently too short to assess 
cytogenetic or molecular remission. In summary, I have identified two novel 
PDGFRA fusion genes in male patients presenting with an imatinib-responsive 
eosinophilic myeloproliferative disorder (MPD). Like PDGFRB, PDGFRA also fuses 
to diverse partner genes in CEL.  
 
3.4  A NOVEL FGFR1 FUSION GENE 
 
A common theme among the myeloproliferative disorders is the diverse tyrosine 
kinase fusion genes. In addition to those involving PDGFRA and PDGFRB, recurrent 
translocations involving chromosome band 8p11 and the tyrosine kinase FGFR1 are 
also described in myeloid malignancies. The 8p11 myeloproliferative syndrome 
(EMS), also known as stem cell leukaemia-lymphoma (SCLL)  is a chronic MPD that 
commonly presents with eosinophilia, T-cell proliferation and acquired reciprocal 
chromosomal translocations with recurrent breakpoints at chromosome band 8p11 
that disrupt the receptor tyrosine kinase FGFR1. To date 8 fusion genes have been 
identified in patients with EMS. The translocations are t(8;13)(p11;q12), 
t(8;9)(p11;q33), t(6;8)(q27;p11), t(8;22)(p11;q22), t(8;19)(p12;q13.3), 
t(8;17)(p11;q23), t(7;8)(q34;p11) and t(8;12)(p11;p11) which fuse ZMYM2 
(ZNF198/RAMP/FIM), CEP110, FGFR1OP (FOP), BCR, HERV-K, MYO18A, 
TRIM24 (TIF1) and FGFR1OP2 to FGFR1, respectively (Belloni, et al 2005, 
Demiroglu, et al 2001, Grand, et al 2004a, Guasch, et al 2003, Guasch, et al 2000, 
Popovici, et al 1999, Walz, et al 2005, Xiao, et al 1998). Imatinib however is inactive 
against FGFR1 and cannot benefit patients with EMS. Other compounds that target 
FGFR1 have been developed including SU5402, PD173074, and TKI258. They 
function by blocking the ATP binding site in a manner analogous to imatinib, but 
none are currently in clinical use (Chase, et al 2007, Demiroglu, et al 2001, 
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Mohammadi, et al 1997). These compounds have been shown to specifically inhibit 
the growth of ZNF198-FGFR1 and BCR-FGFR1 transformed cells, resulting in 
increased levels of apoptosis (Chase, et al 2007). In this study, I have investigated a 
patient that presented with EMS and an acquired chromosomal rearrangement of 
8p11, resulting in the fusion of a new partner gene. 
 
3.4.1  Patient details 
 
The patient referred was a 75-year-old female who presented with cervical, left 
axillary and inguinal lymphadenopathy. A computerised tomography (CT) scan 
showed right pleural effusion, ascites (abnormal build up of fluid around the 
abdomen), splenomegaly, and para-aortic nodes. Axillary node biopsy showed 
effacement of normal architecture by a diffuse population of mononuclear cells. The 
majority expressed strong surface CD3, but there was a scattered population of cells 
expressing neutrophil elastase amongst other myeloid markers. The presenting blood 
count showed haemoglobin of 140 g/L, WBC 16x109 L-1, with neutrophilia (12x109 
L-1) and eosinophilia (0.8x109 L-1) plus platelets of 375x109 L-1. Hypercellular bone 
marrow was observed with an increase in eosinophils and eosinophil precursors but 
no increase in lymphoid cells or blasts. Cytogenetic analysis revealed 46,XX,t(8;12) 
(p11;q15)[19]/46, XX. There was rapid clinical deterioration accompanied by pyrexia 
(fever), lethargy, weight loss, and a widespread rash (biopsy was inconclusive on 
histology). Intensive chemotherapy was not offered and although there was a 
transient clinical response to steroids, the patient died 10 weeks later. 
 
3.4.2  Fluorescence in situ hybridisation 
 
FGFR1 FISH had been performed and previously reported as rearranged in this 
patient (Sohal, et al 2001). The breakpoints for all cases involving the FGFR1 gene 
thus far reported are tightly clustered within or close to exon 9 of this gene, further 
investigation was made easier. I explored the possibility that FGFR1 was rearranged 
by 5’RACE PCR.  
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3.4.3  5’Rapid Amplification of cDNA Ends (5’RACE) PCR 
 
The partner gene was identified using the Gene-RacerTM Kit (Invitrogen). Briefly, 
this involves ligating a known sequence onto the 5’ end of the unknown mRNA, 
enabling subsequent PCR to be performed using an oligonucleotide that is 
complementary to the ligated sequence. A single RNA sample (E0003) was available 
for the t(8;12) patient and this was analysed using 5’RACE PCR primers and nested 
FGFR1 primers as previously described (Grand, et al 2004a). I performed the 
5’RACE PCRs with the High Fidelity PCR Master kit (Roche Diagnostics) enabling 
amplification of up to 3 kb with an annealing temperature of 66°C, according to 
manufacturer instructions. Products were cloned with the TOPO TA Cloning Kit for 
Sequencing (Invitrogen) and sequenced. As shown on Figure 3.30, sequencing of the 
rearranged 5’RACE band revealed a fusion between CPSF6 intron 8 (accession 
number NM_007007) and FGFR1 at nucleotide 1272 from ATG (accession number 
M34185). The CPSF6 breakpoint within intron 8 results in the inclusion of a portion 
of the CPSF6 intron in the fusion mRNA, this fragment of intronic CPSF6 maintains 
the reading frame with FGFR1 and encodes 11 amino acids. 
 
TAT GGT TCT GGA TCA AGG TAC ACC AAA TGT TTG ACC ACC TCA CTT TAT AAG GTG TCT GCT GAC TCC
Y       G       S        G      S       R       Y        T K       C       L      T        T       S        L       Y K       V       S       A       D       S
FGFR1 exon 9CPSF6  exon 8 CPSF6  intron 8
CPSF6, Exon 8, Intron 8 FGFR1, Exon 9
 
 
Figure 3. 20:  Electropherogram (top) and sequence (bottom) of the CPSF6-FGFR1 mRNA fusion 
determined by cloning and sequencing a 5’RACE PCR product. Region highlighted 
in red indicates incorporated CPSF6 intronic sequence. 
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3.4.4  Confirming the CPSF6-FGFR1 fusion 
 
To confirm the CPSF6-FGFR1 fusion, a 224 bp product was specifically amplified 
from patient cDNA but not from control cDNA. The genomic breakpoint product of 
543 bp was also co-amplified in the same reaction and sequenced (Figure 3.31A). A 
reciprocal FGFR1-CPSF6 fusion product was not detected with either single step or 
nested PCR. The CPSF6-FGFR1 fusion mRNA was confirmed by sequencing. The 
genomic breakpoint was confirmed by sequencing the larger amplified 543bp band, 
this is the same as the mRNA fusion due to inclusion of CPSF6 intronic sequence 
(detailed below Figure 3.31B). 
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CPSF6                  ACCTCACTTTATAAGGGAGCAGTTTTCCCTGTCTCT
FGFR1                  TGACCACCTCACTTTATAAGGTGTCTGCTGACTCCA
CPSF6-FGFR1     ACCTCACTTTATAAGGTGTCTGCTGACTCCA
B
 
 
Figure 3. 21:  (A) Amplification of the CPSF6-FGFR1 fusion specifically from cDNA in the 
t(8;12) patient (E0003) but not the normal controls. The reciprocal fusion product 
was not detected; (B) Sequences surrounding the genomic breakpoints in CPSF6 and 
FGFR1 (bold). 
 
3.4.5  Consequence of the t(8;12)  
 
The t(8;12) fuses CPSF6 intron 8 to FGFR1 exon 10 and is the ninth reported FGFR1 
fusion gene. The CPSF6-FGFR1 mRNA fusion is predicted to encode 5171 bp with an 
open reading frame (ORF) of 2688 bp including necessary intronic CPSF6 sequence to 
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maintain the ORF. The chimaeric protein is predicted to encode an 896 amino acid 
protein of which 501 amino acids are derived from CPSF6 and 395 amino acids from 
FGFR1. The predicted molecular weight of the protein is 223.5 kDa.  The chimaeric 
protein retains the N-terminal region and the RNA recognition motif (RRM) from CPSF6 
fused to the entire tyrosine kinase domain of FGFR1 (Figure 3.32). 
 
FGFR1
CPSF6-FGFR1
CPSF6
Signal peptide
Nuclear targeting domain
RNA recognition motif (RRM)
NH2
Kinase Domain
COOH
COOHNH2
Kinase DomainTM
COOHNH2
RNA recognition motif (RRM)
 
 
Figure 3. 22:  Domain structure of FGFR1, CPSF6, and the predicted fusion protein. Relevant 
protein domains are detailed: RNA recognition motif (RRM), nuclear targeting 
domain for CPSF6 and the transmembrane domain, and tyrosine kinase domain for 
FGFR1. 
 
3.4.6  Discussion 
 
CPSF6 is the ninth partner gene found fused to FGFR1. All FGFR1 fusions to date 
involve a breakpoint in exon 9 which disrupts the FRS2 binding domain (Hoch and 
Soriano 2006). No recognisable oligomerisation motifs are identifiable in CPSF6, 
however it has been demonstrated previously that RNA recognition motifs (RRM), 
such as the one retained in CPSF6-FGFR1, may mediate homodimerisation (Handa, 
et al 2006, Simpson, et al 2004) and thus may activate the fusion protein. 
 
CPSF6 is a cleavage and polyadenylation specificity factor. It plays a major role in 
pre-mRNA processing and has a domain organisation (N-terminal RNA binding 
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motif, a proline-rich middle and a C-terminal alternating charge domain that is 
arginine rich) similar to the superfamily of arginine/serine (R/S) -rich splicing factors 
which are also involved in pre-mRNA splicing. These R/S splicesomal proteins are 
thought to bind pre-mRNA and tether other proteins to the RNA via these R/S-
domains and commit the pre-mRNA to splicing. It has been suggested that CPSF6 
could interact via its alternating charge domain with one or more R/S proteins or R/S 
related splicing factors (Caceres, et al 1997). In conjunction with this CPSF6 has also 
been found in purified splicesomes (Dettwiler, et al 2004, Rappsilber, et al 2002, 
Zhou, et al 2002). During pre-mRNA processing, CPSF6 binds the highly conserved 
polyadenylation site (AAUAAA) that is present in almost every mRNA precursor, as 
well as interacting with the poly-A binding protein II (PABII) that binds the growing 
poly-A tail. Together CPSF6 and PABII activate poly (A) polymerase (PAP), by 
directing the enzyme to the RNA allowing polyadenylation of the upstream cleavage 
product (Ruegsegger, et al 1998).  
 
Interestingly, SFPQ and NonO are also found purified in splicosomes along with 
CPSF6 (Dettwiler, et al 2004, Rappsilber, et al 2002, Zhou, et al 2002). SFPQ has 
recently been described as a partner protein found fused to the Abl tyrosine kinase in 
a patient with B-cell progenitor acute lymphoblastic leukaemia (ALL) (Hidalgo-
Curtis, et al 2008). It is required early in splicesome formation and is a pre-mRNA 
splicing factor that binds the poly-pyrimidine tract of mammalian introns. The 
localisation of both CPSF6 and SFPQ suggests a possible interrelated function in 
transcription and processing of pre-mRNAs of these proteins. Of further interest is 
another FGFR1 fusion partner ZMYM2 (ZNF198) (Xiao, et al 1998), that 
immunoprecipitates with SFPQ (Kasyapa, et al 2005). ZMYM2 is thought to act as a 
possible scaffold protein bringing RNA-binding proteins together to facilitate pre-
mRNA splicing (Kasyapa, et al 2005). In addition, FIP1L1, which fuses to PDGFRα 
in chronic eosinophilic leukemia (Cools, et al 2003), also plays a role in 
polyadenylation and pre-mRNA splicing (Kaufmann, et al 2004, Preker, et al 1995). 
All these interconnected partner proteins found fused to tyrosine kinases in human 
leukaemia are involved in pre-mRNA processing, the precise reasons for the recurrent 
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fusion to FGFR1 of this sub-group of interacting  partner proteins involved with 
transcription elongation is still unclear (Hidalgo-Curtis, et al 2008).  
 
 3.4  Discussion  
 
In this chapter I describe the discovery of four new partner proteins found fused to 
three different receptor tyrosine kinases in patients diagnosed with a MPD. All four 
novel fusions represent rare chromosomal abnormalities with only one of these 
fusions being recurrent (GOLGA4-PDGFRB).  
 
The identification of rare fusions involving tyrosine kinase genes is clearly important 
as they are likely to be responsive to targeted therapy with imatinib or other 
compounds. The functional role of the partner protein is often overlooked, as well as 
providing dimerisation motifs accumulating evidence suggests that these partner 
proteins may play additional roles modifying intracellular signalling and disease 
phenotype (Million, et al 2004). 
 
Groups of partner proteins with similar functions and interactions appear to fuse to 
tyrosine kinases more frequently than expected. Examples include proteins involved 
in pre-mRNA processing (Hidalgo-Curtis, et al 2008), endocytosis (this thesis) and a 
number that are targeted to the centrosome (Delaval, et al 2005b). Partner proteins 
provide both oligomerisation and targeting motifs for the fusion protein. The FIG-
ROS fusion found in glioblastoma and the FGFR1OP-FGFR1 fusion found in 
patients with 8p11 myeloproliferative syndrome (EMS) are directed by the partner 
protein to specific sub-cellular compartments, including the centrosome and the Golgi 
(Charest, et al 2003, Delaval, et al 2005b). In the case of FIG-ROS, this is thought to 
be essential for the transforming ability of the fusion.  
 
Delaval et. al., (2005) describe the targeting of FGFR1OP-FGFR1, an oncogenic 
tyrosine kinase, to the centrosome thus activating signalling pathways at this 
organelle allowing cells to sustain continuous cell cycles. This group have also 
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identified a second FGFR1 partner gene localised to the centrosome, and suggest that 
the fusion partners may not only provide dimerisation domains but also target 
oncogenic kinases to a specific cellular locations necessary for transformation. They 
hypothesise that these proteins may exert their oncogenic activity through 
dysregulation of cell processes associated with the centrosome. Thus further research 
into the subcellular localisation of oncoproteins indicates that emerging links between 
partner protein function and localisation may not all be coincidental. Numerous 
studies have been performed that look specifically at the subcellular localisation of 
constitutively activated kinases, Wetzler et. al., (1993) investigated the BCR-ABL 
protein in leukaemic cells and found the fusion resides exclusively in the cytoplasm, 
unlike the wild type ABL protein that is only found in the nucleus (Wetzler, et al 
1993). In addition, Ollendorf et. al., (1999) whom further characterised the FIM-
FGFR1 fusion product as a result of the t(8;13) translocation, studied the subcellular 
localisation of this fusion protein, and in comparison to wild type FIM, they found 
that it was also entirely cytoplasmic (Ollendorff, et al 1999). It is thought that 
localisation of these fusion proteins to the cytosol is enough to abrogate their entry 
into the endocytic pathway, and hence prevent lysosomal degradation.  
 
Functionally, the largest related group of partner proteins is those linked to 
intracellular trafficking and endocytosis. There is increasing evidence of a 
relationship emerging between endocytosis and leukaemia. Removal of specific 
receptors from the cell surface by endocytosis and their degradation in lysosomes is 
an established method for the attenuation of receptor signalling. Genes encoding 
proteins associated with the endocytic pathway are repeatedly being identified as 
targets of chromosomal rearrangements in human haematological malignancies. The 
identification of GOLGA4-PDGFRB, adds further weight to this emerging 
relationship. It is possible that subversion of endocytic control, possibly caused by 
such oncogenic fusion proteins, could play an important role in hyperproliferative 
conditions.  
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Further evidence of the role of endocytic pathways in haematological malignancies is 
becoming increasingly apparent. At least three reported translocations involving 
PDGFRB, identified in patients with aCML/CMML (Table 3.2), make in-frame 
fusions with components of the endocytic machinery. These include Rabaptin-5, 
Hip1 and PDE4DIP. Rab5 in its active GTP-bound form recruits a number of 
effectors to the endosome membranes. Rabaptin-5 is proposed to function as 
molecular linker between Rab5 and Rab4 to coordinate endocytic and recycling 
traffic (Magnusson, et al 2001, Vitale, et al 1998). Zhu et. al., (2004) has also 
recently shown through biochemical and functional analysis that the Rab5-Rabaptin-5 
complex abrogates endosome fusion if disrupted (Zhu, et al 2004). The Rabaptin-5-
PDGFRB fusion results in a loss of the Rab5 binding site and thus might obstruct 
formation of the Rab5-Rabaptin-5 complex, consequently halting endosome fusion. 
 
A second relevant fusion is Hip1-PDGFRB (Ross, et al 1998). Huntington-interacting 
protein 1 (Hip1) was the first component of the endocytic machinery to be directly 
implicated in tumour formation. It interacts with AP-2, phosphoinositides and clathrin 
and is thought to play a role in clathrin-mediated endocytosis. Over-expression of 
Hip1 causes cell transformation and increased cell proliferation and the transformed 
cells also appear to have less clathrin at the plasma membrane. Hyun et. al., (2004) 
also found that over-expression of Hip1 inhibited the degradation of ligand-
stimulated growth factor receptors. Transient transfection of 293T cells with Hip1 
stabilised pools of PDGFRB following ligand-induced endocytosis, thus it is 
proposed that Hip1 may stabilise growth factor receptor levels via altered 
intracellular trafficking. Hip1 also contains an ENTH (epsin N-terminal homology) 
domain, that like other ENTH domains binds predominantly to phosphatidylinositol 
4,5-bisphosphate (PtdIns(4,5)P2), and is important in regulating clathrin-mediated 
endocytosis. Hyun et. al., (2004) suggest that the ENTH domain may be the factor 
involved in regulating growth factor endocytosis and thus could be critical in the 
protein’s ability to promote cell growth or survival (Hyun and Ross 2004). This has 
been further supported by work done using a mutant construct lacking the ENTH 
domain, which when transfected into cells induced apoptosis. The lipid binding 
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Protein Proposed function in receptor downregulation Cancer type Chromosomal translocation References 
Eps15 Ubiquitin-binding protein found in PM clathrin-coated pits and in clathrin coats in sorting 
endosomes. Possible role in receptor recruitment. 
Myeloid 
leukaemia 
ALL/HRX gene; t(1;11)(p32;q23) (Floyd and De 1998) 
Endophilin-2 Putative lysophosphatidic acid acyl transferase. Binds dynamin-2 and synaptojanin. Involved in 
formation of clathrin-coated vesicles. Member of the membrane-bending/GTPase BAR domain
Myeloid 
leukaemia 
ALL/HRX gene; t(11;19)(q23;p13) (Floyd and De 1998) 
CALM Non-neuronal homologue of AP-180. Binds clathrin and phosphoinositides. Strong activator of 
clathrin polymerisation. 
Myeloid 
leukaemia 
AF-10; t(10;11)(p13;q14) (Floyd and De 1998) 
Rabaptin-5 Effector of Rab5. Complexed to the Rab5 GDP/GTP exchange factor Rabex5. Required for 
endosomal fusion. 
CMML PDGFRβ; t(5;17)(q33;p13) (Magnusson, et al 2002) 
Hip1 Homologue of End4/Sla2, which interacts with actin-binding proteins and is required for 
endocytosis in Saccharomyces cerevisae. Role in clathrin-mediated endocytosis. Interacts with 
AP-2, clathrin and phosphoinositides 
CMML PDGFRβ; t(5;7)(q33;q11.2) (Ross, et al 1998) 
PDE4DIP/Myomegalin Functions as an anchor to localise components of the cAMP-dependent pathway to the 
Golgi/centrosome. The cAMP-dependent pathway is thought to be essential for intracellular 
signalling. 
Eosinophilic 
CMPD 
PDGFRβ; t(1;5)(q23;q33) (Wilkinson, et al 2003) 
BIN2 Member of the BAR domain proteins. BAR domain drives membrane curvature, implicating a 
role in vesicular trafficking. BAR also shares significant homology to GTPase binding domain 
of Arfaptin 2, an effector of Rho-and Arf-like GTPases. Arfaptin 2 is known to be involved in 
intracellular transport, especially endocytosis. 
Eosinophilic 
CMPD 
PDGFRβ; t(5;12)(q22.1;q33) Hidalgo-Curtis et. al., 
SUBMITTED 
WDR48 WD-repeat endosomal protein. Eosinophilic 
CMPD 
PDGFRβ; t(3;5)(p22.2;q33) Hidalgo-Curtis et. al.,  
SUBMITTED 
Golgin-245 Golgin family of coiled-coil proteins, associated with the Golgi apparatus. Plays a role in 
tethering events in membrane fusion and as structural supports for Golgi cisternae 
(subcompartments of the TGN). May also function as a vesicle coat. 
aCML PDGFRβ; t(3;5)(p22;q33) Hidalgo-Curtis et. al.,  
SUBMITTED 
KIF5B Important for microtubule-based endosome-motility, by regulating early endosome trafficking. 
If inhibited reduced endosome motility and vesicle fission is observed. 
Eosinophilic 
CMPD 
PDGFRα complex karyotype (Score, et al 2006) 
 
(Charest, et al 2003) FIG Encodes a protein that peripherally associates with the golgi apparatus, and likely plays a role 
in golgi function. 
Glioblastoma del 6(q21) 
 
Table 3.2:   Components of endocytic machinery found as partners of oncogenic fusion proteins. 
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characteristics of the ENTH domains were also analysed and unusually found to 
preferentially bind 3-phosphoinositides not (PtdIns(4,5)P2). Thus, it is suggested that 
Hip1 acts downstream of receptor uptake to inhibit trafficking of receptor tyrosine 
kinases to the lysosome for subsequent degradation. It is speculated that this occurs 
by binding inositol lipid determinants of the early endosome by their ENTH domains, 
acting to either stabilise the early endosome, favouring continued signalling, or by 
stimulating growth factor recycling to the surface. This work certainly provides 
evidence of a strong link between a partner gene of PDGFRB and the targeting of the 
endocytic pathway.  
 
Other examples of oncoproteins involving members of the endocytic pathway include 
AF-1p (Bernard, et al 1994) and EEN (So, et al 1997) both of which are partners 
found fused to the C-terminal region of the MLL gene. In addition, endocytic proteins 
fused to RTKs in other malignancies have been reported, in particular papillary 
thyroid carcinomas. Rabes et. al., (2000) observed a fusion between the RET receptor 
tyrosine kinase and GOLGA5 a golgi integral membrane protein (Bascom, et al 1999, 
Rabes, et al 2000). Further evidence to support the hypothesis that subversion of 
endocytic pathways may be important in leukaemogenesis will be described in 
Chapter 5. 
 
Deregulated, constitutively activated tyrosine kinases are proving to be the main 
driving force behind the MPDs, as substantiated in this chapter with the identification 
of four new tyrosine kinase fusion genes: GOLGA4-PDGFRB, STRN-PDGFRA, 
ETV6-PDGFRA and CPSF6-FGFR1. Moreover, there is now accumulating evidence 
to suggest an additional role for the partner proteins in modifying intracellular 
signalling and disease phenotype. Functionally similar groups of partner proteins 
linked to the centrosome (Delaval, et al 2005a), transcription elongation (Hidalgo-
Curtis, et al 2008) and intracellular trafficking (Hidalgo-Curtis et. al., submitted 
2009) have been identified that are thought to contribute not only the dimerisation 
motif but may impair endocytosis and even direct the oncoprotein to specific 
intracellular compartments, all of which may be critical to their transforming ability.  
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4   IDENTIFICATION OF DEREGULATED 
EXPRESSION OF TYROSINE KINASE GENES 
 
4.1   Introduction 
 
There is increasing evidence to suggest a role for deregulated tyrosine kinases in the 
pathogenesis of MPDs. It is particularly important to recognise patients with 
PDGFRA or PDGFRB fusions as these cases are likely to be responsive to imatinib 
(Apperley, et al 2002, Cools, et al 2003a, Gotlib 2005, Jones and Cross 2004, Klion, 
et al 2004, Pardanani, et al 2003). Identification of patients who are positive for 
PDGFR fusions is therefore critical to appropriate clinical management.  However 
these genes have been shown to fuse to diverse partners in MPDs and it seems likely 
that additional partner genes are yet to be discovered. Furthermore many of these 
cases are very rare and the breakpoint diversity of many fusions is unknown. 
Consequently it is difficult to screen for all PDGFR fusions. 
 
Our research group has studied patients for in vitro sensitivity to imatinib, as 
mentioned above. A number of patients have been found that appear to be responsive 
to imatinib but are negative for the known common fusions (e.g. FIP1L1-PDGFRA 
and ETV6-PDGFRB). This leaves a number of patients where the molecular lesion 
has not been characterised, but we suspect involves an imatinib responsive gene. 
Cytogenetic analysis may suggest that either PDGFRA or PDGFRB might be 
involved, but some fusions are cytogenetically cryptic (e.g. FIP1L1-PDGFRA) and 
several translocation targets have been identified on chromosome 5q that are distinct 
from PDGFRB, for example FLT4 fusions found in a minority of MDS patients 
(Armstrong, et al 1993). Thus cytogenetics alone cannot be used to determine 
unambiguously whether a patient might be sensitive to imatinib or not. FISH may be 
used to look for rearrangements of specific genes, but these results may be misleading 
due to cryptic or complex rearrangements (Kulkarni, et al 2000). Consequently there 
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is a need for new methods to detect PDGFRA and PDGFRB fusion genes. Here I 
describe the design and application of two generic RT-PCR assays to detect over-
expression of PDGFR genes, and an mRNA-based Multiplex Ligation-dependent 
Probe Amplification (MLPA) test. The main aim was to search for new cryptic gene 
fusions that might be responsive to imatinib. 
 
4.1.1   PDGFRB rearrangements 
 
Disruption of PDGFRB was first described by Golub et. al., (1994), as a consequence 
of a t(5;12)(q33;p13), fusing the 5’end of ETV6 (otherwise known as TEL) to the 
3’end, encoding the entire tyrosine kinase domain, of PDGFRB (Golub, et al 1994). 
Subsequently, twenty other translocations involving PDGFRB have been reported 
(See Table 1.1, Section 1.7.3) including three identified by our laboratory 
unpublished at present. The breakpoint for twenty out of the twenty one reported 
oncogenic fusions is within intron 10 of PDGFRB. To date, NIN-PDGFRB is the only 
reported fusion gene that exhibits a different genomic breakpoint (Vizmanos, et al 
2004). The partner genes fuse in frame to the entire PDGFRB tyrosine kinase 
domain. Each partner protein contains an oligomerisation motif that dimerises the 
receptor tyrosine kinase, leading to aberrant phosphorylation of downstream proteins 
promoting growth and resistance to apoptosis. 
 
Under normal conditions PDGFRB mRNA expression is tightly regulated, but when 
fused to the partner gene expression of the tyrosine kinase portion is under the control 
of the partner gene promoter and so may be over-expressed compared to the normal, 
full length PDGFRB mRNA. I developed a PCR-based assay designed to detect the 
expression of the tyrosine kinase domain of PDGFRB compared to a control band 
spanning the exons upstream and downstream of the common reported breakpoints.  
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4.1.2   PDGFRA rearrangements 
 
 
Disruption of PDGFRA was first described by Baxter et. al., (2002), as a consequence 
of a t(4;22)(q12;q11), fusing the 5’end of BCR to the 3’end encoding the entire 
tyrosine kinase domain of PDGFRA. This is a rare variant translocation identified 
initially in only two patients with a CML-like MPD (Baxter, et al 2002). Five further 
rearrangements of PDGFRA have been identified and the breakpoints within 
PDGFRA have been found to be very tightly clustered in all cases, resulting in a 
truncated PDGFRA exon 12 (Baxter, et al 2002, Cools, et al 2003a, Curtis, et al 
2007, Score, et al 2006, Walz, et al 2007). The most common PDGFRA 
rearrangement is the fusion of FIP1L1 to PDGFRA in HES patients described by 
Cools et. al., (2003). The fusion is generated by an interstitial deletion on 
chromosome 4q12. This fusion is cytogenetically cryptic but can be detected by FISH 
or RT-PCR (Cools, et al 2003a, Pardanani, et al 2003).  Detection of this fusion is 
also complicated by the complex alternative splicing and variability of genomic 
breakpoints in FIP1LI, in addition to the low expression of the fusion gene in many 
cases and the significant variability in the proportion of cells involved in the 
malignant clone (Chung, et al 2006, Cools, et al 2003a). I designed a second assay in 
the same manner as that for PDGFRB, but for PDGFRA in an attempt to detect novel 
cryptic rearrangements. It was also hoped that this assay might address the limitation 
of current procedures in detecting FIP1L1-PDGFRA. I designed a second simple 
multiplex RT-PCR assay to determine the relative expression of the PDGFRA kinase 
domain which is retained in all fusions. This was compared to expression of the intact 
receptor, which is usually not detectable or weakly detectable by standard RT-PCR 
from peripheral blood or bone marrow leukocytes. Samples with a possible PDGFRA 
fusion gene were expected to over-express the kinase domain relative to the normal 
receptor mRNA.  
 
109 
4.2   Methods 
 
4.2.1   Design of the PDGFRB RT-PCR assay 
 
Three primers were designed, two that flank the region where the common 
breakpoints are reported (PDB Ex9/10.F and PDB Ex15.1R), and a third after the 
exon in which all the breakpoints are reported (PDBEx13.1F) (Figure 4.1). Primers 
were designed to anneal at 66°C and the PCR was undertaken in a volume of 10µl, 
due to limited cDNA available for each patient. The number of patients eligible for 
screening prompted me to perform all the amplifications in plate format or in 0.2ml 
strips tubes in a MJ Research Inc. thermocycler (Tetrad). After optimisation, the PCR 
protocol was finalised to: 0.4μM PDGFRB exon 9/10.F, 0.1μM PDGFRB exon 
13.1F, 0.5μM PDGFRB exon 15.1R, 0.2mM dNTP, 1x buffer (Hotstar buffer 
containing 15mM MgCl2), 2.5mM MgCl2 (total), 0.4U Hotstart Taq DNA polymerase 
(Qiagen, West Sussex, UK). The PCR cycling parameters use a 15 minute 95°C hot-
start to activate the enzyme and a 30 second, 66°C annealing temperature for 
stringency. The PCR was cycled 30 times.  
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Figure 4. 1:  A diagram representing the position of each of the primers in the multiplex, in 
relation to the common reported breakpoints in PDGRFB and to the tyrosine kinase 
and extracellular domains of PDGFRB. 
 
A patient with normal PDGFRB expression is expected to generate two bands of 
equal intensity (assuming both PCRs worked with the same efficiency), and a patient 
with a rearrangement that results in over-expression of the region encoding the 
tyrosine kinase would exhibit a strong smaller band derived from both the normal 
receptor mRNA and the fusion mRNA, and a faint larger band derived solely from 
the normal receptor mRNA (Figure 4.2A). 
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  230bp 
721bp 
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2kb 
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200bp 
 
 
Figure 4. 2:   PDGFRB RT-PCR assay, a schematic of the expected banding pattern. (A) The 
banding pattern expected from initial design of the PDGFRB multiplex, (B) Gel 
picture of observed bands from a number of patients and controls screened using the 
PDGFRB multiplex. 
 
Figure 4.2B represents an example of a gel of the PDGFRB RT-PCR assay. Lane 1 
(L1) represents a normal individual with an additional band visible at 2kb. I cloned 
and sequenced this aberrant band and found it contained intronic sequence, and was 
therefore a genomic DNA contaminant. Residual genomic DNA is often found in the 
cDNA. I altered the PCR conditions by reducing the amount of the 5’ primer in the 
extracellular domain but was unsuccessful at eliminating this band. I also redesigned 
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the primer, finally resorting to the Ex9/10F primer. This primer was designed to sit 
across the exon boundaries of exon 9 and 10 to prevent amplification of any genomic 
DNA. Although this primer helped to reduce the intensity of this contaminating band 
it was not successful at eradicating it completely. With further work I showed the 
assay was still informative and that this band did not interfere with interpretation of 
the results, and can therefore be disregarded.  Lane 2 (L2) represents my normal 
control, for which I cloned each of the fragments and combined them equally to 
create an artificial mixture. In this lane as expected, the 2kb genomic band is absent. 
Finally, lane 3 (L3) is my positive control, created again through cloning, from a 
patient with a novel PDGFRB rearrangement. The positive control shows only the 
bottom band, representing the tyrosine kinase portion of the gene. Some patients 
showed this same pattern, with the absence of the larger control band, others showed 
the differential expression expected (Lanes 1 and 4) (Figure 4.3). 
 
1kb 
ladder 
1kb 
200bp 
L1          L2          L3          L4          L5          L6          L7          L8 
Genomic b
 
 
and
Figure 4. 3:  A representative agarose gel picture of patients screened by the PDGFRB multiplex. 
Lane 1 (L1) represents a positive patient where the tyrosine kinase band is present 
only; Lanes 2 and 3 (L2 and L3) are negative patients where both bands are clearly 
visible; Lane 4 (L4) is the positive control created from cloning of a patient with a 
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known PDGFRB fusion. Lane 5 (L5) shows the no DNA control, and Lanes 6, 7 and 
8 (L6, L7, and L8) represent patients where the genomic band has out-competed the 
presence of the other bands and were classed as fails. 
 
4.2.2   Design of the PDGFRA RT-PCR assay 
 
Three primers were again designed, two that flank the region where the common 
breakpoints have been reported (PDA Ex10.1F and PDA Ex15.1R). The majority of 
breakpoints in PDGFRA have been reported in exon 12, therefore the third primer, 
designed to prime after the region of common breakpoints was located in exon 13 
(PDA Ex13.1F) (Figure 4.4A). As before, all primers were designed to anneal at 
66°C, the PCR volume was 10µl and the amplifications were in plate or strip-tube 
format, for 30 cycles, in a MJ Research Inc. thermocycler (Tetrad). After optimisation 
the PCR protocol was finalised to: 0.05μM PDGFRA exon 10.1F, 0.2μM PDGFRA 
exon 13.2F, 0.4μM PDGFRA exon 15.1R, 0.2μM dNTP, 1x buffer (Hotstar buffer 
containing 15mM MgCl2), 2.5mM MgCl2 (total), 0.4U Hotstart Taq DNA polymerase 
(Qiagen, West Sussex, UK). The PCR cycling parameter again uses a 15 minute 95°C 
hot-start to activate the enzyme and a 30 second, 66°C annealing temperature for 
stringency.  
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Figure 4. 4:  PDGFRA RT-PCR assay. (A) A schematic representing the position of each primer 
in the multiplex in relation to the common reported breakpoints in PDGRFA, (B) 
The banding pattern expected from initial design of the PDGFRA multiplex, (C) Gel 
picture of observed bands from a number of patients screened using the PDGFRA 
multiplex. 
 
A patient with normal PDGFRA expression is expected to yield two bands of equal 
intensity and a patient with a rearrangement that results in over-expression of the 
tyrosine kinase would exhibit a strong smaller band and a faint larger band as before 
(Figure 4.4B). Lanes 1-3 show normal individuals, however only one band was 
present, and initially presumed to be the larger control band. On analysis of this band, 
it was clear the product was not the size expected from the primer pair. Upon cloning 
and sequencing I found that this band was again due to genomic DNA contamination. 
Alternate primers and differing PCR conditions failed to yield a correct sized control 
band with no intron, or the expression of both mRNA-derived bands in a normal 
individual. This is almost certainly because PDGFRA is not normally expressed or 
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expressed at very low levels in peripheral blood leukocytes. I therefore ordered a cell 
line, MG-63 that has been shown to express normal PDGFRA. MG-63 cDNA 
produced, as expected, two bands of 650 and 290 bp (Figure 4.5). Although the lower 
band is stronger than the upper band, both are clearly visible. Eol-1 cells express 
FIP1L1-PDGFRA and only the smaller 290 bp band derived from the region retained 
in the fusion is visible (Figure 4.5). Most normal individuals didn’t show either of the 
PDGFRA mRNA-derived bands, but instead the 1049 bp genomic DNA fragment 
encompassing exons 13–15 was amplified (Figure 4.5). Although an unexpected 
product, this band served as a useful internal control for successful amplification. On 
screening positive controls I also discovered that although differential expression was 
not observed, the smaller band (290bp) was visible only in patients with confirmed 
PDGFRA rearrangements (Figure 4.4C, Lane 4). Thus, the RT-PCR assay allowed 
identification of over-expression of the tyrosine kinase domain of PDGFRA. 
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Figure 4. 5:  MG-63 cells express normal PDGFRA and both 650 bp and 290 bp bands are visible. 
Eol-1 cells express FIP1L1-PDGFRA but not normal PDGFRA and only the smaller 
290 bp band is visible. Normal individuals 1–3 express PDGFRA very weakly and the 
predominant amplification product (1049 bp) is exons 13–15 from genomic DNA. 
Patient E683 shows the 290 bp band but not the 650 bp band, suggesting the presence 
of a PDGFRA fusion gene (discussed in more detail later). 
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4.3   Results 
 
4.3.1   Identification of patients with possible PDGFRB rearrangements 
 
Having optimised the PDGFR RT-PCR assays I went on to screen a cohort of 199 
MPD patients for over-expression of PDGFRB. Of these 18 were identified that were 
regarded as possibly positive for a PDGFRB rearrangement on the basis of increased 
intensity of the smaller band. Of these 18, 9 were strongly positive with markedly 
increased relative intensity (Table 4.1) and are considered in detail below. 
Identifier Diagnosis/Referral Reason Previously identified fusion gene
P936 EMS ZNF198-FGFR1 
P981 MPD? 8p11 FGFR1OP-FGFR1 
P997 MPD t(5;10) CCDC6-PDGFRB 
P1218 MPD t(5;12) ETV6-PDGFRB 
E285 MDS transformed t(5;12) ETV6-PDGFRB 
E287 HES No 
E354 Eosinophilia No 
E508 ?HES/SM No 
E521 MPD No 
 
Table 4. 1:  Patients observed to have PDGFRB over-expression using the PDGFRB multiplex 
RT-PCR assay. 
 
The samples were screened blind and the multiplex was able to identify all three 
patients with previously characterised PDGFRB fusion genes (P997, P1218 and 
E285), of which two had been found to harbour ETV6-PDGFRB and the third 
CCDC6-PDGFRB Unexpectedly two patients with over-expression of PDGFRB had 
previously been found to have rearrangements of FGFR1 (P936 and P981). Finally, 
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four patients (E287, E354, E508 and E521) had been previously tested negative by 
RT-PCR for ETV6-PDGFRB and were investigated in more detail. 
 
 My initial analysis focused on patient E521 as this case had the most stored material. 
I performed FISH and 5’RACE and discovered the patient had a typical ETV6-
PDGFRB rearrangement, despite the previous RT-PCR negative result. Only after I 
had identified the ETV6-PDGFRB fusion in this patient did we receive notification of 
the patient’s karyotype. The fusion is a consequence of a complex rearrangement 
involving chromosomes 2, 5 and 12 (Figure 4.6). It is not obvious from the karyotype 
that this fusion might exist but the involvement of 5q33 is suggestive of a PDGFRB 
rearrangement. After this discovery the original diagnostic RT-PCR was repeated and 
the patient sample was found to be positive. Why this fusion was missed initially is 
unclear however, he had been treated and responded to imatinib. Of the remaining 
three patients, E508 and E354 were studied extensively performing PDGFRB split 
apart FISH and 5’RACE to detect any possible PDGFRB rearrangements. No 
evidence for disruption of this gene was found. Very little material was available for 
study of the fourth case (E287). 
 
ETV6-PDGFRβ
ETV6-PDGFRB Karyotype: t(5;12)(q33;p13)
Patient Karyotype (E521): 46XY,ins(2;12)(p21;q?13q?22),del(5)(q33q35)
COOHNH2
Helix-loop-
helix domain TM
Tyrosine kinase 
domain 1
Tyrosine kinase 
domain 2
Kinase 
insert
 
 
Figure 4. 6: Structure of the ETV6-PDGFRβ fusion with the usual karyotype associated with this 
fusion and the complex karyotype observed in the bone marrow of patient E521 by 
conventional cytogenetics 
 
Gain-of-function point mutations have also been discovered in certain receptor 
tyrosine kinases that act to constitutively activate the kinase, such as the well 
117 
characterised V617F change in JAK2 associated with PV and other MPDs. 
Additionally, point mutations and small deletions in the activation loop and 
juxtamembrane domains of PDGFRA and KIT have been commonly reported in 
patients with gastrointestinal stromal tumours (Heinrich, et al 2003, Hirota, et al 
1998) and more recently Chiara et. al, (2004) reported the identification of a mutation 
in the activation loop of the murine PDGFRB gene. The mutation conferred 
transforming ability to the embryonic fibroblasts (Chiara, et al 2004). Based on this, I 
screened two patients with available material over-expressing PDGFRB using 
denaturing High Performance Liquid Chromatography (dHPLC) and sequencing. I 
began by screening the key regions of PDGFRB, those encoding the juxtamembrane 
domain and the activation loop (exons 12-18). For both patients each exon was 
individually amplified and the PCR product mixed in a 1:1 ratio with normal 
placental DNA PCR product for each individual exon. The samples were then heated 
to 95°C and slowly allowed to reanneal on a reducing temperature gradient allowing 
the formation of heteroduplexes. When run through a chromatography column under 
partially denaturing conditions changes in sequence usually result in extra peaks or 
shifted peaks compared to normal controls. No activating mutations were identified in 
either patient in the juxtamembrane or activation loop of PDGFRB. I screened all the 
remaining exons of PDGFRB to exclude the possibility of a mutation in these regions 
(exons 1-11 and exons 19-23). Both patients lacked any sequence variants. 
 
A colleague (Kathy Waghorn) had also designed a DNA Multiplex ligation-specific 
probe amplification (MLPA) assay for selected tyrosine kinase genes. MLPA is a 
probe based technique that allows multiple targets to be amplified with only a single 
primer pair (for more detail see Figure 4.8). Amplification of the probe is dependent 
upon the number of target sites present in the sample, permitting detection of 
genomic deletions and amplifications. Each probe is fluorescently labelled and has a 
unique length allowing multiple amplicons to be analysed in one reaction and 
separated by size by capillary electrophoresis. Comparison of the peak pattern 
obtained for a given sample against reference samples allows the relative quantity of 
each amplicon to be determined. The ratio obtained identifies the amount of target 
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sequence present in the sample DNA. The MLPA assay designed by Kathy included 
the PDGFRB gene, and was used to look for possible duplications and deletions of 
specific tyrosine kinase genes. Following the PDGRFB over-expression RT-PCR 
result, E508 (only patient with available DNA) was analysed using MLPA. No 
deletions or duplications were observed (Figure 4.7).  
 
 
BTK
FGFR1 
PDGFRB
 
Figure 4. 7: MLPA traces of patient E508. MLPA traces showing (A) Normal control displaying 
full set of candidate tyrosine kinase genes in order: PDGFRA, MET, PDGFRB, RET, 
FGFR1, SYK, FLT3, ROS, BTK, RRP4, MSTA, TRKB, EPHB4, MPL and FGFR3 
(Note: BTK is an X-linked gene used as control), (B) patient with FGFR1 duplicated 
proving its discriminatory power, (C) E508, set of four genes: EPHB4, MPL, 
PDGFRB and MET, used when looking for rearrangements of a specific gene. 
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4.3.2   Identification of patients with possible PDGFRA rearrangements 
 
A total of 270 cases with IHES or persistent unexplained eosinophilia were referred 
to the Wessex Regional Genetics Laboratory, Salisbury for routine molecular analysis 
between May 2002 and November 2005. Of these, 229 patients were screened using 
the PDGFRA multiplex. The patients were simultaneously screened for the more 
common FIP1L1-PDGFRA fusion using single and nested RT-PCR. All 12 cases in 
this study group who tested FIP1L1-PDGFRA positive by RT-PCR were also 
positive by the PDGFRA assay, that is, the 290bp band was clearly visible and the 
650bp band was either not visible or was barely visible (Table 4.2), confirming the 
multiplex worked to identify rearrangements of PDGFRA. There were no cases 
where a FIP1L1-PDGFRA fusion determined by standard RT-PCR was not identified 
by my PDGFRA expression assay. Interestingly one patient (E293) turned out to be a 
sample from a FIP1L1-PDGFRA positive case that had been treated with imatinib 
and was therefore referred for minimal residual disease analysis. Both single and 
nested RT-PCR of FIP1L1-PDGFRA proved negative, however my assay observed 
over-expression of PDGFRA. This is unusual, as it is expected that the nested RT-
PCR will be more sensitive than the PDGFRA assay. However, analysis of FIP1L1-
PDGFRA breakpoints by a colleague has highlighted breakpoints in regions 
downstream of the common FIP1L1 breakpoint. Due to the position of the nested RT-
PCR primers within PDGFRA, nested RT-PCR using standard primer sets would not 
be able to identify this case efficiently and thus my PDGFRA assay proved useful in 
this case for treatment analysis. The diagnosis of the FIP1L1-PDGFRA fusion by RT-
PCR specific for the fusion itself is often very difficult and part of the reason may be 
the fact that some cases have aberrant breakpoints. Some patients are found to be 
positive only by nested PCR, even at diagnosis. 
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Identifier FIP1L1-PDGFRA RT-PCR result 
243 1 Single step positive 
293 1 Negative 
458 Nested positive 
555 Single step positive 
591 2 Nested positive 
606 Nested positive 
614 Single step positive 
636 Single step positive 
646 2 Nested positive 
759 Single step positive 
794 Single step positive 
905 Single step positive 
939 Single step positive 
1025 Single step positive 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Same patient 
2 Same patient 
 
Table 4. 2:  Validation of the PDGFRA multiplex. Patients that are FIP1L1-PDGFRA positive 
were also positive with the PDGFRA RT-PCR multiplex. 
 
A further 14 patients were identified in the screen of the 217 FIP1L1-PDGFRA-
negative samples to have over-expression of PDGFRA (~6%) (Table 4.3). These 
patients were not characterised molecularly and therefore the over-expression of 
PDGFRA observed by the multiplex offered a possible explanation to the 
pathogenetic cause of the patients’ leukaemia.  
121 
  Case number Referral reason 
94 HES 
200 Idiopathic HES 
271 ?MPD ?HES 
289 Eosinophilia 
344 HES 
349 HES 
421 ? HES 
459 HES 
539 Eosinophilia 
639 ? CML/MPD 
680 ? CML 
683/684 Eosinophilic leukaemia 
748 MPD/MDS 
843 ?MPD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. 3:  FIP1L1-PDGFRA negative cases that tested positive for the PDGFRA RT-PCR 
assay. 
 
A colleague was carrying out work to characterise the exact genomic breakpoints of 
patients with FIP1L1-PDGFRA using bubble PCR (see section 2.2.6 for more 
details). Also included in this analysis was patient E683/E684, who had a complex 
rearrangement; 46XY, del(3)(p21), add(4)(q12),-10,13q?,+der(?)(?→cen→ 
?::4q12→ 4q28.3::10q11.2→ 10qter) and who also tested positive by the PDGFRA 
multiplex in the blood sample (E683) but, interestingly, not the bone marrow (E684). 
My colleague went on to discover a previously undescribed fusion involving a novel 
partner gene to PDGFRA. The partner gene is a member of the Kinesin family, 
KIF5B and is located at chromosome 10p11.22. The patient was treated with imatinib 
and six months later had achieved complete cytogenetic and molecular negativity 
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(Score, et al 2006). At the time of publication this was the third PDGFRA fusion 
partner and highlighted the utility of this the over-expression assay to detect rare 
PDGFRA fusions.  
 
Sufficient material was available for further analysis of six of the fourteen cases 
found to over-express the PDGFRA kinase domain. Because of the success of bubble-
PCR in identifying PDGFRA rearrangements, I used this technique and found a 
rearrangement in one case with both restriction enzymes. Unexpectedly, sequencing 
of these rearranged bands revealed FIP1L1 sequence. Reanalysis of patient cDNA 
confirmed the presence of FIP1L1-PDGFRA mRNA that had been missed on initial 
analysis. The fusion was detectable by nested but not single-step RT-PCR and this 
case highlights the problems in reliably detecting FIP1L1-PDGFRA (Score, et al 
2009). The reason for PDGFRA over-expression in the remaining cases remains 
obscure. 
 
 
4.3.3   Over-expression assays: discussion 
 
 
Detection of PDGFRA and PDGFRB rearrangements is of increasing importance but 
both standard RT-PCR and FISH assays may miss positive cases. Through the blind 
screening of patients using the newly designed PDGFRA and PDGFRB multiplexes, I 
have been able to prove that both assays work well to detect overexpression of these 
kinases. Both multiplex PCRs identified all patients with previously characterised 
PDGFR rearrangements.  
 
To date, only one patient (E521) found positive by the PDGFRB multiplex has 
actually proved to have a 5q33 rearrangement. The patient was clinically diagnosed 
as having a CMPD, that was later found to be as a consequence of a previously 
undetected t(5;12)(q33;p13). None of the remaining patients with over-expression of 
PDGFRB have yielded identification of an oncogene or chromosomal rearrangement 
and the basis for over-expression remains ambiguous. Surprisingly two positive 
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patients were known to have rearrangements of the FGFR1 gene. The reason for this 
is unclear but it is known that active receptor tyrosine kinases activate complex 
intracellular signalling networks that result in a variety of cell responses including 
cell maintenance, mitogenesis, migration and differentiation. Thus it is possible that 
the FGFR1 fusions might activate PDGFRB, however it is unclear why this should 
lead to specific over-expression of the kinase domain. Potentially this could be an 
artifact, for example if PDGFRB in this context was alternatively spliced such that 
the normal full length product was not detected. Alternatively, it is known that 
PDGFRA can be expressed from an internal promoter. (Mosselman, et al 1994, 
Mosselman, et al 1996) and it is possible that PDGFRB might also have an internal 
promoter, transcripts from which might be scored in my assay as a potential fusion.   
 
Of the 7 patients found to over express PDGFRA, one patient who responded to 
imatinib was investigated in detail and found by bubble-PCR to have a previously 
undescribed fusion involving a novel partner gene, KIF5B at chromosome 10p11.22. 
Little is known about KIF5B however it is a member of the Kinesin superfamily. The 
kinesins are microtubule-based motor proteins that play important roles in organelle 
transport and cell division. They have an N-terminal motor domain which converts 
ATP into a motile force along the microtubules (plus-end direction only), a central 
alpha-helical rod domain enabling the protein to dimerise and a globular C-terminal 
domain, that allows interaction with possible organelle receptors. Xia et. al., (1998) 
have demonstrated in mice that KIF5B is ubiquitously expressed, unlike many of the 
other family members that are expressed only in neuronal tissues (Xia, et al 1998). 
 
Confirmation of both the genomic breakpoint and the cDNA breakpoint were later 
performed, and the fusion mRNA demonstrated by single step PCR amplification. 
The complex rearrangement involving chromosomes 2, 4 and 10 is predicted to 
generate a chimaeric fusion protein that is structurally similar to other tyrosine kinase 
fusions. Therefore, it is likely that the KIF5B-PDGFRA fusion deregulates 
haematopoiesis in a manner analogous to BCR-ABL in CML patients. A schematic 
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representation of the normal and chimaeric fusion proteins is presented in (Figure 
4.8).  
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Figure 4. 8:  Schematic representation of the normal PDGFRα, KIF5B and the KIF5B-PDGFRα 
fusion. 
 
 
The PDGFRA RT-PCR assay has not only pointed the way to a new fusion but also 
proved to be extremely useful for detecting patients with FIP1L1-PDGFRA. This 
more common fusion is predominantly tested for diagnostically by RT-PCR using 
single and nested primers, however studies by a colleague have highlighted the 
problem of breakpoints further downstream of the common FIP1L1 breakpoint 
(Score, et al 2009). Clearly, further research is needed to design an optimal protocol 
for detection of FIP1L1-PDGFRA in patients at diagnosis or after treatment, and my 
data indicated that simple expression analysis may be very helpful in this regard. In 
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addition it seems likely that further screening of MPD patients for over-expression of 
PDGFRA and PDGFRB will identify new uncommon gene fusions.  
 
Also frequently described in myeloid malignancies are recurrent translocations 
involving chromosome band 8p11. The 8p11 myeloproliferative syndrome (EMS), 
also known as stem cell leukaemia-lymphoma (SCLL), is associated with disruption 
of FGFR1. EMS is a CMPD that commonly presents with eosinophilia and associated 
T-cell proliferation. To date, nine fusion genes have been identified associated with 
translocations t(8;13)(p11;q12), t(8;9)(p11;q33), t(6;8)(q27;p11), t(8;22)(p11;q22), 
t(8;17)(p11;q23), t(7;8)(q34;p11), t(8;12)(p11;p11), t(8;19)(p12;q13.3) and 
t(8;12)(p11;q15) which fuse ZYMYM2 (ZNF198/RAMP/FIM), CEP110, FGFR1OP 
(FOP), BCR, MYO18A, TRIM24 (TIF1), FGFR1OP2, HERV-K and CPSF6 to 
FGFR1, respectively (Belloni, et al 2005, Demiroglu, et al 2001, Grand, et al 2004a, 
Guasch, et al 2000, Guasch, et al 2003b, Hidalgo-Curtis, et al 2008, Popovici, et al 
1999, Walz, et al 2005, Xiao, et al 1998).  
 
Imatinib is inactive against FGFR1 and cannot benefit patients with EMS. 
Nevertheless, other compounds have been developed such as SU5402, PD173074 and 
TKI258 that function by blocking the ATP binding site analogous to imatinib, but 
also possess anti-FGFR activity (Chase, et al 2007, Demiroglu, et al 2001, 
Mohammadi, et al 1997). These compounds have been shown to specifically inhibit 
the growth of ZNF198-FGFR1 and BCR-FGFR1 transformed cells, and are therefore 
more likely to be important in the treatment of EMS patients, although currently no 
compound is currently available for clinical use.  
 
To encompass the FGFR1 gene I first thought about designing another RT-PCR assay 
analogous to those for the PDGF receptors to assess over-expression in 
uncharacterised MPD patients. However, this would mean testing every patient three 
times for each of the assays, so instead I designed an MLPA mRNA 
detection/quantification assay. MLPA has a further advantage in that it has the 
potential to be expanded further to include other targets.  
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 4.4  Multiplex Ligation-dependent Probe Amplification (MLPA) 
 
MLPA is a probe-based technique used routinely to detect genomic deletions and 
amplifications (Schouten, et al 2002) (Figure 4.9) however it can also be used for 
mRNA profiling. It is a technique capable of establishing the relative copy number of 
up to 45 nucleic acid sequences in one single reaction by yielding amplification 
products of unique size per target. Products are separated by automated fluorescent-
based sequence electrophoresis and the copy number of each target is determined 
from the relative intensities of the products compared to those obtained from controls. 
As only one pair of PCR primers is used, MLPA results in a very reproducible 
pattern. Furthermore, MLPA is a fast technique that is very simple to perform and 
needs only 20ng of DNA. This seemed like an ideal procedure to screen for three 
tyrosine kinase genes in one assay. In addition more genes can easily be added and it 
is easily adapted to screen large numbers of patients. 
Hybridisation
Ligation
Target A Target B
Amplification
 
 
Figure 4. 9: A schematic representation of Multiplex Ligation-dependent Probe Amplification 
(MLPA). Target A represents a normal MLPA trace, the probe is represented in 
black, the ‘stuffer’ sequence in grey (alters the size), and the primers are shown in red 
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and green. The 5’ primer (red) is fluorescently labelled. The probes are first 
hybridised to the target sequence, these are then ligated together and finally 
amplified. The amplified products are analysed on an ABI 3100 genetic analyser, a 
representative trace is shown at the bottom. Target B represents a control where some 
of the peaks are deleted, the star shows an example of a reduction in peak height 
compared to the normal. 
 
4.4.1   Methods – Probe design 
 
MLPA depends on the use of progressively longer oligonucleotide probes in order to 
generate locus-specific amplicons of increasing size that can be resolved by 
electrophoresis. Schouten et. al., 2002 originally designed these long oligonucleotides 
using a series of proprietary M13-based vectors, however it is now possible to 
chemically synthesise long oligonucleotides (Schouten, et al 2002). I used a number 
of rules designated for the design of synthetic MLPA probes published by MRC 
Holland (www.mrc-holland.com/). An important consideration when designing 
synthetic probes is that the second probe of each pair must be 5’ phosphorylated and 
significant variation in the quality of long oligonucleotides and the percentage 
phosphorylation between batches has to be expected. 
 
For each gene I had to design four probes, two that abutted each other within the 
region encoding the tyrosine kinase domain and two that also abutted each other but 
were located in the region encoding the extracellular domain. The extracellular peak 
was then compared to the intracellular peak to determine if there was any over-
expression of the kinase domain (retained in gene fusions) compared to the 
extracellular domain (only present in full length normal transcripts), compared to that 
seen in controls. As my MLPA assay was based on cDNA I needed to consider 
specifically how I might design the probes so they would detect only cDNA and not 
genomic DNA. It was recommended that these probes had an exon boundary close to 
the ligation site (within 7 nucleotides), thus genomic DNA sequences will not be 
detected as an intron separates the hybridisation of these two probes. A number of 
other basic rules have been proposed for optimal probe design: 1) The length of the 
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two immediately adjacent hybridising sequences must be greater than 21 nucleotides 
with a predicted melting temperature of more than 70 °C; 2) the first nucleotide 
following the PCR primer-sequence should preferably not be an adenine as this 
results in low peak size of the probe amplification product. Specifically the peak size 
increases in the order A<T<G<C with the difference between A and C greater than 
two-fold; 3) no more than three G or C residues adjacent to the ligation site; 4) probe 
target sequences must not overlap as probes will compete for binding and 5) the 
probes should be 45-60% GC content. An example of one of my MLPA cDNA 
oligonucleotides is detailed below (Figure 4.10) showing each of the components.  
 
Labelled primer
ATG GAG TAT CTG GCC TCC AAG AAG
GGG TTC CCT AAG GGT TGG A
GC CT
G
TC
T A
GA
 TT
G 
GA
T C
TT
 G
CT
 G
GC
 A
C
TGC ATA CAC CGA GAC CTG GCA GCC
Target sequence X Target sequence Y
Stuffer Sequence
Other Primer
Stuffer Sequence
 
 
Figure 4. 10:  Schematic representing the FGFR1 intracellular domain probe. The target sequence 
spans exons 12 and 13. The total size of the MLPA oligonucleotide is 95bp, this 
includes the complement primer sequences (labelled primer sequence in blue, 
unlabelled primer sequence in purple), the stuffer sequence (green) and the adjacent 
target probe sequences (red and orange). 
 
The primer sequences for all MLPA cDNA oligonucleotides are exactly the same 
allowing amplification of all probes in a single reaction. In addition, only one primer 
(5’primer) is labelled and this is always with 6-FAM which enables the peaks to be 
distinguished using fluorescent based capillary electrophoresis. The primer sequences 
are the same as MRC Holland enabling us to be able to use the kit components from 
this company. The stuffer sequence differs in size enabling each of the probes to be 
differentiated by size on electrophoresis. The stuffer sequence must fit with the rules 
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detailed above and not hybridise to the adjacent target sequence. All other probes are 
detailed in Appendix I, section XIX.  
 
 4.4.2   Methods – Optimisation of the assay 
 
It was anticipated that when samples with known fusion genes were tested the 
tyrosine kinase portion would appear amplified compared to the extracellular domain. 
My assay contained 8 probes, two each for the tyrosine kinase genes: FGFR1, 
PDGFRB, PDGFRA and ABL. ABL was included partly because it is routinely used 
as a control for real time quantitative PCR assessments of minimal residual disease 
but also because it is a target of leukaemia-associated translocations. These were 
added to MRC-Holland MLPA kit components and then used to test sample cDNA 
according to the manufacturer’s protocol (see section 2.2.9). The probes were 
prepared before use. The cDNA MLPA oligonucleotides arrive lyophilised and were 
initially dissolved in sterile dH2O and diluted to achieve a final concentration of 
100pmol/µl. To prevent most of the PCR primers being consumed, low amounts of 
the probe oligonucleotides must be used and the suggested working concentration of 
each primer per reaction is between 1-4 fmol. To determine the amount of each probe 
needed the following calculations were made so a stock solution containing all 16 
probes could be prepared for use in the MLPA reaction: 
 
1)  1.33 fmol X 200µl = 2.66 µl (volume of primer required ) 
       Stock concentration (100pmol/µl) 
 
2) 2.66µl of each probe (16 X 2.66µl = 42.56µl) and make up to 200µl with 
157.44µl sterile dH2O 
 
3) A 1:50 dilution of this probe stock is then required (20µl probe stock + 980µl 
sterile dH2O) 
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4) Followed by a 1:10 dilution of step 3 (10µl from 1:50 dilution + 90µl sterile 
dH2O) to make a final 1:500 dilution. This stock solution is used for the 
MLPA reaction. 
 
To optimise the assay, available cell line cDNA with known fusions was first used 
along with a number of normal cDNA controls to enable me to identify any probes 
that gave false positive or negative results. The cell lines used were EOL-1, K562, 
SD1, Jurkat, HL60, HEL, and 5637.  EOL-1 is an AML cell line which carries 
FIP1L1-PDGFRA; K562 is a CML blast crisis cell line carrying the BCR-ABL b3a2 
fusion gene; SD1 is a pre B-cell ALL which also carries a BCR-ABL fusion (e1a2); 
Jurkat is a human T-cell leukaemia; HL60 is an AML cell line with amplified MYC; 
HEL is an erythroleukaemia cell line containing the JAK2 V617F mutation, and 
finally 5637 is a urinary bladder carcinoma cell line. From these controls it was 
anticipated that only EOL-1, SD1 and K562 would show any differential expression 
due to known fusion genes. The remainder should act as normal controls however 
problems were encountered due to the low expression of some of the targets in 
normal controls (Figure 4.11). 
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Figure 4. 11:  MLPA run 1, electrophoretic traces. (A) A normal control cDNA note the low 
expression of all probes for most RTKs other than ABL; (B) the HEL cell line also 
predicted to act as a normal control, note the similarity with A, and (C) K562 CML 
blast crisis cell line carrying a BCR-ABL fusion gene, as expected the C-terminal 
region of ABL is clearly amplified (star) compared to ABL 1b/a2 extracellular 
domain. 
 
Because of its relatively high expression in normal controls, the ABL probes were 
used as a reference control except for cases where a known ABL fusion was present, 
in which case the FGFR1 probes were used as a control. The table below shows an 
example of the Jurkat cell line (normal relative to RTK fusions) (Table 4.4). The 
expected ratio for all extracellular/intracellular peaks is 1 but this was only seen for 
FGFR1, and a substantial difference was seen for PDGFRA.  
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 Gene Intracellular Extracellular   RATIO 
  Peak area Normalised Peak area Normalised   Intra/Extra 
FGFR1 84234 0.6415678 33229 0.56473487   1.136051 
PDGFRB 317 0.0024144 209 0.00355201   0.679737 
PDGFRA 20012 0.1524213 3059 0.05198844   2.93183 
              
ABL control 131294   58840       
 
Table 4. 4:  Table showing the MLPA results for the cell line Jurkat. Left to right: The RTK 
probe; the intracellular peak area determined by capillary electrophoresis; the 
normalised value when divided by the corresponding control ABL peak (shown at 
bottom); the extracellular peak area the normalised extracellular value when divided 
by the corresponding ABL control peak, and finally the ratio produced from the 
normalised values comparing the intra- and extracellular domains. Based on the cut 
offs used for DNA analysis, a relative value of 1 would indicate a normal 1:1 
intra:extracellular expression, a value of 0.5 would indicate significant under 
expression of the intracellular domain and a value of 1.5 or above would indicate 
over-expression of the kinase (intracellular domain) compared to the extracellular 
domain. 
 
I decided to repeat the MLPA assay using the same samples to determine if the assay 
was reproducible or whether the initial results were biased for any technical reasons. 
Below is a table showing four of cell lines that were tested twice (Table 4.5). Only 
the urinary bladder cancer cell line (5637) appeared to produce reproducible results. 
Unexpectedly, EOL-1 with a known FIP1L1-PDGFRA fusion shows over-expression 
of PDGFRA on the first run as expected, but virtually no expression on the repeat 
assay. It was unclear why the results were so variable, however DNA quality and 
quantity on commercially produced MRC-Holland kits is known to be of utmost 
importance and it seems likely that cDNA quality and quantity is even more difficult 
to control for.  
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Gene EOL1 EOL1 K562 K562 Jurkat Jurkat 5637 5637 
                  
FGFR1 0.808339 2.321555 8.151261 1.650277 2.534954 3.1048 2.935601 3.947915 
PDGFRB 174323 2355 0.810345 3.462349 1.516746 1 1.074525 1.190534 
PDGFRA 392 0.001842 4102 0.001351 6.542007 28615 4.304769 4.050285 
ABL control 2.49143 3.098622 7.562993 13.85285 2.231373 1.90531 1.503822 1.519456 
 
Table 4. 5:  A table showing the comparison between the first MLPA run (black) and the repeat 
MLPA run (red). Only four cell lines have been shown here for comparison (other 
cell line data not shown). Only the 5637 bladder cancer cell line shows reproducible 
results, the remainder are highly variable.  
 
Further experiments were conducted to try and improve the reproducibility using a 
series of freshly prepared cDNAs from normal controls and Eol1 cells. The results 
were more promising with the EOL-1 electrophoretic trace showing a clear over-
amplification of the intracellular kinase domain of PDGFRA consistent with the 
presence of the FIP1L1-PDGFRA fusion gene (Figure 4.12A). Even the normal 
control traces looked cleaner and although expression of both portions of every RTK 
gene was not always observed, the ABL control was always present (Figure 4.12B). 
Despite cleaner traces, the intracellular:extracellular ratio was rarely calculated as 1 
and in fact this still varied considerably, especially where one of the probes was 
lacking completely. Moreover, in most cases the ABL control looked differentially 
expressed implying the ABL 1b/a2 probe may not be as sensitive as its counterpart. 
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Figure 4. 12:  MLPA run 3, electrophoretic traces. (A) EOL-1 cell line showing a clear 
amplification of the PDGFRA intracellular domain, the extracellular domain is 
barely visible; compare this to (B) a normal control where expression of every probe 
is visible yet very tightly regulated. Note however the differential expression of the 
ABL probes. 
 
Fresh cDNA samples were then made from patient samples with available material 
and known fusion genes involving PDGFRA, PDGFRB, ABL and FGFR1 (n=15). All 
the samples with known fusions showed an amplification of the intracellular domain 
of the relevant RTK.  The results were very encouraging, although CML cases 
showed a high degree of variation. Figure 4.13 shows an example MLPA trace 
showing over-amplification for each of the tyrosine kinases in the assay.  
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Figure 4. 13:  MLPA run 4, electrophoretic traces. (A) A patient with a known FGFR1 fusion 
gene, note the over-amplification of FGFR1 intracellular probe compared to the 
extracellular probe (ratio of ~9); (B) a patient with a ETV6-PDGFRB fusion gene 
only the intracellular PDGFRB probe is highly over-expressed; (C) a patient with a 
PDGFRA fusion gene, the extracellular PDGFRA probe is not even visible, and 
finally (D) a CML patient with a BCR-ABL fusion showing clear over-expression of 
the ABL C-terminal probe. 
 
It is important to note here that although over-amplification was observed for the 
intracellular domain of the correct RTK, in all cases the ratios of the other probes 
were rarely 1.0 and the CML patients often showed ABL and PDGFRA intracellular 
domain over-expression. As a result of this work I decided to concentrate only on 
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PDGFRA, PDGFRB and FGFR1, and use the ABL probe only as a control for 
normalisation.  
 
It is clear from these results that sample quality and probe efficiency influence the 
results as well as any genuine difference in expression of the target sequences. In 
addition, distortions in the data and substantial variations between replicates were 
seen when peak sizes were zero or very low. Based on the results I therefore created 
some rules based on +/- 5 standard deviations of the values seen for all normal 
controls compared to cases known to harbour specific fusions (Table 4.6). 
 
Gene Extracellular =0, or very low Extra & Intracellular present 
      
FGFR1 Fail if extracellular not >50 Positive is >10.87  
PDGFRB Positive if intracellular is >200, ideally >500 Positive is >5.10 
PDGFRA Positive if intracellular is >200 Positive is > 4.39 
 
Table 4. 6:  Table shows rules for analysing unknown patients to be screened for possible over-
expression of the kinase domain (intracellular) compared to a control band 
(extracellular) based on normal and positive control data. The data has been split 
according to detection of both probes and only one probe for each RTK. 
 
4.4.3   Validation of cDNA MLPA assay 
 
Having created these rules I had a colleague blind my samples so I could repeat the 
MLPA assay and determine its predictive value. These were the same 14 patient 
samples with known fusions plus four normal controls and the EOL-1 cell line. By 
applying the rules I was able to identify all four patients with known FGFR1 
rearrangements, three of four PDGFRB rearranged patients and four of five PDGFRA 
rearranged patients (including the EOL-1 cell line). The two patients missed with a 
PDGFRA or PDGFRB fusion were scored as normal indicating a false negative result 
of approximately 15%. Nevertheless, all the normal controls were scored as normal 
therefore no false positives were identified. Analysis of a further blinded series 
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correctly identified 9 of 9 cases with PDGFRB rearrangements, and a false positive 
result was seen in one out of sixteen normal controls (6%).  
 
4.4.4   Results 
 
 
A number of patients (n=16) were then screened that had been previously found by 
our laboratory to be sensitive to imatinib in vitro or were of particular interest for 
other reasons such as the presence of a particular chromosome translocation. All of 
these patients had an unknown molecular pathogenesis however the sensitivity to 
imatinib implies they harbour a fusion gene or mutation affecting a tyrosine kinase 
gene that has a response to imatinib such as PDGFRA or PDGFRB. Other cases 
included 5 that were chosen due to possible PDGFRB involvement, including one 
patient that had been tested previously by Western blot and shown to have massive 
over representation of the PDGFRβ protein. Another patient had been found positive 
by my PDGFRA RT-PCR multiplex and the remaining were imatinib responders in 
vitro.  
 
Of the sixteen patients I found only 4 to have an unusual expression of the 
intracellular domains of one of the tyrosine kinases. Three of these patients were in 
vitro imatinib responders, E1009, E281 and E57 and all showed over-expression of 
PDGFRA. The final patient (E1334) showed over-expression of PDGFRB. The 
sample that was screened due to over-expression of PDGFRA by the multiplex assay 
proved to be normal by MLPA analysis, and also by bubble-PCR. E1334, the patient 
with over-expression of PDGFRB was analysed further using 5’RACE PCR but no 
PDGFRB fusion was identified. Insufficient material was available for further 
investigation of the other cases. 
 
More patients were screened using the MLPA assay (n=39), of whom 16 were further 
candidate imatinib responders, 18 were found previously positive by PDGFRA RT-
PCR multiplex and 5 new patients with unusual referrals.  
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I found 2 of the 16 imatinib responders consistently failed, 8 were shown to be 
normal, 5 had over-expression of PDGFRA and one was borderline FGFR1 positive. 
All the PDGFRA positive patients were followed up by bubble-PCR and found to be 
normal. The borderline positive FGFR1 case was later repeated and found to be 
normal. The 18 patients with PDGFRA over-expression first identified by RT-PCR 
multiplex were analysed and only 10 of these were confirmed by MLPA assay to also 
over-express PDGFRA. Of the remaining 8 patients, 5 appeared normal and three 
consistently failed. These patients were also followed up by bubble-PCR to determine 
if any unusual fusions might be identified but none were discovered. Finally, of the 5 
new referrals, 2 were PDGFRA positive, 2 were borderline FGFR1 positive and one 
was normal. The PDGFRA over-expressing patients were analysed by bubble-PCR 
but no rearrangements were identified. The patients with FGFR1 over-expression 
were analysed using 5’RACE PCR as they were both referred with query 8p11 
myeloproliferative syndrome (EMS). Again no rearrangements of the FGFR1 gene 
were discovered.  
 
In summary, although the MLPA expression assay was validated with a large number 
of positive controls and normal controls it is far from a perfect screening test and 
yielded a large number of apparently false positives. Nevertheless, subsequent 
analysis demonstrated that the test could be useful. 
 
 4.4.4.1  A cryptic ETV6-PDGFRB fusion gene 
 
 
The outcome of the t(5;12)(q31-33;p13) is the ETV6-PDGFRB fusion and, although 
rare, is the most frequent of the known PDGFRB fusion genes (Steer and Cross 
2002). In patients with a t(5;12)(q31-33;p13), confirmation of the presence of ETV6-
PDGFRB is particularly important since many cases with this translocation have a 
distinct molecular aetiology, with upregulation of IL-3 expression and no 
involvement of PDGFRB (Cools, et al 2002). Only cases with a PDGFRB fusion are 
expected to be responsive to imatinib. 
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 The fusion of ETV6 exon 4 spliced to PDGFRB exon 11 is found in the great majority 
of positive cases, and is typically detected by RT-PCR using primers directed to 
ETV6 exons 3 or 4 and PDGFRB exon 11 (David, et al 2007). In our laboratory, of 10 
positive cases detected with these primer combinations, only one had a variant fusion 
in which ETV6 exon 4 was fused to PDGFRB exon 9. A patient with idiopathic 
myelofibrosis and an ETV6 exon 7-PDGFRB exon 10 fusion was also recently 
reported and it was suggested that this novel transcript may have accounted for the 
somewhat unusual clinical phenotype seen in this case (Tokita, et al 2007). 
Importantly, both these variants are detectable using the standard primer sets above. 
Here I present an unusual ETV6-PDGFRB case that was missed by standard 
screening. 
 
4.4.4.2  Patient details 
 
The patient was a 19 year old male (E1026) who presented to the outpatient 
department with a fever for two months. On examination he was found to have 
generalised lymphadenopathy, hepatosplenomegaly and bony swellings over the left 
clavicle and right tibia, however there were no bleeding manifestations. A total 
leukocyte count exceeding 100 x 109/L with a left shift was observed on peripheral 
blood smear. Bone marrow aspiration showed an increase in the basophils and 
eosinophils, suggestive of an MPD. Fine needle aspiration showed infiltration of the 
lymph node by blasts that were negative for myeloperoxidase and periodic acid Schiff 
on cytochemistry. Flow cytometry of the peripheral blood and lymph node aspirate 
was positive for myeloid markers (CD11c, 13, 15 and 33) along with CD45 and 
myeloperoxidase. BCR-ABL was not detected by RT-PCR and cytogenetics showed a 
t(5;12)(q31-33;p13), however ETV6-PDGFRB was also not detected by RT-PCR. A 
diagnosis of atypical CML in accelerated phase was made.  
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Despite being negative for ETV6-PDGFRB the patient was started on imatinib 
mesylate (600mg in divided doses) and exhibited a complete haematological and 
cytogenetic response to treatment (including complete regression of the lymph nodes, 
bony swellings and hepatosplenomegaly) at 3 months post treatment. One year after 
diagnosis the patient continues in remission on 600mg/day imatinib. 
 
4.4.4.3  cDNA MLPA analysis of patient E1026 
 
In view of the excellent response to imatinib, we performed further analysis to 
determine if PDGFRB was involved using the cDNA MLPA assay (material was not 
available for molecular cytogenetic analysis). This assay detected relative over-
expression of the PDGFRB kinase domain in this patient (E1026) but not in a number 
of normal controls, suggesting the presence of a PDGFRB fusion (Figure 4.14). 
 
E1026
Normal control
Positive control: ETV6-PDGFRB 
 
 
141 
Figure 4. 14:  The cDNA MLPA assay.  Probes are in order FGFR1 tyrosine kinase domain, 
FGFR1 3’extracellular domain, PDGFRB tyrosine kinase domain, PDGFRB 
3’extracellular domain, PDGFRA tyrosine kinase domain, PDGFRA 3’extracellular 
domain. Under normal circumstances expression of FGFR1, PDGFRB and PDGFRA 
is low level in peripheral blood leukocytes. Over-expression of the PDGFRB 
intracellular domain is apparent in both the previously known ETV6-PDGFRB case 
(middle) and also E1026 (top), compared to the normal control (bottom).  
 
4.4.4.4  5’RACE PCR to identify the potential PDGFRB fusion gene in patient 
E1026 
 
I employed 5’rapid amplification of cDNA ends PCR (Invitrogen, Paisley) to 
characterise the fusion, employing reverse primers derived from sequences located 
downstream of known PDGFRB breakpoint locations (Appendix I, section IV). The 
amplification was performed under long-range PCR conditions (section 2.2.5) to 
enable fragments up to 10kb to be amplified. After nested PCR a smear was observed 
with 4 or 5 possible bands visible, ranging from 250bp – 650bp. The negative control 
was completely blank indicating one of these bands may have been derived from a 
PDGFRB fusion (Figure 4.15).  
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Figure 4. 15:  Agarose gel of nested 5’RACE PCR for patient E1026 versus a control. Lane 1 
indicates a no DNA control, only a primer dimer smear is visible below 100bp; Lane 
2 shows the nested PCR result after E1026 5’RACE PCR a smear is visible 
containing several different sized bands ranging from 250-650bp. Red arrows 
indicate the bands that were cloned and sequenced.  
 
The resulting PCR products were cloned and the digests revealed only two different 
sized bands one at approximately 500bp and the other at approximately 650bp 
(indicated by red arrows, Figure 4.15). Sequencing of the smaller product turned out 
to be PDGFRB and vector sequence only, however sequencing of the larger 650bp 
product revealed an in-frame mRNA fusion between full length ETV6 exon 7, 34bp 
derived from ETV6 intron 7 and a truncated PDGFRB exon 12 (Figure 4.16). This 
fusion involves novel breakpoints, never previously reported. 
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AGG CTT TTG TTC AGt cag aat aag tct aca agc tgc tgc act aga att AGC TCT GAC GGC CAT 
PDGFRB exon 12ETV6 exon 7 ETV6 intron 7
A
B
PDGFRB, NM_002609 Exon 12
3 ’5 ’ TSKQSL L F N S C T RC I S S D G
INSERT SEQUENCE
ETV6, NM_001987, Intron 7ETV6, NM_001987, Exon 7
 
Figure 4. 16:  (A) Electropherogram of the cDNA junction amplified by 5’RACE PCR; (B) 
Sequence of the novel ETV6-PDGFRB fusion showing the insertion of ETV6 
intronic sequence ensuring the fusion reads in-frame. 
 
4.4.4.5  Confirmation of the novel ETV6-PDGFRB fusion 
 
The presence of the fusion was confirmed by RT-PCR using the primers ETV6 exon 
6.2F and PDGFRB exon 14.1R with the High Fidelity PCR master kit according to 
manufacturer’s conditions (see appendix I, section XX for primer sequences). The 
PCR was performed on a generic 66°C annealing temperature PCR protocol. The in-
frame fusion was detectable by single step RT-PCR, as seen in Lane 1, Figure 4.17. 
RT-PCR of the fusion revealed two bands the upper most of which was of the 
expected size, 415bp. On cloning and sequencing the lower band turned out to be an 
ETV6-PDGFRB out-of frame fusion between part of ETV6 exon 7 and PDGFRB 
exon 13. Using the same High Fidelity PCR kit and amplification protocol, I used 
RT-PCR to try and amplify the reciprocal translocation. PDGFRB-ETV6 reciprocal 
products were not detectable by single or nested PCR, Lane 2, Figure 4.17.   
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Figure 4. 17:  Amplification of the ETV6-PDGFRB fusion by single step RT-PCR: Lane 1 
represents patient E1026 fusion RT-PCR; Lane 2 represents the reciprocal 
breakpoint PCR in patient E1026, Lanes 3 & 4 show normal controls, and Lane 5 a 
no DNA control. Note the reciprocal breakpoint was not observed at single-step or 
nested PCR (data not shown). The fusion RT-PCR shows two bands of 300 and 415 
base pairs, these represent an out-of-frame fusion and the confirmed in-frame fusion. 
 
I also went on to determine the genomic breakpoints of this fusion for further 
confirmation using the primers ETV6.E1026.Int7.1F and ETV6.E1026.Int7.2F with 
PDGFRB exon 12R (appendix I, section XX). Both PCRs resulted in a product that 
was subsequently cloned and sequenced. I was able to show the same fusion 
breakpoints between exon 12 of PDGFRB and intron 7 of ETV6 in both PCR 
products (Figure 4.18).  
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PDGFRB exon 12 TGGAAGGTGATTGAGTCTGTGAGCTCTGACGGCCATGAGTAC
ETV6 intron 7 ACAAGCTGCTGCACTAGAATTTTTCTTTCCAGAATTCCTCAT
ETV6-PDGFRB ACAAGCTGCTGCACTAGAATTAGCTCTGACGGCCATGAGTAC
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Figure 4. 18:  (A) Amplification of the genomic ETV6-PDGFRB novel fusion. Lane 1 is 
amplification of the genomic breakpoint using primer ETV6.Int7.1F, Lane 2 is the 
genomic breakpoint amplified using a second primer ETV6.Int7.2F, both at single 
step combined with primer PDGFRB exon12.1R; (B) Schematic showing the 
individual sequences for PDGFRB (italics), ETV6 and the ETV6-PDGFRB fusion 
sequence. 
 
 4.4.4.6  Further ETV6-PDGFRB analysis 
 
The PDGFRB sequence retained in the novel fusion is downstream of the PCR 
primer we had initially used for RT-PCR, explaining why ETV6-PDGFRB fusion was 
not detected. To ascertain if any other similar cases had been missed, 10 cases with a 
t(5;12) that tested negative for ETV6-PDGFRB using the standard primers were re-
analysed using  ETV6.Ex2F and PDGFRB.Ex14R. All those tested proved negative, 
indicating that this variant is not common. Nevertheless, as a result of the finding of 
this novel ETV6-PDGFRB fusion the above primers are now routinely used to screen 
t(5;12) cases referred to our laboratory. 
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  4.4.4.7  ETV6-PDGFRB - discussion 
 
In summary, patient E1026 tested negative by RT-PCR for the ETV6-PDGFRB 
fusion, but following the finding that his disease responded to imatinib, MLPA and 
5’RACE analysis showed the patient to have a novel ETV6-PDGFRB variant with 
breakpoints outside those commonly reported.  
 
The unusual ETV6-PDGFRB fusion is reminiscent of those seen for FIP1L1-
PDGFRA, for which breaks almost always fall within PDGFRA exon 12 and FIP1L1 
intron-derived sequence is frequently incorporated into the mature mRNA (Cools, et 
al 2003a). As a consequence the region encoding the PDGFRα auto-inhibitory WW-
like domain is disrupted, resulting in partner protein independent activation of the 
kinase moiety (Stover, et al 2006). The disruption of PDGFRβ WW-like domain in 
our case is unexpected in view of the fact that ETV6 encodes a dimerisation domain 
that is required for transformation by ‘normal’ ETV6-PDGFRB (Carroll, et al 1996). 
 
Interestingly, this case presented with advanced phase disease, something not 
normally associated with this fusion. The fusion itself retained ETV6 exons 1-7, in 
common with that described by Tokita et. al., (2007) in a case that also presented 
with advanced features, specifically those of chronic idiopathic myelofibrosis. In 
contrast to the most common fusion reported that involves ETV6 exons 1-4, these 
variants are predicted to encode a chimaeric protein that retains the ETV6 internal and 
ETS DNA-binding domain (Figure 4.19). It is possible that retention of this domain 
leads to a more aggressive phenotype however it would be premature to draw any 
clear conclusions from just two cases (Tokita, et al 2007).  
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ETV6 intron 7ETV6 exon 7 ΔPDGFRB exon 12
 
 
 
Figure 4. 19: Schematic of PDGFRβ and the Tel (ETV6) proteins showing relevant domains and 
arrows indicating reported breakpoints. Below, are the sequences of ETV6-PDGFRB 
fusions described to date, with the most common variant at the top and the fusion in 
case E1026 at the bottom. 
 
It is also noteworthy however that our case responded well to imatinib despite being 
treated in advanced phase. Good responses to imatinib have been described for 
FIP1L1-PDGFRA associated chronic eosinophilic leukemia in transformation 
(Metzgeroth, et al 2007) and this may be a general feature of diseases associated with 
PDGFR fusions.  
 
It is clear from this case that the breakpoint diversity for ETV6-PDGFRB fusions is 
greater than originally reported and hence diagnostic screens for this fusion should 
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employ primers capable of detecting all variants in order to provide an accurate 
molecular diagnosis allowing for appropriate clinical management.  
 
4.4.5   MLPA Discussion 
 
MLPA is a technique that utilises probes to detect deletions and amplifications of a 
gene. I designed a cDNA MLPA assay to detect over-expression of the kinase domain 
of specific tyrosine kinase genes relative to a control probe spanning a number of 
exons upstream of the common reported breakpoints. The basis of the assay is that 
under normal conditions the mRNA expression of each tyrosine kinase is tightly 
regulated, but when fused to a partner gene the expression level of the tyrosine kinase 
portion of the gene may be increased as a consequence of gene fusion. By screening 
patients of unknown aetiology I hoped to be able to discover cases with cryptic or 
novel fusion genes. I designed the assay to incorporate both PDGFR RT-PCR assays 
into one reaction whilst also accommodating for the FGFR1 and ABL tyrosine 
kinases.  MLPA is ideal for screening multiple tyrosine kinase genes in one assay, 
and hence is economical on volume of material required. In addition, it is designed to 
screen high numbers of patients quickly and reproducibly. 
 
The assay was validated using numerous normal control cDNA samples sourced from 
a non-leukaemic background along with a number of cell lines and patient samples 
with previously known fusion genes involving one of the tyrosine kinase genes within 
the assay. Most positive controls were identified, with over-amplification of the 
intracellular domain of the correct RTK in these cases however, the 
intracellular:extracellular ratios of the other unaffected probes were rarely 1.0, 
presumably because of differences in probe efficiencies. The false negative result was 
15%, where known positive controls were scored as normal. Analysis of more 
positive controls was more successful with nine out of nine patients identified 
correctly. The normal controls were all scored as normal with only one exception that 
may have been related to poor cDNA quality.  
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A major drawback of the cDNA MLPA assay was the low expression of the tyrosine 
kinases under normal circumstances which made reproducibility difficult. The assay 
was also very dependent on the quality of the cDNA and it appeared that some probes 
were more sensitive than others. This was particularly apparent when I tested known 
CML patients for validation of the assay. ABL over-amplification often appeared 
concomitantly with over-expression of the PDGFRA intracellular domain making 
these patients difficult to distinguish. Despite redesigning new ABL probes to try and 
combat this problem differential expression of the ABL probes themselves was 
always observed. As a result only the PDGFRA, PDFGRB and FGFR1 probes were 
used to try and identify possible fusion genes, and the ABL probe was used as a 
control for normalisation. Despite the drawbacks the results were collated and rules 
of analysis created based on plus or minus five times the standard deviation for all 
normal controls compared to positive controls.  
 
Having validated the assay it was used to screen MPD patients of unknown molecular 
pathogenesis from three basic categories: imatinib responders as previously 
determined by a colleague using in vitro liquid and colony assays (n=26), patients 
found to over-express PDGFRA or PDGFRB by RT-PCR assays (n=24) and finally 
patients with cytogenetic or other indicators of possible gene fusions (n=6). Apparent 
over-expression was seen for several cases but only one (2% of all cases) proved to 
be positive on further investigation   
 
4.5   Discussion 
 
 
Persistent aberrant signalling of PDGF and its receptors is thought to be essential for 
the survival of the many cancer cell types. These findings have influenced the 
pharmaceutical and research communities to design agents that selectively block 
PDGFR signalling (Levitzki 2004). Imatinib mesylate has received the most attention 
and has potent inhibitory activity against both PDGFRα and PDGFRβ. Patients with 
MPDs and rearrangements of PDGFRA and PDGFRB, in particular, have been 
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shown to respond very well to treatment with this compound (Apperley, et al 2002, 
David, et al 2007). However, a shortcoming of imatinib has been the emergence of 
acquired resistance in the form of point mutations in the kinase domain in a subset of 
cases. Furthermore some patients show primary or secondary resistance for unknown 
reason and others are intolerant of therapy. The development of second generation 
ATP-competitive tyrosine kinase inhibitors (TKI) has begun to try and overcome 
these problems. These include nilotinib, a novel aminopyrimidine inhibitor 
(Weisberg, et al 2005). In pre-clinical studies nilotinib has been shown to be 30-fold 
more potent than imatinib in treating chronic-phase CML, and Stover et. al., (2005) 
have also showed it is effective at inhibiting proliferation in vitro of ETV6-PDGFRB, 
FIP1L1-PDGFRA and imatinib resistant ETV6-PDGFRB/T681I, but not FIP1L1-
PDGFRA/T674I mutants (Stover, et al 2005). A second TKI, dasatinib is a potent 
dual Src/Abl kinase inhibitor that is 67-fold more potent than imatinib (Shah, et al 
2004). Its greatest benefits have been observed in patients with CP-CML with 90% 
achieving a complete haematological response (Steinberg 2007). Dasatinib is also 
effective against KIT and PDGFRs, in addition to overcoming resistance exhibited by 
18/19 imatinib resistant mutations reported (Shah, et al 2006). Sunitinib has also been 
studied for its effectiveness against PDGFRs although most of this work has centered 
on PDGFR-associated solid tumours such as colon cancer, non-small cell lung 
carcinoma and melanoma. However, preclinical trials have shown this TKI has both 
potent and robust anti-angiogenic and anti-tumour activity (Chow and Eckhardt 
2007). Finally, other inhibitors have also been developed that have shown activity 
against PDGFR, such as sorafenib. This is a small molecule B-Raf inhibitor currently 
used for the treatment of renal cell carcinoma. It has been shown in vitro to be a 
potent inhibitor of ETV6-PDGFRB by inducing cell cycle block and apoptosis 
(Lierman, et al 2007).  
 
To date, 21 PDGFRB and 6 PDGFRA fusion genes have been reported. It seems 
likely that additional PDGFR rearrangements are yet to be discovered, particularly in 
view of occasional reports of cases that are responsive to imatinib despite being 
negative for known fusions and, in most cases, cytogenetic indicators of variant 
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fusions (i.e. rearrangements involving 4q12 or 5q31-33). To search for new fusions I 
designed RT-PCR and MLPA assays to detect over-expression of the region encoding 
the kinase domain of selected tyrosine kinases. This region is retained in gene fusions 
and may be overexpressed relative to the normal, full length product. Both assays 
were validated using cases with known rearrangements and normal controls and 
although there is no doubt that the assays could be considerably improved, e.g. by 
testing and incorporating other primer combinations, both were applied to screen 
cases of unknown molecular aetiology. 
 
I screened 229 MPD patients negative for FIPL1-PDGFRA by PDGFRA RT-PCR 
and found a total of 14 that over-expressed the kinase domain of PDGFRA. Of these 
cases two yielded identification of unknown fusion genes. The first was a previously 
unreported novel KIF5B-PDGFRA fusion as a consequence of a complex cytogenetic 
rearrangement involving chromosomes 2, 4 and 10. The second case proved to have a 
FIP1L1-PDGFRA fusion that had not previously been detected by standard RT-PCR. 
The remaining cases for whom material was available (n=12) were investigated 
further by bubble-PCR as PDGFRA rearrangements are particularly suited to this 
technique since the breakpoints in all cases reported to date are clustered within exon 
12 of this gene. No PDGFRA rearrangements were identified after screening these 
patients in this way, suggesting a false positive rate for the expression assay of ~6%. 
 
I also screened 199 MPD patients looking for over-expression of the PDGFRB kinase 
domain; of these I found 9 to be strongly positive. Surprisingly, two of these were 
later discovered to have known FGFR1 rearrangements suggesting interplay between 
the signalling cascades affecting both these tyrosine kinase genes. Of the remaining 7 
patients only one was found to harbour an unknown PDGFRB rearrangement. This in 
fact turned out to be the most common of the PDGFRB fusions, ETV6-PDGFRB. It is 
unclear why the patient was initially screened and found negative by standard RT-
PCR but clearly the usefulness of screening all MPD patients using this more 
generalised RT-PCR has proved its worth. Other patients with available material were 
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subsequently screened by 5’RACE PCR but no further rearrangements were 
discovered. This gives a false positive rate of 4%.  
 
The MLPA assay proved to be less reliable:  of 56 MPD patients screened (some of 
whom were also screened by the RT-PCR assays above) 25 were found to over-
express either PDGFRA, PDGFRB or FGFR1. PDGFRA over-expression was the 
most frequent (n=20), 2 over-expressed PDGFRB and three were borderline for over-
expression of FGFR1.  5’RACE PCR and bubble-PCR of all patients where material 
was available was performed and with one exception no rearrangements were 
detected. The exception was a patient referred with a t(5;12) who turned out to have a 
variant ETV6-PDGFRB fusion with breakpoints that could not be detected with 
standard primers. 
 
The most important conclusion to be drawn from these results is that cryptic fusions 
of PDGFRA, PDGFRB and FGFR1 are very uncommon in MPDs, even in cases that 
responded to imatinib but tested negative for known fusions. This is because although 
apparent over-expression of specific kinase domains were seen by the RT-PCR 
and/or MPLA assays, further analysis failed to reveal gene fusions in most cases. 
Although RACE PCR might miss some fusions, particularly if the partner gene is 
very large, we have previously found that bubble PCR is highly effective for isolating 
genomic PDGFRA fusions since the breakpoints within this gene are tightly 
clustered. Most apparent over-expressors involved PDGFRA and thus it seems likely 
that most were false positives. A second conclusion is that although both assays 
proved to be useful in identifying new fusions in the research setting, their false 
positive rates are unacceptable for routine diagnostic use because of the amount of 
effort required to follow these cases up. It seems likely that the false positive rates 
could be reduced by the use of further primer sets in the MPLA assay and possibly 
the more rigorous definitions of cutoffs to define positive and negative results, It is 
also possible that more quantitative techniques such as real time PCR may be useful 
to measure the relative expression of the regions encoding the extracellular and 
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intracellular domains of tyrosine kinases. Other systems such as exon expression 
arrays might also be used, but would be expensive for routine use. 
 
Overall it is estimated that tyrosine kinase fusions account for only about 2-5% of 
atypical MPD cases (Reiter, et al 2007). Other abnormalities of tyrosine kinase or 
downstream signalling components have also been described, e.g V617F JAK2 (10% 
of cases), NRAS mutations (12.5% of cases) and activating FLT3 or KIT mutations 
(5% of cases) (Jones, et al 2005). Collectively these abnormalities account for little 
over a quarter of all atypical MPD cases (Figure 4.20).  
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non-TK fusions/gene disruption
Normal/aneuploid
Translocation
cryptic TK fusions
FIP1L1-PDGFRA
Other TK 
mutations
KIT, FLT3
N-Ras
JAK2 
V617F
 
 
Figure 4. 20:  Pie chart showing the molecular pathogenesis of atypical MPD patients (i.e. atypical 
CML, CMML, CEL, MPD-U, and MDS/MPD-U). The blue region represents 
atypical MPD patients that have a normal or aneuploid karyotype and are of 
unknown aetiology. The section in yellow indicates collectively the number of 
patients defined molecularly with tyrosine kinase mutations or mutations of 
downstream signaling components. The section in green shows the small number of 
patients found specifically to have fusion genes involving tyrosine kinases. 
 
If cryptic tyrosine fusions are uncommon, then other abnormalities must be 
responsible for the majority of atypical MPDs for whom the molecular pathogenesis 
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is currently unknown. There are several possibilities: first, they may harbour gene 
fusions of other tyrosine kinases that I have not investigated. Second, they may 
harbour activating mutations of tyrosine kinases that would not have been detected by 
my over-expression assays. Third, they may harbour activating mutations in other 
signalling components that are either upstream or downstream of tyrosine kinases. 
Fourth, they may harbour mutations in completely different pathways. In the next 
Chapter I describe a novel approach aimed at identifying mutations in atypical MPDs. 
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5  SCREENING FOR NEW ONCOGENES 
MARKED BY ACQUIRED UNIPARENTAL 
DISOMY 
5.1   Introduction 
5.1.1  Loss of heterozygosity (LOH) & acquired uniparental disomy 
(aUPD) 
 
Loss of heterozygosity (LOH) refers to a widespread phenomenon in cancer whereby 
normal inherited heterozygous markers in a genomic or chromosomal region are 
reduced to homozygosity in the malignant clone. LOH frequently marks the presence 
of a recessive tumour suppressor gene, the classic example being retinoblastoma in 
which an inherited inactivating mutation in the Rb gene along with flanking 
heterozygous markers are all reduced to homozygosity in retinal tumours (Knudson 
1971). LOH may originate from diverse mutational events such as deletion of the 
wild-type allele to yield a hemizygous state, mitotic recombination, localised gene 
conversion or non-dysjunction with either loss or reduplication of the mutant 
chromosome (Figure 5.1).  There are various techniques discussed in detail below 
that can identify LOH and help to distinguish between the underlying mutational 
mechanism. In the last few years the discovery of large stretches of somatically 
acquired LOH associated with no net change in copy number, termed as acquired 
isodisomy or acquired uniparental disomy (aUPD) has emerged as a common theme, 
initially in polycythaemia vera but subsequently in acute leukaemia and other 
malignancies (Irving, et al 2005, Kralovics, et al 2002, Raghavan, et al 2005). 
 
Classically, uniparental disomy (UPD) refers to the finding of an individual inheriting 
both homologues of a chromosome pair from only one of their parents as a result of 
an error in meiosis. It is associated with a range of inherited developmental disorders 
such as Beckwith-Wiedemann syndrome (UPD of chromosome 11p15) and Prader-
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Willi syndrome (25% have maternal UPD of chromosome 15). My work is concerned 
with identifying regions of aUPD that are thought to be caused by mitotic 
recombination and selection for one of the derivative products. Recent evidence, 
reviewed below, has suggested that aUPD is usually associated with specific 
oncogenic mutations. Definition of novel, minimal regions of aUPD may therefore be 
an important new route to identify novel oncogenes. 
 
A) Gene conversion
B) Point Mutation
C) Mitotic non-dysjunction
chromosomes chromatids
 
 
Figure 5. 1:  Schematic illustrating the principal classical mutational events that lead to LOH: A) 
Interallelic gene conversion, a non-reciprocal exchange occurring between two 
alleles that reside on homologous chromosomes resulting in loss of the normal allele 
as shown in the last cell at the top; B) A point mutation may occur through a reading 
error during semi-conservative replication resulting in an additional mutant 
chromatid, represented by the end cell at the top, finally C) Mitotic non-dysjunction. 
This example shows non-dysjunction followed by re-duplication of the mutant 
chromosome. 
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5.1.2   aUPD and MPDs 
 
The first description of aUPD in MPDs was reported by Kralovics and colleagues in 
2002 (Kralovics, et al 2002). Previously, studies of rare familial polycythaemia vera 
(PV) had suggested a possible pathogenic role for loss of heterozygosity (LOH) in 
this disease. As a consequence they performed whole genome LOH analysis using a 
series of microsatellite markers on a small number of PV subjects and identified LOH 
at three new genomic loci, by far the most frequent of which was at 9p. They then 
showed that there was no change in copy number at 9p, suggesting that mitotic 
recombination was the mechanism of LOH i.e. aUPD rather than allele loss. The 
prevalence of 9p aUPD was observed to be approximately 33% of all PV cases, and is 
therefore the most frequent chromosomal lesion seen in these patients. This group 
mapped the minimal aUPD region and identified the possible candidate genes within 
this region, which included the JAK2 tyrosine kinase. Although this group went on to 
screen candidate genes in this region including a partial screen of JAK2, no mutations 
were observed and the significance of their observations was unclear.  
 
5.1.3   aUPD & the discovery of the JAK2 V617F acquired  mutation 
 
It took a further 3 years before the observations of 9p aUPD in PV came to fruition. 
In 2005 four groups reported the discovery of an acquired G to T mutation at 
nucleotide 1849 in exon 12 of the JAK2 gene that results in the substitution of a 
valine by a phenylalanine (V617F) (Baxter, et al 2005, James, et al 2005, Kralovics, 
et al 2005a, Levine, et al 2005a). The four groups took three different approaches to 
find this mutation: 
 
(i) James et al., took a functional approach. They observed that the formation of 
erythropoietin (Epo)-independent colony formation (EEC), one of the biological 
hallmarks of PV, was impaired by both JAK2 inhibitors and also short interfering 
RNA (siRNA) against JAK2. They went on to screen the JAK2 gene and identified 
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the mutation. They then showed that introduction of V617F into mouse bone marrow 
cells by retroviral-mediated gene transfer gave rise to a PV-like phenotype which was 
not seen in controls, thus clearly implicating V617F as causative in the disease 
process. This seminal discovery again highlighted the importance of aberrant tyrosine 
kinase signalling in the pathogenesis of MPDs.  
 
(ii) Based largely on the recurrent findings of abnormal tyrosine kinases in atypical 
MPDs, both Baxter et. al., 2005 and Levine et. al., 2005 performed mutational 
screens of genes encoding tyrosine kinases. 
 
(iii) Kralovics et. al., 2005 followed up on their earlier work that identified 9p UPD in 
PV. Analysis of further patients led to a smaller minimally affected region that still 
included JAK2. Despite having been apparently excluded previously, JAK2 remained 
an obvious candidate because of its known importance in erythropoiesis. 
Consequently, this gene was re-screened and the V617F mutation identified in a 
small region that was apparently not covered in their previous analysis (Figure 5.2). 
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Figure 5. 2: Mechanisms and consequences of 9p LOH in PV. The chromosome 9 with the wild-
type JAK2 sequence (G) is shown in red, and the chromosome 9 with the G→T 
substitution (T) is shown in blue. Circles signify the nuclei of cells. Loss of the 
telomeric part of the wild-type chromosome 9p by deletion is shown on the left, as a 
potential mechanism for LOH. Alternatively, on the right mitotic recombination is 
depicted, as a second mechanism of 9p LOH. The events that may occur during 
mitosis are represented, as are the resulting cell progeny.  
 
At the time our group was also screening tyrosine kinase genes for mutations, mainly 
in atypical MPDs. Once the finding of V617F JAK2 emerged, we looked at a series of 
cases for the presence of this mutation. In total, we investigated 480 MPDs and found 
that the percentage of PV, ET and IMF patients positive for the mutation correlated 
well with the other studies. Interestingly the mutation was also seen in a subset of 
atypical MPDs: 30/152 (20%) atypical or unclassified MPD, 2/134 (2%) idiopathic 
hypereosinophilic syndrome were V617F positive but the mutation was not seen in 
any patients with systemic mastocytosis (SM), AML, secondary erythrocytosis or in 
normal individuals (Jones, et al 2005).  
 
5.1.4   The association between JAK2 V617F and 9p aUPD 
 
Work performed by Amy Jones using both direct sequencing and pyrosequencing, 
observed a wide range in the proportion of JAK2 alleles that carried the V617F 
mutation. In many patients the mutation appeared to be homozygous, i.e. the residual 
wild type allele was completely or almost completely lost. Homozygosity was only 
seen in PV and MF and strikingly, the frequency was similar to that of aUPD as 
described previously (Kralovics, et al 2002). To investigate the relationship between 
homozygosity for V617F and aUPD 9p in more detail, I used microsatellite PCR 
analysis to look for chromosome 9p LOH in a series of patients. Microsatellites are 
repetitive sequence elements that are arranged in tandem and dispersed throughout 
almost the entire genome. The length of the core repeats are highly variable, and form 
allelic variants that can be analysed using PCR. I used 8 primer pairs flanking the 
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dinucleotide (CA) highly polymorphic microsatellite markers on chromosome 9p 
(Table 5.1). 
 
Chromosome band Marker Heterozygosity (http://www.gdb.org/) 
 D9S1779 0.64 
p24.3 D9S1858 0.58 
p24.2 D9S288 0.86 
p24.2 D9S1813 0.84 
p24.1 JAK2  
p24.1 D9S286 0.88 
p23 D9S254 0.75 
p22.2 D9S157 0.85 
p21 D9S171 0.80 
 
Table 5. 1:  Microsatellite marker name, location on chromosome 9p in relation to the JAK2 
gene, and the relative heterozygosity of each microsatellite marker. 
 
I analysed 30 MPD cases that did not have the V617F mutation and 27 V617F 
homozygous patients. The products were analysed on an ABI3100 using the 
Genotyper 2.0 program. If only one peak was visible a patient was scored as 
homozygous. To allow for the presence of background normal cells, homozygosity 
was also scored if one peak was one third or smaller than the expected size compared 
to controls. A significant tract of homozygosity was scored if four or more 
consecutive markers abutted or encompassing JAK2 were homozygous, since the 
probability of this occurring by chance was well under 5% as determined by known 
the rates of heterozygosity (http://www.gdb.org/). The results of the analysis are 
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summarised in Table 5.2. Of the 27 V617F homozygotes, 26 were found to have 
chromosome 9 UPD (96%). Of the 30 JAK2 negative PV, IMF and ET patients, only 
four were found to have significant homozygosity (13%) (P<0.0001, Fisher’s exact 
test). This indicates that LOH is significantly associated with homozygosity for the 
V617F mutation. 
 
To determine if the observed homozygosity was due to aUPD or LOH, MLPA was 
performed to look for copy number by another member of our group. One copy of 
JAK2 would indicate LOH due to either a whole chromosome deletion or specific 
chromosomal region, whereas two copies would indicate aUPD. All seven cases 
analysed by MLPA that were homozygous for at least four 9p microsatellites and 
were homozygous for the V617F mutation were shown to have two copies of JAK2, 
consistent with chromosome 9 aUPD (Kralovics, et al 2002). Whilst my analysis was 
ongoing Kralovics et. al., (2005) published similar data showing a strong correlation 
between V617F homozygosity and 9p aUPD (Kralovics, et al 2005a). 
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WT/WT
n=30
V617F/V617F
n=27
 
 
Table 5. 2:  9p LOH in V617F homozygous patients compared to V617F negative cases. The 
V617F genotype of the patient is indicated on the right as either homozygous normal 
(wt/wt; patients 1-30) or homozygous mutant (M/M; patients 31-57). The 
microsatellite markers are shown in order from the most telomeric (D9S1779) to the 
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most centromeric (D9S171) and are scored as homozygous (black), heterozygous 
(white) or not done (grey). 
 
5.1.5   Acquired UPD is not limited to MPDs 
 
More recently it has become apparent that aUPD is widespread in haematological 
malignancies, for example AML (Raghavan, et al 2005), ALL (Irving, et al 2005) 
chronic lymphocytic leukaemia (Pfeifer, et al 2007) and multiple myeloma (Walker 
and Morgan 2006) plus also solid tumours such as basal cell carcinomas (Teh, et al 
2005), prostate cancer (Torring, et al 2007) and colorectal cancer (Gaasenbeek, et al 
2006).  
 
In contrast to the initial studies in PV which used microsatellite analysis, these more 
recent studies used genome-wide microarray single nucleotide polymorphism (SNP) 
analysis. For example, Raghavan et. al., showed that approximately 20% of normal 
karytotype AMLs exhibited large regions of homozygosity that was not associated 
with visible chromosomal abnormalities. They were also able to show that a 
previously identified homozygous CEBPA mutation coincided with a region of large 
scale aUPD of chromosome 19 (Raghavan, et al 2005). Further studies in AML 
determined that aUPD for chromosome 13q was associated with activating FLT3 
mutations (Griffiths, et al 2005), aUPD 11p with inactivating WT1 mutations and 
aUPD 21q with RUNX1 mutations (Fitzgibbon, et al 2005). Mutations in other 
malignancies have also been linked to homozygosity for specific mutations, e.g. the 
glucocorticoid receptor gene in pediatric ALL (Irving, et al 2005), PTPN11 gene in 
ALL associated with Noonan syndrome (Karow, et al 2007), CDKN2A and TP53 in 
follicular lymphoma (Fitzgibbon, et al 2007) and NF1 in JMML (Flotho, et al 2007).  
 
These studies show a strong association between regions of aUPD and specific 
acquired mutations in oncogenes or tumour suppressor genes. In reports where paired 
samples have been studied, it appears the mutation precedes the aUPD and hence the 
aUPD is a ‘second hit’ leading to homozygosity of an oncogenic mutation associated 
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with disease progression (Fitzgibbon, et al 2007, Fitzgibbon, et al 2005). Global UPD 
screens may therefore be a new approach to help identify new oncogenes and tumour 
suppressor genes in malignancy. 
 
5.1.6    Aims of my analysis 
 
The primary aim of my analysis was to determine if aUPD was present in atypical 
MPDs and, if so, to follow up any findings to try and identify new pathogenetic 
lesions in these diseases. As described above, MPDs are characterised by deregulated 
tyrosine kinases and therefore our principal hypothesis was that novel activating 
tyrosine kinase abnormalities were likely to be the root cause of many or all atypical 
MPDs. Acquired UPD has been associated with two activated tyrosine kinases – 
JAK2 and FLT3 – and therefore identification of new regions of aUPD may therefore 
be a particularly good method to provide pointers towards new kinase mutations. In 
addition, since this was an entirely new and potentially very powerful method of 
analysis, I also took the opportunity to analyse a range of other cases of 
haematological disorders. 
 
5.2   SNP CHIPS TO IDENTIFY REGIONS OF UPD 
5.2.1   SNP chips 
 
SNPs are believed to be the most common sequence variation in the human genome, 
occurring every approximately 1,200bp (Sachidanandam, et al 2001) and thus there 
are likely to be more than 2 million polymorphic sites in the human genome. The 
identification of SNPs that are roughly evenly spaced has enabled the realisation of 
whole genome SNP screens. The advent of high density single SNP chips has 
revolutionised the field of genome-wide allelic screening as they can accurately and 
reproducibly detect copy number and loss of heterozygosity simultaneously. A few 
reports have compared LOH differences observed by microsatellite analysis versus  
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those found by SNP array and demonstrated excellent concordance however, as 
expected, additional smaller regions of LOH were detected by SNP arrays due to their 
higher resolution (Dumur, et al 2003, Lindblad-Toh, et al 2000, Wang, et al 2004b).  
 
5.2.2   Plan of analysis and methods 
 
When I started this project there were two platforms available: Affymetrix 10K chips, 
i.e. chips that harboured 10,000 SNPs across the genome, and Affymetrix 100K 
chips, which actually consisted of 2 x 50K chips that each contained 50,000 genome-
spanning SNPs. The studies that had been published at the time had used 10K arrays 
and this density was easily sufficient to identify regions of UPD (Irving, et al 2005, 
Raghavan, et al 2005). However I wanted to explore the possibility of looking at 
more detail at copy number changes and in particular small deletions or 
amplifications that may mark the presence of cryptic fusion genes. Because of the 
relatively high cost of the technique I elected to use just one 50K chip per sample in 
order to maximise the number of cases that could be analysed. 
 
The generic method of sample preparation for SNP chip use was devised by Kennedy 
et. al., (2003) (Kennedy, et al 2003). The whole-genome sampling assay (WGSA) is 
based on a simple restriction enzyme digestion, followed by linker-ligation of a 
common known adaptor sequence to every fragment generated by digestion. Using a 
single primer complementary to this adaptor, multiple loci can be simultaneously 
amplified. Hence, the genomic DNA is converted by PCR into amplified fragments of 
reduced complexity that can be easily hybridised to the SNP arrays (Figure 5.3). This 
method was aided by the completion of the human genome project enabling 
prediction of restriction fragments that should amplify consistently and SNPs that 
reside within these fragments. Oligonucleotides corresponding to these SNPs are then 
synthesised onto high-density microarrays. The XbaI 50K mapping array has 58,960 
SNPs spaced across the whole-genome with 99.1% of the genome within 500Kb of a 
SNP, 91.6% within 100Kb and 40% within 10kb (Matsuzaki, et al 2004).  For each 
SNP there are 40 oligonucleotides (20 perfect matches and 20 mismatches) these are 
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scattered across the chip in order to minimise any problems arising from patchy 
hybridisation. 
 
 
 
Xba I
 
Figure 5. 3:  Schematic representing in brief how the Affymetrix SNP chips work adapted from 
the website of ImaGenes GmbH, Berlin, Germany. Genomic DNA is first digested 
using a restriction enzyme that cut regularly throughout the genome, such as XbaI or 
HindIII. An adapter sequence (represented in blue) is then ligated on to both ends of 
every fragment. A primer is designed to the adapter sequence that is capable of 
amplifying all the digested and ligated fragments. These fragments are then end 
labeled and hybridised to the chip. The results are typed as homozygous (AA or BB) 
or heterozygous (AB), and a measure of the intensity of the hybridisation signal 
relates to the copy number of the SNP. 
 
 
We do not have the local facility to perform Affymetrix analysis ourselves and 
therefore the laboratory elements were performed as a service by the RZPD in Berlin 
(now ImaGenes GmbH). The RZPD performed the labelling and hybridisation to the 
XbaI 50K Affymetrix GeneChip SNP array using our samples. After hybridisation, 
the array was washed and stained using an Affymetrix Fluidics station. The staining 
protocol is designed to amplify the signal from the annealed probe. Scanning was 
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then carried out using an Agilent GeneArray Scanner and the raw data was provided 
to us as a cabinet (.CAB) file of approximately 50Mb for each sample. 
 
The .CAB file is first read by the Affymetrix GeneChip® Operating System (GCOS) 
in conjunction with the library files for the 50K mapping array, which contain the 
details of all SNP and probe locations (http://www.affymetrix.com/index.affx).  
Further analysis to genotype each call was then carried out using Affymetrix 
GeneChip® Genotyping Analysis Software (GTYPE 4.1). This is specifically 
designed to give highly accurate, automated SNP allele calls for the mapping arrays, 
including the 50K SNP array. The programme includes a new genotyping algorithm, 
designated BRLMM that produces a quality score for each genotyping call (Rabbee 
and Speed 2006). Copy-number estimations were then determined using the 
Affymetrix GeneChip® Chromosome Copy Number Analysis Tool (CNAT 4.0) 
which is integrated into GTYPE 4.1. The copy number algorithm jointly uses 
genotype information and perfect match (PM) probe intensity and discrimination 
ratios between paired PM and mismatched (MM) probe intensity values to identify 
and estimate genetic copy number changes. Values from an experimental sample are 
compared with SNP-specific distributions derived from a reference set containing 
over 100 normal individuals (provided by Affymetrix) to gain statistical power. Once 
the data was fully analysed using Affymetrix GeneChip® software, it was exported to 
Excel spreadsheets developed in Newcastle by Professor Andy Hall which displays 
LOH and copy number changes in ideogram format for individual samples or across 
multiple samples for the ready detection of common areas of deletion.  
 
5.2.3   Patient samples  
 
DNA from specific patient groups was selected, quantified, tested by agarose gel 
electrophoresis to check for degradation and 250ng sent to the RZPD. The samples I 
sent for analysis (in four batches) are shown in Table 5.3. For the cases of CML in 
blast crisis (CML-BC) cases, samples were selected that had at least 75% blasts. No 
specific criteria were employed for other patient subgroups, although for 
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aCML/aMPD I focused preferentially on cases with a high leucocyte count, i.e > 
20x109/L. 
 
Leukaemia subgroup Nos. sent for analysis 
aCML/aMPD 30 
CML: myeloid blast crisis 10 
CML: lymphoid blast crisis 10 
JAK2 V617F negative IMF 18 
JAK2 V617F positive IMF 10 
JAK2 V617F negative PV 10 
 
 
Table 5. 1:  Number of samples sent to the RZPD for 50K SNP chip analysis from each 
leukaemic subgroup.  
 
Although my main aim was to investigate the pathogenesis of aMPD/aCML patients, 
I also took the opportunity to investigate other related patient groups for whom the 
pathogenesis was completely or largely unknown.  
 
5.2.4   SNP array results 
 
5.2.4.1  Overview of results 
 
Data was returned from all samples along with a series of quality metrics, the most 
important of which was the SNP call rate. Overall a median of 98.2% SNPs gave 
readable calls with a range from 91.5% - 99.6% for individual samples. Only 6 
samples were below 95%. Analysis of the data led to the identification of copy 
number and LOH anomalies and the results are summarised in detail in Table 5.4 
169 
below. Using the analysis software it was easy to observe the different causes of LOH 
when the affected regions were relatively large, i.e. deletions, amplifications or copy 
number neutral loss (aUPD). In Table 5.4 these have been classified as copy number 
(CN) changes and acquired uniparental disomy (aUPD). 
 
The main aim of my study was to identify large regions of aUPD as an indicator 
towards novel oncogenes or tumour suppressor genes. However since we did not 
have constitutional DNA from most of our cases we could not formally prove that 
regions of homozygosity were acquired and not inherited. Instead we inferred that 
they are highly likely to be acquired from the patterns of homozygosity seen in 
normal individuals. A recent study used SNP arrays to genotype 276 DNA samples 
derived from lymphocytes of elderly neurologically normal subjects. They found 
extended regions of homozygosity (contiguous tracts >5Mb) in 9.5% patients but 
structural genomic variations in 66.9%. Of the patients exhibiting extended 
homozygosity, 42.3% showed multiple tracts ranging from 5-39Mb that were 
attributed to parental consanguinity. Regions of homozygosity were rarely greater 
than 15-20Mb in size (Simon-Sanchez, et al 2007). To avoid regions that may be 
inherited rather than acquired, we therefore focused primarily on larger regions of 
copy neutral LOH, which we arbitrarily defined as greater than 20Mb running to a 
telomere (Figure 5.4), although regions >10Mb running to a telomere were also 
considered. Smaller, interstitial regions of LOH were also identified within most 
subgroups however, as previously mentioned, the lack of constitutional matched 
DNA for any of the samples made it impossible to know if these were acquired or 
inherited. I therefore discounted these regions from the initial analysis. 
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Figure 5. 1:  Ideograms showing UPD. A) The graph on the left shows the copy number trace and 
indicates no large abnormalities. The graph on the right shows zygosity and shows a 
large block of homozygous SNP calls at 9p. Since there is no copy number change it 
is likely that the homozygosity arose by aUPD; B) Apparently patchy 11q aUPD 
observed in some patients that may to be due to poor DNA quality or a high 
proportion of background normal cells affecting the SNP calls. 
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Leukaemic subgroup Identifier aUPD CN imbalances
aCML/aMPD E110, E129, E639 7q  
 P951 1p (~15Mb)  
 E160 17q   
 E484, E632, E1191 
(granulocyte pellet) 
11q  
 E632 8p (~15Mb)  
 P1304 20q  
 E180 whole chr 13   
 E155   
 E1445 21q   
 P1213  Del 20q, 7q, Del 17q 
 E674  Del Chr 7 
 P981, E139  Del 8p 
    
Myeloid blast crisis mBC3 15p (~10Mb) Del 17p 
 mBC6  Del 2q, Del 11p 
 mBC10  Del 7q 
    
Lymphoid blast crisis LyBC1  Gain Chr1, Del 16q 
 LyBC5  Del 9p, Del 11q and 
Del 20q. 
 LyBC8  Del 7p, Del 9p 
 LyBC10  Del 16q, Gain 1q 
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 LyBC11  Del 7p, Del 9p 
    
JAK2 V617F negative 
IMF 
E996 1pUPD   
 E887 9pUPD   
 04/1345 11qUPD  
 04/4885  Gain 21q, Gain 22 
 01/4124  Gain 1q, Del 7q 
 01/1755  Gain Chr8 
    
JAK2 V617F positive 
(homozygous) IMF 
E1936 9p  
 E1530 9p  
 E1302 9p  
 E1190 9p  
 E904 9p Del 20q 
 0604544 9p  
 0512361 Low level 9p  
 00/1180 9p and 5q  
 04/3974 9p   
 
Table 5. 2:  Summary of SNP array results. aUPD was scored as regions of LOH greater than 
20Mb running to a telomere with no change in copy number. Regions of extended 
copy neutral homozygosity that were between 10Mb and 20Mb but which extended 
to a telomere are also shown. Copy number (CN) anomalies (deletions and 
amplifications) are also shown.  
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 Cytogenetic information was only available for some cases and in general the 
correspondence between visible cytogenetic abnormalities and SNP array results, 
particularly deletions, was very good. However since the main focus of my analysis 
was to identify regions of aUPD and other groups have already shown a good 
correlation between array results and karyotype, I did not perform a detailed 
comparison of the two techniques. Candidate regions of aUPD for each patient 
subgroup are considered in detail in the following sections. 
 
5.2.4.2  JAK2 V617F negative Polycythaemia Vera  
 
About 5% of PV patients are negative for the V617F JAK2 mutation. By screening a 
small subset of V617F negative patients I hoped to identify another region of 
recurrent aUPD or imbalance that might indicate a novel chromosomal area 
harbouring a new candidate gene. However I observed no regions of aUPD or copy 
number changes in the 10 cases I analysed. 
 
Subsequently it has emerged that many V617F negative PV cases have mutations in 
exon 12 of the JAK2 gene (Butcher, et al 2008, Pietra, et al 2008, Scott, et al 2007a, 
Scott, et al 2007b, Williams, et al 2007) and further analysis by our group indicated 
that two of the cases analysed were exon 12 mutation positive.  However in contrast 
to V617F, these exon 12 mutations are not generally reduced to homozygosity by 
aUPD.  
 
5.2.4.3  JAK2 V617F negative myelofibrosis  
 
Of the 18 cases analysed, two were apparently positive for regions on 1p and 9p, 
respectively. The 9p abnormality was a surprise as this is the location of JAK2, and 
negativity for V617F was confirmed. One possibility was that the homozygous tract 
was marking the presence of a novel JAK2 mutation, however since the patient was 
local a mouthbrush sample was obtained in order to see if the small region of 
homozygosity was really acquired. Rather than performing expensive array analysis 
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on the mouthbrush sample, microsatellite PCR markers were used to assess the region 
of 9p LOH in both the mouthbrush DNA sample, the PB DNA sample as well as 
three normal controls (Table 5.5). 
 
Chr 
location Marker 
E887 
(PB) 
E2357 
(MOUTHBRUSH) NORMAL1  NORMAL2  NORMAL3 
TEL D9S1779 HOM HOM HET HOM HOM 
9p24.3 D9S913 HOM HOM HOM  HET HET 
9p24.3 D9S1858 HOM HOM HET HET HET 
9p24.3 D9S143 HOM HOM HET HOM HOM 
9p24.2 D9S1871 HET HET HET HET HET 
9p24.2 D9S228 HOM HOM HOM HOM HET 
9p24.2 D9S288 HET HET HET HET HET 
9p24.2 D9S178 FAIL FAIL FAIL FAIL FAIL 
9p24.2 D9S1813 HET HET HET HET HET 
9p24.1 JAK2           
 
Table 5. 3:   Results of microsatellite analysis on the MF case with 9p homozygosity. 
 
This analysis revealed first that the region of homozygosity did not include JAK2 
(something that was also obvious from the SNP array results) and second, that the 
region is also present in the mouthbrush DNA and is thus inherited not acquired. 
 
The remaining patient, E996 had 1p UPD (Figure 5.5A). At about this time, a report 
by Pikman et. al., (2006) detailed the discovery of a mutation in the thrombopoietin 
receptor (MPL). The somatic activating mutation in the transmembrane domain of 
MPL (W515L or W515K) was found in 9% of the JAK2 V617F-negative MF 
patients. Subsequently other variants were found that affected the same residue. The 
reason this was of interest to me is that this gene is located on chromosome 1p. I 
investigated the region of 1p UPD in this patient to confirm if this region harboured 
this gene and indeed this was the case.  
 
We had an assay set up for investigating this mutation by pyrosequencing so I used 
this to initially test for W515L or W515K mutations (Figure 5.5B). The 
pyrosequencing trace shows my patient (E996) has a significantly higher percentage 
of the ‘T’ allele compared to the normal control indicating the G>T mutation  
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(W515L). This was further confirmed by sequencing (Figure 5.5C), which clearly 
indicates that the normal G has been completely replaced by a T. This therefore 
provides another example of aUPD being associated with a particular oncogenic 
change.  
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Figure 5. 5: A) the two graphs generated by the customised excel tool supplied by Professor Hall 
detailing the SNP chip results for chromosome one in this patient (E996). The graph 
on the left shows the copy number, whilst the graph on the right details regions of 
loss of heterozygosity; B) shows the pyrograms for E996 (above) versus a normal 
control (below). E996 shows a greater proportion of the T allele compared to the 
normal control indicating the G>T mutation; C) the mutation was further confirmed 
by sequencing. The trace on the left shows the wild-type sequence and the trace on 
the right E996 showing the homozygous G>T mutation. 
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5.2.4.4  JAK2 V617F positive myelofibrosis 
 
It is unclear why the V617F mutation is associated with distinct clinical phenotypes, 
(PV, ET and MF) but it has been suggested that these are multistep diseases with 
other genetic abnormalities that remain to be identified. In particular, PV and ET may 
evolve to MF and the appearance of new cytogenetic abnormalities during disease 
evolution suggests that the transition may be driven by new mutations. I therefore 
examined 10 V617F positive MF cases with high levels of the mutant clone (>50%) 
to see if any other abnormalities were apparent. 
 
Of the 10 JAK2 cases, 9 exhibited 9p LOH, all of which showed no change in copy 
number. The single case that did not show 9p LOH was only 53% V617F positive 
and hence was probably heterozygous. In addition to 9p, one case also had clear 5q 
aUPD (Figure 5.6). There are no known haematologically relevant oncogenes at 5q 
and currently the significance of this finding remains unclear. 
 
 
 
 
 
 
 
 
 
 
 
 
Chr 5 CN
-2 -1 0 1 2
Figure 5.6:   Figure showing the SNP chip results for Patient 00/1180. The patient shows 9p 
aUPD and 5q aUPD determined by the large region of LOH on the graphs on the 
right, compared to the left-hand graphs depicting copy number changes of which 
there are none.  
 
Chr 5 LOH
0 10 20 30 40 50
2030575
10308821
20085845
31588495
40429958
54263116
62093955
75635361
83694245
93668872
101581893
110518996
115732465
124350370
131954612
144191544
151738645
158601066
165431452
179301894
Chr 9 CN
-2 -1 0 1 2
Chr 9 LOH
0 10 20 30 40 50
378900
4135340
9720366
13983595
18735134
25297811
28888968
35269814
73904711
82180780
93976588
102409771
109232711
117184531
129544858
177 
In addition, a second patient had an additional copy number imbalance, specifically 
deletion of 20q. Deletion of 20q is a known recurrent finding in a range of MPDs.  
 
 
5.2.4.5  CML in transformation 
 
Although BCR-ABL is probably the sole abnormality that drives chronic phase CML, 
it is widely believed that a series of additional genetic events precipitate 
transformation to acute leukaemia, or blast crisis. I analysed 20 cases (10 in lymphoid 
transformation and 10 in myeloid transformation) to see if these putative changes are 
associated with aUPD. In fact, none of the lymphoid cases showed copy neutral LOH 
and just one of the myeloid cases showed one possible region at the tip of 15p that 
was approximately 10 Mb in size. Unfortunately there was no chronic phase or 
constitutional DNA available to confirm that this was acquired. Several copy number 
changes were identified that correlated with the results of chromosome analysis. 
 
5.2.4.6  aCML/aMPDs  
 
Strikingly, this subgroup showed a high frequency of aUPD compared to other 
patient groups. Of the 30 cases analysed, 12 (40%) were affected by aUPD (including 
two cases with regions estimated to be 15 Mb in size). In one case (E1191) it was 
possible to show that the abnormality was indeed acquired by array analysis of DNA 
extracted from mononuclear cells (MNC; includes B-cells and T-cells that are not 
usually involved in the disease) and DNA extracted from granulocytes pellet (which 
would be expected to be predominantly clonal). As shown on Figure 5.7, 11q LOH is 
clearly visible in granulocyte DNA but is not visible or barely detectable in MNC 
DNA.  
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Figure 5.7: Comparison of MNC and granulocyte DNA for patient E1191. No copy number 
changes are observed in either DNA sample (first and third panels) however clear 
11q LOH is observed in the DNA extracted from granulocytes (fourth panel) that is 
absent in MNC DNA (second panel), indicating an acquired abnormality.  
 
In total, eight different chromosomal regions were affected by aUPD suggesting 
substantial genetic heterogeneity in these diseases. Recurrent regions were identified 
at 7q and 11q (3 cases of each, i.e. 10% of cases) and single cases with aUPD were 
seen at 1p, 8p, whole chromosome 13, 17q, 20q and 21q.  
 
One patient, E632, showed both whole arm 8p aUPD and 11q aUPD. This patient 
also showed many regions of interstitial LOH, far more than any other patient (Figure 
5.8). Limited clinical history suggests this patient may be consanguineous, suggesting 
that at least some of these multiple homozygous regions may be autozygous, i.e. 
inherited rather than acquired. 
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Figure 5. 8: Ideograms depicting E632 SNP array results. A) Top panels show tracts of 
homozygosity at 11q and 8p, both of which extend to a telomere; B) bottom panels 
show an example of two of the ten interstitial regions of homozygosity.  
 
One patient (E180) showed whole chromosome 13 aUPD (Figure 5.9a). The receptor 
tyrosine kinase FLT3 is located on this chromosome and is the most frequently 
mutated gene in acute myelogenous leukemia (AML), usually associated with an 
internal tandem duplication (ITD) of the region encoding the juxtamembrane domain. 
Furthermore it has already been reported that aUPD for chromosome 13 is associated 
with FLT3 mutations in AML (Griffiths, et al 2005). The ITD is within exon 14 
and/or 15 of the FLT3 gene, so primers were designed initially to amplify exon 14. 
As shown on (Figure 5.9b), patient E180 is indeed homozygous for a FLT3 ITD. 
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Figure 5. 9: A) Analysis of aMPD patient E180. The graph on the left shows there has been no 
copy number change, whilst the graph on the right indicates complete chromosome 
13 homozygosity; B) PCR assay for FLT3 ITD. Lanes 1 & 2 represent patient E180, 
lane 3 is a positive control (an AML patient with a known FLT3 ITD and lane 4 is a 
normal control. The bottom band is the normal FLT3, the top band is FLT3 with an 
ITD. 
 
Other regions of aUPD could not be simply linked to known mutations. My analysis 
focused on the recurrent regions at 7q and 11q and these are discussed in detail 
below. The abnormalities at 1p, 8p, 17q, 20q and 21q were not investigated. The 
region at 17q may target NF1, a gene that has long been associated with juvenile 
myelomonocytic leukaemia (JMML) (Side, et al 1998). More recently, Flotho et. al., 
(2007) screened JMML patients and found regions (>55Kb) of copy number neutral 
17q LOH leading to loss of the normal NF1 allele that was associated with an 
increased incidence of JMML in NF1 patients. However, NF1 is a large gene with 58 
exons and therefore very expensive to screen for mutations (Flotho, et al 2007).  
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In addition to large regions of copy number neutral LOH, copy number imbalances 
were also observed in aMPD cases. One patient exhibited three deletions of the long 
arms of chromosomes 20, 17 and 7. As discussed previously deletions of 
chromosome 20q are a common abnormality associated with myeloid disorders as are 
deletions of 7q (Luna-Fineman, et al 1995). The 17q deletion may again be 
associated with an NF1 mutation. Another patient was also found to have a deletion 
of entire chromosome 7, and two patients had a deletion of 8p. Deletions of 8p have 
been described previously in association with MDS and the evolution of CML 
(Kerndrup, et al 1987, Pedersen and Kerndrup 1986, Wada, et al 1994).  
 
5.3   RECURRENT aUPD OF CHROMOSOME 7q 
5.3.1   7q abnormalities in myeloid disorders 
 
LOH for chromosome 7, commonly in the form of monosomy 7 or deletion of the 
long arm of chromosome 7 is a very frequent occurrence in a variety of human 
malignancies including gastric cancer (Weng, et al 2006), breast cancer (Zenklusen, 
et al 1994), prostate cancer (Latil, et al 1995), colon cancer and primary cell 
carcinoma of the head and neck (Zenklusen, et al 1995). It has been hypothesised that 
a tumour suppressor gene is located at 7q that is ubiquitously expressed thereby 
accounting for the numerous cancers associated with abnormalities of chromosome 7.  
 
More relevant to my work is the consistent reports of chromosome 7 LOH in myeloid 
abnormalities (Dohner, et al 1998, Fischer, et al 1997, Kere, et al 1989, Kere, et al 
1987, Le Beau, et al 1996, Lewis, et al 1996, Liang, et al 1998, Tosi, et al 1999). 
Monosomy 7 and del(7q) are frequently found associated with MDS, AML and 
juvenile CML (Aktas, et al 1999, Hasle, et al 1999, Mantadakis, et al 1999, Tosi, et 
al 1996), as well as therapy related MDS (t-MDS) and therapy related AML (t-AML) 
occurring after treatment with alkylating agents or exposure to certain carcinogens 
(Rowley 1976). Although much work has been performed in defining critical regions 
of LOH based on deletions and translocations, no group has yet identified a definitive 
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tumor suppressor gene. Furthermore, at least three distinct minimal regions of LOH 
have been identified suggesting that multiple loci may be important. Some have also 
argued that the complexity of 7q rearrangements might indicate that this region is 
prone to breakage and instability as a consequence of different genetic factors that 
play a general role in oncogenesis rather than the presence of a specific tumour 
suppressor gene involved in myeloid disorders (Basirico, et al 2003, Gonzalez, et al 
2004). 
5.3.2   Recurrent 7q aUPD identified by SNP chip  analysis 
 
 
As a result of screening 30 aCML/aMPD patients using Affymetrix 50K SNP arrays I 
identified three cases with varying sized regions of aUPD of chromosome 7q (Figure 
5.10). 
 
 
 
Figure 5.10: Copy number and LOH graphs produced for chromosome 7 for three aCML/aMPD 
patients: E639, E129 and E110. In all three cases the copy number graph shows no 
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copy number changes. All three LOH charts show varying sized regions of LOH 
affecting the q arm of chromosome 7. 
 
 
No copy number alterations or aUPD was observed elsewhere in the genome of these 
patients. Cytogenetics was only known for E639 and this was normal. Patients E110 
and E129 had regions of aUPD spanning approximately 98Mb, almost the entire 
length of the long arm of chromosome 7, specifically 7q11.21-tel and 7q11.22-tel, 
respectively (Figure 5.11). The third patient has a smaller region of partial 7q aUPD 
spanning 53Mb from cytogenetic bands 7q22.3-tel. This region represents the 
minimal overlapping region of aUPD observed in all three patients (Figure 5.11). 
 
 
 
 
 
            
Patient Identifier Region of LOH/Chromosomal region Size of region of LOH  
E110 63,695,332-158,554,645 (q11.21-qter) 94,859,313 (95Mb)  
E129 71,178,702-158,554,645 (q11.22-qter) 87,375,943 (87Mb)  
E639 105,954,360-158,554,645 (q22.3-qter) 52,600,285 (53Mb)  
 
 
 
E110 & E129 
E639 
 
Figure 5. 11: Schematic representation of chromosome 7 and the regions of aUPD (highlighted in 
red) observed in the three aCML/aMPD patients E110, E129 and E639.  
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5.3.3   Screening for mutations in 7q aUPD patients 
 
The minimal region 53Mb is still very large and encompasses approximately 400 
genes so prioritising candidate genes for screening was of primary concern. Due to 
the growing evidence linking aberrant tyrosine kinase signalling to the MPDs, I 
began by screening genes encoding tyrosine kinases and hoped to find mutations that 
were homozygous as a consequence of the aUPD. 
 
5.3.3.1  Candidate tyrosine kinases located within the region of 7qUPD 
 
There are 3 tyrosine kinase genes in the minimal region, MET (7q31.2), EPHA1 
(7q34-35) and EPHB6 (7q34). The MET proto-oncogene, encoding the tyrosine 
kinase receptor for the hepatocyte growth factor (HGF), controls cell growth, 
invasiveness, and protection from apoptosis. Deregulated MET signalling has long 
been associated with tumour progression and metastasis in a variety of tumours 
(Jeffers, et al 1996), as well as being deregulated in a few cases of human leukaemia 
and lymphoma (Jucker, et al 1994). Activating MET mutations have also been 
identified in hereditary and sporadic forms of papillary renal carcinoma (Schmidt, et 
al 1997). Recently, missense mutations have also been identified in this gene in a 
variety of human cancers (Lee, et al 2000, Ma, et al 2003). This seemed like an ideal 
candidate to screen for possible mutations in these three patients with 7q UPD.  
The Ephrin receptors and their ligands, the ephrins, regulate numerous developmental 
and cellular processes, particularly in the nervous system. They are divided into two 
groups based on their sequence similarities and structures, the ephrin-A (EFNA) 
class, which are anchored to the membrane by a glycosylphosphatidylinositol linkage, 
and the ephrin-B (EFNB) class, which are transmembrane proteins. They make up the 
largest subgroup of receptor tyrosine kinases. Although relatively little is known 
about these receptors over-expression and loss of expression of some family members 
have been related to specific cancers (Noren, et al 2006, Song, et al 2007).  
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5.3.3.2  Expression analysis 
It would be expected that any relevant mutated gene would be expressed in 
haematopoietic progenitor cells and probably in myeloid cells. As a first step towards 
prioritising these three genes, the expression of each was checked by RT-PCR using 
cDNA made from peripheral blood (PB) and bone marrow (BM) from 5 cases with 
other haematological disorders. cDNA-specific primers were designed to amplify the 
kinase domain (See Appendix I, section XXI) for all three receptor tyrosine kinases. 
Standard PCR conditions were used (annealing temperature of 66°C and 30 cycles). 
Clear products for EPHA1 and EPHB6 were seen in all samples but no amplification 
was seen for MET. I therefore focused initially on analysis of the two Ephrin 
receptors. 
Genomic DNA primers were designed, again to anneal at 66°C, to cover exons 
encoding the transmembrane and kinase domain as these are known hotspots for 
oncogenic mutations (for all primer sequences see Appendix I, section XXII). PCR 
products were directly sequenced and compared to the RefSeq entries for each gene. 
No mutations were identified so further primers were designed to cover all exons of 
each gene. As summarised on Table 5.6, no abnormalities were detected. 
Exon number E110 E129 E639 
EPHA1.5'UTR.F N N N 
EPHA1.Int1.1F N N N 
EPHA1.Int2.1F N N N 
EPHA1.Int3.1F 
T>C @479 HOM 
V160A 
T>C @479 HOM 
V160A 
T>C @479 HOM 
V160A 
EPHA1.Int4.1F N N N 
EPHA1.Int5.1F N N N 
EPHA1.Int6.1F N N N 
EPHA1.Int7.1F N N N 
EPHA1.Int8.1F N N N 
EPHA1.Int9.1F N N N 
EPHA1.Int10.1F N N N 
EPHA1.Int11.1F N N N 
EPHA1.Int12.1F N N N 
EPHA1.Int13.1F N N N 
EPHA1.Int14.1F N N N 
EPHA1.Int15.1F  N N N 
EPHA1.Int16.1F N N N 
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EPHA1.Int17.1F N N N 
        
EPHB6.Int 5'UTR.1F N N N 
EPHB6.Int 1.1F N N N 
EPHB6.Int 2.1F N N N 
EPHB6.Int3.1F N N N 
EPHB6.Ex4.1F N N N 
EPHB6.Int4.1F N N N 
EPHB6.Int5.1F N N N 
EPHB6.Int6.1F N N N 
EPHB6.Int7.1F N N N 
EPHB6.Int8.1F N N N 
EPHB6.Int9.1F N N N 
EPHB6.Int10.1F N N N 
EPHB6.Int11.1F N N N 
EPHB6.Int12.1F N N N 
EPHB6.In13.1F N N N 
EPHB6.Int14.1F N N N 
EPHB6.Int15.1F N N N 
EPHB6.Int16.1F N N N 
 
Table 5. 6: Mutation screening of EPHA1 and EPHB6. The variant found in all three patients in 
exon 4 of EPHA1 is a known SNP reported in various databases. Exon 1 of EPHA1 
proved difficult to amplify, so it was cloned and ten colonies sequenced for each 
patient. 
Although the MET tyrosine kinase was not obviously expressed in the PB or BM of 
controls, the possibility that its expression might be limited to a small population of 
myeloid precursor cells plus the strong association of activated tyrosine kinases with 
MPDs persuaded me that I should screen this gene as well. Genomic DNA primers 
were designed for the entire coding region of MET (Appendix I, section XXII). An 
identical intronic sequence change was identified upstream of exon 6 but was ruled 
out as causative due to the location, 60bp away from the exon start site. Other 
variants were identified in exons 20 and 21 but corresponded to known reported 
SNPs. The results are summarised in Table 5.7. 
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 Exon no. Exon E110 E129 E639
Int1.F 2 N N N 
Ex2F 2 N N N 
Int2.F 3 N N N 
Int3.F 4 N N N 
Int4.F 5 N N N 
Int5.F 6 82799C>T (Intronic) 82799C>T (Intronic) 82799C>T (Intronic) 
Int6.F 7 N N N 
Int7.F 8 N N N 
Int8.F 9 N N N 
Int9.F 10 N N N 
Int10.F 11 N N N 
Int12.R 12 N N N 
Int12.F 13 N N N 
Int13.F 14 9 clones = N 7 clones = N 9 clones = N 
Int14.F 15 N N N 
Int15.F 16 N N N 
Int16.F 17 N N N 
Int17.F 18 N N N 
Int18.F 19 N N N 
Int19.F 20 123310 C>T: 1304 D>D 123310 C>T: 1304 D>D 123310 C>T: 1304 D>D 
Int20.F 21 
HOM G>A: 1357 A>A & 
HOM G>A: 1382 P>P 
HET G>A: 1357 A>A &  
HET G>A: 1382 P>P  
HOM G>A: 1357 A>A &  
HET G>A: 1382 P>P 
 
Table 5. 7: Mutational analysis of the MET gene in the three aMPD patients with 7q aUPD. All 
exons were directly sequenced apart from exon 14 which was subcloned and then 
sequenced.  
Although it is conceivable that either EPHA1, EPHB6 or MET could be activated by 
another mechanism which cannot be detected by the strategy I used, e.g. a deep 
intronic mutation giving rise to a splicing abnormality or an internal 
deletion/duplication that encompasses at least one of the primer binding sites, it is 
much more likely that these genes are normal. Since these are the only tyrosine 
kinases on 7q, I therefore focused on the prioritisation of other candidate genes. 
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5.3.3.3  Other candidate genes 
 
To prioritise further genes I decided to look at those located within the minimal 
region of aUPD that impact on tyrosine kinase signalling pathways and for which 
there was a known link with leukaemia or cancer. There were no obvious candidates 
specifically implicated in leukaemia but there were two genes encoding signalling 
components more generally associated with cancer: BRAF and PIK3CG. 
The BRAF gene is located at 7q34 and seemed an obvious candidate as it encodes a 
member of the RAS-RAF-MEK-ERK-MAP kinase signalling pathway which is 
responsible for mediating the transduction of mitogenic signals from the cell 
membrane to the nucleus. It is a cytoplasmic member of the serine-threonine protein 
kinase family that is regulated by binding to RAS. Davies et. al., (2002) were the first 
to report mutations in this gene by high throughput sequence analysis. They screened 
genomic DNA from a number of different cancer cell lines and identified BRAF 
somatic missense mutations in a wide variety of cancers, notably malignant 
melanoma (66% of cases).  All mutations were within the kinase domain, with a 
single missense mutation (V599E) accounting for over 80% of the mutations 
observed. Of 53 leukaemia/lymphoma cell lines analysed no mutations were 
identified. However, it has been suggested that these mutations are commonly found 
in cancers that are also known to have a high frequency of RAS mutations (Davies, et 
al 2002). RAS mutations are seen in a substantial proportion of JMML and CMML 
patients (Bowen, et al 2005, Emanuel 2004, Emanuel 2008). Additionally, 
Christiansen et. al., (2005) screened 29 AML patients and identified 3 (21%) with 
BRAF mutations so it was entirely possibly that mutations in this gene may be found 
in patients with MPDs. Since the original report, BRAF mutations have been 
identified in a wide variety of human cancers including papillary thyroid carcinomas 
(Espinosa, et al 2007), non-small cell lung carcinomas (Brose, et al 2002), and 
colorectal carcinomas (Oikonomou and Pintzas 2006) with all mutations being 
located in either exons 11 or 15. 
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Based on these reports I decided to screen my aMPD patients with 7q aUPD for these 
two BRAF exons. Primers were taken from Brose et. al., (2002) and performed as 
suggested, using standard PCR conditions with a 58°C annealing temperature and 30 
cycles, however no sequence variants were found. These negative results fit with a 
recent report by de Vries et. al., (2007) who screened 65 JMML patients for 
mutations of the BRAF gene but found no mutations (de Vries, et al 2007). 
 
The second candidate I considered was PIK3CG (PI3-kinase p110 subunit gamma), 
located at 7q22.3. PIK3CG is highly related to PIK3CA at 3q26, which is commonly 
mutated in colorectal cancer (Oikonomou and Pintzas 2006) and other cancer types 
including bladder tumours, breast & ovarian cancer, and brain tumours (Bachman, et 
al 2004, Broderick, et al 2004, Campbell, et al 2004, Lopez-Knowles, et al 2006). 
Most of the mutations are clustered in two hotspots within the gene, as seen in Figure 
5.12. The mutations are thought to confer resistance to apoptosis and facilitate tumour 
invasion of solid tumours.  
 
 
KinaseHelical
 
 
 
Figure 5. 12: Adapted from Samuels et. al., (2004) (Samuels and Velculescu 2004). Clustering of 
reported mutations in PIK3CA identified in various human cancers. The arrow heads 
indicate the location of reported missense mutations. The percentage of mutations 
identified in each tumour group from this paper is indicated. 
 
Although no mutations have been described in PIK3CG, I decided to analyse the 
regions that were homologous to the hotspots in PIK3CA. Following alignment of the 
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two genes, I designed primers to amplify exons 2 and 11 of PIK3CG, which are 
homologous to exons 9 and 20 of PIK3CA. All primers were designed to anneal at 
66°C using standard PCR conditions with 30 cycles (Appendix I, section XXIII) but 
again no mutations were found.  
 
Having eliminated the likely hotspots in BRAF and PIK3CG, I considered full 
mutation screens and also created a shortlist of possible new candidate genes for 
analysis (Table 5.8). However at this point, the analysis of genes within the second 
recurrent region of aUPD at 11q was generating interesting results and this is where I 
focused my attention. 
 
Accession 
No. 
Gene 
Name 
Chr. 
Location 
Description 
NM_005515 HLXB9 q36.3 Homeobox protein HB9. Fused to ETV6 in infant 
AML. Activates IL6 via PI3K in Hodgkins 
Lymphoma. Also fused to MYB. Mutations found 
in Currarino syndrome. 
NM_002847; 
NM_130843; 
NM_130842 
PTPRN2 q36.3 Receptor-type tyrosine-protein phosphatase N2 
precursor. It is a member of the protein tyrosine 
phosphatase (PTP) family. PTPs are known to be 
signalling molecules that regulate a variety of 
cellular processes including cell growth, 
differentiation, mitotic cycle, and oncogenic 
transformation.  
NM_194071 CREB3L2 q33-q34 cAMP responsive element binding protein 3-like. 
The chimeric FUS/CREB3l2 gene is specific for 
low-grade fibromyxoid sarcoma. It belongs to a 
family of transcription factors. Fused to FUS in 
liposarcomas 
NM_178562 TSPAN33 q32.1 Tetraspanin 33, alternatively known as Penumbra 
whose mouse homologue has growth suppressive 
activity 
NM_170606; 
NM_021230 
MLL3 q36.1 Myeloid/lymphoid or mixed-lineage leukemia 3. 
It is involved in transcriptional co-activation.  
May be involved in leukaemogenesis and 
developmental disorder. 
NM_198267; 
NM_019071 
ING3 q31.31 Inhibitor of growth protein 3 (p47ING3 protein). 
The protein is similar to ING1, a tumor suppressor 
protein that can interact with TP53, inhibit cell 
growth, and induce apoptosis. This gene can 
activate p53 trans-activated promoters, including 
promoters of p21/waf1 and bax. Over-expression 
of this gene has been shown to inhibit cell growth 
and induce apoptosis. Allelic loss and reduced 
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expression of this gene were detected in head and 
neck cancers. 
NM_004935 CDK5 q36.1 Cell division protein kinase 5 (Tau protein kinase 
II catalytic subunit). Probably involved in the 
control of the cell cycle.  
 
 
Table 5. 8: Table showing the gene name, accession number and chromosomal location of some 
potential candidate genes on 7q. A brief list of known facts relevant to why these 
genes were short listed is also included. 
 
5.4   Recurrent aUPD of chromosome 11q 
5.4.1   11q abnormalities in myeloid disorders 
 
Like chromosome 7, chromosome 11 has also long been reported as a region 
commonly affected by imbalances in cancer. Both gains and losses of chromosome 
11 have been described. Gains of 11q are less common than losses but are often seen 
in neuroblastoma cell lines (Carr, et al 2007). LOH of this region is frequent and 
associated with cervical, ovarian, breast, colon and skin cancers (Bethwaite, et al 
1995, Carter, et al 1994, Foulkes, et al 1993, Hampton, et al 1994, Keldysh, et al 
1993, Tomlinson, et al 1993). By far the most frequent region of imbalance reported 
is centered round the cytogenetic band 11q23, in solid tumours as well as 
haematological malignancies such as T-cell prolymphocytic leukemia (T-PLL), B-
cell chronic lymphocytic leukemia (B-CLL) and mantle cell lymphoma (MCL). 
Amplifications of specific regions of 11q have also been identified in cases of AML 
and MDS. One group identified 11q genomic gain in more than 40% of AML cases 
with high level amplification again centered on 11q23, whilst another group reported 
the rare but recurrent occurrence of 11q amplifications of 11q23 and 11q13 in AML 
and MDS cases (Rucker, et al 2006, Zatkova, et al 2006). 11q LOH associated with 
leukaemia has also been described (Siu, et al 2000, Takeuchi, et al 2003). 
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 5.4.2   Recurrent 11q aUPD identified by SNP chip analysis 
 
From screening 30 aMPD patients with Affymetrix 50K SNP arrays I identified three 
aCML/aMPD patients with varying sized regions of aUPD at chromosome 11q 
(Figure 5.13). 
 
 
 
Figure 5. 13: 50K SNP array analysis of chromosome 11 in three aCML/aMPD patients: E484, 
E632 & E1191. The graphs on the left represent the copy number distribution 
observed across the chromosome whilst the graphs on the right hand side represent 
the loss of heterozygosity observed. All three have varying degrees of LOH with no 
corresponding copy number alterations, indicating aUPD. 
 
 
Previous cytogenetics was only available for one of the patients, E484, and this was 
found to be normal. All three patients had partial 11q aUPD of varying size as 
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illustrated on Figure 5.14. E632 and E1191 had the largest regions spanning 
approximately 69Mb, almost the entire long arm of chromosome 11. Cytogenetically, 
these correspond to 11q13.1-qter and 11q12.2-qter in E632 and E1191, respectively 
(Figure 5.14). E484 had a slightly smaller region of aUPD spanning 57Mb and 
covering cytogenetic bands 11q13.5-qter. This therefore represents the minimal 
region and includes about 350 known genes. 
 
 
 
 E484 
E632 
E1191 
 
 
 
 
 
 Patient Identifier
 
Region of LOH/Chromosomal region Size of region of 
LOH
E484 76,606,755-134,082,843 (q13.5-qter) 57476088 (57Mb) 
E632 64,698,446 -134,082,843 (q13.1-qter) 69384397 (69Mb) 
E1191 (Granulocyte) 61,241,557-134,082,843 (q12.2-qter) 67413720 (67Mb) 
 
 
 
 
 
 
 
 
Figure 5. 14: Schematic representation of chromosome 11 and the regions of aUPD observed in 
the three aCML/aMPD patients E484, E632 & E1191.   
 
5.4.3   Screening 11q aUPD patients 
 
5.4.3.1  Candidate genes located within the region of 11q aUPD 
 
 
Interestingly no tyrosine kinase genes are located within the minimal region of 11q 
aUPD, or indeed anywhere on 11q. Instead, I looked for genes associated with 
leukaemia or cancer in general within the minimal region. As expected there were 
several possible candidates (Table 5.9). However, only a few really stood out due to 
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previous reports of defects associated with specific leukaemias or very specific 
pathway links to receptor tyrosine kinases (those highlighted in yellow). 
 
 
Accession No. Gene 
Name 
Chr. 
Location 
Description 
NM_002576  PAK1 q14.1 p21-activated kinase 1, a serine/threonine kinase.  
 
NM_138292 ATM q22.3 Belongs to the PI3/PI4-kinase family. It is an important 
cell cycle checkpoint kinase. Defects in ATM 
contribute to T-cell acute lymphoblastic leukemia 
(TALL) and T-prolymphocytic leukemia (TPLL). 
Defects in ATM also contribute to B-cell non-Hodgkin 
lymphomas (BNHL), including mantle cell lymphoma 
(MCL) and B-cell chronic lymphocytic leukemia 
(BCLL).  
NM_003904 ZNF259 q23.2 May be a signalling molecule that communicates 
mitogenic signals from the cytoplasm to the nucleus. 
Binds to the EGF and PDGF receptors.  
NM_005933   MLL q23.3 Myeloid/lymphoid or mixed-lineage leukemia. 
Possibly acts as a transcriptional regulatory factor. 
Numerous chromosomal aberrations involving MLL 
are a cause of acute leukaemias. To name a few, 
translocation t(1;11)(q21;q23) with MLLT11/AF1Q; 
translocation t(3;11)(p21;q23) with 
NCKIPSD/AF3p21; translocation t(11;19)(q23;p13.3) 
with MLLT1/ENL; translocation t(11;19)(q23;p23) 
with GAS7; translocation t(X;11)(q13;q23) with 
MLLT7/AFX1.  
NM_005188  CBL  q23.3 Participates in signal transduction in haematopoietic 
cells. Adapter protein that functions as a negative 
regulator of many signalling pathways that starts from 
receptors at the cell surface. Acts as an E3 ubiquitin-
protein ligase, which accepts ubiquitin from specific 
E2 ubiquitin-conjugating enzymes, and then transfers it 
to substrates promoting their degradation by the 
proteasome. Recognises activated receptor tyrosine 
kinases, including PDGFA, EGF and CSF1, and 
terminates signalling. Can be converted to an 
oncogenic protein by deletions or mutations that 
disturb its ability to down-regulate RTKs 
NM_032873.3  STS-1 q24.1 Encodes a protein that contains an ubiquitin associated 
domain at the N-terminus. The encoded protein was 
found to inhibit endocytosis of epidermal growth factor 
receptor (EGFR) and platelet-derived growth factor 
receptor. 
NM_005238 ETS1 q24.3 v-ets erythroblastosis virus E26 oncogene. ETS is 
responsible for erythroblast and fibroblast 
transformation. The juxtaposition of the interferon and 
c-ETS-1 proto-oncogene may be involved in the 
pathogenesis of human monocytic leukemia. 
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NM_032811 TBRG1 q24.2 Transforming growth factor-beta (TGF-beta) is 
perhaps the most potent endogenous negative regulator 
of haematopoiesis. 
NM_001165  BIRC3 q22.2 Inhibits apoptosis by binding to tumor necrosis factor 
receptor-associated factors TRAF1 and TRAF2, 
probably by interfering with activation of ICE-like 
proteases.  
NM_033306 CASP4 q22.3 This gene encodes a protein that is a member of the 
cysteine-aspartic acid protease (caspase) family. 
Sequential activation of caspases plays a central role in 
the execution-phase of cell apoptosis.  
NM_004347  CASP5 q22.3 As above. Over-expression of the active form of this 
enzyme induces apoptosis in fibroblasts.  
NM_001223  CASP1 q22.3 As above. 
NM_006235 POU2AF1 q23.1  A chromosomal aberration involving 
POU2AF1/OBF1 may be a cause of a form of B-cell 
leukemia. Translocation t(3;11)(q27;q23) with BCL6. 
NM_002017 FLI-1 q24.3 Friend leukemia virus integration 1. A chromosomal 
aberration involving FLI1 is a cause of Ewing 
sarcoma. Translocation t(11;22)(q24;q12) with EWS.  
 
 
Table 5.9: Initial list of candidate genes on 11q. 
 
 
Of the three highlighted genes (yellow), I decided to begin with the mixed-lineage 
leukemia (MLL) gene due to its strong links with acute leukaemia, and its location at 
11q23.  
 
 
5.4.3.2  Screening the Mixed lineage leukaemia (MLL) gene 
 
 
The MLL gene, otherwise known as ALL-1, HTRX1 or HRX amongst others, encodes 
a DNA-binding protein that methylates histone H3 lysine 4 as well as positively 
regulating expression of numerous HOX genes, which are in turn essential for 
haematopoietic development (Krivtsov and Armstrong 2007). Rearrangements of 
MLL were first recognised as a consequence of chromosomal translocation in AML 
(Ziemin-van der Poel, et al 1991). In fact there have now been reports of 
translocations involving MLL and greater than 50 different fusion partners (Meyer, et 
al 2006). In addition, partial tandem duplications (PTD) within MLL gene have also 
been reported in AML with a normal karyotype or trisomy 11 (Caligiuri, et al 1994, 
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Schichman, et al 1994). Numerous in frame MLL-PTDs have been identified and 
named according to the fused exons, the most frequent being e9/e3 (under previous 
nomenclature this was e2/e6), followed by e11/e3 (e2/e8) and e10/e3 (e2/e7). The 
MLL-PTD is found in approximately 5-20% of adult AML with a normal karyotype 
and significantly higher proportion (25-54%) in adult AML patients with trisomy 11. 
Although the precise role of the MLL-PTD in leukaemogenesis remains a matter of 
debate (Marcucci, et al 1998, Schnittger, et al 1998, Weisser, et al 2005) I decided to 
see if the 11q aUPD patients were positive for the MLL-PTD. 
 
The single step primers, 3.1c and E3AS, were ordered according to the Schichman et. 
al., (1994) paper, and nested primers, MLLint and 6.1, were later ordered according 
to the Schnittger et. al., (1998) paper. RT-PCR was performed as described in 
Schnittger et. al., (1998) using cDNA from each of the three 11q aUPD patients plus 
a positive control, the eosinophilic cell line EOL-1 that is known to harbour a MLL-
PTD (Schichman, et al 1994, Schnittger, et al 1998). Applied Biosystems AmpliTaq 
Gold and buffer were used as an alternative to that stated in the paper. The results of 
the RT-PCR are shown below in Figure 5.15. As can be seen, the EOL-1 cell line 
clearly shows an MLL-PTD by standard single step PCR, whilst none of the aMPD 
patients with 11q UPD show any sign of a MLL-PTD by either single step or nested 
RT-PCR (gel picture not shown). 
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Figure 5. 15: Exon structure of the 5’ region of the MLL gene illustrating the common e9/e3 PTD 
(only the new nomenclature is detailed). The boxes represent individual exons, those 
in blue are the WT and those in green indicate the PTD. The red arrows indicate the 
primers as taken from Schnittger et. al.,(1998). The gel picture below shows an 
Invitrogen 1kb plus ladder (lane 1) and the product observed from all three patients 
with 11q aUPD (lanes 3-5) versus the cell line EOL-1 (lanes 1-2). The EOL-1 cell 
line has been shown to harbour a MLL-PTD so was used as a positive control (Saito 
H 1985).  
 
MLL is a very large gene and point mutations have not been reported so I went on to 
consider other candidates. The ATM gene seemed a strong possibility with mutations 
reported in this gene responsible for genomic instability and an increased risk of 
cancer. ATM gene mutations are seen in subtypes of lymphoid leukaemia and 
lymphoma (Boultwood 2001) but have not been reported in myeloid disease. The 
third gene that stood out was CBL. This gene encodes a member of the Casitas B-
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lineage lymphoma gene family of ubiquitin ligases which function as negative 
regulators of several receptor protein tyrosine kinase signalling pathways. CBL 
achieves this by ubiquitinating activated receptor tyrosine kinases, thus promoting 
their sorting for endosomal degradation or recycling to the plasma membrane. Whilst 
deliberating which of these candidate genes to screen next, two interesting papers 
were published reporting the finding of CBL mutations in AML. Sargin et al., found a 
missense mutations in 1 of 150 cases analysed and demonstrated that the mutation 
had transforming activity (Sargin, et al 2007). Cagliuri et. al., (2007) found 
abnormalities in 4 of 12 cases, none of which were functionally analysed (Caligiuri, 
et al 2007, Langdon, et al 1989). The reason for the marked discrepancy in the 
proportion of mutation positive cases is unclear, however the technical details for the 
second paper were very scant and in particular it is unclear whether the sequence 
changes were verified or not. Nevertheless, given these findings and the known 
interaction of CBL with tyrosine kinases, I therefore decided to screen this gene next. 
 
 
5.4.3.3  The CBL gene – introduction 
 
 
The CBL proto-oncogene (originally called c-CBL) was first discovered as the 
cellular homologue of v-CBL, a viral transforming gene from the Cas NS-1 murine 
retrovirus that causes pre-B cell lymphomas and myelogenous leukaemias in mice 
(Langdon, et al 1989). It is a large, ubiquitously expressed, principally cytoplasmic 
protein. There are three members of the CBL family: CBL, CBLB and CBLC, all of 
which play an important role in regulating signalling by many receptor tyrosine 
kinases. Structurally, the CBL family members are modular proteins that contain a 
conserved N-terminal tyrosine kinase binding domain (TKB) that has been shown to 
bind to over 40 proteins involved in cellular regulation. For example it has been 
shown to bind phosphorylated cytoplasmic kinases such as ZAP70, and several 
receptor tyrosine kinases such as EGFR and PDGFR. They also have a RING finger 
domain that has been shown to interact with and recruit the E3 ubiquitin-ligase 
enzymes (E3) as well as other negative regulators of signalling. Finally, they all 
contain a proline-rich region that interacts with SH3-domain containing signalling 
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proteins such as GRB2, SRC and CIN85. As a consequence of this multifunctionality, 
CBL has been shown to play both a positive and negative role in signalling.  
 
The negative regulatory role of CBL is summarised in the diagram below (Figure 
5.16). In brief, activated receptor tyrosine kinases recruit CBL, and CBL mediates the 
ubiquitination of the receptor on lysine residues. Ubiquitination is the signal that 
targets the receptors for internalisation via clathrin coated pits, followed by endocytic 
sorting resulting in either recycling or degradation of the receptor (Shtiegman and 
Yarden 2003).  
 
In addition, CBL proteins may also play a positive role in mediating positive RTK 
signalling events to downstream effectors. Schmidt et. al., (2005) have shown that 
phosphorylation of CBL results in it binding to positive signalling regulators such as 
SHP-2, Gab2 and PI3-kinase via its C-terminal multi-adaptor domain (Schmidt and 
Dikic 2005). In other words, CBL can act as a scaffold to the recruitment of 
downstream effectors of tyrosine kinases. 
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Figure 5. 16: (Adapted from Marmor & Yarden, Oncogene, 2004) (Marmor and Yarden 2004) 
Receptor tyrosine kinase (RTK) negative regulation and the role of CBL. RTK 
stimulation with ligand induces dimerisation and hence activation.  This leads to 
autophosphorylation and recruitment of CBL, which itself is then phosphorylated 
and ubiquitinates the RTK. The ubiquitylated receptors are then sorted into clathrin-
coated pits by a multiprotein complex that includes coat adaptors such as Epsin and 
Eps15. Fission of clathrin-coated vesicles is mediated by a GTPase, dynamin. In 
addition, CBL-mediated recruitment of CIN85 and endophilin is thought to promote 
negative membrane curvature and invagination. Shedding of clathrin, a decrease in 
the internal pH and the accumulation of hydrolytic enzymes, signals progression 
through the endocytic pathway. The RTK trafficking from early to late endosomes is 
dependent on its continued association with CBL and its sustained ubiquitination. 
The endocytic vesicle finally uncoats (facilitated by synaptojanin) and fuses with an 
early endosome, by a mechanism catalysed by the small GTPase Rab5 and its 
effectors. From here, the RTK is sorted into intraluminal vessicles of the endosome, 
in a process mediated by ESCRT-I, ESCRT-II and ESCRT-III. The RTK is probably 
dephosphorylated and deubiquitinated during this sorting step. The multivesicular 
body (MVB)/endosomal carrier vesicle is formed in an Annexin-II-dependent 
fashion, which ultimately fuses with a late endosome or a lysosome. Fusion of the 
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MVB with the lysosome results in degradation of the contents of the internal 
vesicles. Recycling of receptors back to the plasma membrane can occur throughout 
the endocytic pathway, albeit with decreasing efficiency. 
 
 
5.4.3.4  The CBL gene – screening 11q aUPD patients 
 
 
Mutations of CBL in AML patients were restricted to the RING domain, encoded by 
exons 8 and 9. Primers were therefore designed to anneal at 66°C within the introns 
surrounding these exons to allow the whole exons to be screened using genomic 
DNA (for primer sequences see Appendix I, section XXIV). PCRs were undertaken 
in a volume of 25μl using standard conditions and yielded exon 8 and exon 9 PCR 
products of 424bp and 369bp, respectively (Figure 5.17). 
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Figure 5. 17: Agarose gels showing amplification of CBL exon 8 (left) and 9 (right) for all three 
aMPD patients with 11qUPD. In both cases, the 1Kb plus ladder (Invitrogen) is 
shown in the first lane to accurately size the products. For both gels: Lane 1, E1191; 
Lane 2, E632; Lane 3, E484, Lanes 4-6 normal controls, and Lane 7 no DNA 
control. The correct sized product for CBL exon 8 (~424bp) and exon 9 (~360bp) is 
seen for all patients and controls. 
 
 
Direct sequencing identified changes in all three patients. In two patients, E484 and 
E1191, a T>C change at nucleotide 1277 in exon 8 (Figure 5.18), was seen that is 
202 
predicted to change leucine 380 to a proline (L380P). The mutation for E1191 
appeared to be predominant with only a small residual wild type T peak visible on the 
sequence traces. E484 showed a more substantial T peak, which is consistent with the 
relatively low LOH peaks detected by array analysis as shown in Figure 5.13 above. 
 
 
 
 
Figure 5. 18: Electropherograms showing part of CBL exon 8 amplified from aCML/aMPD 
patients E484 (left) and E1191 (right). Each panel show 6 traces: those at the top and 
bottom (traces 1 and 6) represent the reference CBL sequence (NM_005188). Traces 
2 and 5 represent patient sequence in forward and reverse orientations, respectively. 
The traces in the centre (traces 3 and 4) show a comparison between the reference 
and the patient sequence highlighting any sequence changes with a peak. Both 
patients show a T>C mutation at nucleotide 1277 which is predicted to result in the 
substitution of the amino acid leucine by proline. 
 
 
The third case (E632) was also found to have a sequence change, this time in exon 9. 
The mutation is a C>G missense change at nucleotide 1387 that is predicted to result 
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in the substitution of the proline 417 by alanine (P417A; Figure 5.19). The wild type 
C residue was barely detectable, consistent with the high level of LOH seen by array 
analysis. Both sequence changes were different to those described in AML patients. 
 
 
E632
 
 
Figure 5. 19: Sequence analysis of patient E632 showing a portion of CBL exon 9. The order of 
the traces is the same as Figure 5.18, with traces 3 and 4 showing the C>G mutation 
at nucleotide 1387 that results in a P417A amino acid substitution. 
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5.4.3.5  Screening other MPD patients for CBL mutations 
 
 
Following the detection of the CBL mutation in all three 11q aUPD patients I wanted 
to next determine if mutations of this gene might be more widespread in both typical 
and atypical MPDs. I therefore screened 547 patients as detailed in Table 5.10 by 
sequence analysis of exons 8 and 9.  
 
I identified mutations in a further 23 patients, making 26 in total. Surprisingly, one 
patient was found to have a mutation in both exons 8 and exon 9 making a total of 15 
cases with exon 8 mutations and 12 cases with exon 9 mutations (Table 5.10). 
Comparison with MPD subtype indicates that CBL mutations are seen in cases with 
CMML (12.8%), aCML/aMPD (7.9%) and IMF (5.7%). 
 
Disease 
classification
No. 
screened
Total no. of 
patients with 
mutations
CBL ex8 
mutations
CBL ex9 
mutations
% with CBL 
mutation
PV 74 0 0 0 0% 
IMF 53 3 1 2 5.7% 
ET 24 0 0 0 0% 
SM 60 0 0 0 0% 
CMML/MDS 78 10 8 2 12.8% 
aCML/aMPD 152 12 6 7 7.9% 
HES/Eosinophilia 96 1 0 1 1% 
CNL 9 0 0 0 0% 
AML 1 0 0 0 0% 
TOTAL 547 
26 patients 
 (27 mutations) 15 12 4.9% 
 
Table 5. 10: Summary of CBL mutations according to disease subtype. 
 
The mutations are summarised in Table 5.11. Most were missense changes, although 
I identified some candidate splice site mutations (n=4) and a heterozygous deletion 
(n=1). The majority of these sequence changes were novel however I did detect the 
R420Q mutation originally found in an AML patient (Sargin, et al 2007) in 4 of my 
26 patients. This mutation was present in two IMF, one aCML and one unclassified 
aMPD cases and thus does not appear to be associated with a specific disease 
subtype. R420 is highly conserved in all CBL proteins and is the predicted contact 
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point of interaction between CBL and E2 ubiquitin-conjugating enzymes (Zheng, et 
al 2000) (Figure 5.20). This mutation was shown by Sargin et. al., (2007) to prevent 
FLT3 receptor internalisation and ubiquitination and is the first human CBL mutation 
causatively linked to the development of leukaemia. I also identified one patient with 
an amino acid alteration of the same codon, 420 that results in an arginine to leucine 
(R420L) substitution.  
 
Patient Identifier Diagnosis Exon 8 amplicon Exon 9 amplicon 
E484 aCML 71930T>T/C: 380L>L/P N 
E632 aCML N 72252C>G:417P>A 
E1191 aCML 71930T>T/C: 380L>L/P N 
E001 aCML 71918C>C/T:376S>S/F N 
E088 CMML 71933G>G/A:381C>C/Y N 
E106 aMPD 71902T>T/C:371Y>Y/H 462R>R/X 
E110 CMML HET DEL GGTAC (DEL Exon 8) N 
E435 aMPD N 72252C>G:417P>A 
NP277 aMPD N 72262G>G/T:420R>R/L 
04/1345 IMF N 72262G>G/A:420R>R/Q
E879 IMF 71930T>T/C:380L>L/P N 
E2167 CMML 71977T>G:396C>G N 
E492 CEL N A>AG -2 
04/4357 IMF N 72262G>G/A R420R/Q 
E140 CMML 72022C>CT (+4)  N 
E2015 CMML 71886G>GC -1 (DEL Exon 8) N 
P42 aCML 72023 G>GA (+5) N 
E674.2 aCML N 72262 G>GA R420R/Q 
P607 aMPD N 72262 G>GA R420R/Q 
0607621 CMML N 72253C>C/T 417P>P/L 
1383 CMML N 72363A>AG: 454N>N/D 
1457 CMML 71941T>TC: 384C>C/R N 
1617 CMML 71983C>CT: 398H>H/Y N 
826 CMML 71942G>GA 384C>C/Y N 
03/2231 aCML 72015G>C: W408C N 
06/5197 aCML N 72257C>CA: F418F/L 
 
Table 5. 11:  Summary of CBL mutations identified in this study.  
 
Another oncogenic CBL mutation (C381A) in the same region of the protein has been 
reported in an animal model (Andoniou, et al 1994, Thien, et al 2001). Although I did 
not detect this mutation in any of my patients, I did discover a mutation that occurred 
in the same codon, C381Y. This residue is also highly conserved among the CBL 
206 
proteins and hence is likely to have a causative affect equivalent to constitutive 
receptor tyrosine kinase signalling (Figure 5.20). 
 
 
 
                                            
                                           * 
                              *    *   **  *           * *         *
Homo            PQDHIKVTQEQYELYCEMGSTFQLCKICAENDKDVKIEPCGHLMCTSCLTSWQE-SEGQG 415 
 
Pongo           PQDHIKVTQEQYELYCEMGSTFQLCKICAENDKDVKIEPCGHLMCTSCLTSWQE-SEGQG 414 
Bos             PQDHIKVTQEQYELYCEMGSTFQLCKICAENDKDVKIEPCGHLMCTSCLTSWQE-SEGQG 415 
Mus             PQDHIKVTQEQYELYCEMGSTFQLCKICAENDKDVKIEPCGHLMCTSCLTSWQE-SEGQG 413 
Drosophila      TEDHITVTQEQYELYCEMGSTFQLCKICAENDKDIRIEPCGHLLCTPCLTSWQVDSEGQG 404 
                .:***.****************************::*******:**.******  ***** 
 
                    * 
                    * 
                    *  
                 *  * 
                 ** *                                 * 
Homo            CPFCRCEIKGTEPIVVDPFDPRGSGSLLRQGAEGAPSPNYDDDDDERADDTLFMMKELAG 475 
Pongo           CPFCRCEIKGTEPIVVDPFDPRGSGSLLRQGAEGAPSPNYDDDDDERADDTLFMMKELAG 474 
Bos             CPFCRCEIKGTEPIVVDPFDPRGSGSLLRQGAEGAPSPNYEDDDDERADDSLFMMKELAG 475 
Mus             CPFCRCEIKGTEPIVVDPFDPRGSGSLLRQGAEGAPSPNYDDDDDERADDSLFMMKELAG 473 
Drosophila      CPFCRAEIKGTEQIVVDAFDPR---KQHNRNVTNGRQQQQEEDDTEV------------- 448 
                *****.****** ****.****   .  .:.. .. . : ::** *               
 
 
RING 
 
Figure 5. 20: Schematic showing the CBL protein domain structure at the top and a 5 species 
alignment of the RING domain below (Homo sapiens, Pongo Pygmaeus, Bos 
Taurus, Mus musculus & Drosophila melanogaster). The stars in black at the bottom 
of each alignment indicate the homology between species. The asterisks at the top of 
each alignment indicate the site of mutations found in this study. 
 
 
All other missense mutations affect novel residues in the same region. In addition I 
identified 5 other sequence changes. The 5bp heterozygous deletion of GGTAC in 
patient E110 involved the last base pair of exon 8 and was similar to the deletion 
identified previously in the AML MOLM-13 cell line (Caligiuri, et al 2007) (Figure 
5.21).
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Figure 5. 21: The 5bp deletion in patient E110. Top panel: Comparison of the 14bp deletion in the 
MOLM-13 cell line with the deletion in patient E110. Bottom panel: the sequencing 
electropherogram showing the 5bp deletion. 
 
 
In addition four sequence changes in patients P42, E140, E492 and E2015 were 
identified in the non-coding regions of exons 8 and 9 (Figure 5.22). It is possible that 
these mutations represent new splice donor or acceptor sites thus altering the protein 
structure.  
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Figure 5. 22: Schematic showing the locations and sequencing electropherograms of all four 
intronic CBL mutations.  The trace highlighted in green (1) was discovered in intron 
7 a G>C mutation at -1 of exon 8 in patient E2015. The traces highlighted in blue 
represent the three non-coding mutations identified in intron 8; (2) is the +4C>T 
substitution in patient E140, (3) shows the +5G>C mutation found in patient P42, 
and (4) depicts patient E492 and the -2A>G mutation.  
 
 
The mutation scan that yielded these sequence changes focused exclusively on exons 
8 and 9. Upon identification of a mutation the patient DNA was subjected to repeat 
PCR for the exon in question and resequenced to confirm the mutation was in fact 
present. Given the strong association of the mutations with an aCML/CMML/MF 
phenotype, all other CBL exons were amplified and screened for mutations in a total 
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of 70 of aCML/CMML/MF patients that were negative for exon 8 or 9 mutations. 
Although a number of known SNPs were identified, no other mutations were found. 
 
5.4.3.6  11q LOH studies 
 
 
I aimed to determine if the CBL mutations were usually associated with 11q aUPD. 
Apart from the three initial cases, the other mutation positive cases had not been 
analysed by SNP arrays. Since sequence analysis is poorly quantitative and arrays are 
expensive, I used microsatellite PCR analysis to look for chromosome 11q LOH in all 
26 CBL mutation positive samples. In total I used 9 fluorescently labelled primer 
pairs targeting highly polymorphic microsatellite markers spanning chromosome 11q 
(Table 5.12). 
 
Chromosome band Marker Heterozygosity 
(http://www.gdb.org/) 
11q13.1 D11S1883 0.74 
11q14.1 D11S937 0.88 
11q21 D11S4182 0.73 
11q23.2 D11S1885 0.71 
11q23.3 D11S925 0.85 
11q D11S4107 0.78 
11q24.1 D11S982 0.77 
11q24.2 D11S934 0.85 
11q25 CA rpt unknown 
 
Table 5. 12:  Microsatellite marker name, location on chromosome 11q and heterozygosity where 
known (www.gdb.org/). 
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The products were analysed on an ABI3100 using the Genotyper 2.0 program. As 
previously described for JAK2, if only one peak was visible a patient was scored as 
homozygous. To allow for the presence of background normal cells, homozygosity 
was also scored if one peak was one third or smaller than the expected size compared 
to controls (Jones, et al 2005). Of the 26 CBL mutation positive patients tested, 9 
(including all three known 11q LOH patients (E484, E632 & E1191) displayed 
patterns that were suggestive of LOH (Table 5.13).  
 
Patient I.D 
D11S 
1883 
D11S 
937 
D11S 
4182 
D11S 
1885 
D11S 
925 
D11S 
4107 
D11S 
982 
D11S 
934 
11q25 
CA rpt Tel 
E484                     
E632                     
E1191                     
E001                     
E088                     
E106                     
E110                     
E435                     
NP277                     
04/1345                     
E879                         
E2167                         
E492                     
04/4357                     
E140                     
E2015                     
P42                     
E674.2                     
P607                     
0607621                     
1383                     
1457                     
1617                     
826                     
03/2231                     
06/5197                     
  
Table 5. 13: 11q LOH in CBL mutation positive patients. The microsatellite markers are shown 
in order from the most centromeric (D11S1883) to the most telomeric (11q25 CA 
repeat) and are scored as homozygous (black) or heterozygous (white). The marker 
highlighted in yellow is the first that is distal to CBL. 
 
211 
Of these nine, six showed complete homozygosity at all microsatellite loci tested (the 
three 11q LOH patients detected by arrays plus E001, E2167 and 1457). The others 
(E879, 1617 and 03/2231) showed varying degrees of homozygosity however all ran 
from a centromeric to telomeric marker, consistent with mitotic recombination. A 
further three patients (04/1345, P42 & E140) also had regions of homozygosity over a 
region of 4 or 5 microsatellite markers however they did not extend to a telomere. 
Unfortunately constitutional DNA was not available from any case to determine if 
these regions were acquired or not, however the mean heterozygosity of the markers 
employed was 0.79 and thus the chance of four sequential homozygous calls 
randomly is (0.21)4 = 0.0019, assuming that all are independent of each other. 
 
Patient E106 was heterozygous for all markers. This is the only patient for whom I 
identified two CBL mutations, one in exon 8 the other in exon 9. The exon 8 mutation 
is missense and predicted to result in a unique Y371H amino acid substitution. The 
exon 9 mutation is also unique to this patient, R462X, and is also the only nonsense 
mutation identified. I carried out a PCR to determine if these mutations were on the 
same or different chromosomes as this may tell us more about how they are acting. I 
designed two intronic primers that would anneal at 66°C, and amplified both exons 8 
and 9 of the CBL gene (see Appendix I, section XXVII) in a single amplicon of 
786bp. This was then sub-cloned and several colonies sequenced. I was able to show 
that the mutations were never in the same clone indicating that the mutations were on 
different chromosomes. One possibility is that the truncating mutation serves to 
reduce the Y371H mutation to functional homozygosity. 
 
5.4.3.7  Copy number analysis 
 
I next went on to determine whether the CBL locus was present in two copies, which 
would implicate aUPD as the cause of the homozygosity, or one copy which would 
implicate a deletion. Multiplex ligation-dependent probe amplification (MLPA) is a 
robust technique used to look at copy number differences and a number of different 
kits have been developed by MRC Holland (www.mlpa.com) for genes of diagnostic 
interest. In particular, the Marfan probeset 1 (P065) kit contains 4 control probes at 
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11q including one at 11q23.3 the exact cytogenetic location of CBL. I therefore used 
this kit to examine CBL copy number and the results are summarised below in Table 
5.14. 
 
Patient I.D MLPA results 
E484 N  
E632 N  
E1191 N  
E001 N 
E088 N 
E106 N 
E110 no material 
E435 no material 
NP277 N 
04/1345 N 
E879 N 
E2167 N 
E492 N 
04/4357 no material 
E140 no material 
E2015 N 
P42 N 
E674.2 N 
P607 N 
0607621 no material 
1383 no material 
1457 N 
1617 N 
826 no material 
03/2231 N 
06/5197 N 
 
Table 5. 14: Patient identifier versus MLPA copy number result. N= normal (no copy number 
alteration) indicating the patient has two copies of chromosome 11q. 
 
Of the 26 patients with CBL mutations, only 19 were analysed by MLPA due to the 
paucity of suitable material for some cases (MLPA is very sensitive to DNA quality). 
The three original 11q LOH patients identified by SNP array analysis were included 
as controls and all three were confirmed by MLPA to have two 11q chromosomes.  
Of the remaining 16 patients, all apparently had two intact chromosomes 11q 
including the six cases for whom I found LOH by microsatellite analysis. This 
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implies the LOH is likely to be due to mitotic recombination following an initial CBL 
mutation. 
 
5.4.3.8  Are the CBL mutations acquired? 
 
It is important to determine if the CBL mutations were acquired or constitutional. An 
acquired mutation implies the genetic change occurred in a somatic cell and provided 
it with a selective advantage and thus giving rise to a clone. Since this required 
obtaining fresh samples, it was only possible to perform the analysis on three cases. 
A fresh blood sample was received from E1191 who was positive for the L380P 
mutation. I set up a phytohaemagglutinin (PHA) culture to enrich for T-cells and 
compared DNA prepared from a granulocytic fraction to DNA from a T-cell fraction. 
Previously studies in our group have shown that growth in PHA typically results in 
>80% T-cells after 5 days. As shown in Figure 5.23, the mutation is present in 
granulocytes but absent from T-cells. 
214 
 
 
Figure 5. 23: Electropherogram for patient E1191 showing a) CBL exon 8 reference sequence; b) 
T-cell enriched DNA; c) comparison of a and b showing no differences in sequence; 
d) comparison between reference sequence and granulocyte DNA with the peak 
indicating a sequence difference, and e) granulocytic DNA sequence showing the 
T>C mutation. 
 
Patient E879 also had the L380P mutation and in this case we were able to obtain a 
mouthbrush sample. Sequencing showed again that the mutation was only present in 
the PB DNA sample and not in the epithelial (mouthbrush) fraction (Figure 5.24). 
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 Figure 5. 24: Electropherogram depicting a) CBL reference sequence, part of exon 8; b) E879 PB 
DNA sample sequence trace showing T>C missense mutation; c) comparison 
between the reference sequence and E879 sequence, the peak indicates the position 
of the mutation; d) CBL reference sequence; e) mouthbrush DNA sequence, and f) 
comparison between the reference and the mouthbrush sequence showing no 
differences. 
 
Finally, patient 04/1345 with a R420Q mutation was analysed. The sample I had 
originally analysed from this case was taken in 2004 when MF was diagnosed, 
however he had originally presented with ET in 1989. I was able to obtain and extract 
DNA from bone marrow slides taken in 1989, 1992, 1995 and 1997 and found no 
evidence of the CBL mutation. Unfortunately no slides were available between 1997 
and 2004, however these findings suggest that the mutation may have appeared on 
transformation from ET to MF. 
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 In conclusion, I have been able to determine that the CBL mutation was acquired in 
three of three cases analysed. It is likely that the other 23 patients also acquired CBL 
mutations however this remains a matter of conjecture. 
 
5.4.3.9  Analysis of non-coding CBL mutations  
 
 
As mentioned above, intronic sequence changes were identified in four cases and a 
5bp deletion was found in a further patient. To determine if these variants affected 
splicing, I performed RT-PCR on the three cases for which material was available: 
E140 and E2015 with intronic changes and E110 with the heterozygous 5bp deletion. 
 
Primers were designed over two exon boundaries to ensure they would only amplify 
the coding sequence and not any residual genomic DNA if present in the cDNA 
sample. The primers were designed to anneal at 66°C and cover exons 6/7 and exons 
10/11, thus ensuring the region comprising exons 7-10 would be amplified (for 
primer sequences see Appendix I, section XXV). A normal control was also run 
alongside and the resulting amplifications are shown in Figure 5.25. 
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1kb
500bp
1             2           3              4
 
 
Figure 5. 25: Agarose gel picture. Lane 1 represents E140; Lane 2, E2015; Lane 3, normal control, 
and Lane 4, no DNA control run alongside the 1kb Plus ladder (Invitrogen) for 
sizing. The normal control (Lane 3) is the expected size (~585bp) and when 
compared to E140 it is clear this patient also only has this normal band suggesting no 
splicing differences are created with the presence of this mutation. The other patient, 
E2015 exhibits two bands a normal 585bp band and a smaller band that upon cloning 
and sequencing revealed a deletion of exon 8. 
 
Patient E140 showed a single band that corresponds to the size of the normal control. 
Upon sequencing I confirmed exons 7-10 were fully intact thus it appears the variant 
at 72022C>C/T(+4) does not affect the structure of the protein. Although I did not 
have material to prove this, it seems likely that the 72023G>G/A(+5) variant seen in 
patient P42 is also likely to be of no consequence. To test this possibility, I put both 
these altered sequences into a splice site predictor programme 
(www.fruitfly.org/seq_tools/splice.html) which predicts if an unknown sequence 
change might create a better or different splice acceptor or donor site compared to the 
reference sequence (Reese MG 1997). Neither of the mutations showed improved 
splice donor or acceptor sites supporting the idea that they are non-functional and are 
presumably rare polymorphisms or pathogenetically unimportant passenger 
mutations. 
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Patients E110 (not shown) and E2015 both exhibited double bands by RT-PCR. 
Cloning and sequencing showed that the larger band corresponded to the normal 
product and the smaller band resulted from the complete deletion of exon 8 in both 
cases. It therefore appears that both patients harbour heterozygous mutations with one 
normal allele and one allele with a deletion of exon 8. The mutation in MOLM-13 
also causes skipping of exon 8 and siRNA targeting the exon 7-9 mutant transcript in 
this cell line was found to be growth inhibitory strongly suggesting that it is indeed of 
functional importance (Caligiuri, et al 2007). 
 
 
5.4.3.10  The relationship between CBL and other mutations in MPDs 
 
 
It is possible that the CBL mutants provide a growth advantage by interfering with the 
normal negative regulation of tyrosine kinase signalling, however it is unclear if they 
might act as sole abnormalities or if they co-operate with other acquired genetic 
events. All the cases I studied were negative for known tyrosine kinase fusion genes 
but they had not been tested for other oncogenic mutations seen in MPDs such as the 
FLT3 ITD, JAK2 V617F and NRAS mutations. These mutations have been reported in 
approximately 5%, 10-15% and 10% of aMPD cases, respectively (Jones, et al 2005). 
 
The FLT3 ITD analysis was performed as described previously. The JAK2 V617F 
mutation analysis was carried out by a colleague using a specific ARMS test (Jones, 
et al 2005). For NRAS I designed primers to exons 2 and 3 which includes the two 
mutation hotspots at codons 12, 13 and codon 61 (for primer sequences see Appendix 
I, section XXVI). All CBL mutation positive patients were analysed and the results 
are shown in Table 5.15.  
 
Patient ID JAK2 status NRAS status FLT3 ITD status 
E484 Normal N Normal 
E632 Normal N Normal 
E1191 Normal N Normal 
E001 Normal N Normal 
E088 Normal N Normal 
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E106 Normal N Normal 
E110 Normal N Normal 
E435 Normal N Normal 
NP277 Normal N Normal 
04/1345 Normal N Normal 
E879 Het Positive N Normal 
E2167 Normal N Normal 
E492 Normal N Normal 
04/4357 Normal N Normal 
E140 Normal N Normal 
E2015 Normal N Normal 
P42 Normal N Normal 
E674.2 Normal N Normal 
P607 Normal N Normal 
0607621 Normal N Normal 
1383 Normal N Normal 
1457 Normal N Normal 
1617 Normal N Normal 
826 Normal N Normal 
03/2231 Normal N Normal 
06/5197 Normal N Normal 
 
Table 5. 15: Results of JAK2 V617F, NRAS & FLT3 ITD mutation analysis in CBL mutated 
cases. Het = heterozygous mutation. 
 
Only one patient was found to harbour another mutation: E879 was heterozygous 
positive for JAK2 V617F. Since this finding was unusual, i.e. only seen in a single 
case, it raised the question whether both mutations arose in the same clone or not. To 
address this issue a fresh blood sample (taken approximately 2.5 years after the 
original sample) was obtained and set up in methylcellulose cultures in order to grow 
haematopoietic colonies for clonal analysis. However in contrast to typical V617F 
positive cases, the colony growth was very poor and, furthermore, analysis of the 
blood leucocytes showed the CBL mutation was present as expected but V617F JAK2 
was no longer detectable. This raised the question of a technical error at some point in 
the analysis. To address this, I used the Promega Powerplex® 16 kit to determine if 
the two samples, plus also other samples we had from this case, were indeed from the 
same individual. This kit amplifies 16 highly polymorphic loci across the genome and 
was designed to allow a high discriminatory power for analysis of identity and 
paternity. I tested four different samples (E40, E879, E2763 and E2772) received at 
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various time points from this individual All four samples concurred at all 16 loci, 
proving they were in fact all from the same individual. These samples and others that 
were received were analysed for V617F JAK2 and CBL as shown on Table 5.16.  
 
Sample ID Date Sample type JAK2 mutation CBL mutation 
E1064 1998 BM Slide YES (5% V617F) NO 
E40 2000 PB YES NO 
E2922 2003 BM slide not tested NO 
E879 2005 PB YES (7% V617F) YES 
E2763 2008 BM NO YES 
E2772 2008 PB NO YES 
E2915 2008 mouthbrush NO NO 
 
Table 5. 16: Time course of disease in patient E879 showing the disappearance of JAK2 V617F 
and the appearance of the CBL mutation over time. 
 
The early samples received were all JAK2 V617F positive (albeit at relatively low 
levels) and CBL L380P negative. Between 2005 and 2008 this appears to have 
changed with the CBL L380P clone becoming more dominant and the JAK2 V617F 
clone being lost. The proportion of CBL mutation positive alleles as called by the 
mutation surveyor sequencing programme was 86% in 2005 and had increased to 
100% by 2008. This transition coincided with an increase in leukocyte numbers that 
has proved difficult to control by standard therapy. This situation is reminiscent of the 
evolution of V617F positive PV to acute leukaemia in which it has been reported that 
roughly half of cases have leukaemia blasts that are V617F negative (Campbell, et al 
2006, Theocharides, et al 2007). One possible explanation for this unexpected finding 
is that an unknown mutation results in a clinically covert clonal expansion prior to the 
acquisition of V617F. Another explanation is that there may be a hereditary 
predisposition to acquisition of independent mutations. In our case, the fact that 
V617F disappeared must presumably mean that the CBL mutation was acquired in a 
V617F negative clone and that it had a relative growth advantage.  
 
One other case had two mutations: E2167 was originally diagnosed as systemic 
mastocytosis (SM) before evolving to CMML and had previously tested positive for 
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the KIT D816V mutation before I found a CBL mutation in the same sample. 
Unfortunately it was not possible to obtain any further samples from this case. 
 
5.5   DISCUSSION  
 
5.5.1   SNP arrays to identify new pathogenetic abnormalities 
 
 
LOH is a genetic mechanism that creates a homozygous or hemizygous somatic cell 
by loss of the wild-type allele. This can be as a result of various mutational events 
such as a deletion, mitotic recombination, localised gene conversion, point mutation, 
or non-dysjunction. My aim has been to identify new oncogenes or tumour 
suppressor genes that are marked by these regions of LOH, and specifically regions 
of aUPD, or copy number neutral LOH formed as a consequence of mitotic 
recombination.  
 
Regions of aUPD have been described in many human malignancies. Furthermore, 
these regions are now being commonly associated with oncogenic mutations, the first 
example of which was the discovery of 9p aUPD and the JAK2 V617F mutation 
(Kralovics, et al 2002, Kralovics, et al 2005b). Since these initial reports, other 
oncogenic mutations have been associated with aUPD involving distinct 
chromosomal regions, such as CEBPA and chromosome 19 (Raghavan, et al 2005), 
FLT3 mutations and 13q (Griffiths, et al 2005), NF1 and 17q (Flotho, et al 2007), 
WT1 mutations and 11p and finally RUNX1 and 21q (Fitzgibbon, et al 2005). 
Moreover, reports where paired samples have been studied often show that the 
mutation precedes the aUPD and hence the aUPD represents a ‘second hit’ associated 
with disease progression (Fitzgibbon, et al 2007, Fitzgibbon, et al 2005). These 
studies all highlight the potential for discovering new pathogenetic abnormalities by 
the finding of regions of aUPD. Obviously this approach has limitations, e.g. it will 
not detect cryptic fusion genes or point mutations that do not have a selective 
advantage when homozygous. However I was particularly encouraged by the 
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observations that activating mutations of two tyrosine kinases are subject to aUPD 
and that these are the gene class that is most commonly mutated in MPDs. 
 
There are various techniques that can aid identification of these regions of LOH 
however SNP arrays have the advantage of being able to detect copy number in 
addition to zygosity. In my study, I employed 50K SNP arrays and focused almost 
exclusively on regions of aUPD however it was clear that large copy number changes 
were also detected that correlated with cytogenetic data. Although I did not 
investigate this aspect in any detail, others have found that copy number information 
generated by 50K arrays is relatively poor but is greatly improved by using arrays of 
a higher density, in particular the Affymetrix 500K arrays (Mullighan, et al 2007) and 
more recently SNP 6.0 arrays which include 1.8 million markers. However for the 
purpose of identifying aUPD the lower density arrays are sufficient. 
 
In total 88 samples were sent to the RZPD German Resource Centre for Affymetrix 
50K SNP array analysis, including 30 aMPDs (predominantly aCML), 28 IMF, 10 
PV, 10 myeloid & 10 lymphoid CML blast crisis patients. Results were successfully 
obtained for all samples. The principal weakness of my study was the absence of 
constitutional DNA, e.g. from mouthbrush swabs or remission DNA and so it was not 
possible to determine if tracts of homozygosity were indeed acquired or whether they 
were inherited. Consequently I did not attempt to analyse the smaller regions of 
homozygosity in any detail, although I did determine that there were no obvious 
recurrent abnormalities that were restricted to particular patient subgroups and also 
no recurrent regions that might target tyrosine kinases. 
 
I was fortunate that my principal study group – atypical MPDs – were particularly 
informative with 40% of cases showing large regions of copy number neutral 
homozygosity. Because such large regions are not seen in normal individuals it is 
reasonable to infer that they are most likely acquired, although I was only able to 
prove this in three cases. I found eight different chromosomal regions affected by 
aUPD of which two were recurrent (7q and 11q; 3 cases each) and not seen in other 
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patient subgroups. These regions are discussed in detail below. Acquired UPD was 
also seen at 1p, 8p, whole chromosome 13, 17q, 20q and 21q. The 1p abnormality 
was linked to an oncogenic MPL 515 mutation and the patient with whole 
chromosome 13 aUPD was homozygous for a FLT3 ITD. It is likely that these two 
oncogenic changes are the targets of the aUPD, i.e. homozygosity for these mutations 
confers a growth advantage over the heterozygotes and so following random mitotic 
recombination the homozygous clone has a selective advantage. However I cannot 
exclude the possibility that there are other relevant abnormalities in the affected 
regions that are being selected for. 
 
In the other patient subgroups, aUPD was uncommon. I was particularly hopeful that 
SNP analysis might be helpful in understanding disease progression in CML. CML-
BC may be myeloid or lymphoid in phenotype and the molecular basis for 
transformation is poorly defined (Calabretta and Perrotti 2004). It is likely, but not 
certain, that disease progression involves several genetic steps and that different 
combinations of a limited number of genes are involved in different patients. The 
genes involved in myeloid transformation may be distinct from those in lymphoid 
transformation, but cytogenetic and molecular evidence (Chase, et al 2001, 
Johansson, et al 2002) suggest that there is an appreciable overlap in the molecular 
basis of myeloid blast crisis and AML and similarly in the molecular basis of 
lymphoid blast crisis and ALL. aUPD has been reported in both AML and ALL 
(Fitzgibbon, et al 2005, Irving, et al 2005, Raghavan, et al 2005) and therefore it was 
a disappointment that all BC cases were negative, apart from a possible small region 
at the tip of 15p in one case with myeloid disease. As mentioned above, the copy 
number resolution of the 50K arrays was insufficient to detect small deletions such as 
those recently described to target Ikaros in lymphoid BC and Ph+ALL (Mullighan, et 
al 2007). 
 
Similarly, patients with PV and MF were largely uninformative, although one case 
with V617F positive MF had extensive aUPD on 5q. The significance of this finding 
is unclear, although it suggests that there may be a gene on 5q that co-operates with 
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V617F to induce progression to MF. One possibility is the recently identified 5q- 
MDS gene RPS14 (Ebert, et al 2008), however this is perhaps unlikely given that 
RPS14 appears to exert its effects through heterozygous deletion rather than 
homozygous mutations. Instead of analysing this single abnormality I focused on the 
recurrent regions in aCML/aMPD patients. 
 
5.5.2  7q aUPD  
 
 
I identified three patients with varying sized regions of aUPD at chromosome 7q with 
no further copy number alterations or aUPD observed elsewhere in the genome. This 
is the first report of recurrent 7q aUPD amongst MPDs although deletions of 7q and 
monosomy 7 are associated with diverse human cancers such as gastric and breast 
cancer (Weng, et al 2006, Zenklusen, et al 1994), lymphoid leukaemia (Dascalescu, 
et al 1999, Hernandez, et al 1997, Offit, et al 1995) and also occasionally in myeloid 
malignancies such as MDS, AML and juvenile CML (Aktas, et al 1999, Hasle, et al 
1999, Mantadakis, et al 1999, Tosi, et al 1996).  
 
The region of 7q aUPD in each patient varied, however the minimal overlapping 
region spanned approximately 53Kb covering cytogenetic bands 7q22.3-qter. This is 
a colossal amount of sequence and is thought to comprise some 400 different genes. 
Much work has already been performed on cases in the literature trying to define 
critical regions of deletion, yet no group has yet identified any definitive tumor 
suppressor gene(s) that is thought to be located within this region. However I was 
more concerned with identifying activating mutations, based on the strong linkage 
between aberrant tyrosine kinase signalling and MPDs. The most obvious candidate 
genes were the three tyrosine kinases EPHA1, EPHB6 and MET but no mutations 
were identified. Partial screens of BRAF and PI3KCG were also negative. These 
genes were selected because they participate in tyrosine kinase signalling pathways 
and are either known to be mutated in cancer (BRAF) or highly related to a gene that 
is mutated in cancer (PI3KCG is related to PI3KCA). Since these are such good 
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candidates it might be worth screening the complete sequence of all exons in case the 
previously described hotspots are limited to epithelial cell tumours. A similar 
situation has been described previously: the activating D816V KIT mutation is seen in 
>80% of cases of systemic mastocytosis but in gastrointestinal stromal tumours, 
D816V is very uncommon and instead activating mutations are seen elsewhere in the 
same gene. I looked for other genes on 7q but it is easy to find large numbers of 
candidates, none of which were obviously outstanding. 
 
Subsequent to my work, a number of papers have been published by Gondek and 
colleagues (Gondek, et al 2007a, Gondek, et al 2007b, Gondek, et al 2008). This 
group’s main focus is on MDS and MDS/MPD using 250K SNP arrays. Copy 
number neutral LOH was seen in 30% of cases, particularly 1p, 1q, 4q, 7q and 11q. 
Figure 5.26 shows the regions of 7q aUPD in my cases compared to the five 
identified by Gondek and colleagues, three of which had CMML, one AML and one 
refractory anaemia (RA, a subtype of MDS). 
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Figure 5. 26: Schematic detailing chromosome 7 and the regions of aUPD identified by Gondek & 
colleagues (2008), highlighted in green and my aCML/aMPD patients highlighted in 
red. 
 
The smallest area of overlapping aUPD is now represented by the Gondek patient 
with RA, but the minimal region is only marginally smaller than that defined by 
E639. It will be important to analyse more cases to try and narrow the region down 
and it might be expected that with enough cases the proximal end of the minimal 
region might converge to a point close to the key gene (Figure 5.27). However this 
may well require analysis of a very large number of cases.  
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Figure 5. 27:  Schematic detailing a theoretical analysis of chromosome 7 and how identification of 
more regions of aUPD might narrow down the region and converge at the proximal 
end (indicated by the red dashed line) near the gene of interest. 
 
Whether the underlying abnormality is the same as the elusive 7q candidate gene 
believed to be at the root of recurrent deletions in AML is unclear, but since aUPD 
for 7q is uncommon in AML (Fitzgibbon, et al 2005, Gondek, et al 2008, Raghavan, 
et al 2005) it may well be that the two abnormalities are different. Over the years 
much work has been performed in myeloid disorders with 7q deletions and 
translocations trying to narrow down a minimal region in the hope of highlighting a 
specific mutated oncogenic or tumour suppressor gene. Some people have suggested 
that the complexity of 7q rearrangements might simply indicate that this is a region 
prone to breakage and instability, and thus a synergy of different genetic factors may 
play a general role in oncogenesis rather than a gene harbouring a specific mutation. 
However it seems more likely that there is a specific target for the cases affected by 
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aUPD. Interestingly, one of the 7qUPD cases (E110) was found to have a 
heterozygous deletion of the CBL gene.  Assuming that this CBL abnormality is 
functionally important, this might indicate that the 7q gene functionally co-operates 
with CBL to produce an aCML phenotype. 
 
Although the analysis of further cases by arrays will help to define a smaller minimal 
region, identification of the critical target will probably require the sequence analysis 
of a large number of genes to identify mutations that are homozygous in cases with 
7q aUPD and absent or heterozygous in cases without 7q aUPD. Although this could 
be achieved by the stepwise of candidate genes such as those listed in Table 5.8, very 
soon it should be possible to systematically sequence all genes in the minimal region 
using a combination of pull-down hybridisation arrays covering all 7q exons in the 
critical region and next generation sequencing, which currently has the capacity to 
sequence approximately 108 -109 bases per run depending on the platform employed 
(Chan 2005, Mardis 2008, Morozova and Marra 2008, Schuster 2008, von Bubnoff 
2008, Wheeler, et al 2008).  
 
5.5.3   11q aUPD 
Chromosome 11 has also been reported in the literature as a region commonly 
affected by imbalances in human malignancy. Reports of LOH are far more frequent 
than deletions, and have been associated with cervical, ovarian, breast, colon and skin 
cancers (Bethwaite, et al 1995, Carter, et al 1994, Foulkes, et al 1993, Hampton, et al 
1994, Keldysh, et al 1993, Tomlinson, et al 1993). Nevertheless, deletions and 
translocations of 11q appear to be more common than LOH in haematological 
malignancies. LOH has rarely been reported to be associated with leukaemia and so 
the identification of a recurrent region of 11q aUPD in aMPD patients is particularly 
interesting and suggests an abnormality specifically associated with an MDS/MPD 
phenotype. 
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The smallest overlapping region of aUPD was represented by patient E484 and spans 
57Mb covering cytogenetic bands 11q13.5-qter. This covers almost three quarters of 
the long arm of chromosome 11 and is thought to comprise greater than 350 genes. I 
had anticipated that the identification of regions of aUPD might provide a pointer 
towards novel tyrosine kinase mutations, however there are no tyrosine kinase genes 
on 11q and the three at 7q were eliminated by sequence analysis. A number of 
candidate genes were then short-listed according to association with leukaemia, and 
screening for the MLL partial tandem duplication (PTD) was carried out as a priority, 
but this was found to be negative in all three cases with 11q aUPD. Because of the 
strong association of MPDs and deregulated tyrosine kinase signalling, the next step 
was to look at genes that are known to impact on this process. 
The CBL gene is located at 11q23.3 and encodes an ubiquitin ligase which functions 
as a negative regulator of several receptor protein tyrosine kinase signalling 
pathways. It acts by inducing ubiquitination of the RTK, thus promoting their sorting 
for endosomal degradation or recycling, however CBL also acts in a positive way by 
serving as a scaffold for the recruitment of downstream signalling substrates. CBL 
was an obvious candidate for mutation screening, particularly as two papers were 
published that reported the discovery of rare CBL mutations in AML patients 
(Caligiuri, et al 2007, Sargin, et al 2007). Based on the clustering of mutations in 
these cases I screened the three 11q aUPD cases and found that two had changes in 
exon 8 predictive of an L380P missense mutation whilst the third had a mutation of 
exon 9, P417A. 
 
To determine if these mutations were more widespread among the MPDs I screened 
547 patients, including cases with PV, IMF, ET, SM, HES, CMML and aMPD. I 
identified a further 23 patients (total 26 including 11q aUPD patients) with CBL 
mutations, 15 of that were missense and one nonsense as illustrated on Figure 5.28. 
One patient had a mutation in both exons 8 and 9 so in total there were 15 exon 8 
mutations and 12 exon 9 mutations. The mutations were strongly associated with 
CMML (12.8%) and aCML/aMPD (7.9%) and in 3 cases I was able to demonstrate 
that they were acquired. Further analysis is being taken by other members of the 
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group to try and determine the specific clinical features associated with CBL 
mutations and their impact on prognosis. 
 
     Human CBL  RNQNPDLTGLCEPTPQDHIKVTQEQYELYCEMGSTFQLCKICAENDKDVKIEPCGHLMCTSCLTSWQ-ESEGQGCPFCRCEIKGTEPIVVDPFDPRGSG--SLLRQGAEGAPSPNY- 
     Mouse CBL  RNQNPDLTGLCEPTPQDHIKVTQEQYELYCEMGSTFQLCKICAENDKDVKIEPCGHLMCTSCLTSWQ-ESEGQGCPFCRCEIKGTEPIVVDPFDPRGSG--SLLRQGAEGAPSPNY- 
       Rat CBL  RNQNPDLTGLCEPTPQDHIKVTQEQYELYCEMGSTFQLCKICAENDKDVKIEPCGHLMCTSCLTSWQ-ESEGQGCPFCRCEIKGTEPIVVDPFDPRGSG--SLLRQGAEGAPSPNY- 
   Xenopus CBL  RNQNPDLTGLCEPTPQDHIKVTQEQYELYCEMGSTFQLCKICAENDKDVKIEPCGHLMCTSCLTSWQ-ESEGQGCPFCRCEIKGTEPIVVDPFDPRGGGMAELLRHCMDGTPSPCY- 
Drosophila CBL  QAYNPDLSSAVQSPTEDHITVTQEQYELYCEMGSTFQLCKICAENDKDIRIEPCGHLLCTPCLTSWQVDSEGQGCPFCRAEIKGTEQIVVDAFDPRKQH----NRNVTNGRQQQQ-- 
    Human CBLb  RSYNPDLTGLCEPTPHDHIKVTQEQYELYCEMGSTFQLCKICAENDKDVKIEPCGHLMCTSCLTAWQ-ESDGQGCPFCRCEIKGTEPIIVDPFDPRDEG--SRCCSIIDPFGMPMLD 
    Human CBLc  KTHNPDLTELGQAEPQQRIHVSEEQLQLYWAMDSTFELCKICAESNKDVKIEPCGHLLCSCCLAAWQ-HSDSQTCPFCRCEIKGWEAVSIYQFHGQATA—------EDSGNSSDQ-- 
                :  ****:   :. ..::* *::** :**  *.***:*******.:**::*******:*: **::** .*:.* *****.**** * : :  *. :     
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Figure 5. 28: Location of CBL missense mutations. Top panel: schematic showing the protein 
structure of CBL detailing the tyrosine kinase binding (TKB), RING, proline-rich (P-
rich) and ubiquitin-associated/leucine zipper (UBA/LZ) domains. Bottom panel: 
ClustalW alignment of the entire linker and RING domains plus part of the distal 
sequence. The ring domain is shaded in grey. Residues affected by missense 
mutations identified by this study to date are indicated by arrowheads above the 
clustalW alignment. Those underneath the alignment are previously reported 
mutations. 
 
I found four cases with R420Q, the same mutation described by Sargin et. al., (2007) 
but the majority of mutations was novel. Codon 420 is highly conserved in all CBL 
proteins and is the predicted contact point of interaction between CBL and the E2 
ubiquitin-conjugating enzyme (Zheng, et al 2000). Functional work by Sargin et al. 
showed this mutant co-operates with overexpression of FLT3 to induce growth factor 
independence of 32D cells. R420Q prevents FLT3 receptor internalisation and 
ubiquitination and is the first description of a CBL mutation that is very likely to be a 
causative event in the development of human leukaemia. There have also been 
previous reports of animal models with oncogenic mutations in the RING finger 
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domain or linker sequence of CBL, at codon 381 (C381A) (Andoniou, et al 1994, 
Thien, et al 2001). I also discovered a mutation of the same codon (C381Y).  
 
It is thought that alteration of signals for sorting tyrosine kinases to the lysosomes 
may contribute to the progression of neoplasia or even be an initiating event (Bache, 
et al 2004, Peschard, et al 2004). For example, several oncogenic variants of EGFR, 
MET, CSF1R and KIT have been shown to escape lysosomal degradation by a 
number of methods such as loss of PTB-mediated CBL binding sites (Peschard and 
Park 2003), or through the formation of oncoproteins caused by chromosomal 
translocations. The TPR-MET (Park, et al 1986) fusion gene, found originally in a 
mutagenised human osteogenic sarcoma cell line, results in deletion of sequence 
encoding the MET juxtamembrane domain that includes a binding domain site for 
CBL. As a consequence, the TPR-MET fusion escapes ubiquitination (Peschard, et al 
2001) suggesting that its inability to be targeted to the lysosomes for degradation may 
contribute to its pathogenicity. Analysis performed by Sargin & colleagues proved 
that R420Q prevented ubiquitination and internalisation of not just FLT3 but also 
PDGFR and EGFR, suggesting that its oncogenicity might be mediated by failure to 
properly regulate many different receptors. 
 
The critical analysis that is missing from my study is the functional determination of 
the consequences of the missense mutations plus the abnormalities leading to 
skipping exon 8. It was my intention to undertake this analysis but there was 
insufficient time and this is now being undertaken by another member of the group. 
The work is being conducted in collaboration with Sargin et al. who have provided 
the key reagents: pMY based plasmids expressing wild type and R420Q CBL (as a 
positive control) plus parental 32D cells and 32Ds expressing wild type FLT3. 32D 
cells are murine myeloid precursor cells that normally require IL-3 for growth but 
32D/FLT3 can be propagated in the presence of FLT3 ligand. 
 
Preliminary studies have included transfection of the WT CBL and R420Q 
expression vectors into 32D and 32D/FLT3 and show they are transforming in our 
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hands, as well as producing stable clones. To do this, a retroviral transfection protocol 
was used. The pMY vectors were developed from pMX (originally based on MuLV), 
which utilise pCMVs long terminal repeat (LTR) required for replication, integration, 
and expression of viral RNA. They also express green fluorescent protein (GFP) and 
thus transfected cells can be selected by fluorescent-activated cell sorting (FACS). 
The selected cells are expanded and proliferation assays (MTS assay and manual cell 
counting after trypan blue staining) performed after starving the cells of FLT3 ligand 
overnight. Sargin et al. showed that the R420Q mutant expressed in 32D/FLT3 
continued to proliferate under these conditions whereas all other combinations failed 
to proliferate. 
 
Sargin et. al., also demonstrated that R420Q resulted in prolongation of signalling. 
This will be addressed by starving transfected cells of cytokines and then stimulating 
them briefly with FLT3 ligand. Samples will be taken over a time course and Western 
blotting used to look at levels of phospho-ERK compared to total ERK. Other 
substrates will also be examined; in particular STAT5 which is known to be an 
important tyrosine kinase substrate in haematopoietic cells (Kato, et al 2005, 
Spiekermann, et al 2002). 
 
Sargin et al. also demonstrated that the R420Q was deficient in ubiquitination activity 
and thus the mutant has lost its ability to negatively regulate tyrosine kinases by 
inducing receptor turnover but has presumably retained its ability to act as a scaffold 
for the recruitment of other signalling proteins. Loss of ubiquitin ligase activity has 
been confirmed for some of the mutants by transiently transfecting them into 293T 
cells along with FLT3 and HA-tagged ubiquitin. After 48 hours, FLT3 ligand was 
used to stimulate the receptor which was then immunoprecipitated and blotted with 
anti-HA. The strength of the signal indicated the degree of ubiquitination which was 
found to be greatly reduced for most CBL mutants (Grand FH 2009).  
 
Another aspect that needs further investigation is functional consequences of 
homozygosity of CBL mutations. Both functionally important mutations that had 
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been identified previously (R420Q and C381A) were believed to act in a dominant 
negative fashion, however the finding of aUPD strongly suggests that there is a 
further selective advantage by reduction to homozygosity and that therefore the 
mutations are co-dominant. Following the array analysis, I tested CBL mutation 
positive cases by a combination of microsatellite PCR and MLPA and found a further 
6 of the 26 patients exhibited 11q aUPD. Of the 9 patients in total (includes the 3 
aMPD patients diagnosed by SNP array) 5 had aCML/aMPD, 3 CMML and 1 IMF 
(Table 5.17).  
 
Patient Identifier CBL mutation 
E484 L380P 
E632 P417A 
E1191 L380P 
E001 S376F 
E879 L380P 
E2167 C396G 
1457 C384R 
1617 H398Y 
03/2231 W408C 
 
Table 5. 17: Nine patients with 11q aUPD and a CBL mutation. 
 
The majority of mutations associated with 11q aUPD are found in exon 8 of CBL 
gene with the exception of E632 (P417A). It also appears that the L380P mutation is 
significantly associated with homozygosity as all three patients identified with this 
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mutation also exhibited 11q aUPD. This is not true of the other cases where the same 
mutation or codon has been altered, such as codon 417 and 384, for which some cases 
were homozygous and others were heterozygous. Although it is conceivable that 
another, unknown locus on 11q is the target of aUPD, the finding of one case with a 
Y371H mutation and a stop codon on opposite alleles strongly suggests that 
homozygous CBL mutations do indeed confer a direct selective advantage. 
 
There may be an analogy between the CBL mutations and JAK2 V617F, which is also 
subject to reduction to homozygosity by aUPD in a similar proportion of cases. 
Homozygosity for V617F is relatively common in PV and MF but rare in ET 
however many patients with all three disease types are heterozygous. When large 
numbers of cases are analysed it appears that homozygosity is associated with a 
slightly more aggressive disease and it would be interesting to determine if cases with 
homozygous CBL mutants were also more aggressive. Interestingly, most 
‘heterozygous’ PV patients have a proportion of haematopoietic colonies that are 
homozygous for V617F. This is not seen in ET and thus strengthens the association 
between V617F zygosity and disease phenotype (Scott, et al 2005). It will be 
interesting to test haematopoietic colonies from CBL mutated cases to see if they are 
homozygous. This might indicate that the observed heterozygosity was only apparent 
and in fact caused by a mixture of homozygous mutated cells with normal cells that 
are not part of the malignant clone. 
 
Finally there is the question of whether CBL mutations are sufficient to give rise to 
disease by themselves, or if they require other co-operating genetic events. The 
requirement for over-expression of a tyrosine kinase for transformation of 32D cells 
may simply reflect the paucity of receptor tyrosine kinase gene expression in this cell 
line or, alternatively, may indicate that the mutants are only weakly transforming and 
require the co-operation of other events to give rise to clinically manifest disease. 
Consistent with the latter hypothesis, I identified two cases in which CBL mutations 
were acquired following progression of a pre-existing MPD. One of these presented 
with a relatively low level V617F JAK2 mutation that disappeared on progression to 
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CBL L380P positive disease, indicating that the two mutations must have arisen 
independently in different clones. It remains to be established, however, if CBL 
mutations are usually secondary events or whether the two cases we identified are 
exceptional.  
 
Further evidence for the requirement for additional co-operating genetic events comes 
from published mouse studies in which neither complete CBL knockout nor 
heterozygous knock-in of the RING finger inactivating mutant C379A (mouse 
equivalent of C381) resulted in evidence of an MPD or other malignancy (Rathinam, 
et al 2008, Thien, et al 2005). However closer analysis revealed subtle haemopoietic 
perturbations that clearly relate to the pathogenesis of MPDs. Specifically, 
haemopoietic stem cells (HSC) from these animals were increased in number, hyper-
responsive to thrombopoietin and more potent than wild type HSC in repopulating the 
haematopoietic system. These effects were associated with increased STAT5 
accumulation and phosphorylation. Hyper-responsiveness to growth factors and stem 
cell involvement are two of the cardinal features of MPDs. Furthermore, the 
association between STAT5 activation and MPDs is well documented (Cain, et al 
2007, Kotecha, et al 2008). Whilst it is possible that overt haematological disease 
might have been induced by a homozygous knock-in mutant, these findings suggest 
that CBL mutations may not be solely responsible for a full MPD phenotype. Possibly 
this could be tested further by transfecting bone marrow cells from CBL knockout 
mice, which are viable and fertile (Murphy, et al 1998). Nevertheless, since the CBL 
mutants appear to be acting by enhancing tyrosine kinase signalling, it may prove 
possible to treat patients in the future with tyrosine kinase inhibitors. 
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6   DISCUSSION 
 
The unifying theme of my research is the development and use of different 
approaches to identify deregulated tyrosine kinases and associated signalling 
components in MPDs. The paradigm of BCR-ABL in CML paved the way for the 
identification of other deregulated tyrosine kinase genes in the MPDs, although it 
took several years for the association between MPDs and deregulated signalling to 
emerge. Initially I focused on the analysis of chromosome translocations, 
subsequently moving onto screens for over-expression of selected tyrosine kinase 
genes and finally to genome-wide approaches that took into account the fact that 
genes other than tyrosine kinase may be responsible for the substantial proportion of 
MPDs of unknown pathogenesis. 
 
6.1   Novel fusion genes and roles of partner proteins 
 
In this thesis I have described the identification of six novel fusion genes. Four of 
these were completely novel with partner genes identified by me (GOLGA4, STRN 
and CPSF6) or by another member of the group (KIF5B) that have not been 
previously described as being involved in leukaemia. All four are very rare and as yet 
only GOLGA4-PDGFRB has been found in more than one patient. The fifth resulted 
from fusion of a known partner protein, ETV6, to PDGFRA. The final fusion was a 
variant ETV6-PDGFRB fusion with rare breakpoints never reported before.  
 
Five of the six fusions involved PDGFR genes and are therefore diagnostically 
important because of the known sensitivity of both PDGFRα and PDGFRβ to 
targeted therapy with the tyrosine kinase inhibitor imatinib. Indeed all five received 
imatinib, of who four achieved complete cytogenetic remission, and for the fifth case 
the follow up is still too short to assess remission status. The remaining fusion 
involved the FGFR1 gene, known to be involved in a specific MPD referred to as 
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8p11 myeloproliferative syndrome (EMS) that is refractory to imatinib but may be 
sensitive to inhibitors that are active against FGFR1 (Chase, et al 2007) although 
none are currently available for clinical use. 
 
Fusions of PDGFRA, PDGFRB and FGFR1 are all known to be associated with 
MPDs. Translocations involving PDGFRB appear the most diverse with reports of 
partner genes at more than 20 chromosomal locations (Figure 6.1). Only one, ETV6-
PDGFRB, has been found relatively frequently with the remainder being very rare 
and many only described in one or two patients. FGFR1 in EMS has been reported to 
fuse to 8 partners in addition to the one I found. The three PDGFRA fusions I found 
take the current total to six, by far the most common of which is FIP1L1-PDGFRA.  
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Figure 6. 1: Spider diagram illustrating translocations associated with MPDs and related 
disorders. The tyrosine kinase genes are indicated in white and the fusion partner 
genes in green. 
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I took a number of different approaches to identify the fusion genes: 
  
• Both GOLGA4-PDGFRB and CPSF6-FGFR1 were identified following 
initial FISH analysis to confirm the involvement of the respective tyrosine 
kinase genes, both of which were suspected from the cytogenetic results and 
clinical phenotype. Once this was confirmed I performed 5’RACE PCR from 
the kinase to identify the partner gene. 
 
• STRN-PDGFRA and ETV6-PDGFRA were cloned by bubble PCR from 
genomic DNA, exploiting the fact that the genomic breakpoints for all 
reported PDGFRA fusions are very tightly clustered. This approach was 
particularly useful for the STRN-PDGFRA case since no RNA was available, 
and in fact the fusion was cloned from DNA extracted from a single bone 
marrow slide. As above, involvement of PDGFRA in both cases was 
suspected by the finding of a translocation involving 4q12 in patients with a 
MPD and eosinophilia. 
 
• KIF5B-PDGFRA was identified following a screen for over-expression of 
PDGFRA by the generic RT-PCR assay I developed. Of 200 patients 
screened, just one strongly over-expressed PDGFRA (although unknown to us 
at the time, the patient had a complex rearrangement involving 4q12). The 
fusion was identified by bubble PCR from genomic DNA. 
 
• The variant ETV6-PDGFRB case was referred with a t(5;12) karyotype and a 
clinical response to imatinib, strongly suggesting involvement of PDGFRB, 
however RT-PCR for ETV6-PDGFRB was negative, Over-expression of 
PDGFRB was confirmed by the MLPA RT-PCR assay and therefore I 
performed 5’-RACE PCR leading to the unexpected finding of the variant 
fusion. 
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All the fusions I found conformed broadly to the consensus structure of tyrosine 
kinase fusions following the paradigm of BCR-ABL (Figure 6.2). The N-terminal 
region of the partner gene was fused in-frame to the C-terminal region of the kinase, 
including the entire catalytic domain.  
 
Dimerisation domain
NH2 COOH
Catalytic domain
C-term tyrosine kinaseN-term partner protein
 
 
Figure 6. 2:  Schematic showing the universal structure of tyrosine kinase fusions based on the 
BCR-ABL paradigm. The N-terminal dimerisation domain of the partner is fused to 
the entire catalytic C-terminal domain of the tyrosine kinase. 
 
The partner genes are widely expressed, usually in all normal tissues but certainly in 
haematopoietic cells and thus provide a promoter to drive transcription of the fusion. 
All partner proteins analysed to date (except FIP1L1) contain one or more 
dimerisation domains that are also required for the transforming activity of the fusion 
proteins. Homotypic interactions between these domains lead to dimerisation or 
oligomerisation of the fusion protein, thus mimicking the normal process of ligand-
mediated dimerisation that is essential for the activation of normal tyrosine kinases. 
Although I was unable to test my fusions functionally, all the partner proteins had 
plausible dimerisation domains that are retained in the fusion genes, e.g.  
 
• GOLGA4: extensive coiled-coil domains (Barr 1999, Kjer-Nielsen, et al 
1999, Lu, et al 2006, Luke, et al 2003, Munro and Nichols 1999, Panic, et al 
2003, Wu, et al 2004). 
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• STRN: an N-terminus coiled-coil region is thought to be crucial for homo- 
and hetero-oligomerisation of the protein and hence of the fusion protein 
(Gaillard, et al 2006).  
• CPSF6: no classic domains but the RNA recognition motif (RRM) may 
mediate homodimerisation (Handa, et al 2006, Simpson, et al 2004). 
•  KIF5B: a central alpha-helical rod domain that enables the protein to 
dimerise (Huang, et al 1994). 
• ETV6: the pointed (helix-loop-helix) domain has been established 
functionally as a self association motif that is essential for the transforming 
activity of ETV6-PDGFRβ (Carroll, et al 1996, Golub, et al 1994). 
 
The normal functions of the partner proteins are diverse, however with the 
characterisation of increasing numbers of tyrosine kinase fusions, some intriguing 
patterns have emerged. Indeed it is possible that the partner proteins are not just 
contributing oligomerisation motifs and ubiquitous promoter expression but may also 
be playing a more direct role in cell dysregulation, as discussed below. 
 
Deregulated endocytosis. Several translocations involving PDGFRA or PDGFRB 
generate in-frame fusions with components of the endocytic machinery e.g. Rabaptin-
5, Hip1 and PDE4DIP. My work adds three further endocytosis-related partners, 
GOLGA4, KIF5B and STRN and, in addition, a further two PDGFRB partner genes 
submitted for publication (Bin2 and WDR48) identified in our laboratory also have 
endocytic links. Endocytosis is recognised as a fundamental mechanism of signal 
attenuation by committing receptors to degradation or recycling back to the plasma 
membrane. Potentially, interference with endocytosis may affect normal receptor 
down-regulation, resulting in hyper-proliferation (Mosesson, et al 2008). 
Furthermore, if signalling can occur at the endosomes, as has been reported by Wang 
Y et al., (2004) for Rabaptin5-PDGFRβ, then this may suggest a mechanism for 
prolonged signalling (Wang, et al 2004a). 
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GOLGA4 (tGolgin1; Golgin-245). tGolgin-1 is a member of the Golgin family of 
coiled-coil proteins associated with specific sub-domains of the trans-Golgi network 
(TGN) and is thought to play a role in Rab6-regulated tethering events in membrane 
fusion and as a structural support for the Golgi cisternae (Barr 1999, Kjer-Nielsen, et 
al 1999, Munro and Nichols 1999).  
 
The TGN itself is a series of interconnected tubules and vesicles located at the trans 
face of the golgi stack and its purpose is to process and sort glycoproteins and 
glycolipids at the periphery of the endosomal pathway (Figure 6.3A). The Golgins are 
further characterised by a highly conserved C-terminal GRIP domain that localises 
the proteins to the TGN. Over-expression of the isolated GRIP domain has been 
shown to result in alteration of the pericentriolar distribution of the TGN integral 
membrane and coat components whilst concomitantly inhibiting vesicular transport 
from the TGN to the plasma membrane (PM). This suggests that these proteins help 
maintain the integrity of the TGN by regulating resident protein localisation 
(Yoshino, et al 2003). tGolgin-1 is suggested therefore to be a tubulovesicular carrier 
that emerges from the TGN and hence is likely to be a regulator of transport from the 
TGN to the recycling endosome and PM. Recently Lieu et. al., (2008) have further 
defined the role of tGolgin-1 and shown that not only is it essential for intracellular 
trafficking but it might additionally act as a vesicle coat, however its complete 
function still remains to be fully elucidated (Lieu, et al 2008).  
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Figure 6. 3A:  Schematic showing anterograde and endocytotic/retrograde transport through 
cellular organelles. ‘Stop signs’ indicate which pathways might be affected by the 
GOLGA4-PDGFRβ fusion, leading to possible aberrant endocytosis and increased 
cellular transformation. tGolgin-1 is a tubulovesicular carrier likely to be a regulator 
of transport from the TGN to the recycling endosome and PM. This is a retrograde 
pathway that allows signalling proteins to escape the degradative environment of the 
late endosomes and lysosomes and to reach internal sites where they can interact 
with their intracellular targets or be exported back to the PM via the recycling 
endosomes permiting increased signaling (represented by arrow in green box). EE, 
early endosome; ERGIC, ER-Golgi intermediate compartment; Glut4, a glucose 
transporter molecule; LE, late endosome; RE, recycling endosome, and TGN, trans-
Golgi network. 
 
It can only be speculated upon how the fusion of tGolgin-1 and PDGFRβ might 
abrogate endocytosis and enhance the oncogenic potential of the fusion. One such 
hypothesis is that the partner protein plays a role in localising the fusion to a 
particular subcellular compartment, in this case the TGN. However for this specific 
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fusion the c-terminal GRIP domain (essential for localisation to the Golgi) is lost and 
it is unclear where in the cell the fusion would be. It has also been shown that in 
general tyrosine kinase fusions are found to be cytosolic due to deletion of the N-
terminal signalling peptide from the kinase (Lamorte and Park 2001). Hence they 
avoid entry to the endocytic pathway anyway, thereby presumably preventing 
degradation and prolonging signalling.  
 
A second hypothesis concerns the method of uptake of the fusion/constitutively 
activated receptor. It has been suggested that differential clathrin and caveolae 
mediated endocytic routes of the same cargo may regulate signalling capacity and 
endocytic fate (Di Guglielmo, et al 2003, Sigismund, et al 2005).  Clathrin mediated 
endocytosis is a form of membrane invagination and vesicle scission of receptors 
clustering in clathrin coated pits. The released vesicles discard the coat before fusing 
with tubulovesicular compartments such as the early endosomes where the cargo is 
sorted for either degradation in the lysosomes or recycling back to the PM. The 
caveolae pathway also involves membrane invagination and vesicle budding, 
however the vesicles are caveolin-positive and are directed first to larger caveolin-
enriched organelles termed caveosomes before being further targeted to the early 
endosomes, thereby allowing convergence with the clathrin mediated pathway. Both 
pathways are a means of signal attenuation however it is possible that one or the other 
might promote recycling over degradation further compounded by the role of 
tGolgin-1 as regulator of transport from the TGN to the recycling endosome and 
plasma membrane. 
 
Finally and perhaps most interestingly, is the role of tGolgin-1 in retrograde transport 
from the endosomes to the TGN. This pathway is regulated by specific SNAREs and 
Rab proteins signifying it is a pre-existing cellular pathway not just a subversive 
pathway. This retrograde pathway may allow signalling proteins to escape the 
degradative environment of the late endosomes and lysosomes to reach internal sites 
where they can interact with their intracellular targets or be exported back to the PM 
via the recycling endosomes (Figure 6.3A) (Mallard, et al 2002). Therefore, efficient 
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retrograde transport from the early endosomes to the TGN is important for the 
recycling of endogenous proteins (Lieu, et al 2007). A role for Golgin-1 in this 
pathway has been proposed by Yoshino et. al., (2005), who showed that recruitment 
of microtubule motors (such as the kinesins) to the Golgi requires tGolgin1-
dependent retrograde transport from the endosomes. This was observed after 
experiments over-expressing the GRIP domain were performed that resulted in 
specific disruption of TGN morphology, protein localisation and function. 
Concomitantly, vesicular transport from the TGN to the PM was inhibited (Yoshino, 
et al 2005). This suggests the GRIP domain proteins, such as tGolgin-1 function in 
TGN maintenance probably by regulating recycling from the endosomes. Thus the 
TGN requires a functional GRIP domain, shown not only by over-expression of 
GRIP domains competing for binding, but also by inactivity observed with N-
terminal tGolgin-1 fragments that lack the GRIP domain, such as might be observed 
with the GOLGA4-PDGFRβ fusion. This would imply the fusion may not be 
recycled back to the PM but instead retained at the TGN or in the early endosomes 
where conceivably signalling can still occur, aiding oncogenicity.  
 
Yoshino et. al., 2005 have also shown that cells depleted of tGolgin-1 mis-sort 
internalised glycolipids to the late endosomes/lysosomes and accumulate aberrant 
endosomal structures, highlighting a possible secondary outcome of disrupting 
membrane recycling. These results are consistent with the function of golgin-97 (Lu, 
et al 2004a) and the dominant-negative GRIP-domain over-production in which 
endosome to TGN recycling is inhibited (Yoshino, et al 2003). The consequence of 
such mis-sorting to the late endosomes would be eventual depletion from the Golgi of 
recycling glycosphingolipids, so proteins and receptors cannot be modified and 
shipped back to the PM. This could mean prolonged signalling and reduced 
degradation and could also perturb multiple other pathways if required proteins are 
not modified or transported where required, adding to cellular transformation. 
 
KIF5B. KIF5B is an N-terminal (plus-end motor) kinesin that is a member of the 
superfamily of Kinesin-1 molecular motor proteins that are responsible for 
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microtubule-dependent transport of cargo in eukaryotic cells (Goldstein and Yang 
2000). These motor proteins are powered by the hydrolysis of ATP enabling them to 
move cargo such as vesicles, proteins and lipids throughout the cell. The plus-end and 
minus-end microtubule specific motors are responsible for opposing movement along 
the filaments within the cell (Hirokawa and Takemura 2005). KIF5B in particular, is 
important for microtubule-based endosome-motility, by regulating early endosome 
trafficking and has been further implicated specifically in lysosomal and 
mitochondrial transport (Nakata and Hirokawa 1995, Tanaka, et al 1998). 
 
It is important to highlight the link between the Golgi and the motor protein Kinesin 
to comprehend how these proteins found fused to a PDGFR tyrosine kinase are 
related not only to endocytosis but also how these proteins interact at the cellular 
level. As discussed previously, proteins sequestered at the TGN are selectively sorted 
and packaged into distinct carrier vesicles destined for either the PM or endosomal 
compartments. The Golgi is a dynamic structure and to maintain this level of activity 
it is sustained by a complex cytoskeletal matrix composed of microtubules and actin-
spectrin networks as well as by temporal localised proteins such as the Golgins. The 
interaction between these filaments and the Golgi membrane is further mediated by 
diverse families of ‘motor proteins’ such as the kinesins. Interestingly, these two 
endocytic proteins interact at the Golgi and together help maintain the overall 
integrity of the Golgi structure whilst also supporting protein transport. 
Overwhelming evidence now suggests that KIF5B is specifically involved in 
transporting vesicles from the TGN to the PM or endosomes further localising both 
KIF5B and tGolgin1 to the same subcellular domain: the TGN. Additionally, if 
KIF5B expression is reduced the Golgi apparatus has been shown to switch from an 
extended ribbon to a much more compact structure (Feiguin, et al 1994) with ensuing 
inefficient protein modification and sorting, and decreased trafficking. An additional 
layer of complexity within the trafficking of vesicles from the TGN is the 
requirement of different motor proteins depending on the cargo being transported and 
the specific cell type, for example epithelial or fibroblasts. Due to the constitutive 
activity of the kinase caused by the KIF5B-PDGFRA fusion it is likely that KIF5B 
expression is enhanced. This may cause specific proteins to be modified and 
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transported far more efficiently than others, resulting in an unbalanced accumulation 
of specific proteins and a reduction in others creating generalised cell defects perhaps 
adding to the transforming potential of this fusion. 
 
Another hypothesis for this fusion’s oncogenicity is related to KIF5B’s role in plus-
end motility of vesicles. It has been shown to work in association with the minus-end 
motility kinesin KIFC1, and if either Kinesin is inhibited reduced vesicle fission 
occurs suggesting that the opposing forces from the activity of both motors are 
required for fission to occur (Nath, et al 2007). This could imply that vesicles 
containing activated receptors are unable to be sorted for degradation to the 
lysosomes due to inefficient vesicle fission. The active receptors may then be able to 
continue signalling increasing the transformation potential and disrupting receptor 
attenuation via lysosomal degradation (Figure 6.3B). 
 
KIF5B is a tetramer composed of two heavy chains and two light chains that together 
form a rod-like molecule consisting of two globular head domains, a stalk domain 
and a fan-like tail domain. The head domain is thought to bind to the microtubules, 
and the fan-like ends are thought to be associated with vesicles and membranous 
organelles requiring transport (Hirokawa, et al 1989). The N-terminal motor/head 
domain is present within the fusion with PDGFRA so it still retains the ability to 
move along the microtubules, however with the c-terminal fan-like region absent it 
may not be able to interact with the vesicles, organelles and proteins requiring 
intracellular transport. Transport is very important for the proper targeting of lipids, 
proteins and organelles to distinct subcellular domains without this function it is 
plausible that more generalised defects within the cell may occur. This also implies 
the fusion itself would remain cytosolic, possibly bound to the microtubule network, 
avoiding endocytosis resulting in increased signalling. 
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Figure 6.3 B:  Schematic showing anterograde and endocytotic/retrograde transport through 
cellular organelles. ‘Stop signs’ indicate which pathways might be affected by the 
KIF5B-PDGFRα fusion, leading to possible aberrant endocytosis and increased 
cellular transformation. The plus-end and minus-end microtubule specific motors are 
responsible for opposing movement along the filaments within the cell, represented 
by purple arrows. KIF5B is specifically involved in TGN-to-PM or endosome 
trafficking, enhanced expression of this protein caused by the fusion may cause 
specific proteins to be modified and transported far more efficiently than others, 
resulting in an unbalanced accumulation of specific proteins and a reduction in 
others creating generalised cell defects. Vesicles containing the activated fusion may 
also be unable to be sorted for degradation to the lysosomes due to inefficient vesicle 
fission. The active receptors may then be able to continue signalling within the EE or 
be recycled (represented by arrow in green box) increasing the transformation 
potential and disrupting receptor attenuation via lysosomal degradation. It is also 
speculated that overexpression of KIF5B may result in continuous transportation to 
the required subcellular domains and subsequent enhanced signalling and cell 
turnover and reduced lysosomal degradation. EE, early endosome; ERGIC, ER-
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Golgi intermediate compartment; Glut4, a glucose transporter molecule; LE, late 
endosome; RE, recycling endosome, and TGN, trans-Golgi network. 
 
Additionally, Cardoso et. al., (2009) have recently reported up-regulation of KIF5B 
mRNA in several types of cancer including bladder cancer, advanced gastric cancer, 
squamous cell carcinoma and BRCA1-associated breast cancer. (Cardoso, et al 
2009). They were also able to show that when KIF5B was depleted in vitro HeLa 
cells acquired an elongated cellular phenotype concomitant with significant growth 
inhibition and cell death. It could be speculated that over-expression of KIF5B may 
have the opposite effect with effective continuous transportation to the required 
subcellular domains and subsequent enhanced signalling and cell turnover. Further 
work from this group implicates that KIF5B may function in transporting lysosomes 
to the plasma membrane destined for exocytosis and moreover may play a role in 
positioning lysosomes at distinct sites in the cytoplasm, particularly perinuclear. 
Consequently, depletion of KIF5B would allow other motor proteins to transport the 
lysosomes to the cortical areas of the cell resulting in lysosomal aggregation. 
 
STRN. Striatin is a multimodular, WD-repeat, and calmodulin-binding protein. It is 
found in the cytosol in addition to being associated with membranes, and is composed 
of several different, colinearly aligned protein-protein association modules. These 
include a caveolin-1 binding motif, a coiled-coil structure, a Ca2+-calmodulin-binding 
motif and a large WD-repeat domain (Bartoli, et al 1998, Castets, et al 1996, 
Gaillard, et al 2001). Striatin is a scaffolding protein involved in calcium dependent 
signalling (Bartoli, et al 1999) with a putative role in trafficking (Baillat, et al 2001), 
whilst also being shown to directly bind caveolin-1 (Gaillard, et al 2001).  
 
To further define the role of Striatin, Baillat et. al., 2001 used a yeast two-hybrid 
strategy to search for partners and identified phocein, an intracellular protein. Its 
distribution mirrors that of striatin, due to its association and a lack of transmembrane 
binding motifs. Interestingly, phocein is also highly localised to the Golgi complex 
indicating a link between this organelle and striatin (Baillat, et al 2001). It is 
hypothesised that phocein may be a component of a novel vesicular coat allowing 
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transport to the Golgi complex and further adding to striatins’ role in membrane 
trafficking. 
 
Additionally, it is speculated that caveolin-1 binding the caveolin binding site of 
striatin may directly regulate its function by concentrating it within caveolin-enriched 
domains, concordant with its putative role in membrane trafficking (Baillat, et al 
2001). The caveolae themselves are thought to be subcellular domains that regulate 
among other things, intracellular Ca2+- concentration and Ca2+–dependent signal 
transduction (Isshiki and Anderson 1999). This links both the Ca2+-calmodulin 
binding domain of striatin and the caveolin-1 binding domain. It is also well known 
that caveolins interact with signalling proteins from the plasma membrane, such as 
tyrosine kinases, Ras and G-proteins (Chang, et al 1994, Lisanti, et al 1994, 
Sargiacomo, et al 1993), and is consistent with a role for caveolae in sequestering 
signalling molecules to attenuate signalling after receptor stimulation, similar to 
clathrin coated pits. This further addresses the role of striatin as a possible signalling 
transduction component due to its links and enrichment at the caveolae. Furthermore, 
it has been shown that transformation of NIH3T3 cells by various oncogenes leads to 
a reduction in cellular levels of caveolin, suggesting functional alterations in caveolae 
may play a critical role in oncogenic transformation, perhaps by disrupting contact 
inhibition and negatively regulating the activation state of the p42/44 MAP kinase 
cascade (Engelman, et al 1997, Galbiati, et al 1998, Koleske, et al 1995). 
Additionally the reduction of caveolae in transformed cells could further prevent the 
down-regulation of growth-promoting signals, thus contributing to uncontrolled 
proliferation. It is possible that the STRN-PDGFRα fusion, by interacting with 
caveolin via the caveolin-1 binding site of striatin, is either maintained at the cell 
surface constitutively active, or is sequestered from the cell surface and internalised 
via the caveolae where it may be transported through the endocytic pathway and 
recycled due to its interaction with caveolin back to the cell surface thereby allowing 
continuous signalling and promoting further to cell transformation (Figure 6.3C). 
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In conclusion, it is possible this protein with its calmodulin-binding site a WD-repeat, 
scaffolding domain and a caveolin-1 binding motif enhances cell transformation, 
adding to the growing list of proteins now known to have a dual capacity in 
endocytosis and signalling (Di Fiore and De Camilli 2001). 
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Figure 6.3 C:  Schematic showing anterograde and endocytotic/retrograde transport through 
cellular organelles. ‘Stop signs’ indicate which pathways might be affected by the 
STRN-PDGFRα fusion and lead to possible aberrant endocytosis and increased 
cellular transformation. Reduction of caveolae in transformed cells is thought to 
prevent the down-regulation of growth-promoting signals, thus contributing to 
uncontrolled proliferation. It is speculated that the striatin caveolin-1 binding site 
within STRN-PDGFRα enables it to be either retained at the cell surface 
constitutively active (represented by arrow in green box), due to reduced levels of 
caveolae or is sequestered from the cell surface and internalised via the caveolae and 
recycled allowing continuous signaling whilst promoting cell transformation. EE, 
early endosome; ERGIC, ER-Golgi intermediate compartment; Glut4, a glucose 
transporter molecule; LE, late endosome; RE, recycling endosome, and TGN, trans-
Golgi network. 
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Finally, the finding of mutations in CBL, a protein that is normally involved in 
attenuating receptor tyrosine kinase signalling, further strengthens the hypothesis that 
subversion of endocytic control is pathogenetically important. These mutations have 
been shown to prevent internalisation and ubiquitination of the RTKs FLT3, 
PDGFRα/β and EGFR, leading to prolonged signalling (Sargin, et al 2007). 
 
Pre-mRNA processing. The characterisation of a second novel fusion gene: CPSF6-
FGFR1 in parallel with the discovery in our laboratory of a novel ABL fusion: SFPQ-
ABL led us to the identification of a second functionally related group of partner 
proteins (Hidalgo-Curtis, et al 2008). Both CPSF6 and SFPQ encode proteins that are 
involved in pre-mRNA processing. SFPQ is an essential factor involved in RNA 
splicing and was first identified in a complex with polypyrimidine tract-binding 
protein (PTB)(Patton, et al 1993). Interestingly, CPSF6 co-localises in purified 
spliceosomes with SFPQ and another splicing factor NonO, linking these proteins to 
both transcription and processing of pre-mRNAs (Dettwiler, et al 2004, Rappsilber, et 
al 2002, Zhou, et al 2002). ZMYM2 (ZNF198), a partner protein commonly fused to 
FGFR1, is also thought to be involved in this process, possibly by acting as a 
scaffolding protein that brings RNA-binding proteins together to facilitate pre-mRNA 
splicing (Kasyapa, et al 2005). Strikingly, ZMYM2 has also been found to 
immunoprecipitate with SFPQ (Kasyapa, et al 2005). Adding further weight to this 
group of proteins is FIP1L1, which fuses to PDGFRα in CEL (Cools, et al 2003a). 
Not only is this one of the most common fusion genes described in eosinophilic MPD 
patients, FIP1L1 has also been show to have a role in polyadenylation and pre-mRNA 
splicing (Kaufmann, et al 2004, Preker, et al 1995).  
 
How these functionally related proteins might impact on neoplastic growth is not 
clear. It is possible that the fusions may interfere with normal pre-mRNA processing 
complexes thereby inhibiting processing of many transcripts. Alternatively they may 
result in increased processing. Both splicing and polyadenylation are known to be 
important control points with regard to gene expression and it is conceivable that 
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alterations could disrupt the fine balance between proliferation, differentiation and 
apoptosis of these cells by altering mature mRNA levels of key genes. Consistent 
with this idea, it has been shown that high levels of poly(A)polymerase (PAP), the 
enzyme that causes elongation of the poly(A) tail, are associated with proliferating 
cells and that the levels reduce in cells undergoing apoptosis (Thomadaki, et al 2008). 
 
Centrosomal proteins. A third group of functionally related partner proteins has also 
been observed by Delaval et. al., (2005). This group initially observed that FGFR1OP 
is a centrosomal protein and that the FGFR1OP-FGFR1 fusion is also centrosomal, 
Furthermore, FGFR1OP1-FGFR1 was shown to be active at the centrosome and 
activate multiple signalling pathways (Delaval, et al 2005a). Several other 
centrosomal partner proteins have been described, e.g. CEP110 fuses to FGFR1, 
PCM1 fuses to JAK2, CDK5RAP2 fuses to PDGFRα, NDE1 and NIN fuse to 
PDGFRβ. 
 
The centrosome consists of a pair of centrioles surrounded by pericentriolar material 
and plays an integral role in directing the organisation of the cytoplasmic 
microtubules and the assembly of the mitotic spindles (Rieder, et al 2001). 
Aberrations in the number of centrosomes lead to mitotic defects and cause 
chromosome mis-segregation and centrosome abnormalities and are therefore 
frequent in many common cancers (Nigg 2002). Delaval et. al,. hypothesise that the 
centrosome, which is linked to the microtubules, is close to the nucleus, and is 
connected to the Golgi apparatus and the proteasome, could serve to integrate 
multiple signalling pathways controlling cell division, cell migration and cell fate. 
Abnormal kinase activity at the centrosome may be an efficient way to pervert cell 
division in malignancy. In support of this idea, it has been reported that an 
unidentified centrosomal mechanism controls the number of neurons generated by 
neural precursor cells (Bond, et al 2005). It is conceivable that similar mechanisms 
might operate in haematopoietic development. 
 
253 
These three functional clusters of partner proteins are striking and, as discussed 
above, may directly impact on cellular processes and promote transformation. 
However since the clusters impact on such functionally diverse processes, it is 
perhaps unlikely that any of the postulated interactions are critical for transformation, 
although they might produce cellular changes that modify the phenotype. In support 
of this, it has been observed that the clinical features in patients with FGFR1 
rearrangements are slightly different depending on the identity of the partner protein 
(Macdonald, et al 2002b). However other interpretations are also possible, for 
example it might be that endocytic, pre-mRNA processing and centrosomal proteins 
are simply large families, widely expressed and tend to contain dimerisation domains. 
It is also possible that altered subcellular localisation may be important, by enabling 
the kinase to interact with novel substrates. For example, the FIG-ROS fusion found 
in glioblastoma has been shown to be directed by the partner protein to the Golgi 
(Charest, et al 2003), a localisation that is thought to be essential to its transforming 
ability. However whether this is due to interactions with novel substrates or whether 
specific localisation increases the effective concentration of the fusion protein above 
a critical threshold is unclear. 
 
6.2   Routine detection of tyrosine kinase fusions 
 
Detection of tyrosine kinase fusions is important for several reasons. First, the finding 
of a fusion such as FIP1L1-PDGFRA in a cytogenetically normal patient confirms the 
diagnosis of a clonal neoplastic disorder. Second, specific fusions are indicators for 
specific targeted therapies, e.g. patients with PDGFRA or PDGFRB translocations 
respond very well to imatinib. Third, the involvement of particular tyrosine kinases 
may be prognostically important, e.g. patients with FGFR1 translocations have a 
strong propensity to progress to AML and should be considered as candidates for 
allogeneic bone marrow transplantation. It is clearly important therefore that 
diagnostic procedures are available to detect fusion tyrosine kinases accurately. The 
problem arises from the sheer number of different fusions that have been described, 
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which makes it impractical and very expensive to screen for each by RT-PCR. 
Furthermore it is likely that additional fusions with novel partners remain to be 
discovered. For many cases it would be possible to use FISH with split-apart probes 
however rare translocations often mask complex rearrangements at the molecular 
level and consequently split-apart FISH may fail to detect a rearrangement (Kulkarni, 
et al 2000, Reiter, et al 1998). 
 
To help address this problem, and also to try and screen for new fusions, I developed 
two generic RT-PCR assays to detect over-expression of PDGFR genes. The assays 
were designed to look for over-expression of the tyrosine kinase domain relative to an 
extracellular control band and which might therefore indicate the presence of a 
PDGFR fusion gene. Following validation using samples with known PDGFR 
fusions, I screened approximately 200 patients for both PDGFRA and PDGFRB over-
expression. Of the six patients found to over-express PDGFRB, one had a previously 
undetected variant ETV6-PDGFRB fusion that had arisen as a result of a complex 
translocation. Unexpectedly, 2 had FGFR1 rearrangements. The reason for this is 
unclear and requires further investigation, initially to see if this is a consistent finding 
in cases with FGFR1 fusions. Of the remaining 3 patients, only 2 had material 
available for further study and no abnormalities were found. Over-expression of 
PDGFRA was identified in 14 patients. Of the 7 that had sufficient material to 
investigate further with bubble PCR one had the novel KIF5B-PDGFRA fusion, one 
had a previously undetected FIP1LI-PDGFRA fusions and five showed no 
abnormalities.  
 
Overall then, the generic RT-PCR assays led to the identification of fusions that had 
not been detected previously and is therefore clearly a useful diagnostic tool. 
However it does produce quite a large number of false positives that require extensive 
further investigation. It would be desirable to have a technique that reduced these, 
and was also more readily extendable to screen for fusions involving additional 
tyrosine kinases. I therefore designed a cDNA MLPA assay to look at expression of 
the four kinases most commonly involved in MPDs: ABL, FGFR1, PDGFRA and 
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PDGFRB. MLPA is a probe-based technique that was originally designed to detect 
deletions and amplifications of multiple target genomic DNA sequences in a single 
reaction. The cDNA MLPA assay was designed on the same principle as that of the 
generic RT-PCR assays i.e. to look at differential expression of the tyrosine kinase 
portion of the gene (which would be retained from any fusion) compared to a second 
probe that hybridised to a portion of the extracellular domain or 5’ region that would 
not be retained in the fusion.  
 
The assay was validated using normal control cDNA samples, cell lines and patient 
cDNA with known tyrosine kinase gene fusions. The majority of positive controls 
were correctly identified, however the intracellular:extracellular ratio of the other 
unaffected probes was rarely 1.0 as predicted. Furthermore due to the differing levels 
of expression of each gene it proved difficult to define a single set of conditions that 
effectively covered all four genes and, in addition, the assay was very dependent on 
the quality of the cDNA and probe sensitivity. Nevertheless, this technique did lead 
to the discovery of a novel variant ETV6-PDGFRB fusion in one case who over-
expressed the PDGFRB kinase domain. Overall, the cDNA MLPA seemed to be 
more useful as a general screen allowing the analysis of 3 tyrosine kinase genes in 
one test limiting sample volume which is always precious, however it was time 
consuming and less reproducible. The generic RT-PCRs worked relatively well for 
the two targets that are clinically most important, PDGFRA and PDGFRB, however 
over time they also proved temperamental with sensitivity to cDNA quality, primer 
age and the thermocycler that was used. The yield of previously unknown positive 
cases from either technique was low and perhaps the most effective approach would 
be to use the generic RT-PCR assays to screen for PDGFRA over-expression 
associated with FIP1L1-PDGFRA in cases with eosinophilia, and to screen for 
PDGFRA and PDGFRB abnormalities in cases with a complex karyotype. This 
strategy is unlikely to miss any true positives but will minimise the number of false 
positives. Other generic strategies to detect gene fusions are also possible, e.g. exon 
arrays or real time PCR assays to look at expression across target genes, but these 
would be much more expensive. 
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 6.3  Loss of heterozygosity analysis as an approach to identify 
genes harbouring activating mutations 
 
The main focus of my work was to identify new abnormalities in atypical MPDs. 
LOH is a genetic mechanism that creates a homozygous or hemizygous cell by loss of 
the wild-type allele as a result of various mutational events. These include deletion, 
mitotic recombination, localised gene conversion, point mutation, or non-dysjunction. 
My objective was to identify new oncogenes or tumour suppressor genes that are 
marked by these regions of LOH, and specifically regions of acquired uniparental 
disomy (aUPD), or copy number neutral LOH, formed as a consequence of mitotic 
recombination. Uniparental disomy (UPD) refers to a mechanism in which both 
copies of a chromosome pair have originated from one parent. This can result in 
diverse clinical conditions as a consequence of homozygosity for recessive mutations 
or aberrant patterns of imprinting. Somatic UPD has also been shown to arise as a 
consequence of recombination occurring during mitotic cell divisions. This acquired 
UPD (aUPD) has been shown be associated with pathogenetic driver mutations in 
genes within the region of homozygosity such as JAK2 V617F, FLT3 ITD, CEBPA 
and WT1 mutations (Fitzgibbon, et al 2005, Griffiths, et al 2005, Kralovics, et al 
2005b, Raghavan, et al 2005). I aimed to search for new regions of aUPD as a means 
to identify regions harbouring genes that are mutated in aMPDs and transformed 
CML. 
 
Numerous techniques are capable of identifying regions of LOH however SNP arrays 
have the advantage as they can simultaneously detect copy number and zygosity. For 
my study, I utilised 50K SNP arrays which are entirely adequate for detecting large 
regions of aUPD although the resolution of copy number changes turned out to be 
very limited. A major drawback of my study was that paired sample analysis was not 
possible due to the lack of constitutional DNA, thus I was unable to determine if 
tracts of homozygosity were acquired or whether they were inherited. Fortunately 
though I found that 40% of aMPD cases had large (>20Mb) tracts of copy neutral 
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homozygosity that are very unlikely to have been inherited. However, aUPD was 
uncommon in the other patient subgroups (CML-BC, MF and V617F negative PV). 
 
In aMPDs, 8 distinct regions of aUPD were identified indicating considerable genetic 
heterogeneity in these disorders. However two novel, recurrent regions were seen at 
7q and 11q, each in 10% of cases. Initially, because of the strong association between 
MPDs and tyrosine kinases, I fully re-sequenced the three tyrosine kinase genes on 
7q, (EPHA1, EPHB6 and MET) but no mutations were found. There are no tyrosine 
kinase genes on 11q so it was apparent that both abnormalities must be targeting 
other genes. I then went on to select candidates at both locations for further analysis. 
Both regions were relatively large and contained several hundred genes, including a 
large number of candidates that could potentially be involved in malignancy. I 
focused mainly on those that were known to encode signal transduction components 
and were either known oncogenes (BRAF, CBL) or closely related to known 
oncogenes (PI3KCG). I also checked for the MLL ITD as this gene is widely involved 
in leukaemia. This analysis led to the finding of CBL mutations in all three cases with 
11q aUPD. 
 
The CBL gene is located at 11q23.3 and encodes a widely expressed ubiquitin ligase 
that functions as a negative regulator of several receptor protein tyrosine kinases by 
inducing ubiquitination of the receptors, thereby promoting their sorting for 
endosomal degradation or recycling. In addition, CBL plays a positive role in 
signalling by serving as a scaffold for the recruitment of downstream substrates. The 
mutations I found predicted missense substitutions in the RING/linker domain, 
L380P in two cases and P417A in the third. This region is responsible for the 
ubiquitin ligase activity and it is likely that these mutations, like the R420Q 
substitution previously described in AML, have transforming activity and are 
therefore causative driver mutations (Sargin, et al 2007).  
 
Having found CBL mutations in the three 11q aUPD cases, I next screened 547 
patients, including those with PV, IMF, ET, SM, HES, CMML, aCML and other 
258 
aMPDs. A further 23 patients with CBL mutations were identified, the majority of 
which were missense changes, plus one nonsense mutation and some intronic 
changes, two of which were shown to result in skipping of exon 8. Although I found 
the R420Q in 4 cases, the majority of mutations were novel. The mutations were 
associated predominantly with a diagnosis of aCML, CMML and MF i.e. highly 
related and relatively aggressive diseases. In three cases for which suitable material 
was available, the mutations were shown to be acquired. In two cases, the mutations 
were acquired during progression of a pre-existing MPD indicating that in these cases 
at least, CBL mutations were secondary events.  
 
There are a number of obvious future avenues of investigation that should be 
undertaken following the results of my studies, e.g. 
 
• Functional analysis to prove that the CBL mutations I found are indeed 
transforming. This has been achieved for some of the mutants by testing if 
they transform 32D cells over-expressing FLT3, as has been described for 
R420Q (Grand 2009, Sargin, et al 2007).  
• Investigation of genetic events that might co-operate with CBL mutations. 
One possibility is over-expression of one or more tyrosine kinases, and 
potentially this could be investigated by gene expression profiling. Another is 
indicated by the fact that one of my cases has both a CBL mutation and 7q 
aUPD suggesting that they might co-operate. Once the 7q aUPD mutation is 
identified this can be formally tested, probably most appropriately in mouse 
models. 
• If CBL mutants function by increasing tyrosine kinase signalling then it is 
likely that the malignant clone might be susceptible to inhibition by tyrosine 
kinase inhibitors. This could be investigated by testing the effects of inhibitors 
against patient and control cells. 
• The clinical phenotype associated with CBL mutations needs to be more 
closely defined. Ultimately it should be possible to see if any clinical features 
are correlated with specific mutations and also since aUPD is effectively a 
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second hit, it is possible that homozygous mutations are associated with more 
aggressive disease.  
• Identification of the gene underlying 7q aUPD. Other members of the group 
have eliminated other candidate genes and are planning to sequence the 
coding sequence (exons) of all genes in the region using custom designed pull 
down arrays and Illumina sequencing. 
• Investigation of smaller regions of aUPD that may have been missed by my 
analysis. Efficient algorithms have been described to pick up low level aUPD 
that is missed by standard approaches (Yamamoto, et al 2001) and this, in 
combination with the current state-of-the-art SNP 6.0 arrays, may prove to be 
a powerful approach to identify novel regions harbouring mutated genes. 
 
6.4   Current knowledge of the pathogenesis of atypical MPDs 
 
Prior to my findings it was estimated that at least part of the genetic basis of 
approximately a third of aMPDs was understood, with roughly 2% having tyrosine 
kinase fusions, 5% having FLT3 ITD or KIT D816V, 12.5% V617F JAK2 and 12.5% 
activating NRAS mutations. (Cross 2006, Jones, et al 2005). Clearly a lot of detail 
remains to be filled in, especially the targets of 7q and other regions of aUPD plus 
how different mutations may co-operate together, but following my work, I estimate 
that we now know something about two thirds of cases (Figure 6.4) with CBL 
mutations, 7q aUPD and other regions of aUPD each seen in roughly 10% of aMPDs. 
Further works needs to be performed to determine which combinations of mutations 
occur in individual patients, how they co-operate and how they might be targeted 
therapeutically. 
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Figure 6. 4:  Pie chart illustrating the proportion of aMPD cases related to known genetic variants, 
such as V617F and CBL mutations aUPD compared to unknown pathogenicity. 
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APPENDIX  
 
I)   Bubble-PCR primers 
BUB-T: 
5’ AAGGATCCTAGTCTAGCTGTCTGTCGAAGGTAAGGAACGGACGAGCACTGAG 
 
BUB-B: 
5’ CTCAGTGCTCGTAGTAATCGTTCGCACGAGAATCGCAAGATCTAGGATCCTT 
 
NVAMP1: 
5’ TGCTCGTAGTAATCGTTCGCAC 
 
NVAMP2: 
5’ GTTCGCACGAGAATCGCAAGAT 
 
PDAI12R3: 
5’ AGGTTACCCCATGGAACTTACCA 
 
PDA112R4: 
5’ AAGTTGTGTGCAAGGGAAAAGGG 
 
II)   PDGFRB Exons 2 to 23 
 
PDBI1F3  5’ AGA GCC AAA GCA AAG GCC AG 3’ 
PDBI2R3  5’ AGA GCC CAC TGG AAA TCC TG 3’ 
 
PDBI2F  5’ CCC CTG TTT CCT GAT GTC TG 3’ 
PDBI3R  5’ATG CCT CCA GTT GAC AAG AG 3’ 
 
PDBI3F  5’ CTT GCC ACA CAG CAA TTC AG 3’ 
PDBI4R  5’ CTG AGC ATC AGG CCA GAA AG 3’ 
 
PDBI4F  5’ GAC CTA AGC CAA TCT CTC TC 3’ 
PDBI6R  5’ GAA TTG GGG ATT GGG CTG AG 3’ 
 
PDBI6F  5’ TGG CCT CCT TTG GGA TTC AG 3’ 
PDBI7R2  5’ CCT AGG TTT GTG GCT GAA AG 3’ 
 
PDBI7F  5’AGT CCT TCC GAC TCT GAC AG 3’ 
PDBI8R  5’ATC CAT CTC CTG AGT TCC AG 3’ 
 
PDBI8F  5’TAA CTG TCC TGA CCC TCC CG 3’ 
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PDBI9R  5’TCC TAG CCA GCT GGG GAC AC 3’ 
 
PDBI9F  5’ TCA GTT TCC CTG TCT GCA AG 3’ 
PDBI10R  5’ GTA GGG ATT GGG ATC GTC AG 3’ 
 
PDBI10F  5’ GAT GCC AAA GAT GGG GTG AG 3’ 
PDBI11R2  5’ ATG TGC CAG TCT TCA CCC AC 3’ 
 
PDBI11F  5’ CCT GAG ACT CCC TCT GAT AA 
PDBI12R  5’ ACA TGA GGC CTC TCA GGA CT 
 
PDBI12F  5’ CTG GTA GGC CAG GAG CTA AT 
PDBI13R  5’ TGG AGG GCT CCA AGG ACT A 
 
PDBI13F  5’ GGG GCA GAA GAG TCA GAA TA 
PDBI14R  5’ CCT TGG TGG TGG GCA CTT T 
 
PDBI14F  5’ CCT TGA AGG GAC GCC TGA 
PDBI15R  5’ AAA GAT TCA GTC CCT GGC CT 
 
PDBI15F  5’ CTG CAG GCT CTC CTG TGA T 
PDBI16R  5’ AGC CTG TTT GGA TGT GGG GT 3’ 
 
PDBI16F  5’ TAG CAG GTG ACC CTC TGC TT 3’ 
PDBI18R  5’ AGG GGC CAG GGA AGG TA 3’ 
 
PDBI18F  5’ CAC TCA GCA CCT GTC CTG A 3’ 
PDBI19R  5’ GGC TGG AGG AGG AAG CAA 3’ 
 
PDBI19F  5’ CCC CTG AGC CTG TGT ATC T 3’ 
PDBI20R  5’ TCC CAA ATG CAT GAG ACT CCA 3’ 
 
PDBI20F  5’ AAG GGA ATA TCC AGA GAC AGG A 3’  
PDBI21R  5’ TAA ATG CCA GCC CAT CAC GCA 3’ 
 
PDBI21F  5’ CGG TTA GAA GAT CCC TGA AG 3’ 
PDBI22R2  5’ TGT GCA CAA TTT CCT TGG CC 3’ 
 
PDBI22F  5’ ATG AGC CGG AGT GTG TGA AG 3’ 
PDBE23R  5’ GGG ACA GCT GAT AAG GGC AG 3’ 
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III) PCR and dHPLC conditions     
 
GENE EXON FORWARD REVERSE ANNEALING DHPLC TIME-SHIFT 
PRIMER PRIMER TEMPERATURE TEMPERATURE (SEC) 
PDGFRB 2 PDBI1F3 PDBI2R3 62 63, 64 0, -0.5 
 3 PDBI2F PDBI3R 60 61, 62, 63 -0.5, 0, 0.5 
 4 PDB13F PDBI4R 60 59, 60, 61 -0.5, 0, 0.5 
 5+6 PDBI4F PDBI6R 60 60, 61, 63 -0.5, 0, 1 
 7 PDBI6F PDBI7R2 62 64, 65 0.5, 1 
 8 PDBI7F PDBI8R 60 62, 63, 64 -0.5, 0, 0.5 
 9 PDBI8F PDBI9R 64 63, 64, 65 0, 0, 0.5 
 10 PDBI9F PDBI10R 60 64, 65, 66 0, 0.5, 1 
 11 PDBI10F PDBI11R 62 61, 62, 63 -0.5, 0, 0.5 
 12 PDBI11F PDBI12R 62 62, 63, 64 0, 0.5, 1 
 13 PDBI12F PDBI13R 62 60, 62, 63 -0.5, 0, 0.5 
 14 PDBI13F PDBI14R 64 63, 64 -0.5, 0 
 15 PDBI14F PDBI15R 60 62, 63, 64, 66 -0.5, 0, 0.5, 1 
 16 PDBI15F PDBI16R 60 60, 61, 62, 63 -0.5, 0, 0.5, 1 
 17+18 PDBI16F PDBI18R 62 60, 61, 62 -1, -0.5, 0 
 19 PDBI18F PDBI19R 60 60, 62, 63 -1, 0, 0.5 
 20 PDBI19F PDBI20R 62 60, 63, 64 -1.5, 0, 0.5 
 21 PDBI20F PDBI21R 62 60, 61, 62 -1, -0.5, 0 
 22 PDBI21F PDBI22R 58 61, 62, 63 -0.5, 0, 0.5 
 23 PDBI22F PDBI23R 62 62, 63, 64 0, 0.5, 1 
 
 
IV)   PDGFRB 
First step 
PDGFRB exon 15.1R  5’ agg tag tcc acc agg tct ccg ta 3’ 
Nested  
 PDGFRB exon 14.1R  5’ aag ggc ttg ctt ctc act gct gcg 3’ 
 
 
V)  Sequencing 
M13F    5’ gta aaa cga cgg cca g 3’ 
 M13R    5’ cag gaa aca gct atg ac 3’ 
 
 
VI)  Fusion 
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GOLGA4 exon 8.1F  5’ act tat cac tca gtt gcg tga tg 3’ 
PDGFRB exon 12.1R  5’ acc ttc cat cgg atc tcg taa cgt  3’ 
 
Reciprocal 
GOLGA4 exon 10.1R  5’ ttc ctg ttg aag act gat gcg tt 3’ 
PDGFRB exon 9.1F  5’ aca tca tct ggt ctg cct gca g 3’ 
 
 
VII)   PDGFRB 
 PDB.I11.1R   5’ gag agc agg cca tga gca aac 3’ 
 PDB.I11.1aR    5’ gag acc ccc agc ctg atg aat 3’ 
 PDB.I11.2R   5’ cat gag gtc cta tgg aac tca tt 3’ 
 PDB.I11.3R   5’ tcc cgc tca ggc ttt agt cac 3’ 
 PDB.I11.4R   5’ ggc agc tct aga cag gca cg 3’ 
 PDB.I11.5R    5’ aag gtg tgc tcc aat tat atg ctt 3’ 
 PDB.I11.6R    5’ cag gca tag tgc aca ggt gta 3’ 
 PDB.I11.7R    5’ tgc cag aat gtg ttc cta tgc at 3’ 
 
 
VIII) GOLGA4 
 (Note: all primers are designed in intron 10, just labelled wrong) 
 gGOLGA4.I9.1F   5’ tct taa cta tag agg ctc cta ata a 3’ 
 gGOLGA4.I9.2F  5’ gaa gac tga ctt gaa gca gtt tg 3’ 
gGOLGA4.I9.3F   5’ cag aac tgt tca agt agg aag tg 3’ 
gGOLGA4.I9.4F   5’ ctt tgg ctc act tat tct gga tgt 3’ 
gGOLGA4.I9.5F   5’ tct tat cat ggg tac tta gaa taa g 3’ 
gGOLGA4.I9.6F   5’ cca tgg atg tga gtg aac ctc a 3’ 
gGOLGA4.I9.7F   5’ caa tgg agc tcg atc cat ttc ag 3’ 
gGOLGA4.I9.8F   5’ tca atg gta gag gga agg ctg g 3’ 
gGOLGA4.I9.9F   5’ gca gaa aat tat atc taa aca gga ac 3’ 
gGOLGA4.I9.10F   5’ gtg cca agt tac aca cct gtt g 3’  
 gGOLGA4.I9.11F   5’ tta tac agt aca gaa ata ggg aca t 3’ 
 
 
IX)   GOLGA4 RT-PCR 
 
cGOLGA4.exon 10.1F  5’ cag atg act acc cag gga gag 3’ 
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X)  GOLGA4 genomic fusion 
  
gGOLGA4.I9.7F  5’ caa tgg agc tcg atc cat ttc ag 3’ 
PDB.I11.Brkpt.R  5’ aac aga tgt ctg gga att agg ca 3’ 
 
  
 
XI)  Reciprocal PDGFRB 
 PDB.I11.recip.F   5’ gtg agt ccc cag cct cag tg 3’ 
 PDB.I11.recip.2F  5’ atg cat agg aac aca ttc tgg ca 3’ 
 
  Reciprocal GOLGA4 
 gGOLGA4.I9.recip.R  5’ gat tcc tat tct aac ttt act g 3’ 
 
 
XII)  RT-PCR Fusion 
 
cGOLGA4 exon 7.1F  5’ tcc agc aaa gag tga agc gtc a 3’  
PDGFRB exon 12.1R  5’ acc ttc cat cgg atc tcg taa cgt 3’ 
 
 
XIII)   KIAA1449  
 KIAA1449.2F   5’ cat acc gag tcc atg atg aag 3’ 
PDGFRB.exon15.2R  5’ tgc tgc agg aag gtg tgt ttg ttg 3’ 
 
 
XIV)   Bin2-PDGFRB construct primers 
Full-length fusion amplification 
Bin2-PDB.Fus.1F  5’ agt tgg cag gat ggc aga ggg 3’ 
Bin2-PDB.Fus.2F  5’ gtt ggc agg atg gca gag g 3’ 
Bin2-PDB.Fus.2R  5’ acg gcc cct gca gtt ttc tt 3’ 
 
Overlapping primers for sequencing 
M13F & M13R   (as previous – section V) 
Bin.e5.1F   5’ ttg gga aga cta cga gga 3’ 
Bin.e9.1F  5’ cta cga ggt gat gag caa 3’ 
PDB.e15.2F  5’ caa caa aca cac ctt cct gca gca 3’ 
PDB.e18.1F  5’ att aca tct cca aag gca gca cct 3’ 
PDB.e15.2R   5’ tgc tgc agg aag gtg tgt ttg ttg 3’ 
 
pcDNA3.1(+) vector primers 
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T7 F    5’ taa tac gac tca cta tag gg 3’ 
BGH R  5’ tag aag gca cag tcg agg 3’ 
 
 
XV)   GOLGA4-PDGFRB construct primers 
 
Fragment 1 construct amplification (GOLGA4 only) 
NheI.1F  5’ tac gct agc cca tgt tca aga aac tg 3’ 
cGOLGA4.e10.3R  5’ cct ctc cct ggg tag tca tct g 3’ 
 
Overlapping primers for sequencing fragment 1 
M13F & M13R  (as previous – section V) 
BC/GOL.3F   5’ tgg aac gaa gct taa gta gct ac 3’ 
BC/GOL.2F  5’ gca cag aag ctc cag ctc cg 3’ 
cGOLGA4.e6.2F  5’ tgc atc ttt aga gga gaa aga tca 3’ 
 
Fragment 2 construct amplification (GOLGA4 only) 
cGOLGA4.e7.1F 5’ tcc agc aaa gag tga agc gtc a 3’ 
PDGFRB.e15.1R  (as previous – section IV) 
cGOLGA4.e8.1F 5’ tta tca ctc agt tgc gtg atg ca 3’ 
 
 
XVI)   STRN-PDGFRA fusion primers 
 
Fusion 
STRN.Fusion.Ex6.1F  5’ tct gag tta aca gat tct gcc tc 3’ 
PDGFRA.Fusion.Ex12.2R  5’ caa gca cta gtc cat ctc ttg g 3’ 
 
Reciprocal 
PDGFRA.recip.Ex11.1F  5’acg gtg gct gct gca gtc ct 3’ 
STRN.Recip.Int6.1R   5’act ata ttc atc tgc ccc ata gaa 3’ 
 
 
XVII)  ETV6-PDGFRA fusion primers 
Genomic DNA Fusion 
ETV6.Fusion.Int6.4F   5’ ctt cta aga agg cag tgg gta at 3’ 
PDGFRA.fusion.Ex12.1R  5’ cca gcg aat ttc ata cct cgg 3’ 
 
mRNA Fusion 
ETV6.Fusion.Ex6.1F:  5’ act gta gac tgc ttt ggg att ac 3’ 
PDGFRA.Fusion.Ex12.2R  5’ caa gca cta gtc cat ctc ttg g 3’ 
 
Reciprocal 
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PDGFRA.recip.Ex11.1F  5’ acg gtg gct gct gca gtc ct 3’ 
ETV6.Recip.Ex7.1R  5’ ttg tag tag tgg cgc agg gct 3’ 
 
 
XVIII)   STRN-PDGFRA & ETV6-PDGFRA MRD primers 
 
STRN Fusion – SINGLE STEP 
STRN.Fusion.Ex6.1F  5’ tct gag tta aca gat tct gcc tc 3’ 
PDGFRA.Fusion.Ex12.2R  5’ caa gca cta gtc cat ctc ttg g 3’ 
 
STRN Fusion – NEST STEP 
STRN.Ex.6.2F   5’ tct gag tta aca gat tct gcc tc 3’  
PDGFRA.STRN.Ex12.1R  5’ cac tag tcc atc tct tgg aaa ct 3’  
 
 
ETV6 Fusion – SINGLE STEP 
ETV6.Fusion.Ex6.1F:  5’ act gta gac tgc ttt ggg att ac 3’ 
PDGFRA.Fusion.Ex12.2R  5’ caa gca cta gtc cat ctc ttg g 3’ 
 
ETV6 Fusion – NEST STEP 
ETV6.Ex6.2F    5’att ccg gat agt gga tcc caa c 3’ 
PDGFRA.STRN.Ex12.1R  5’ cac tag tcc atc tct tgg aaa ct 3’  
 
 
XIX)    MLPA cDNA oligonucleotides 
Labelled primer 
Target sequence X 
Target sequence Y 
Stuffer Sequence 
Other Primer 
 
 
1. FGFR1 intracellular (exons 12/13) (95bp) 
 
A: GGG TTC CCT AAG GGT TGG AGC ATG GAG TAT CTG GCC TCC 
AAG AAG  
 
B: TGC ATA CAC CGA GAC CTG GCA GCC CTG TCT AGA TTG GAT 
CTT GCT GGC AC 
 
 
 329
2. FGFR1 extracellular (exons 3/4) (100bp) 
 
A: GGG TTC CCT AAG GGT TGG AGA GCC ATA ACA CCA AAC CAA 
ACC GTA TGC  
 
B: CCG TAG CTC CAT ATT GGA CAT CCC GAA TCT CTA GAT TGG 
ATC TTG CTG GCA C 
 
 
3. PDGFRB intracellular (exons 20/21) (105bp) 
 
A: GGG TTC CCT AAG GGT TGG AGT ACT ACG CCT GCC CAT GCC 
TCC GAC GAG AT 
 
B: CTA TGA GAT CAT GCA GAA GTG CTG GCA CTA TGT CTA GAT 
TGG ATC TTG CTG GCA C 
 
 
 
 
4. PDGFRB extracellular (exons 4/5) (110bp) 
 
 
A: GGG TTC CCT AAG GGT TGG ACT GAC GTA CGC CTA CTA TGT 
CTA CAG ACT CCA GG  
 
B: TGT CAT CCA TCA ACG TCT CTG TGA CCT AGC TGA GTC TAG ATT 
GGA TCT TGC TGG CAC  
 
 
5. PDGFRA intracellular (exons 20/21) (115bp) 
 
A: GGG TTC CCT AAG GGT TGG AGT ATG ACT GTA CCG CCT GAC 
CAC GCT ACC AGT GAA GT  
 
B: CTA CGA GAT CAT GGT GAA ATG CTG CTG ACA TAG CAG TCT 
AGA TTG GAT CTT GCT GGC AC 
 
 
6. PDGFRA extracellular (exons 2/3) (120bp) 
 
A: GGG TTC CCT AAG GGT TGG ACA CTC TAG GTA CGT GTG GTC 
TTA GGC TGT CTT CTC ACA G  
 
B: GGC TGA GCC TAA TCC TCT GCC AGC GTC AGA GAC CGA TAC 
TCT AGA TTG GAT CTT GCT GGC AC 
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7. ABL C-terminal domain (exons 8/9) (125bp) 
 
A: GGG TTC CCT AAG GGT TGG AGC TGA ATC AGA CCT ACC AGG 
TCT ATG AAC TCA TGC GAG CAT  
 
B: GTT GGC AGT GGA ATC CCT CTG ACC CAG TCA ACA GGC TCG 
ATC TCT AGA TTG GAT CTT GCT GGC AC  
 
 
8. ABL 1b start (exons 1b/a2) (130bp) 
 
A: GGG TTC CCT AAG GGT TGG AGC TAC CGC TAC AAG TTC TAG 
GGT CCA CAC TGC AAT GTT TTT GTG  
 
B: GAA CAT GAA GCC CTT CAG CGG CCA CTA GAT CCA TTA TCG 
TAT ACT CTA GAT TGG ATC TTG CTG GCA C  
 
 
XX)   Cryptic ETV6-PDGFRB fusion primers  
 
Fusion 
ETV6.Ex6.2F 5’ATT CCG GAT AGT GGA TCC CAA C 3’ 
PDGFRB.Ex14R  5’- CCC CAA CAG GTT GAC CAC GTT CAG -3’ 
 
Genomic Fusion 
ETV6.E1026.Int7.1F  5’ AGG ATA GGA TAG GAT AGA GTT 
GAA -3’ 
ETV6.E1026.Int7.2F  5’ AAT GCC AGA CTG CAT GAC ATG -3’ 
PDGFRB.Exon 12R 5’- CCA CGT AGA TGT ACT CAT GGC -3’ 
 
 
XXI)  Primer sequences designed to amplify the kinase domain 
of the RTKs EPHA1, EPHB6 & Met     
 
EPHA1.Ex12F  5’ tgg aag gcg tcg tca caa agc 3’ 
EPHA1.Ex16R 5’ cca tcc tca atg ctc ttc ata ac 3’  
 
EPHB6.Ex11F  5’ gat cct gct tat atc aag att gag 3’ 
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EPHB6.Ex14R 5’ tat gct ttc cat gtg caa tga cc 3’ 
 
Met.Ex15F   5’ gac aag tgc agt atc ctc tga c 3’ 
Met.Ex19R  5’ cca tcc act tca ctg gca gct 3’ 
 
 
XXII)  EPHA1 genomic DNA primers to screen the whole gene 
          
Primer name Primer sequence 
EPHA1.5'UTRF  gacgcctccggttcttgaatttga 
EPHA1.i1R aacatggcccctaggaatg 
EPHA1.i1F tctttggtctttaaccccaagcg 
EPHA1.i2R ctctgttcctccacccacctctc 
EPHA1.i2F gggatgatctggtccctgactct 
EPHA1.i3R ccttctctggcacccaataagga 
EPHA1.i3F agaagcggactttgccattgct 
EPHA1.i4R gtactcctgcaatcctcccgagt 
EPHA1.i4F tggtggtggttctgcctgtaaaa 
EPHA1.i5R ccaaccctgacaaagtctcagca 
EPHA1.i5F gaggacatcgagaattgggtggt 
EPHA1.i6R tatggcttcctgcccatcagttt 
EPHA1.i6F gatgggcaggaagccatagaaaa 
EPHA1.i7R ggcatggacactgaagaccatct 
EPHA1.i7F ggctcagcactgcccacttaat 
EPHA1.i8R aggtgtatgtgtgttggggcaga 
EPHA1.i8F gatgggcaggaagccatagaaaa 
EPHA1.i9R ggcatggacactgaagaccatct 
EPHA1.Int8.1F cctacggactgtgagtcccaaca 
EPHA1.Int9.1R tactaggggatgggagggtcgtt 
EPHA1.Int9.1F tctggggaagattcagccagagt 
EPHA1.Int10.1R gatcccttcccagtggcatctc 
EPHA1.Int10.1F cctgatgttggtactccccaacc 
EPHA1.Int11.1R ctgctggtggctctgtgctg 
EPHA1.Int11.1F gggccacagcctgttttctttc 
EPHA1.Int12.1R agctgagggagaccactcatcgt 
EPHA1.Int12.1F gaaagaggggtgaaaccactgga 
EPHA1.Int13.1R cagctagtcctctgccctcctca 
EPHA1.Int13.1F ccatcccctgactcacccact 
EPHA1.Int14.1R catgttacggggcaatgtgaatg 
EPHA1.Int14.1F ccctgacccatgtgccttcttag 
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EPHA1.Int15.1R gggaggaccttgggaggaaataa 
EPHA1.Int15.1F tttctcatgggcctccaggttag 
EPHA1.Int16.1R ctgcctctgggttccctagtcct 
EPHA1.Int16.1F gccaaccagatcagcccatgta 
EPHA1.Int17.1R cccagacagctccagctccttac 
EPHA1.Ex17.1F caccatggagtgtgtgctgga 
EPHA1.Ex 18.1R agggttctcctgaaagtgggc 
 
 
Primer name Primer sequence 
EPHB6.Int5'UTR.F aggatgcagcagcttcttaacca 
EPHB6.Int.1R gcctactccctgtgtgaccctgt 
EPHB6.Int.1F cctgcctcttctggtcttgtgtg 
EPHB6.Int.2R acttccccctttcactgggtctc 
EPHB6.Int.2F gccactgtgtgcccctcttattt 
EPHB6.Int3R aatcctcacccagggtttccttc 
EPHB6.Int.3F ctaaagcttctcctggcccttcc 
EPHB6.Int4R caattgtgtccaccttggtccag 
EPHB6.Ex4F ccgggagaccttcaccctttact 
EPHB6.Int.5R aagtgcaagacgagtgggctct 
EPHB6.Int5F cgaggatacctgcctgctgtgt 
EPHB6.Int6R acttctggcccctctccaagtct 
EPHB6.Int6F ggctccttccttcctcaatcac 
EPHB6.Int.7R ccaggctggagatcaggagtagg 
EPHB6.Int.7F atcctgctcccagggactcctat 
EPHB6.Int.8R tgaggcctatgagctcctaccag 
EPHB6.Int 7.1F cagggagtgagtggctgttaccc 
EPHB6.Int 8.1R actacccacttgggccttcacct 
EPHB6.Int 8.1F gcacatgaacaagcacctgtgag 
EPHB6.Int 9.1R acttggcaggacttgaggtttgg 
EPHB6.Int 9.1F gtcatccccagtcaccgttttgt 
EPHB6.Int 10.1R gcccacttacctccagaaggttg 
EPHB6.Int10.1F ctgcctttcacaacacgctcataa 
EPHB6.Int11.1R cctgctgtgtttggatgggact 
EPHB6.Int11.1F agggccaaagcagggatcag 
EPHB6.Int12.1R cctcgtctcctggaagctttcc 
EPHB6.Int12.1F ccgtctccgatcactgacctct 
EPHB6.Int13.1R gtgtccccaaggctgtgctct 
EPHB6.Int13.1F gtaaaacccttggcatatctgagcac 
EPHB6.Int14.1R ggtgggaaatcagcagtgtctagg 
EPHB6.Int14.1F agcccaccctcttacccaacaa 
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EPHB6.Int15.1R agcagggtcaaggtctcct 
EPHB6.Int15.1F agaggagaccttgaccctgcttg 
EPHB6.Int16.1R cagcttctccgagatccccaata 
EPHB6.Int16.1F tattggggatctcggagaagctg 
EPHB6.Ex17.1R atgtcccttctcggaccagtgtc 
 
 
  
Primername Primersequence 
MET.5UTR.F tctccggctgtgctaacttcagac 
MET.Int1.1R gtctcttcagtttccgaagccccta 
MET.Int1.1F tccagttgggaagctttatttctga 
MET.Int2.2R tctgaaatgtcacgaacatgcaaa 
MET.Int2.1F gccattatcctccaggctctgaaa 
MET.Int3.1R ggcttcattgtttggctttcagtc 
MET.Int3.1F gaggggaactgttgggtcttcagt 
MET.Int4.1R aagggccaagtgacactggttgta 
MET.Int4.1F ccgttatgacaggatttgcacaca 
MET.Int5.1R catgtatgccagctgttagagattcc 
MET.Int5.1F tgtcccatctttggatctcctgaa 
MET.Int6.1R tgtgacaggccaagacccttttta 
MET,Int6.1F tgcttgctattcaaagcagtcagc 
MET.Int7.1R tggaggggagataaaaacaaaacaaa 
MET.Int7.1F tttgttttgtttttatctcccctcca 
MET.Int8.1R ttctccacacacacacacaaaaca 
MET.Int8.1F gcttccactcaggaaattcccact 
MET.Int9.1R ttggaaagaagccttcaaaagcaa 
MET.Int9.2F tttgtcctgcctgctttacacaca 
MET.Int10.2R tggttagaggcaaagatgcagagc 
MET.Int10.1F tgctatggatgttgccaagctgta 
MET.Int11.1R tttgtgtcccacatttgctacgtt 
MET.Int11.1F acaacatggcctgtgtttgcagta 
MET.Int12.1R aggaatgcaggctgagttgatgag 
MET.Int.12.2F tcctgaaggcagttatgccatttg 
MET.Int13.2R cttcgggcacttacaagcctatcc 
MET.Int13.2F attgtcgtcgattcttgtgtgctg 
MET.Int14.2R ttcaatgtttgggcttcaacaggt 
MET.Int.14.1F gctcttcctgtttcagtccccatt 
MET.Int15.1R ctgctctgtcagttgctttcacca 
MET.Int15.1F cgcagtgctaaccaagttctttcttt 
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MET.Int16.1R tgatttttccacaaggggaaagtg 
MET.Int.16.1F ctgcagtcaaaccctcaggacaag 
MET.Int17.1R gagcaggcctattttgaagggatg 
MET.Int17.1F caggcttgagccattaagaccaaa 
MET.Int18.1R tggattgtggcacagagattctgata 
MET.Int.18.1F aggccagatgaaatacttccttcaga 
MET.Int19.1R tgaagaaaactggaattggtggtg 
MET.Int19.1F tggtcacatctctcacctcatctgtc 
MET.Int20.1R cctttgaaggcatttctgta 
MET.Int20.1F gcctgccttcaaagggtctcttac 
MET.3UTR.1R ccaatatgacaggagtgttgtcacg 
 
 
 
XXIII)   PIK3CG primer sequences
  
PIK3CG.Codons.542.5.1F 5’ taa gca tca gcc cac ccc tga 3’ 
 PIK3CG.Codons 542.5.1R 5’ ctt gct gtc ccc att tca ctg a 3’ 
 
 PIK3CG.Codon 1007.2F  5’ ggc tta tct agc cct tcg tca tca 3’ 
 PIK3CG.Codon.1007.2R 5’ tgc aca gtc gat cct ttg tgg tct g 3’ 
 
 PIK3CG.Codon.1047.1F  5’ cct act gat cat cct gtt ctc c 3’ 
 PIK3CG.Codon.1047.1R 5’ gca ttt gaa atc caa gtt cga tg 3’ 
 
 
XXIV)   c-CBL RING finger domain primers 
   
CBL.Int7.1F 5’ tgt ggt ttc act tta aac cct gga 3’ 
  CBL.Int8.1R 5’ gc cag gcc acc cct tgt atc 3’ 
      
  CBL.Int8.1F  5’ ggc ctg gct ttt ggg tta gg 3’ 
  CBL.Int9.1R  5’ ca caa tgg att ttg cca gtc tcc 3’ 
 
 
XXV)   c-CBL cDNA primers 
   
CBL.Ex6/7.F   5’ ggc tc agg gaa ggc ttc ta 3’ 
  CBL.Ex10/11.R  5’ gcc aga agc agc ctt aga agc a 3’ 
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XXVI)   NRAS primers 
2       f: 5’gat gtg gct cgc caa tta ac 3’ 
                     r: 5’tgc ata act gaa tgt ata ccc aaa 3’ 
 
  3          f: 5’ttg cat tcc ctg tgg ttt tt 3’ 
r: 5’cct cat ttc ccc ata aag att c 3’ 
 
  4      f: 5’cct ccc aaa gtg ctg aga tt 3’ 
r: 5’gca aac tct tgc aca aat gc 3’ 
 
  5       f: 5’tgg aat ctt atg tcc aca taa aga 3’ 
r: 5’tca gaa agg gtg tca tat gga 3’ 
 
These primers cover the entire coding sequence of the NRAS gene, however only 
primers to exons 2 & 3 were used to look at the mutation hotspots at codons 12, 
13 and 61. 
 
 
XXVII)   c-CBL intronic primers to amplify exons 8 & 9 
  
CBL.i7F 5’ tgt ggt ttc act tta aac cct gga 3’ 
 
               CBL.i9R 5’ca caa tgg att ttg cca gtc tcc 3’  
 
 
 
 336
List of Publications  
 
Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic 
leukaemia.
Curtis CE, Grand FH, Musto P, Clark A, Murphy J, Perla G, Minervini MM, Stewart 
J, Reiter A, Cross NC. 
Br J Haematol. 2007 Jul;138(1):77-81. 
 
A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient 
with an imatinib responsive chronic myeloproliferative disease.
Curtis CE, Grand FH, Waghorn K, Sahoo TP, George J, Cross NC. 
Leukemia. 2007 Aug;21(8):1839-41. Epub 2007 May 17.  
 
The t(1;9)(p34;q34) and t(8;12)(p11;q15) fuse pre-mRNA processing proteins SFPQ 
(PSF) and CPSF6 to ABL and FGFR1.
Hidalgo-Curtis C, Chase A, Drachenberg M, Roberts MW, Finkelstein JZ, Mould S, 
Oscier D, Cross NC, Grand FH. 
Genes Chromosomes Cancer. 2008 May;47(5):379-85. 
 
Frequent CBL mutations associated with 11q acquired uniparental disomy in 
myeloproliferative neoplasms.
Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire C, Kreil S, Jones A, 
Score J, Metzgeroth G, Oscier D, Hall A, Brandts C, Serve H, Reiter A, Chase AJ, 
Cross NC. 
Blood. 2009 Apr 22. [Epub ahead of print] 
 
Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following 
screening for PDGFRA overexpression in patients with hypereosinophilia.
Score J, Curtis C, Waghorn K, Stalder M, Jotterand M, Grand FH, Cross NC. 
Leukemia. 2006 May;20(5):827-32. 
 
Durable responses to imatinib in patients with PDGFRB fusion gene-positive and 
BCR-ABL-negative chronic myeloproliferative disorders.
337 
David M, Cross NC, Burgstaller S, Chase A, Curtis C, Dang R, Gardembas M, 
Goldman JM, Grand F, Hughes G, Huguet F, Lavender L, McArthur GA, Mahon FX, 
Massimini G, Melo J, Rousselot P, Russell-Jones RJ, Seymour JF, Smith G, Stark A, 
Waghorn K, Nikolova Z, Apperley JF. 
Blood. 2007 Jan 1;109(1):61-4. Epub 2006 Sep 7. 
Transient response to imatinib in a chronic eosinophilic leukemia associated with 
ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene.
Walz C, Curtis C, Schnittger S, Schultheis B, Metzgeroth G, Schoch C, Lengfelder E, 
Erben P, Müller MC, Haferlach T, Hochhaus A, Hehlmann R, Cross NC, Reiter A. 
Genes Chromosomes Cancer. 2006 Oct;45(10):950-6. 
 
Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by 
analysis of patient-specific genomic DNA fusion junctions.
Score J, Walz C, Jovanovic JV, Jones AV, Waghorn K, Hidalgo-Curtis C, Lin F, 
Grimwade D, Grand F, Reiter A, Cross NC. 
Leukemia. 2009 Feb;23(2):332-9. Epub 2008 Nov 6. 
 
Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R 
signaling abnormalities in the cell line GDM1.
Chase A, Schultheis B, Kreil S, Baxter J, Hidalgo-Curtis C, Jones A, Zhang L, Grand 
FH, Melo JV, Cross NC. 
Leukemia. 2009 Feb;23(2):358-64. Epub 2008 Oct 30. 
 
Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by 
analysis of patient-specific genomic DNA fusion junctions.
Score J, Walz C, Jovanovic JV, Jones AV, Waghorn K, Hidalgo-Curtis C, Lin F, 
Grimwade D, Grand F, Reiter A, Cross NC. 
Leukemia. 2009 Feb;23(2):332-9. Epub 2008 Nov 6. 
 
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative 
disorders.
Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase 
AJ, Grand FH, White H, Zoi C, Loukopoulos D, Terpos E, Vervessou EC, Schultheis 
B, Emig M, Ernst T, Lengfelder E, Hehlmann R, Hochhaus A, Oscier D, Silver RT, 
Reiter A, Cross NC. 
Blood. 2005 Sep 15;106(6):2162-8. Epub 2005 May 26. 
338 
 Minimal molecular response in polycythemia vera patients treated with imatinib or 
interferon alpha.
Jones AV, Silver RT, Waghorn K, Curtis C, Kreil S, Zoi K, Hochhaus A, Oscier D, 
Metzgeroth G, Lengfelder E, Reiter A, Chase AJ, Cross NC. 
Blood. 2006 Apr 15;107(8):3339-41. Epub 2005 Dec 13. 
 
339 
Two novel imatinib-responsive PDGFRA fusion genes
in chronic eosinophilic leukaemia
FIP1L1-PDGFRA is currently the most common abnormality
in chronic eosinophilic leukaemia (CEL), being seen in
approximately 12% of cases with a provisional diagnosis of
idiopathic hypereosinophilic syndrome (Cools et al, 2003;
Griffin et al, 2003; Score et al, 2006). Other abnormalities
associated with CEL include a variety of translocations and
fusion genes involving PDGFRA at 4q12, PDGFRB at 5q31-33,
FGFR1 at 8p11 or JAK2 at 9p24 (Reiter et al, 2007).
Identification of patients that harbour PDGFRA or PDGFRB
fusions is particularly important as they usually respond very
well to targeted therapy with imatinib (Cools et al, 2003; Reiter
et al, 2007). To date, four fusion partners have been identified
for PDGFRA: BCR, FIP1L1, KIF5B and CDK5RAP2 (Baxter
et al, 2002; Cools et al, 2003; Score et al, 2006; Walz et al,
2006). Here, we report two patients with imatinib responsive
CEL who presented with acquired chromosomal rearrange-
ments of 4q.
Patients and methods
Patients
Case 1 had CEL and has been described in detail elsewhere
(Musto et al, 2004). Briefly, a 64-year-old male presented with
an eosinophil count of 12 · 109/l and a bone marrow
indicative of a myeloproliferative disorder (MPD). Cytogen-
etics revealed a t(2;4)(p24;q12) in 60% of bone marrow
metaphases. Haematological and cytogenetic remission was
achieved following treatment with 100 mg imatinib daily. This
dose was continued for 9 months and then progressively
reduced to 100 mg on alternate days followed by 100 mg twice
a week. Following 24 months of imatinib, he refused further
therapy despite not having any significant side effects. Elevated
eosinophil counts were again detected 14 months after
discontinuation of treatment.
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Summary
We identified two patients with a t(2;4)(p24;q12) and a t(4;12)(q2?3;p1?2),
respectively, in association with BCR-ABL and FIP1L1-PDGFRA negative
chronic eosinophilic leukaemia. Molecular analysis revealed a novel STRN-
PDGFRA fusion for the t(2;4) and ETV6-PDGFRA for the t(4;12). The
fusions were confirmed by specific amplification of the genomic breakpoints,
reverse transcription polymerase chain reaction and fluorescence in situ
hybridisation. Both patients were treated with imatinib and, following a rapid
haematological response, achieved cytogenetic remission and a major
molecular response. In conclusion, PDGFRA fuses to diverse partner genes
in myeloid disorders. Identification of these fusions is important as they are
particularly sensitive to imatinib.
Keywords: PDGFRA, ETV6, STRN, chronic eosinophilic leukaemia,
imatinib.
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Case 2 was a 51-year-old male who presented with late onset
asthma and type 2 diabetes. He had an eosinophil count of
12Æ9 · 109/l and a hypercellular bone marrow suggestive of an
MPD. Cytogenetics revealed a t(4;12)(q2?3;p1?2) in 100% of
bone marrow metaphases. The patient was managed with
hydroxycarbamide for over 7 years but with recurrent prob-
lems due to anaemia, thrombocytopenia and very poor control
of the eosinophil count. Cytogenetic analysis at 6 years after
diagnosis showed 46,XY,t(4;12)(q2?3;p1?2)[14]/46,XY[6].
Following the molecular diagnosis detailed below, hydroxy-
carbamide was stopped and imatinib started at 100 mg daily.
The full blood counts completely normalised within 4 weeks,
resulting in significant resolution of symptoms (apart from the
asthma) and greatly improved quality of life. Cytogenetic
analysis was performed 9 months later and indicated complete
cytogenetic remission (30 metaphases).
Polymerase chain reaction (PCR) and reverse transcription
polymerase chain reaction (RT-PCR)
Conditions for amplifying PDGFRA rearrangements by bubble
PCR have been described in detail elsewhere (Score et al,
2006). Primers used to detect STRN-PDGFRA DNA were
STRN.Fusion.Ex6.1F (5¢-TCTGAGTTAACAGATTCTGC-
CTC3-¢) and PDGFRA.Fusion.Ex12.2R (5¢-CAAGCACTAGT-
CCATCTCTTGG3-¢) Primers for ETV6-PDGFRA mRNA from
random hexamer reverse transcribed cDNA were ETV6.Fusio-
n.Ex6.1F: 5¢-ACTGTAGACTGCTTTGGGATTAC3-¢ and
PDGFRA.Fusion.Ex12.2R. Primer sequences for analysis of
reciprocal breakpoints and minimal residual disease (MRD)
are available on request.
Fluorescence in situ hybridisation (FISH)
Fluorescence in situ hybridisation (FISH) was performed using
bacterial artificial chromosome (BAC) clones selected from
sequences flanking PDGFRA and ETV6 (http://www.ensembl.
org) or commercially available probe sets. BAC DNA was
grown, extracted and labelled by nick translation with digo-
xygenin or biotin-16-2¢deoxy-uridine-5¢-triphosphate (Roche,
East Sussex, UK) and hybridised using standard procedures.
Case 2 was analysed using BACs RP11-24O10 (3¢ of PDGFRA);
RP11-434C1 (5¢ of ETV6).
Results
Bubble PCR to identify PDGFRA rearrangements
Both cases were negative for BCR-ABL and FIP1L1-PDGFRA
by RT-PCR or FISH analysis using standard procedures. The
presence of a 4q translocation in conjunction with persistent
eosinophilia suggested that PDGFRA might be involved. As the
genomic breakpoints for all cases involving this gene thus far
reported are tightly clustered within or close to PDGFRA exon
12 (Reiter et al, 2007) we investigated the possibility that
PDGFRA was rearranged, by bubble PCR. As shown in Fig 1A,
rearranged bands were detected for both cases 1 and 2.
Identification and confirmation of the STRN-PDGFRA
fusion
Sequencing of the rearranged allele for case 1 identified a novel
fusion between STRN (STRN; NM_003162) intron 6 and a
truncated PDGFRA exon 12. To confirm the fusion, a 285 bp
product was amplified from patient genomic DNA but not
from control DNA. A reciprocal PDGFRA-STRN fusion
product was not detected with various primer combinations
using either single step or nested PCR. Identification of the
mRNA fusion was not possible due to lack of adequate patient
material, however analogous PDGFRA breakpoints for FIP1L1-
PDGFRA usually result in the use of cryptic splice sites within
PDGFRA exon 12 downstream of the breakpoint. Two
potential AG splice acceptor sites would produce in-frame
mRNA fusions with STRN exon 6 and it is likely that either or
both of these might represent the real mRNA fusion in case 1
(Fig 1B).
Identification and confirmation of the ETV6-PDGFRA
fusion
Sequencing of the rearranged bubble PCR band from case 2
identified a second novel fusion between ets-variant gene 6
(ETV6; NM_001987) intron 6 and PDGFRA intron 11. To
confirm the fusion a 210 bp product was specifically amplified
from case 2 peripheral blood genomic DNA but not from
control DNA using breakpoint-specific primers. A reciprocal
PDGFRA-ETV6 fusion product was not detected with various
primer combinations with either single or nested PCR.
Expression of ETV6-PDGFRA was confirmed by single-step
PCR from case 2, yielding a 276 bp product that was not
observed in normal control cDNA. Sequencing of the product
revealed an in-frame whole exon fusion between ETV6 exon 6
and PDGFRA exon 12 (Fig 2A). To further confirm the
presence of the ETV6-PDGFRA fusion, two-colour interphase
FISH analysis was performed. On normal cells BACs RP11-
24O10 and RP11-434C1 gave four separate signals corres-
ponding to the normal chromosomes 4 and 12. However, in
56% of cells for case 2, overlapping probe signals consistent
with co-localisation of ETV6 and PDGFRA were observed
(Fig 2B).
Response to imatinib
For cases 1 and 2, peripheral blood was analysed approximately
28 and 9 months after starting imatinib respectively. MRD was
not detected using cDNA or genomic DNA for case 1,
indicating the achievement of molecular remission. For case 2,
analysis was only performed using genomic DNA. Of four
replicate reactions, two were positive indicating low-level
disease consistent with a major molecular response.
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Discussion
This study has characterised the genomic breakpoints in two
CEL cases with chromosome 4q rearrangements and identified
STRN at 2p22 and ETV6 at 12p13 as novel PDGFRA fusion
partners. This brings the number of known PDGFRA partner
genes to six, with PDGFRA being the tenth tyrosine kinase
reported to fuse to ETV6. As these fusions were referred
specifically for investigation of 4q rearrangements and were
not part of a series that underwent systematic cytogenetic
investigation, it is not possible to accurately determine the
frequency of these abnormalities. However, we estimate that
they probably account for <1% of CEL cases.
STRN encodes striatin, a 780 amino acid member of the
calmodulin-binding WD repeat family of proteins. It has four
protein–protein interaction domains, a caveolin binding
domain (55–63aa), a coiled-coil domain (70–116aa), a calcium
dependent calmodulin-binding domain (149–166aa) and a
series of WD repeat motifs (419–780aa) (Bartoli et al, 1998).
Striatin is thought to be a scaffolding protein that targets
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Fig 1. Characterisation of STRN-PDGFRA. (A) Left panel: Bubble PCR strategy showing PCR primers and restriction sites in the region where all
breakpoints have been reported to fall; right panel: Nested bubble PCR gel after digestion with HaeIII and RsaI. The normal controls show the
expected germline bands of 1011 and 648 bp respectively (the distance between primer PDAI12-R4 and the relevant restriction site plus 33 bp
contributed by the bubble oligo). Smaller bands are visible for cases 1 and 2 after HaeIII digestion and for case 2 after RsaI digestion derived from the
rearranged allele. The normal allele is not always visible due to out competition in the amplification reaction. (B) Electropherogram of the genomic
DNA junction amplified by bubble PCR, the two predicted in frame STRN-PDGFRA mRNA fusions and gel showing amplification of STRN-PDGFRA
but not the reciprocal genomic DNA fusion specifically from case 1. (C) Structure of Pdgfra, Striatin and the predicted fusion protein. Relevant
domains are shown: transmembrane (tm), WW-like (WW) and tyrosine kinase domains for Pdgfra; coiled-coiled region and WD40 repeats for
striatin; partially deleted WW domain for striatin-Pdgfra (DWW).
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proteins, such as the oestrogen receptor to the cell membrane,
facilitating the assembly of other proteins required for rapid
receptor activation (Lu et al, 2004). In case 1, we identified a
DNA fusion of STRN intron 6 to a truncated PDGFRA exon 12
and thus the large region of WD repeat motifs within striatin
are not retained in the fusion. However, the N-terminal coiled-
coil domain remains that may act as an oligomerisation motif,
constitutively activating the Pdgfra-derived tyrosine kinase
moiety (Fig 1C). Alternatively, truncation of the WW-like
domain may be the critical activating event (Stover et al,
2006).
Etv6 (ets translocation variant 6) is a member of the ets
family of transcription factors and is frequently rearranged in
both myeloid and lymphoid malignancies (Bohlander, 2005).
ETV6 fuses to a second gene at 4q12, CHIC2/BTL in
undifferentiated AML (Cools et al, 1999). Since PGFRA and
CHIC2/BTL are only 200 kb apart, ETV6-PDGFRA and ETV6-
CHIC2 would be expected to have a cytogenetically indistin-
guishable t(4;12)(q12;p13), however our case was reported to
have a t(4;12)(q2?3;p1?2) which suggests that the rearrange-
ment may have been more complex.
In common with other PDGFRA fusions, we found that
STRN disrupts the region encoding negative regulatory
WW-like domain of Pdgfra. In contrast, for ETV6-PDGFRA
the WW-like domain is intact (Fig 2C). Recently, Stover et al
(2006) showed that truncation of the PdgfraWW-like domain
is sufficient to activate the kinase in the absence of an
oligomerisation domain provided by the partner protein. An
artificial ETV6-PDGFRA fusion that retained the region
encoding the WW-like domain transformed Ba/F3 cells to
growth factor independence, indicating that autoinhibition by
the WW-like domain can be overcome by enforced
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Fig 2. Characterisation of the ETV6-PDGFRA fusion. (A) Electropherogram of the genomic DNA junction amplified by bubble PCR; mRNA fusion
between ETV6 exon 6 and PDGFRA exon 12 as determined by sequence analysis of case 2 RT-PCR product and gel showing amplification of ETV6-
PDGFRA specifically from genomic DNA of case 2. (B) Relative positions of FISH probes with the orientation of each gene indicated by the arrows.
A normal cell shows four distinct signals whereas 56% of cells from case 2 showed a fused red/green signal indicative of the t(4;12). (C) Structure of
Pdgfra, Etv6 and the predicted fusion protein. The pointed and ETS domains are shown for Etv6; other domains are as shown in Fig 1.
Short Report
ª 2007 The Authors
80 Journal Compilation ª 2007 Blackwell Publishing Ltd, British Journal of Haematology, 138, 77–81
homodimerisation. However, the growth of the transformed
cells was slower than those transformed by similar fusions in
which the WW-like domain was truncated (Stover et al, 2006).
It remains unclear why the WW-like domain is truncated with
other fusion partners that provide an oligomerisation domain
such as Bcr, and also why truncation of this domain is not
usually seen for fusions involving Pdgfrb.
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A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient
with an imatinib responsive chronic myeloproliferative disease
Leukemia (2007) 21, 1839–1841; doi:10.1038/sj.leu.2404728;
published online 17 May 2007
ETV6-PDGFRB results from the t(5;12)(q31–33;p13) and,
although rare, is the most frequent of at least 15 known
PDGFRB fusion genes. ETV6-PDGFRB is usually seen in patients
with chronic myelomonocytic leukaemia, atypical chronic
myeloid leukaemia (aCML) or chronic eosinophilic leukaemia
(CEL), with most patients exhibiting peripheral blood or bone
marrow eosinophilia. Although ETV6-PDGFRB disease may be
controlled with conventional therapy (hydroxyurea, busulphan,
interferon-a), many die from transformed disease or other
causes. More recently, however, imatinib has emerged as the
standard therapy for PDGFR-rearranged patients, with most
experiencing sustained haematologic and cytogenetic remis-
sion, and many achieving molecular remission.1 Molecular
confirmation of a PDGFR rearrangement is therefore important
for appropriate clinical management and monitoring response to
therapy. For the t(5;12)(q31–33;p13), confirmation of the
presence of ETV6-PDGFRB is particularly important since many
cases with this translocation have a distinct molecular aetiology,
with upregulation of IL-3 expression and no involvement of
PDGFRB.2
In the great majority of positive cases, ETV6 exon 4 splices to
PDGFRB exon 11 and is typically detected by reverse
transcription PCR (RT-PCR) using primers directed to ETV6
exon 3 or 4 and PDGFRB exon 11. Out of 10 positive cases we
have detected with these primer combinations, only one had a
variant fusion in which ETV6 exon 4 was fused to PDGFRB exon
9 (unpublished data). Recently, a patient with idiopathic
myelofibrosis and an ETV6 exon 7–PDGFRB exon 10 fusion was
reported and it was suggested that this novel transcript may have
accounted for the somewhat unusual clinical phenotype seen in
this case.3 Importantly, both these variants are detectable using the
standard primer sets above. Here we report a novel ETV6-PDGFRB
fusion with breakpoints outside this region.
A 19–year-old male (E1026) presented to the outpatient
department with a 2-month history of fever. On examination he
was found to have generalized lymphadenopathy, hepatospleno-
megaly and bony swellings over the left clavicle and right tibia.
There were no bleeding manifestations. A peripheral blood smear
showed a total leucocyte count exceeding 100 109/l with a left
shift. The bone marrow aspirate was suggestive of a myelopro-
liferative disorder with an increase in the number of basophils
and eosinophils. Fine needle aspiration of the lymph node
showed infiltration by blasts which cytochemistry revealed to be
negative for myeloperoxidase and periodic acid schiff. Flow
cytometry of the peripheral blood and lymph node aspirate was
positive for myeloid markers (CD 11c, 13, 15 and 33) along with
CD45 and myeloperoxidase. BCR-ABL was not detected by RT-
PCR and cytogenetics showed a t(5;12)(q31–33;p13). A diagnosis
of atypical CML in blast crisis was made. Despite the fact that
ETV6-PDGFRB was not detected by RT-PCR, he was started on
imatinib mesylate (300 mg twice a day) after taking informed
consent. The patient had a complete haematological and
cytogenetic response (including complete regression of the lymph
nodes, bony swellings and hepatosplenomegaly) at
3 months post-treatment. He continues in remission on 600 mg/
day imatinib, 1 year after diagnosis.
In view of the excellent response to imatinib, we performed
further analysis to determine if PDGFRB was involved (material
was not available for molecular cytogenetic analysis). We have
previously reported a simple multiplex RT-PCR assay to identify
PDGFRA fusions by looking for overexpression of sequence
encoding the kinase domain (which is retained in any fusion)
relative to that encoding the extracellular domain (which is
expressed only by the normal, unrearranged gene).4 Attempts to
establish a similar assay for PDGFRB were only partially
successful and therefore we developed an analogous strategy
using multiplex ligation-dependent probe amplification (MLPA).
We designed probes targeting the region encoding the kinase
domain and upstream sequences of PDGFRA, PDGFRB and
FGFR1. MLPA was performed on patient and control cDNA
essentially as described.5 The cDNA MLPA assay detected
relative overexpression of the PDGFRB kinase domain in 9 of 9
patients known to harbour PDGFRB fusion genes but not in 16
normal controls. Overexpression of the kinase domain was also
seen for E1026, suggesting the presence of a PDGFRB fusion
(Figure 1a).
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Figure 1 (a) The cDNA MLPA assay. Probes are in the following order: FGFR1 tyrosine kinase domain, FGFR1 30 extracellular domain,
PDGFRB tyrosine kinase domain, PDGFRB 30 extracellular domain, PDGFRA tyrosine kinase domain, PDGFRA 30 extracellular domain. Primer
sequences and exact conditions are available on request. Under normal circumstances, expression of FGFR1, PDGFRB and PDGFRA is low in
level in peripheral blood leucocytes. Overexpression of the PDGFRB intracellular domain is apparent in both the previously known ETV6-PDGFRB
case and also E1026. (b) Electropherogram of the cDNA junction amplified by 50rapid amplification of cDNA ends PCR. MLPA, multiplex ligation-
dependent probe amplification.
CAG AAC CAT GAA GAA GTC CCT GTC CGA GTG CTG
Q   N   H   E   E   V   P   V   R   V   L
CAG AAC CAT GAA GAA GCC TTG CCC TTT AAG GTG
Q   N   H   E   E   A   L   P   F   K   V
CAA AGG CTT TTG TTC AGG TGT CCA CGT GAG CTG
Q   R   L   L   F   R   C   P   R   E   L
AGG CTT TTG TTC AGt cag aat aag tct aca agc tgc tgc act aga att AGC TCT GAC GGC CAT
Q   R   L   L   S   Q   N  K   S   T   S   C   C   T   R   I  S   S   D   G   H
ETV6 exon 4 PDGFRB exon 11
ETV6 exon 4 PDGFRB exon 9
ETV6 exon 7 PDGFRB exon 10
∆PDGFRB exon 12ETV6 exon 7 ETV6 intron 7
Figure 2 Sequence of ETV6-PDGFRB fusions described to date, with the most common variant at the top and the fusion in case E1026 at the
bottom.
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We used 50 rapid amplification of cDNA ends PCR (Invitrogen,
Paisley, UK) to characterize the fusion, employing reverse primers
derived from sequences located downstream of known PDGFRB
breakpoint locations. The resulting PCR products were cloned and
sequencing revealed an in-frame mRNA fusion between full-length
ETV6 exon 7, 34 bp derived from ETV6 intron 7 and a truncated
PDGFRB exon 12 (Figures 1b and 2). The presence of the fusion
was confirmed by RT-PCR and by amplifying and sequencing
fusion point from genomic DNA (not shown).
The PDGFRB sequence retained in the novel fusion is down-
stream of the PCR primer we had initially used, explaining why
ETV6-PDGFRB was not detected. To determine if we might have
missed other similar cases, we analyzed 10 cases with a t(5;12)
who tested negative for ETV6-PDGFRB using primers ETV6.Ex2F
(50-TCAGGATGGAGGAAGACTCG-30) and PDGFRB.Ex14R (50-
CCCCAACAGGTTGACCACGTTCAG-30). All were negative, in-
dicating that this variant is not common, but nevertheless we now
routinely use these primers to screen t(5;12) cases.
This unusual fusion in our case is reminiscent of that seen for
FIP1L1-PDGFRA, for which breaks almost always fall within
PDGFRA exon 12 and FIP1L1 intron-derived sequence is
frequently incorporated into the mature mRNA.6 As a con-
sequence, the PDGFRa autoinhibitory WW-like domain is
disrupted resulting in partner protein-independent activation of
the kinase moiety.7 The disruption of PDGFRb WW-like domain
in our case is unexpected in view of the fact that ETV6 encodes a
dimerization domain that is required for transformation by
‘normal’ ETV6-PDGFRB.
It is notable that our case presented with advanced phase
disease. The fusion retained ETV6 exons 1–7, in common with
that described by Tokita et al.3 in a case that also presented with
advanced features. In contrast to the most common fusion
involving ETV6 exons 1–4, these variants are predicted
to encode a chimaeric protein that retains the ETV6 internal
and ETS DNA-binding domains. It is possible that retention
of these domains leads to a more aggressive phenotype;
however, it would be premature to draw any clear conclusions
from just two cases. It is noteworthy, however, that our
case responded well to imatinib despite being treated in
advanced phase. Good responses to imatinib have been
described for FIP1L1-PDGFRA-associated CEL in transforma-
tion8 and this may be a general feature of diseases associated
with PDGFR fusions.
In summary, it appears that breakpoint diversity for the ETV6-
PDGFRB fusion is more common than originally reported.
Screens for this fusion should employ primers capable of
detecting all variants in order to provide an accurate molecular
diagnosis and appropriate clinical management.
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Treatment of severe autoimmune hemolytic anemia in B-cell chronic lymphocytic
leukemia with alemtuzumab
Leukemia (2007) 21, 1841–1842; doi:10.1038/sj.leu.2404713;
published online 26 April 2007
We read with interest the article by Karlsson et al.1 in Leukemia
(2007), which reports five patients treated successfully with
alemtuzumab (anti-CD52) for refractory autoimmune hemolytic
anemia (AIHA) complicating B-cell chronic lymphocytic leuke-
mia (B-CLL). AIHA occurs in about 5% of patients with B-CLL
and requires treatment including corticosteroids, cytotoxic
drugs, splenectomy or immunosuppressive drugs.2 Recently,
rituximab (anti-CD20) has been used with efficacy in AHAI
complicating B-CLL.3 But relapses are frequent and some
patients become refractory.
We report the case of a 69-year-old woman who presented
B-CLL complicated by AIHA. B-CLL was diagnosed in 1994 and
was treated with different chemotherapy regimens (chlorambu-
cile, cyclophosphamide and then fludarabine) between 1994
and 2002. In October 2003 chlorambucile was introduced for
progressing B-CLL; the direct antiglobulin test (DAT) was
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The t(1;9)(p34;q34) and t(8;12)(p11;q15)
Fuse Pre-mRNA Processing Proteins SFPQ (PSF)
and CPSF6 to ABL and FGFR1
Claire Hidalgo-Curtis,1 Andrew Chase,1 Milton Drachenberg,2 MarkW. Roberts,2
Jerry Z. Finkelstein,2 Sarah Mould,3 David Oscier,3 Nicholas C. P. Cross,1 and Francis H. Grand1*
1Wessex Regional Genetics Laboratory,Salisbury District Hospital and HumanGenetics Division,
Universityof Southampton,Southampton,United Kingdom
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We have investigated two patients with acquired chromosomal rearrangements, a male presenting with a t(1;9)(p34;q34) and
B cell progenitor acute lymphoid leukemia and a female presenting with a t(8;12)(p11;q15) and the 8p11 myeloproliferative
syndrome. We determined that the t(1;9) fused ABL to SFPQ (also known as PSF), a gene mapping to 1p34 that encodes a poly-
pyrimidine tract-binding protein-associated splicing factor. The t(8;12) fused CPSF6, a cleavage and polyadenylation speciﬁcity
factor, to FGFR1. The fusions were conﬁrmed by ampliﬁcation of the genomic breakpoints and RT-PCR. The predicted onco-
genic products of these fusions, SFPQ-ABL and CPSF6-FGFR1, are in-frame and encode the N-terminal domain of the partner
protein and the entire tyrosine kinase domain and C-terminal sequences of ABL and FGFR1. SFPQ interacts with two FGFR1
fusion partners, ZNF198 and CPSF6, that are functionally related to the recurrent PDGFRa partner FIP1L1. Our ﬁndings thus
identify a group of proteins that are important for pre-mRNA processing as fusion partners for tyrosine kinases in hematologi-
cal malignancies. VC 2008 Wiley-Liss, Inc.
INTRODUCTION
Diverse tyrosine kinase fusion genes have been
identiﬁed in hematological malignancies, particu-
larly myeloproliferative disorders (MPD), acute
lymphoblastic leukemia (ALL), and certain sub-
types of lymphoma. The 8p11 myeloproliferative
syndrome (EMS) is a chronic MPD that commonly
presents with eosinophilia, T-cell proliferation and
acquired reciprocal chromosomal translocations
with recurrent breakpoints at chromosome band
8p11 that disrupt the receptor tyrosine kinase
FGFR1. To date, eight fusion genes have been
identiﬁed by the molecular investigation of chro-
mosomal rearrangements in patients with EMS;
these are the t(8;13)(p11;q12), t(6;8)(q27;p11), t(8;9)
(p11;q33), t(8;22)(p11;q22), t(8;19)(p12;q13.3), ins(12;8)
(p11;p11p22), t(7;8)(q34;p11), t(8;17)(p11;q23), and
which fuse ZMYM2, FGFR1OP, CEP110, BCR,
HERV-K, FGFR1OP2, TRIM24, MYO18A, to
FGFR1, respectively (Xiao et al., 1998; Popovici et
al., 1999; Guasch et al., 2000, 2003; Demiroglu et
al., 2001; Grand et al., 2004; Belloni et al., 2005;
Walz et al., 2005). The FGFR1 fusion genes
encode constitutively active proteins that are func-
tionally and structurally similar to BCR-ABL. The
ABL gene has also been described as being fused
to multiple partner genes: BCR (Groffen et al.,
1984), ETV6 (also known as TEL) (Golub, 1997),
NUP214 (Graux et al., 2004), and EML1 (De
Keersmaecker et al., 2005). Although uncommon,
these fusions are important to recognise because of
their potential to be targeted effectively by small
molecular inhibitors (Cross and Reiter, 2006).
For most tyrosine kinase fusions, the partner
proteins provide dimerisation motifs that are essen-
tial for transforming activity; however, accumulat-
ing evidence suggests that partner proteins may
play additional roles in modifying intracellular sig-
nalling and disease phenotype. Fusions such as
FIG-ROS (Charest et al., 2003) and FGFR1OP-
FGFR1 (Delaval et al., 2005) are directed by the
partner protein to speciﬁc intracellular compart-
ments, which may be critical to their transforming
ability. BCR fuses to multiple kinases including
PDGFRA (Baxter et al., 2002), FGFR1 (Demi-
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roglu et al., 2001), and ABL (Groffen et al., 1984).
BCR-FGFR1 binds GRB2 via BCR Tyr177 and
induces a CML-like leukaemia in mice, whereas
BCR-FGFR1/Y177F (which lacks the GRB2 bind-
ing site) causes EMS-like disease. These results
implicate different signalling pathways originating
from both the kinase and the fusion partner in the
differential pathogenesis of CML and EMS (Rou-
miantsev et al., 2004).
In this study, we have investigated an acquired
t(1;9)(p34;q34), and identiﬁed SFPQ as a new
fusion partner to ABL. The second patient pre-
sented with EMS and an acquired chromosomal
rearrangement of 8p11, resulting in the fusion of a
new partner gene, CPSF6 to FGFR1. Both partner
genes share a common role associated with pre-
mRNA processing and our ﬁndings thus identify a
group of proteins that are important for pre-mRNA
processing as fusion partners for multiple tyrosine
kinases in hematological malignancies.
MATERIALS ANDMETHODS
Patient Details
Case 1: A 22-year-old male patient presented
with CD34 positive ALL of pre-B immunopheno-
type. His full blood count at presentation was as
follows: hemoglobin 7.8 g/L; WBC 39.7 3 109 L21
(89% blasts); platelets 25 3 109 L21. Bone marrow
analysis revealed 94% blasts and cytogenetics
showed a t(1;9)(p34;q34)[7]/47, idem, 121[6]/46,
XY [7]. The patient was treated according to the
Children’s Cancer Group Protocol, 1961, and sub-
sequently received augmented BFM therapy with
doxorubicin and double delayed intensiﬁcation.
He achieved complete remission but suffered
extramedullary testicular relapse at 4.5 years. Fol-
lowing orchidectomy and intensive chemotherapy,
he remains in complete remission more than 6
years after diagnosis.
Case 2: A 75-year-old female presented with cer-
vical, left axillary, and inguinal lymphadenopathy.
A CT scan showed right pleural effusion, ascites,
splenomegaly, and para-aortic nodes. Axillary node
biopsy showed effacement of normal architecture
by a diffuse population of mononuclear cells. The
majority expressed strong surface CD3, but there
was a scattered population of cells expressing mye-
loid markers such as neutrophil elastase. The pre-
senting blood count showed a hemoglobin of 140
g/L, WBC 16 3 109 L21, with neutrophilia (12 3
109 L21) and eosinophilia (0.8 3 109 L21) plus pla-
telets of 375 3 109 L21. The marrow was hypercel-
lular with an increase in eosinophils and eosinophil
precursors but no increase in lymphoid cells or
blasts. Cytogenetics analysis revealed 46,XX,t(8;12)
(p11;q15)[19]/46, XX [1]. There was rapid clinical
deterioration accompanied by pyrexia, lethargy,
weight loss, and a widespread rash (biopsy was incon-
clusive on histology). Intensive chemotherapy was
not offered and although there was a transient clini-
cal response to steroids, she died 10 weeks later.
50 Rapid Ampliﬁcation of cDNA
Ends (50 RACE) PCR
Partner genes were identiﬁed using the Gene-
RacerTM Kit (Invitrogen, Paisley, UK). Brieﬂy,
5 lg of total RNA extracted using the Qiagen
RNeasy kit (Qiagen, Boundary Court, UK) was de-
phosphorylated, decapped, and ligated to the
GeneRacerTM RNA oligo according to the manu-
facturer’s instructions. The ligated RNA was
reverse transcribed using Superscript IITM reverse
transcriptase (Invitrogen, Paisley, UK) and random
primers (100 ng). Single step 50RACE PCR was
performed using the 50 GeneRacerTM primer from
the kit in combination with a reverse primer from
ABL exon 4 (1R: 50-CCA CCG TTG AAT GAT
GAT GAA CC-30) for Case 1. For Case 2, 50RACE
was performed using nested FGFR1 primers as
previously described (Grand et al., 2004). The
PCR cycles were designed to amplify fragments up
to 3 kb, with an annealing temperature of 668C
using the High Fidelity PCR Master kit (Roche,
Mannheim, Germany) according to the manufac-
turer’s instructions. Products were cloned with the
TOPO TA Cloning Kit for Sequencing (Invi-
trogen, Paisley, UK) and sequenced.
RT-PCR Methods
Case 1: The presence of SFPQ-ABL mRNA was
conﬁrmed on random hexamer reverse transcribed
cDNA using primers to SFPQ (Exon 5 1F: 50-GAT
GCC TAT CAT GAA CAT CAG GC-30) with the
reverse ABL exon 4 1R (see above). Because of
limited patient material the genomic breakpoint
was initially ampliﬁed by long PCR using a forward
genomic primer from intron 9 of SFPQ (2F: 50-
GTG TAG GCT GCT GTG TTT GCAT-30) and
reverse primer ABL exon 4 1R. This product was
cloned (Invitrogen, Paisley, UK) and sequenced
using a reverse ABL primer from intron 4 (50-TCT
TTT GAC AGC CAC ACT GAC AG).
Case 2: The presence of CPSF6-FGFR1 fusion
mRNA was conﬁrmed on random hexamer reverse
transcribed cDNA using primers to CPSF6 (Exon 8
Genes, Chromosomes & Cancer DOI 10.1002/gcc
380 HIDALGO-CURTIS ET AL.
1F: 50-GGA GTG CTA TTG AGA CAC TGG
TA-30) with the reverse FGFR1 RACE 1R (50-AGA
AGA ACC CCA GAG TTC ATG GA-30). These
primers were also used to amplify the genomic
breakpoint.
Fluorescence In Situ Hybridization Analysis
To our knowledge, no other cases have been
reported with a t(1;9)(p34;q34) or t(8;12)(p11;q15).
For Case 1, FISH was performed using the Vysis
ES BCR-ABL probes as described (Chase et al.,
1997). Previous analysis suggested disruption of
FGFR1 in Case 2 (Sohal et al., 2001).
RESULTS
Characterization of the t(1;9)
FISH using the Vysis ES probes that immedi-
ately ﬂank the ABL gene hybridized to the normal
copy of chromosome 9, also the der(9) and the
der(1), indicating that the translocation targeted
ABL; however, no BCR-ABL fusion was seen by
FISH or RT-PCR. All ABL fusions reported to date
result in the partner gene fusing to ABL exons a2
or a3. To identify the t(1;9) partner, we, therefore,
performed 50-RACE PCR from both these exons.
These initial attempts failed despite the fact that
normal 50 ABL sequence was readily obtained (data
not shown). 50RACE primers were subsequently
designed in ABL exon 4 (accession number
M14752). Sequencing of the products revealed
several clones in which exon 9 SFPQ (accession
number X70944) was fused in frame to ABL exon 4
(a4) (Fig. 1a).
Conﬁrmation of the SFPQ-ABL Fusion
The presence of the SFPQ-ABL fusion was con-
ﬁrmed initially by RT-PCR. The reciprocal ABL-
SFPQ product was also detectable by single step
PCR. Cloning and sequencing revealed that the
reciprocal product fuses ABL exon 3 (a3) to an
alternative RNA isoform (see GenBank accession
number 4685098) of SFPQ (Fig. 1a). As shown in
Figure 1b, the SFPQ-ABL fusion was speciﬁcally
ampliﬁed from patient cells by single step PCR,
but was not detectable in normal controls. To fur-
ther conﬁrm the presence of the fusion the
genomic breakpoint was ampliﬁed by long PCR,
cloned, and sequenced. The genomic sequence
near the breakpoint on the derivative chromosome
1 was 30 of exon 10 of SFPQ (GenBank accession
number NM_005066.1) and was fused to sequence
derived from intron 3 of ABL (Fig. 1c). The chi-
meric fusion mRNA is formed through splicing to
exon 9 (nucleotide 2072) of the SFPQ gene
(NM_005066.1). The SFPQ-ABL fusion mRNA is
predicted to encode a 1609 amino acid protein of
174 KDa that retains the N-terminal proline rich
region and the two RNA recognition motifs (RRM)
from SFPQ fused to part of the SH2 domain of
ABL (Fig. 1d).
Characterization of the t(8;12)
FGFR1 had previously been reported as rear-
ranged by FISH in this patient (Sohal et al., 2001).
Because the breakpoints for all cases involving the
FGFR1 gene thus far reported are tightly clustered
within or close to exon 9, we investigated the pos-
sibility that FGFR1 was rearranged by 50-RACE
PCR. As shown on Figure 2a, sequencing of
the rearranged 50RACE band revealed a fusion
between CPSF6 intron 8 (accession number
NM_007007) and FGFR1 at nucleotide 1272 from
ATG (accession number M34185).
Conﬁrmation of the CPSF6-FGFR1 Fusion
To conﬁrm the CPSF6-FGFR1 fusion, a 224 bp
product was speciﬁcally ampliﬁed from patient
cDNA but not from control DNA. The genomic
breakpoint product of 543 bp was coampliﬁed in
the same reaction and sequenced (Figs. 2b and 2c)
The CPSF6 breakpoint within intron 8 (Fig. 2c)
results in the incorporation of part of the CPSF6
intron in the fusion mRNA; the CPSF6 intronic
fragment maintains the reading frame with FGFR1
and encodes 11 amino acids.
A reciprocal FGFR1-CPSF6 fusion product was
not detected with either single step or nested PCR
(Fig. 2b). The CPSF6-FGFR1 fusion mRNA is
predicted to encode a 895 amino acid protein of 97
KDa, that retains the N-terminal region and the
RNA recognition motif (RRM) from CPSF6 fused
to the entire tyrosine kinase domain of FGFR1
(Fig. 2d).
DISCUSSION
The SFPQ-ABL fusion is unique in that it is the
ﬁrst description of an ABL fusion to involve the
fourth exon of ABL (exon a4). This is a structurally
unusual ABL fusion protein as amino acids W127-
K183 (accession number M14752) of the SH2
domain are not included whereas all previously
described ABL fusion proteins retain the whole
SH2 domain. Mouse models with BCR-ABL con-
structs in which the SH2 domain was inactivated
have shown the fusion protein retained the ability
to cause leukemia in mice. Under conditions in
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which P210 and P190 forms of BCR-ABL cause
fatal CML within 4 weeks, P210 SH2 mutants pro-
duced CML-like disease in some mice after a sig-
niﬁcant delay, with others developing a B-lymph-
oid leukemia (Roumiantsev et al., 2001).
SFPQ is a multifunctional protein able to bind
single and double stranded DNA as well as RNA
(Shav-Tal et al., 2002). SFPQ was ﬁrst identiﬁed in
a complex with polypyrimidine tract-binding pro-
tein (PTB), and is an essential factor for RNA
splicing. SFPQ has previously been identiﬁed in
papillary renal cell carcinoma as the fusion partner
of the transcription factor TFE3. As with the
SFPQ-ABL fusion, SFPQ-TFE3 includes exons
1–9 of SFPQ (NM_005066.1). SFPQ also binds
to NPM-ALK (Crockett et al., 2004) and is
Figure 1. A: Sequence of SFPQ-ABL and reciprocal ABL-SFPQ mRNA fusions; (B) ampliﬁcation of SFPQ-
ABL by single step RT-PCR from the t(1;9) patient but not normal controls (N1-N3). B1 is a blank; (C)
sequences surrounding the genomic breakpoints in SFPQ (underlined) and ABL; (D) schematic representa-
tion of SFPQ, ABL, and the SFPQ-ABL fusion protein. The breakpoint within ABL for the great majority
(M) of BCR-ABL cases is upstream of the SH3 and SH2 domains and is indicated by an arrow.
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phosphorylated at Y293F by the NPM-ALK
fusion. It has been postulated that SFPQ function
is perturbed in NPM-ALK transformed cells
(Crockett et al., 2004; Galietta et al., 2007).
As described above, constitutive activation of
fusion tyrosine kinases is mediated by an oligome-
rization domain in the partner protein. The coiled-
coil prediction program ncoils (http://www.sanger.
ac.uk/cgi-bin/Pfam/swisspfamget.pl?name5P23246)
(Lupas et al., 1994) indicated the presence of two
coiled-coil domains between SFPQ amino acids
498–529 and amino acids 532–595. It is possible
that one or more of these domains is responsible
for oligomerization of SFPQ-ABL.
CPSF6 is the ninth partner gene found fused to
FGFR1. All these fusions involve FGFR1 exon 9,
and therefore disrupt the FRS2 binding domain
(Hoch and Soriano, 2006). No recognisable oligo-
merisation motifs are identiﬁable in CPSF6, al-
though it has been demonstrated previously that
RNA recognition motifs (RRM), such as the one
retained in CPSF6-FGFR1, may mediate homodi-
merization (Simpson et al., 2004; Handa et al.,
2006) and it is possible that this domain causes the
oligomerization of CPSF6-FGFR1.
CPSF6 has also been found in puriﬁed spliceo-
somes with SFPQ and NonO, linking these pro-
teins to both transcription and processing of pre-
mRNAs (Rappsilber et al., 2002; Zhou et al., 2002;
Dettwiler et al., 2004). During pre-mRNA process-
ing, CPSF6 binds the highly conserved poly-
adenylation site AAUAAA that is present in almost
every mRNA precursor, as well as interacting with
the poly-A binding protein II (PABII) that binds
the growing poly-A tail. Together CPSF6 and
PABII activate poly (A) polymerase (PAP), by
Figure 2. A: Sequence of the CPSF6-FGFR1 mRNA fusion; (B) ampliﬁcation of the CPSF6-FGFR1 fusion
speciﬁcally from cDNA in the t(8;12) patient (E0003) but not the normal controls. The reciprocal fusion
product was not detected (C) Sequences surrounding the genomic breakpoints in CPSF6 (underlined) and
FGFR1; (D) domain structure of FGFR1, CPSF6, and the predicted fusion protein. Relevant protein domains
are shown: RNA recognition motif (RRM), transmembrane domain, and tyrosine kinase domain for FGFR1.
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directing the enzyme to the RNA allowing poly-
adenylation of the upstream cleavage product
(Ruegsegger et al., 1998).
The U1 snRNP has been shown to function in
polyadenylation and has been found in complex
with SFPQ (Lutz et al., 1998; Liang and Lutz,
2006). Another FGFR1 fusion partner, ZNF198
(Xiao et al., 1998), has been found to immunopre-
cipitate with SFPQ (Kasyapa et al., 2005). ZNF198
was proposed as a possible scaffold protein bring-
ing RNA-binding proteins together to facilitate
pre-mRNA splicing (Kasyapa et al., 2005). In addi-
tion, FIP1L1, which fuses to PDGFRa in chronic
eosinophilic leukemia (Cools et al., 2003), also
plays a role in polyadenylation and pre-mRNA
splicing (Preker et al., 1995; Kaufmann et al.,
2004). Our ﬁndings, thus, identify proteins
involved in pre-mRNA processing as a functionally
related group that fuse to tyrosine kinase genes in
hematological malignancies.
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Recent evidence has demonstrated that
acquired uniparental disomy (aUPD) is a
novel mechanism by which pathogenetic
mutations in cancer may be reduced to
homozygosity. To help identify novel mu-
tations in myeloproliferative neoplasms
(MPNs), we performed a genome-wide
single nucleotide polymorphism (SNP)
screen to identify aUPD in 58 patients
with atypical chronic myeloid leukemia
(aCML; n  30), JAK2 mutation–negative
myelofibrosis (MF; n  18), or JAK2
mutation–negative polycythemia vera (PV;
n  10). Stretches of homozygous, copy
neutral SNP calls greater than 20Mb were
seen in 10 (33%) aCML and 1 (6%) MF, but
were absent in PV. In total, 7 different
chromosomes were involved with 7q and
11q each affected in 10% of aCML cases.
CBL mutations were identified in all
3 cases with 11q aUPD and analysis of
574 additional MPNs revealed a total of
27 CBL variants in 26 patients with aCML,
myelofibrosis or chronic myelomono-
cytic leukemia. Most variants were mis-
sense substitutions in the RING or linker
domains that abrogated CBL ubiquitin
ligase activity and conferred a prolifera-
tive advantage to 32D cells overexpress-
ing FLT3. We conclude that acquired,
transforming CBL mutations are a novel
and widespread pathogenetic abnormal-
ity in morphologically related, clinically
aggressive MPNs. (Blood. 2009;113:
6182-6192)
Introduction
Myeloproliferative neoplasms (MPNs) are clonal hematopoietic
stem cell disorders characterized by overproliferation of one or
more myeloid cell lineages in the bone marrow and increased
numbers of mature and immature myeloid cells in the peripheral
blood. Excess proliferation is frequently associated with spleno-
megaly and cardiovascular complications as well as increased risk
of transformation to acute leukemia. MPNs are categorized into
subtypes based on specific morphologic, hematologic, and labora-
tory parameters, the best characterized being the 4 so-called classic
MPNs: polycythemia vera (PV), essential thrombocythemia (ET),
primary myelofibrosis (MF), and chronic myeloid leukemia (CML).1
In addition, several atypical MPNs are recognized, some of which
show both dysplastic and proliferative features, such as atypical,
BCR-ABL negative CML (aCML).2
MPNs are associated with acquired, activating mutations or
gene fusions of tyrosine kinases, abnormalities that are believed to
be critical drivers of excess proliferation as a result of deregulated
or constitutive signaling.3 The 2 most prominent examples are
BCR-ABL in CML4 and the V617F JAK2 mutation in PV, ET, and
MF,5-8 but more than 40 variant tyrosine kinase fusions have been
identified in MPNs as well as other mutations in JAK2 and FLT3.2
Activating mutations have been described in components that
signal upstream (eg, MPL) or downstream (eg, NRAS) of tyrosine
kinases9,10; however, the molecular pathogenesis of the majority of
atypical MPNs and approximately 50% of ET and MF cases
remains obscure.
V617F JAK2 was initially identified by several different routes,
one of which was based on the observation that many PV patients
show evidence of acquired uniparental disomy (aUPD) at
chromosome 9p.11,12 Regions of aUPD exhibit loss of heterozygos-
ity (LOH) compared with constitutional DNA without change of
copy number and arise by mitotic recombination followed by
selection for one of the products. After the initial observations in
PV, it has emerged that aUPD is common in both hematologic and
epithelial malignancies, and is associated with known oncogenic
changes in a variety of genes within the affected regions.13 In this
study we set out to determine whether aUPD characterizes MPNs
of unknown molecular etiology and, if so, whether it could be used
as a tool to help identify novel driver mutations.
Methods
Patients
Peripheral blood or bone marrow samples were received from patients
diagnosed with an MPN or other hematologic malignancy according to
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standard morphologic, hematologic, and laboratory criteria. Clinical data
were available from a subset of these cases. The study was approved by the
Internal Review Boards from participating institutions and informed
consent was obtained in accordance with the Declaration of Helsinki.
SNP array analysis
DNA labeling and hybridization to Affymetrix 50k XbaI chips was
performed at the Deutsches Ressourcenzentrum fu¨r Genomforschung
(RZPD, Berlin, Germany). Raw data were imported into the Affymetrix
GeneChip Operating Software, analyzed using Affymetrix (High Wy-
combe, United Kingdom) GeneChip Genotyping Analysis Software (GTYPE
4.1) and copy number analysis tool (CNAT). Data were exported to
custom-designed spreadsheets that display loss of heterozygosity and copy
number changes in ideogram format. Data were also analyzed using
Affymetrix Genotyping Console (version 2.1). Overall, a median of 98.2%
(range, 91.5%-99.6%) of SNPs gave readable calls.
Mutation analysis
Detection of mutations by high resolution melting (HRM) analysis was
performed as described14 using a Rotor-Gene 6000 (Corbett Life Sciences,
St Neots, United Kingdom). Direct sequencing of polymerase chain
reaction (PCR) products was performed by standard techniques on an ABI
3130 Genetic Analyzer (Applied Biosystems, Warrington, United King-
dom) and analyzed using Mutation Surveyor (SoftGenetics, State College,
PA). CBL mutations are numbered relative to the ATG (A  1) in the
Ensembl cDNA sequence ENSG00000110395. A dropping factor (relative
intensity drop of the wild-type allele peak relative to that seen in a
concurrently run normal sample) of 60% or more was considered indicative
of a biallelic mutation whereas a dropping factor of less than 60% was
considered as monoallelic. Primer sequences for CBL exon 8 were CBL_i7f
(5-tgtggtttcactttaaaccctgga-3) and CBL_i8r (5-gccaggccaccccttgtatc-3)
and for CBL exon 9 were CBL_i8f (5-ggcctggcttttgggttagg-3) and CBL_i9r
(5-cacaatggattttgccagtctcc-3). CBL reverse-transcriptase PCR (RT-PCR)
was performed on random hexamer–reverse transcribed RNA using primers
CBLe7F: 5-gaatcctgatctgactggcttatg-3 and CBLe10R 5-gctgcggcagaaggt-
caagt-3. Other primer sequences are available on request.
Microsatellite analysis
DNA samples were amplified with a series of fluorescently labeled primer
pairs flanking highly polymorphic microsatellite markers on
chromosome 11q as described.10 aUPD was scored if 4 or more consecutive
markers encompassing CBL were homozygous without change in allelic
copy number (P  .05 of this occurring in the absence of aUPD based on
published rates of heterozygosity). Copy number at 11q was estimated by
multiplex ligation probe amplification (MLPA) using the Marfan probeset 1
(P065; MRC Holland, Amsterdam, The Netherlands), a kit that contains
four 11q control probes including one at 11q23.3.
Constructs
pMY-wtCBL and pMY-CBLR420Q express wild-type and R420Q CBL,
respectively, along with green fluorescent protein (GFP).15 Other CBL
mutant constructs were derived from pMY-wtCBL using the QuikChange
Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA). pAL/FLT3 and
pCMV–HA ubiquitin have also been described previously.15
Cell lines
The IL-3–dependent murine myeloid cell 32Dcl3 (32D) was purchased
from the Deutsche Sammlung von Mikroorganismen und Zellkulturen
(Braunschweig, Germany) and was maintained in 90% RPMI 1640 medium
with 10% fetal bovine serum (FBS) and 10% WEHI-3B conditioned
medium (WEHI). All cells were maintained in a humidified incubator at
37°C and 5% carbon dioxide. 32D cells were stably transduced by
electroporation with wt-FLT3 in a pAL vector as previously described16 and
maintained in 15 ng/mL blastocidin (Invitrogen, Paisley United Kingdom).
The Platinum-E (Plat-E) retrovirus packaging cell line17 was transfected
using the calcium phosphate method with 5 g CBL construct DNA:
106 32D/wtFLT3 cells were cocultivated with the Plat-E cells for 48 hours
in a volume of 2 mL (50% RPMI, 50% DMEM, 10% FBS, 5% WEHI). GFP
positive cells were flow sorted to highest possible purity using a BD
FACSAria cell sorter (Becton Dickinson, Stanford, CA). If insufficient cells
were obtained for experiments after flow sorting, the cells were maintained
in culture and resorted to greater than 95% purity.
Growth factor withdrawal assays
Cell growth was compared with wt-FLT3, vector-only transfected cells and
the parental 32D line in stably transfected cells. Cells (105/mL) were grown
over 3 days in triplicate for each CBL mutant and a wt-CBL control in
96-well plates. Cultures were analyzed daily for proliferation using the
Aqueous One Solution Cell Proliferation Assay kit (MTS assay; Promega,
Southampton, United Kingdom). All experiments were performed at least
3 times independently and results were analyzed using GraphPad Prism 4
software (GraphPad Software, San Diego, CA).
Ubiquitin ligase activity
The ubiquitin ligase activity of CBL mutants in comparison to wild-type
CBL was determined by transiently transfecting 107 32D/wtFLT3 cells
expressing wild-type or CBL mutants by electroporation with 20 g
pCMV-HA ubiquitin. Cells were maintained in culture with WEHI for
12 hours after transfection before being washed, serum deprived overnight,
exposed to FLT3 ligand for 10 minutes, and lysed in buffer as described.18
Lysates were incubated with a FLT3-specific polyclonal antibody overnight
at 4°C. Protein G agarose beads (100 L) were added and incubated at 4°C
for 4 hours. The beads were washed 4 times in ice-cold radioimmunoprecipi-
tation assay (RIPA) lysis buffer. The supernatant was mixed with sodium
dodecyl sulphate (SDS) sample loading buffer before immunoblot analyses
with antibodies against HA-ubiquitin (sc-805; Santa Cruz Biotechnology,
Santa Cruz, CA), CBL (2111C3a; Abcam, Cambridge, United Kingdom),
and FLT3 (sc-479; Cell Signaling Technology, Danvers, MA).
Results
SNP array analysis
We performed genome-wide SNP analysis on leukocyte DNA
extracted from 58 MPD patients: aCML (n  30), V617F JAK2
negative MF (n  18), and JAK2 mutation negative PV/idiopathic
erythrocytosis (n  10). As comparators, we also analyzed cases of
CML in transformation to blast crisis (n  30, of which 20 were
myeloid and 10 lymphoid) and chronic lymphocytic leukemia
(CLL; n  20). We conservatively defined likely regions of aUPD
as at least 20 Mb of absent or significantly reduced heterozygous
SNP calls (ie,  5% SNPs called as heterozygous) running to a
telomere without change in copy number (Figure 1A). Such large
regions are uncommon in healthy individuals.19 Strikingly, we
found that aUPD was common in aCML with 10 (33%) of cases
affected. In contrast, aUPD was only seen in a single case of MF
and was not seen in other patient subgroups. In total, 7 different
chromosomes were affected, with abnormalities at 7q and 11q each
seen recurrently in 10% of aCML cases. The affected regions
ranged in size from 29 Mb to a complete copy of chromosome 13
(Table 1).
Association between aUPD and known acquired oncogenic
mutations
Although we did not have constitutional DNA to formally confirm
that the regions of homozygosity were acquired, in 1 individual we
found a marked reduction in the proportion of 11q aUPD positive
cells on comparison of mononuclear cells and granulocytes,
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Figure 1. Single nucleotide polymorphism array results and initial mutation analysis. (A) Array analysis of 2 control patients showing copy number (CN) and loss of
heterozygosity (LOH) outputs. The x-axis for the CN plots show (copy number)2 as determined by CNAT, with values approaching or exceeding 1 indicating deletions and
greater than1 indicating amplifications. The x-axis for LOH shows log10 P values (ie, 20 indicates 1020). The 2 panels on the left are from a polycythemia vera (PV) case with
a homozygous V617F JAK2 mutation. There is no gross copy number change (individual datapoints spread around the zero line), but a large block of homozygous SNP calls at
9p indicative of aUPD. The 2 panels on the right are from a chronic myeloid leukemia (CML) blast crisis case and show LOH accompanied by a 20q deletion. (B) For case
UPN 5, a large block of 11q aUPD is apparent on analysis of granulocytes but almost completely absent from mononuclear cells (MNCs) extracted from the same sample.
(C) Chromosome 1p aUPD in case UPN 27 is associated with a biallelic GT MPL mutation that is predicted to result in a W515L substitution. (D) Whole
chromosome 13 isodisomy in case UPN 28 associated with a homozygous FLT3 ITD. Two controls are shown: an acute myeloid leukemia (AML) patient previously known to
have a heterozygous FLT3 ITD and a healthy individual.
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consistent with an acquired abnormality (Figure 1B). Some of the
affected regions harbor genes known to be relevant to hematologic
malignancies and therefore we assessed their mutational status.
Sequencing of the MPL gene in the case UPN 27 with 1p aUPD
revealed a homozygous GT change (Figure 1C) that results in the
previously reported W515L substitution.9 Case UPN 28 with whole
chromosome 13 UPD had a homozygous FLT3 internal tandem
duplication (ITD; Figure 1D). Candidate genes for the abnormali-
ties at 17q and 21q include NF1 and RUNX1, respectively;
however, these were not investigated.
11q aUPD is associated with CBL mutations
Next, we focused our analysis on the 2 recurrent regions of aUPD
at 7q and 11q. Because of the strong association between MPNs
and aberrant tyrosine kinase signaling, we analyzed genes encoding
tyrosine kinases and associated signaling components. The mini-
mally affected region at chromosome 7q contains 3 tyrosine ki-
nases: MET, EPHA1, and EPHB6. We fully sequenced the coding
exons of these genes in the 3 cases with 7q aUPD and 2 normal
controls but found no abnormalities. Similarly, we found no
sequence changes in exons 11 through 17 of BRAF, a gene
encoding a downstream component of RAS signaling that is
mutated in malignant melanoma and other cancers.20 There are no
tyrosine kinase genes on chromosome 11q, and although there are
several genes encoding signal transduction components, CBL stood
out as a known oncogene that negatively regulates tyrosine kinase
signaling.21 Sequencing of CBL in the three 11q aUPD cases
revealed that UPN 2 and UPN 5 each had a TC change at
nucleotide 1277 in exon 8 that predicts a L380P substitution. Case
UPN 3 had a CG missense change in exon 9 at nucleotide 1387
that predicts a P417A change (Figure 2). Consistent with the array
results, the mutations in cases UPN 3 and UPN 5 were predominant
with the residual wild-type alleles only weakly visible. For case
UPN 2 both the mutation and level of aUPD was less prominent,
presumably due to a greater background of normal cells.
Prevalence and nature of CBL mutations
To determine the prevalence of CBL mutations, we sequenced
exons 8 and 9 (that encode amino acids 366 through 409 and 410
through 477, respectively) in an additional 574 MPN cases. A total
of 27 sequence variants were identified in 26 patients, of whom
3 had MF, 10 had chronic myelomonocytic leukemia (CMML),
12 had aCML and 1 had hypereosinophilic syndrome/chronic eosin-
ophilic leukemia (HES/CEL; Tables 2 and 3). To ensure that we
were not missing mutations elsewhere in the gene we analyzed all
coding exons in 70 CBL mutation negative aCML or unclassified,
CML-like MPN cases by high resolution melt (HRM) analysis but
failed to detect any further sequence changes apart from known
polymorphisms. Similarly, no mutations in CBLB exons 9 or 10 or
CBLC exons 7 and 8 (the exons that correspond to CBL ex-
ons 8 and 9) were identified. The activity of BCR-ABL is known to
increase during progression of CML from chronic phase to blast
crisis22 and we speculated that abrogation of CBL activity might be
at least partially responsible for this increase. HRM analysis of
CBL exons 8 and 9 in blast crisis cases (n  31), however, failed to
reveal any mutations.
Of the 27 CBL variants, 21 (78%) were missense substitutions
affecting 12 amino acids (15 different substitutions), 5 (19%) were
candidate splicing abnormalities, and 1 (3%) produced a stop
codon (Table 3). Most of the changes were novel, although 4 cases
had R420Q as previously identified in a single case of AML.15
Apart from N454D, all residues affected by missense mutations
were completely conserved in CBL orthologues as well as the
2 other human CBL family members (Figure 3). The mutation to a
stop codon was found in a patient (UPN 9) who also had the Y371H
variant; PCR across the affected regions and sequencing indicated
that the 2 changes were on different alleles.
CBL mutations are acquired and rarely seen in conjunction
with other known mutations
For 2 cases (UPN 5 and UPN 14) we were able to compare the
mutational status of leukocytes and T cells or buccal epithelia cells. In
both cases the L380P mutation was only present in leukocytes and was
therefore acquired (Figure 4A). A third case (UPN 15) originally pre-
sented with V617F JAK2 negative ET in 1989 but progressed to MF in
2004. Analysis of DNA extracted from sequential bone marrow slides
indicated that the R420Q mutation was absent at the ET phase but
acquired on transformation (Figure 4B). The 3 CBL-positive MF cases
tested negative for MPL 515 mutations and all CBL mutation positive
cases were negative for cytogenetic indicators of tyrosine kinase fusions,
FLT3 ITD, activating NRAS mutations and V617F JAK2, with the
exception of 1 case (UPN 14) with MF who tested positive for both
L380P CBL and V617F JAK2. Analysis of retrospective bone marrow
slides for this case indicated the presence of V617F JAK2 at low level
initially but absence of L380P CBL. The CBL mutation was detectable
7 years later and completely displaced V617F after a further 3 years,
corresponding with a significant rise is peripheral leukocyte counts
(Figure 4C). A further case (UPN 21) presented with systemic mastocy-
tosis before evolving to CBL mutation-positive CMML but retrospec-
tive samples were unavailable.
Splicing abnormalities
RNA was available for 3 of the 5 cases with potential splicing
mutations. Patients UPN 18 and UPN 20 both exhibited double
bands by RT-PCR, sequencing of which showed one to be the
normal product and the smaller band to result from the complete
deletion of exon 8 in each case (Figure 4D), similar to that
described in the cell line MOLM-13.23 Patient UPN 19 showed a
single band by RT-PCR that was entirely normal on sequence
analysis indicating that the exon 84 CT change does not alter
splicing. It seems likely, therefore, that the variant identified in case
UPN 6 is also of no consequence. The pathogenicity of the intronic
variant seen in case UPN 13 remains unknown.
Table 1. Chromosomal regions and cases affected by aUPD
Disease
category
No. with aUPD /
no. analyzed
Region
affected
Size of affected
region; Mb
aCML 10/30 7q11.21-qter 95
7q11.22-qter 87
7q22.3-qter 53
11q12.1-qter 73
11q13.1-qter 69
11q13.5-qter 57
13pter-qter 114
17cen-qter 55
20q11.22-qter 30
21q21.1-qter 29
MF 1/18 1pter-1p21.3 95
PV 0/10
CML-BC 0/30
CLL 0/20
aUPD indicates acquired uniparental disomy; aCML, atypical chronic myeloid
leukemia; MF, myelofibrosis; PV, polycythemia vera; CML-BC, CML in transformation
to blast crisis; and CLL, chronic lymphocytic leukemia.
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The association between CBL mutations and UPD
To examine the association between CBL mutations and aUPD in
more detail we performed microsatellite analysis on all mutated
cases using 9 polymorphic markers spanning chromosome 11q13-
qter. Of the 26 cases, 11 displayed patterns that indicated signifi-
cant tracts of homozygosity, including all 3 with 11q aUPD
detected by SNP arrays. Case UPN 9 with 2 mutations was
heterozygous for all markers. Of the 11 cases with biallelic CBL
mutations as judged by sequence analysis, 5 showed complete
homozygosity at all microsatellite loci tested and 6 had at least
4 consecutive homozygous calls encompassing the location of the
CBL gene at 11q23.3 (Figure 5). We performed multiplex ligation
probe amplification (MLPA) analysis to determine whether the
observed homozygosity was a consequence of a deletion but no
copy number changes were detected (data not shown) and therefore
it is likely that homozygosity arose by aUPD. The number of
A
B
Chr 11 CN Chr 11 LOHChr 11 CN Chr 11 LOH Chr 11 CN Chr 11 LOH
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Figure 2. CBL mutations in the 3 cases with 11q aUPD. (A) Genotyping Console output indicating homozygous SNP calls in green, copy number state as estimated by a
Hidden Markov Model in blue, and smoothed copy number log(2) ratio values in red. (B) Ideograms showing lack of large copy number changes and blocks of homozygosity at
11q. Abbreviations are as in Figure 1. (C) Sequence changes indicated by ™ in each case compared with normal controls. UPN 2 and UPN 5 each have the c.1139TC: L380P
mutation whereas UPN 3 has c.1249CG: P417A.
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mutated alleles estimated by sequencing was concordant with the
microsatellite analysis in 20 cases (Figure 5). Of those that were
discordant, UPN 6 and UPN 25 had significant tracts of 11q
homozygosity but had a monoallelic CBL mutation whereas
UPN 10 and UPN 16 did not show 11q homozygosity but had clear
biallelic CBL mutations. The reason for these discrepant cases is
unclear, but it is possible that the aUPD seen in UPN 6 and UPN 25
targeted another gene at 11q before acquisition of the CBL
mutation. Homozygosity for the CBL mutations in the absence of
11q aUPD in UPN 10 and UPN 16 might be explained by a
subcytogenetic deletion of 1 allele.
Correlation between CBL mutations and clinical features
We compared clinical and hematologic features in patients with or
without CBL mutations, restricting the analysis to cases with
aCML, MF and CMML because these were the subgroups in which
CBL mutations were most commonly found. Patients with CBL
mutations had a shorter overall survival and progression-free
survival compared with mutation negative cases (overall survival:
33 months vs 39 months; progression-free survival: 22 months vs
32 months) but the differences were not significant (Figure 6).
Similarly there was no significant difference in gender distribution,
age and standard hematologic parameters between mutation posi-
tive and mutation negative cases and no differences emerged when
individual disease entities were considered.
Transforming activities of CBL mutants
We determined whether selected CBL variants had oncogenic
activity by testing whether they could transform the interleukin-3
(IL-3)–dependent cell line 32D to growth factor independence in
conjunction with overexpression of wild-type FLT3, as has been
described previously for R420Q.15 We found that S376F, H398Y,
P417A, and R420Q alone each conferred a degree of growth factor
independence to 32D cells, but this effect was considerably
enhanced in 32Ds that overexpressed wild-type FLT3. In contrast,
wild-type CBL conferred no growth advantage either with or
without FLT3 overexpression. The N454D change was not trans-
forming, indicating that it is probably a rare polymorphism or a
pathogenetically unimportant passenger mutation (Figure 7). Repro-
ducible differences in survival between the different mutants were
seen, as illustrated in Figure 8A.
Abrogation of E3 ubiquitin ligase activity
It has been shown that FLT3 physically associates with CBL and
that, upon ligand stimulation, FLT3 is rapidly ubiquitinylated by
wild-type but not R420Q CBL.15 We found that transforming
activity correlated directly with the ubiquitin ligase activity of the
CBL variants, as assayed by their ability to transfer HA-tagged
ubiquitin to FLT3 after stimulation with FLT3 ligand. The S376F,
H398Y, P417A and R420Q mutants showed loss of ubiquitin ligase
activity, whereas N454D was comparable to wild-type CBL
(Figure 8B).
Discussion
The initial aim of our study was to identify large regions of aUPD
and therefore we undertook a relatively low resolution genome
scan using 50k SNP arrays. Because we did not have constitutional
DNA available from most of our cases, we were not able to
unambiguously determine whether the extended blocks of homozy-
gosity that we observed were a consequence of aUPD, constitu-
tional UPD or autozygosity due to consaguinity, however we used a
very conservative definition of candidate aUPD regions (at least
20 Mb homozygous SNPs calls running to a telomere) and
therefore expected that most or all would be acquired. We found
that aUPD was relatively common in aCML, but was uncommon in
other MPNs that were negative for known mutations, plus also
CML blast crisis and CLL. Six distinct regions of aUPD were
identified in aCML, indicating substantial genetic heterogeneity in
the genesis of this disorder. However, we identified 2 recurrent
regions of aUPD at 7q and 11q that were each seen in 10% of cases
indicating the presence of common molecular abnormalities.
Table 2. Cases analyzed for CBL mutations
Disease category Cases analyzed Cases with CBL variants
PV 74 0
MF 53 3 (6%)
ET 24 0
SM 60 0
CMML 78 10 (13%)
aCML 152 12 (8%)
HES/CEL 96 1 (1%)
CNL 9 0
CML-BC 31 0
Total 577
PV indicates polycythemia vera; MF, myelofibrosis; ET, essential thrombocythe-
mia; SM, systemic mastocytosis; CMML, chronic myelomonocytic leukemia; aCML,
atypical chronic myeloid leukemia; HES/CEL, hypereosinophilic syndrome/chronic
eosinophilic leukemia; CNL, chronic neutrophilic leukemia; and CML-BC, CML in
transformation to blast crisis.
Table 3. List of CBL sequence variants
Patient
identifier Diagnosis Exon 8 amplicon Exon 9 amplicon
UPN 1 aCML c.1127CT: S376F N
UPN 2 aCML c.1139TC: L380P N
UPN 3 aCML N c.1249CG: P417A
UPN 4 aCML N c.1259GA: R420Q
UPN 5 aCML c.1139TC: L380P N
UPN 6 aCML int5 GA N
UPN 7 aCML c.1224GC: W408C N
UPN 8 aCML N c.1254CA: F418L
UPN 9 aCML c.1111TC: Y371H c.1384CT R462X
UPN 10 aCML N c.1249CG: P417A
UPN 11 aCML N c.1259GT: R420L
UPN 12 aCML N c.1259GA R420Q
UPN 13 CEL N int-2 AG
UPN 14 MF c.1139TC: L380P N
UPN 15 MF N c.1259GA: R420Q
UPN 16 MF N c.1259GA: R420Q
UPN 17 CMML c.1142GA: C381Y N
UPN 18 CMML c.1227–12274 del ggtac N
UPN 19 CMML int4 CT N
UPN 20 CMML int-1 GC N
UPN 21 CMML c.1186TG: C396G N
UPN 22 CMML N c.1250CT P417L
UPN 23 CMML c.1151GA: C384Y N
UPN 24 CMML N c.1360AG: N454D
UPN 25 CMML c.1150TC: C384R N
UPN 26 CMML c.1192CT: H398Y N
UPN indicates unique patient number; aCML, atypical chronic myeloid leukemia;
CEL, chronic eosinophilic leukemia; MF, myelofibrosis; CMML, chronic myelomono-
cytic leukemia; and N, normal.
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Our mutation screening focused primarily on tyrosine kinases
and associated signal transduction components because of the
known association between deregulated tyrosine kinase signaling
and MPNs.3 Although we failed thus far to identify any abnormal-
ity on chromosome 7q, we found missense CBL mutations in all
three 11q aUPD cases. Screening of further MPNs revealed a total
of 27 CBL variants in 26 patients who had been diagnosed with
aCML (n  12; 8%), MF (n  3, 6%), CMML (n  10, 13%), or
CBL
     Human CBL  RNQNPDLTGLCEPTPQDHIKVTQEQYELYCEMGSTFQLCKICAENDKDVKIEPCGHLMCTSCLTSWQ-ESEGQGCPFCRCEIKGTEPIVVDPFDPRGSG--SLLRQGAEGAPSPNY- 
     Mouse CBL  RNQNPDLTGLCEPTPQDHIKVTQEQYELYCEMGSTFQLCKICAENDKDVKIEPCGHLMCTSCLTSWQ-ESEGQGCPFCRCEIKGTEPIVVDPFDPRGSG--SLLRQGAEGAPSPNY- 
       Rat CBL  RNQNPDLTGLCEPTPQDHIKVTQEQYELYCEMGSTFQLCKICAENDKDVKIEPCGHLMCTSCLTSWQ-ESEGQGCPFCRCEIKGTEPIVVDPFDPRGSG--SLLRQGAEGAPSPNY- 
   Xenopus CBL  RNQNPDLTGLCEPTPQDHIKVTQEQYELYCEMGSTFQLCKICAENDKDVKIEPCGHLMCTSCLTSWQ-ESEGQGCPFCRCEIKGTEPIVVDPFDPRGGGMAELLRHCMDGTPSPCY- 
Drosophila CBL  QAYNPDLSSAVQSPTEDHITVTQEQYELYCEMGSTFQLCKICAENDKDIRIEPCGHLLCTPCLTSWQVDSEGQGCPFCRAEIKGTEQIVVDAFDPRKQH----NRNVTNGRQQQQ-- 
    Human CBLb  RSYNPDLTGLCEPTPHDHIKVTQEQYELYCEMGSTFQLCKICAENDKDVKIEPCGHLMCTSCLTAWQ-ESDGQGCPFCRCEIKGTEPIIVDPFDPRDEG--SRCCSIIDPFGMPMLD 
    Human CBLc  KTHNPDLTELGQAEPQQRIHVSEEQLQLYWAMDSTFELCKICAESNKDVKIEPCGHLLCSCCLAAWQ-HSDSQTCPFCRCEIKGWEAVSIYQFHGQATA—------EDSGNSSDQ-- 
                :  ****:   :. ..::* *::** :**  *.***:*******.:**::*******:*: **::** .*:.* *****.**** * : :  *. :    
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Figure 3. Location of missense mutations. (Top panel) Schematic representation of the CBL protein showing the tyrosine kinase binding (TKB), linker, RING, proline-rich
(P-rich), and ubiquitin-associated/leucine zipper (UBA/LZ) domains. (Bottom panel) ClustalW alignment of the entire linker and RING domains plus part of the distal sequence.
The RING domain is shaded in gray with the defining C and H residues shaded pale blue. Residues affected by missense mutations found in this study are indicated by .
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Figure 4. Acquisition of CBL mutations. (A) Comparison of granulocytes (gran) with buccal epithelial cells (bucc) or T cells (T) demonstrates that the L380P mutations in
cases UPN 5 and 14 are acquired. (B) Sequential leukocyte and platelet counts for case, who presented in 1989 with essential thrombocythemia (ET) but progressed to
myelofibrosis (MF) in 2004. Homozygous CBL R420Q, indicated by *, was detected on transformation but was undetectable in previous specimens. (C) Clinical course of case
UPN 14, who presented with MF in 1998 but experienced elevated leukocyte counts in 2005, concomitant with the appearance of the CBL L380P mutation. The JAK2 V617F
mutation, which had been present at low level since diagnosis, was still detectable when CBL L380P first appeared but was undetectable in the 2008 sample, when the CBL
mutated clone predominated (* on sequence trace). (D) RT-PCR analysis. All cases and controls show the expected product from CBL exons 7-10. Cases UPN 18 and UPN 20
show smaller bands that result from complete deletion of exon 8.
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HES/CEL (n  1, 1%); that is, morphologically and clinically
related diseases that generally exhibit a poor prognosis. We were
unable to discern, however, any specific clinical or prognostic
features specifically associated with CBL mutated cases.
Casitas B-lineage lymphoma (CBL) is a well characterized
protein that plays both positive and negative regulatory roles in
tyrosine kinase signaling. In its positive role, CBL binds to
activated receptor tyrosine kinases via its N-terminal tyrosine
kinase binding (TKB) domain and serves as an adaptor by
recruiting downstream signal transduction components such as
SHP2 and P13K. However the RING domain of CBL has E3 ligase
activity and ubiquitinylates activated receptor tyrosine kinases on
lysine residues, a signal that triggers internalization of the receptor/
ligand complex and subsequent recycling or degradation.21,24,25
CBL was originally identified after the characterization of v-Cbl,
the transforming component of the Cas NS-1 retrovirus, and thus
its association with neoplasia is well established26; however, it is
only very recently that CBL mutations were first identified in a
human malignancy, specifically occasional cases of AML.15,23,27
We have found that CBL mutations are much more common in
MPNs, and previous reports of 11q aUPD in MDS28 suggest that
CBL mutations will also prove to be common in this disease.
Indeed, 7 of 12 MDS cases with aUPD at 11q were recently shown
to harbor CBL mutations.29 There are 2 other human CBL family
members, CBLB and CBLC, but we did not identify aUPD in the
regions containing these genes and did not detect any mutations of
the linker/RING domain of CBLB.
We identified a total of 15 different CBL missense mutations
affecting 12 residues (Table 2; Figure 3). Mutations of some of
these residues (eg, Y371, C381, H398 and W408) have been
Figure 5. Microsatellite analysis of CBL mutation
positive cases. The number of CBL mutated alleles
(1 monoallelic; 2 biallelic) was estimated by sequence
analysis as described in “Experimental procedures.”
Microsatellites were scored as homozygous ( ) or het-
erozygous () for each case and their positions on
chromosome 11q are indicated.
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analyzed previously in a study that concluded that loss of E3
ubiquitin ligase activity and concomitant impairment of EGFR
internalization by RING finger mutations was insufficient for
oncogenicity, as assayed in NIH3T3 cells. However mutations of
key residues within the -helix of the linker region abolished
ubiquitin ligase activity and were transforming.30 Although the
precise amino acid substitutions we identified were different from
those studied, we found that mutations in both the RING finger and
linker regions conferred autonomous growth to 32D/wt-FLT3 cells,
consistent with a causal relationship to the MPN phenotype. The fact
that one mutation (N454D) was not transforming emphasizes the
importance of functional analysis to distinguish driver mutations from
irrelevant passengers or infrequent polymorphisms.31 Notably, this
mutation was only weakly conserved between species, in contrast to all
other missense mutations that affected highly conserved residues and are
therefore likely to be functionally significant.
Enhanced autonomous growth in the presence of CBL muta-
tions and overexpression of wild-type FLT3 may simply reflect the
paucity of receptor tyrosine kinase gene expression in 32D cells or,
alternatively, may indicate that the mutants are only weakly
transforming and require the cooperation of other events to give
rise to clinically manifest disease. Consistent with the latter
hypothesis, we identified 2 cases in which CBL mutations were
acquired during progression of a preexisting MPN (Figure 4). In
both cases the identity of the cooperating change is unknown:
although one presented with a (relatively low level) V617F JAK2
mutation, this disappeared on progression to CBL L380P positive
disease, indicating that the 2 mutations must have arisen independently
in different clones. This is reminiscent of the observation that the
leukemic blasts of approximately half of V617F positive MPNs that
evolve to AML are negative for the JAK2 mutation.32,33 It remains to be
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Figure 6. Clinical significance of CBL mutations. Overall survival (A) and
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established, however, if CBL mutations are usually secondary events or
whether the 2 cases we identified are exceptional.
Further evidence for the requirement for additional cooperating
genetic events comes from published mouse studies in which
neither complete CBL knockout nor heterozygous knockin of the
RING finger inactivating mutant C379A (mouse C379 is equivalent
to human C381) resulted in evidence of an MPN or other
malignancy.34,35 However, closer analysis revealed subtle hemopoi-
etic perturbations that clearly relate to the pathogenesis of MPNs.
Specifically, hemopoietic stem cells (HSCs) from these animals
were increased in number, hyperresponsive to thrombopoietin and
more potent than wild-type HSCs in repopulating the hemopoietic
system. These effects were associated with increased STAT5
accumulation and phosphorylation.34,35 Hyperresponsiveness to
growth factors and stem cell involvement are 2 of the cardinal
features of MPNs. Furthermore, the association between STAT5
activation and MPNs is well documented.36,37 While it is possible
that overt hematologic disease might have been induced by a
homozygous knockin mutant, these findings suggest that CBL
mutations may not be solely responsible for a full MPN phenotype.
The nature of any cooperating abnormalities remains largely
obscure. Our results show that overexpression of a tyrosine kinase
can cooperate with CBL mutants to promote transformation,
however we failed to identify any kinase that was consistently
overexpressed in mutation positive cases by tyrosine kinase
expression profiling (data not shown). One CBL mutation positive
case, however, also tested positive for 7q UPD by SNP array,
suggesting that these 2 abnormalities may complement each other.
A CBL mutation resulting in skipping of exon 8 has also been
identified in a murine model of NUP98-HOXD13 on progression
from MDS to AML,38 further corroborating the theory that acute
leukemia arises from complementary mutations, one of which
inhibits differentiation, and a second (in this case CBL) that
enhances proliferation or inhibits apoptosis.
The fact that many CBL mutations are associated with aUPD
strongly suggests that clones with homozygous mutations have a
selective advantage over those that are heterozygous. This contrasts
with the prevailing view that transforming CBL RING finger and
linker region mutants act in a dominant negative fashion. Although
it is conceivable that another, unknown locus on 11q is the target of
aUPD, the finding of 1 case with a Y371H mutation and a stop
codon on opposite alleles strongly suggests that homozygous CBL
mutations do indeed confer a direct selective advantage. Because
we did not screen the entire gene for mutations, it is possible that
other cases with heterozygous mutations may also be functionally
homozygous due to premature stop codons on the other allele.
Alternatively, heterozygosity in these cases may only be apparent
due to variable proportions of background normal cells that are not
part of the malignant clone. Although the nontransforming N454D
mutant was heterozygous, 2 cases with heterozygous R420Q were
observed and thus absence of homozygosity cannot be used to infer
the presence of an irrelevant, nontransforming sequence variant.
In summary, we have found that oncogenic CBL mutations are
acquired in a subset of hematologically related, poor prognosis MPNs.
Our findings further strengthen the notion that MPNs are primarily
“tyrosine kinopathies,” that is, diseases caused by aberrant activation of
proliferation and survival pathways as a consequence of mutations that
either directly or indirectly promote excess tyrosine kinase signaling. In
view of the fact that tyrosine kinases are such good drug targets, the
possibility that CBL-mutated cases might be amenable to therapeutic
inhibition is clearly attractive.
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